histamine profile

ID Source	ID
PubMed CID	774
CHEMBL ID	90
CHEBI ID	18295
SCHEMBL ID	2279
MeSH ID	M0010390

Synonym
AC-13185
BB 0241907
2-(3h-imidazol-4-yl)ethanamine
gtpl1204
gtpl1247
CHEBI:18295 ,
MLS000069447 ,
smr000059091
wln: t5m cnj d2z
imidazole, 4-(2-aminoethyl)-
eramin
4-imidazoleethylamine
5-imidazoleethylamine
nsc33792
nsc-33792
ergamine
.beta.-imidazolyl-4-ethylamine
imidazole-4-ethylamine
theramine
ethylamine, 2-imidazol-4-yl-
ergotidine
free histamine
DIVK1C_000308
KBIO1_000308
SDCCGMLS-0066601.P001
2-(1h-imidazol-5-yl)ethanamine
4-(2-aminoethyl)-1h-imidazole
histamine base
beta-aminothethylglyoxaline
beta-aminoethylimidazole
SPECTRUM_000845
SMP1_000151
BSPBIO_001117
nsc 33792
histamine [usan]
istamina [italian]
einecs 200-100-6
beta-aminoethylglyoxaline
hsdb 3338
ccris 6535
beta-imidazolyl-4-ethylamine
bdbm7966
BIO2_000869
chembl90 ,
l-histamine
NCGC00015513-01
BIO1_001465
BIO1_000976
BIO2_000389
BIO1_000487
2-(1h-imidazol-4-yl)ethan-1-amine
lopac-h-7250
[3h]histamine
IDI1_002144
2-imidazol-4-ylethylamine
2-(1h-imidazol-4-yl)ethanamine
LOPAC0_000595
BCBCMAP01_000250
SPECTRUM5_000796
BSPBIO_002124
IDI1_000308
2-(3h-imidazol-4-yl)-ethylamine
51-45-6
HISTAMINE ,
1h-imidazole-4-ethanamine
C00388
2-(4-imidazolyl)ethylamine
histamine, >=97.0%
1QFT
1AVN
NCGC00093371-03
histamine, free base
NCGC00093371-04
KBIO2_000457
KBIO3_000854
KBIOSS_001325
KBIOSS_000457
KBIO3_000853
KBIO2_001325
KBIO2_003893
KBIO2_006461
KBIOGR_001580
KBIO2_003025
KBIOGR_000457
KBIO3_001344
KBIO2_005593
SPECTRUM2_000665
SPBIO_000729
SPECTRUM4_000960
SPECTRUM3_000452
NINDS_000308
NCGC00093371-02
NCGC00093371-05
STK346752
HMS1990G19
F411C768-A159-4FC0-A195-291A08BB03AA ,
NCGC00015513-08
AKOS000274386
L000292
.beta.-aminoethylglyoxaline
histamine (dcf)
histaminum (tn)
D08040
HMS1792G19
HMS1362G19
1h-imidazole-5-ethanamine
BMSE000744
istamina
NCGC00015513-04
AKOS009158347
unii-820484n8i3
820484n8i3 ,
BBL004932
2-imidazol-5-ylethylamine
A828600
tox21_110166
dtxcid103125
dtxsid4023125 ,
cas-51-45-6
CCG-204684
S3968
NCGC00015513-07
NCGC00015513-06
NCGC00015513-10
NCGC00015513-02
NCGC00015513-09
NCGC00015513-05
NCGC00015513-03
BP-11484
FT-0627839
AM20100377
histamine [vandf]
histamine [mi]
histamine [who-dd]
.beta.-aminoethylimidazole
histamine [mart.]
histamine [hsdb]
S10979
65592-96-3
DB05381
4-(2-aminoethyl)imidazole
[2-(1h-imidazol-4-yl)ethyl]amine
2-(1h-imidazol-4-yl)ethylamine
racemic histamine
(1h-imidazol-4-yl)ethylamine
2-(1h-imidazol-4-yl)-ethylamine
2-(3h-imidazol-4-yl)ethylamine
SCHEMBL2279
tox21_110166_1
NCGC00015513-11
CS-4697
3h-histamine
2-(1h-imidazol-4-yl)ethanamine #
histamine dihydrochloride (salt/mix)
HY-B1204
HMS3403G19
AB00053481_21
AB00053481_20
OPERA_ID_1772
mfcd00005210
2-(1h-imidazol-5-yl)ethan-1-amine
F2173-0575
bdbm50121205
histamine, analytical standard
histamine, base, >=97.0% (nt)
histamine, vetec(tm) reagent grade, >=97%
histamine, europepharmacopoeia (ep) reference standard
J-505349
SBI-0050577.P004
l-histamin base
2-imidazol-4-yl-ethylamine
2-(1h-imidazol-5-yl)ethylamine
2-(4-imidazolyl)ethanamine
b-imidazolyl-4-ethylamine
[2-(1h-imidazol-5-yl)ethyl]amine dihydrochloride
histamine, free base - cas 51-45-6
SY041787
histaminum
117932-92-0
Q61233
FS-5386
EN300-78991
SDCCGSBI-0050577.P005
HMS3885M14
NCGC00015513-25
AMY33457
HMS3743G03
mfcd00128939
imido-
F10913
CS-0368357
histamine free base crystalline
748 - fish based sample
2-(1h-imidazol-4-yl)-1-ethanamine
histamine (mart.)
aleroff

Research Excerpts

Overview

Excerpt	Reference
"Histamine is a multifunctional hormone that regulates smooth muscle contraction in the airways, acid secretion in the gut, and neurotransmitter release in the central nervous system through three well characterized receptor subtypes, H(1), H(2), H(3), respectively. "	( Blevitt, J; Carruthers, N; Chai, W; Hofstra, CL; Jiang, X; Li, X; Liu, C; Lovenberg, TW; Ma, X; Pyati, J; Wilson, SJ, 2001)
"The histamine H(4) receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. "	( Bessembinder, K; de Esch, IJ; Kuhne, S; Leurs, R; Lim, HD; Smits, RA; van der Meer, T; Wijtmans, M; Zuiderveld, OP, 2012)
"Histamine is an important endogenous signaling molecule that is involved in a number of physiological processes including allergic reactions, gastric acid secretion, neurotransmitter release, and inflammation. "	( Savall, BM; Thurmond, RL; Tichenor, MS; Venable, JD, 2015)
"Histamine is a natural amine derived from L-histidine. "	( Deeva, TA; Ivashkin, VT; Kaysheva, AL; Kopylov, AT; Malsagova, KA; Nechaev, VM; Popova, IR; Shulpekova, YO, 2021)
"Histamine is a small monoamine signaling molecule that plays a role in many peripheral and central physiological processes, including the regulation of wakefulness. "	( Arrigoni, E; Fuller, PM, 2022)
"Histamine is a mediator produced by mast cells in the conjunctiva during the allergic response."	( Bair, J; Botten, N; Dartt, DA; Hodges, R; Serhan, CN; Utheim, TP; Yang, M, 2021)
"Histamine is an interesting biomarker released in scalp affected by dandruff and SD even though the mechanism is not well understood yet."	( Bourokba, N; Choudhury, RP; Eilstein, J; Jourdain, R; Ngo, T; Roy, N; Vedula, SK; Vijayaraghavan, S, 2022)
"Histamine is a biogenic amine significantly formed in fish sauce leading to a major concern in consumers. "	( Abhisingha, M; Booncharoen, A; Chantarasakha, K; Mhuantong, W; Pitaksutheepong, C; Santiyanont, P; Tepaamorndech, S; Tepkasikul, P; Visessanguan, W, 2022)
"Histamine (HA) is an indicator of food freshness and quality. "	( Chen, ZJ; Fu, HJ; Hildebrandt, N; Luo, L; Su, R; Sørensen, TJ; Xu, ZL, 2022)
"Histamine is a fermented food product that exerts adverse health effects on animals when consumed in high amounts. "	( Aryal, B; Lee, Y, 2022)
"Histamine is a biogenic amine with four types of receptors."	( Di Ciano, P; Hendershot, CS; Le Foll, B, 2022)
"Histamine is a biogenic amine produced in fish by the action of certain groups of bacteria which are capable of producing an exogenous enzyme called histidine decarboxylase (HDC)."	( Dam Roy, S; Devivilla, S; Kumar H, S; Lekshmi, M; Nayak, BB; Salam, F; Valappil, RK, 2023)
"Histamine is an organic nitrogenous compound that mediates a plethora of cell processes via different receptors."	( Cai, Y; Chen, X; Dai, Y; Deng, G; Guo, J; Long, X; Mo, S; Peng, B; Xiao, W; Xu, D; Xu, Y; Ye, T; Zeng, J; Zhang, P; Zhang, X, 2022)
"Histamine is a pivotal mammalian immune modulator, and recently it was shown to be present in high concentrations in household dust from homes infested with bed bugs."	( DeVries, ZC; Gaire, S; Principato, S; Schal, C, 2022)
"Histamine is a major neurotransmitter and alleviates neuronal damage after ischemic injury via H"	( Awane, H; Ezaki, M; Hishinuma, S; Inazuki, N; Michinaga, S; Mizuguchi, H; Shimizu, K; Sonoda, K, 2022)
"Histamine is a major mediator released by mast cells in allergic inflammation and response."	( Gao, S; Ku, W; Liu, K; Nishibori, M; Qiao, H; Teshigawara, K; Wake, H; Wang, D, 2022)
"Histamine is an important monoamine neurotransmitter that regulates multiple physiological activities in both vertebrates and invertebrates. "	( Han, Y; Liang, Y; Peng, L; Wang, T; Xie, J, 2022)
"Histamine (HIS) is a potent vasodilator that contributes to anaphylactic reactions. "	( Hassanen, EI; Kamel, S; Mahmoud, MA; Mansour, HA; Mohamed, WA, 2023)
"Histamine is a critical mediator of anaphylaxis, a neurotransmitter, and a regulator of gastric acid secretion. "	( Finkelman, FD; Gao, J; Guan, X; Huang, H; Li, Y; Morris, SC; Zhao, D, 2023)
"Histamine (HA) is a key biogenic monoamine involved in a wide range of physiological and pathological processes in both the central and peripheral nervous systems. "	( Dong, H; Leurs, R; Li, G; Li, M; Li, Y; Lin, Y; Liu, C; Ma, X; Qian, T; Vischer, HF; Wang, H; Yan, Y, 2023)
"Histamine is a well-known inflammatory mediator, but how histamine induces angiogenesis remains poorly understood. "	( Hatipoglu, OF; Mori, S; Nishibori, M; Nishinaka, T; Takahashi, H; Toyomura, T; Wake, H; Watanabe, M; Yaykasli, KO, 2023)
"Histamine is a conserved neuromodulator in mammalian brains and critically involved in many physiological functions. "	( An, S; Chen, Z; Dong, H; Gong, H; Hu, W; Li, A; Li, M; Li, Y; Lin, W; Luo, Q; Pan, G; Wang, Y; Xu, L; Zhao, M; Zheng, Y, 2023)
"Histamine is a component of the bed bug aggregation pheromone. "	( DeVries, ZC; González-Morales, MA; Gordon, JM; Menechella, M; Santangelo, RG; Schal, C, 2023)
"Histamine is a biologically active molecule that serves as a reliable predictor of the quality of fish. "	( Jha, R; Kumar, S; Li, G; Marques, C; Singh, R; Wang, Z; Xie, Y; Zhang, B; Zhang, W, 2023)
"Histamine is a biogenic amine implicated in various biological and pathological processes. "	( Annabi, B; Lafortune, C; Marcocci, L; Mateescu, MA; Neree, AT; Paquin, J; Perez, MG; Pietrangeli, P; Suarez, NG; Tanasie, G, 2023)
"Histamine is a biogenic amine that regulates multiple physiological functions in diverse organisms, specifically playing a central role in the mammalian immune response. "	( Campbell, K; Choe, DH; DeVries, Z; Lee, CY; Principato, S; Romero, A; Schal, C, 2023)
"Histamine is a biogenic amine that participates in allergic and inflammatory processes by stimulating histamine receptors. "	( Asada, H; Fujita-Fujiharu, Y; Hisano, H; Im, D; Ito, A; Iwata, S; Kato, T; Kishikawa, JI; Noda, T; Shiimura, Y; Sugita, Y, 2023)
"Histamine is a neuromodulator that affects gut motility and visceral sensitivity through intrinsic and extrinsic neural pathways, yet the mechanisms regulating histamine availability in these pathways remain poorly understood. "	( Demireva, EY; Gonzales, J; Gulbransen, BD; McClain, JL; Morales-Soto, W; Parmar, V, 2023)
"XC8 (histamine glutarimide) is a novel agent which targets eosinophilic migration and mast cell degranulation and has shown anti-asthmatic effects in animal studies."	( Badorrek, P; Ferko, B; Marth, K; Müller, M; Nebolsin, V; Pohl, W; Renner, A; Romanova, J; Schmutz, H, 2019)
"Histamine is a key molecule required for the functioning of the photoreceptor as well as mechanoreceptors."	( Jayabalan, R; Mishra, M; Priyadarsini, S; Sahoo, M; Sahu, S, 2019)
"Histamine is a biogenic amine that is chiefly produced in mast cells and basophils and elicits an allergic response upon stimulation. "	( Fujimura, T; Moriguchi, T; Ohtsu, H; Sato, A; Takai, J; Uemura, S; Yamamoto, M, 2019)
"Histamine is a major peripheral inflammatory mediator and a neurotransmitter in the central nervous system. "	( Qu, C; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhou, X, 2020)
"Histamine is a key inflammatory mediator known to trigger vasodilation and vessel hyperpermeability upon binding to its receptors and evoking intracellular Ca"	( Meininger, CJ; Peng, X; Si, H; Wang, J; Zawieja, DC; Zhang, SL, 2020)
"Histamine is a biogenic amine, produced in spoiled fish and some fermented products, which causes a foodborne disease similar to an allergic reaction. "	( Bakke, M; Isono, E; Shimoji, K, 2020)
"Histamine is a biogenic amine, produced in spoiled fish and some fermented products, which causes a foodborne disease similar to an allergic reaction. "	( Bakke, M; Isono, E; Shimoji, K, 2020)
"Histamine is a bioactive monoamine that is synthesized by the enzymatic activity of histidine decarboxylase (HDC) in basophils, mast cells, gastric enterochromaffin-like (ECL) cells and histaminergic neuronal cells. "	( Moriguchi, T; Takai, J, 2020)
"Histamine (HA) is a major molecular mediator of inflammation, and mast cells residing in the gut are a primary source of histamine."	( Ahnstedt, H; Ayyaswamy, S; Blasco, MP; Blixt, F; Bryan, R; Chauhan, A; d'Aigle, J; Durgan, D; Ganesan, A; Ganesh, BP; Haag, A; Honarpisheh, P; Kofler, J; Major, A; McCullough, LD; Venable, S, 2020)
"Histamine acts as a neurotransmitter to regulate various physiological processes. "	( Kikkawa, T; Naganuma, F; Osumi, N; Yamada, Y; Yanai, K; Yoshikawa, T, 2020)
"Histamine, which is a naturally occurring chemical in seafood, is known to cause undesirable inflammatory response when consumed in large amounts. "	( Lam, MHW; Lau, SC; Li, JH; Li, LY; Li, T; Roy, VAL; Sun, QJ; Venkatesh, S; Yeung, CC, 2021)
"Histamine is a key mediator in allergic and inflammatory processes in the small intestines; however, it is a challenge to determine histamine levels at the duodenal mucosa, and classical bioreceptors are unsuitable for use in the digestive medium of bowel fluid."	( Cornelis, P; Doll, T; Peeters, M; Putzeys, T; Tack, J; Troost, F; Verhaert, N; Wackers, G; Wagner, P, 2021)
"Histamine poisoning is a significant public health and safety concern. "	( Botello-Morte, L; García-Gonzalo, D; Moniente, M; Ontañón, I; Pagán, R, 2021)
"Histamine acts as a neurotransmitter in the central nervous system and is involved in numerous physiological functions. "	( Naganuma, F; Yoshikawa, T, 2021)
"Histamine is a critical inflammatory mediator in allergic diseases. "	( Alcañiz, L; Bellido, V; Chacón, P; Cornejo-García, JA; Del Valle Rodríguez, A; Doukkali, B; Monteseirín, J; Palacios, R; Puente, Y; Rivas-Pérez, D; Rodríguez, D; Vega-Rioja, A, 2021)
"Histamine is a highly pleiotropic biogenic amine involved in key physiological processes including neurotransmission, immune response, nutrition, and cell growth and differentiation. "	( Medina, MÁ; Moya-García, AA; Pino-Ángeles, A; Sánchez-Jiménez, F; Urdiales, JL, 2021)
"Histamine is a biogenic amine and a food safety hazard, and it is the only biogenic amine regulated by statute or hazard analysis and critical control point guidance. "	( Arcieri, J; Bell, JW; Correa, G; DeBEER, J; Nolte, F, 2021)
"Histamine is a monoaminergic neurotransmitter which is released within the entire brain from ascending axons originating in the tuberomammillary nucleus in a sleep state-dependent fashion. "	( Huang, Y; Kettenmann, H; Logiacco, F; Semtner, M; Xia, P, 2021)
"Histamine is a pleiotropic mediator involved in a broad spectrum of (patho)-physiological processes, one of which is the regulation of inflammation. "	( Neumann, D; Schirmer, B, 2021)
"Histamine is a key signal molecule in humans, with multiple functions, such as being a neurotransmitter or modulator of immune responses."	( Fernández, M; Gavira, JA; Krell, T; Matilla, MA; Monteagudo-Cascales, E; Roca, A; Velando, F, 2021)
"Histamine is a biogenic amine playing a central role in allergy and peripheral inflammatory reactions and acts as a neurotransmitter and neuromodulator in the brain. "	( Bernardino, L, 2022)
"Histamine is a well-characterized neuromodulator that follows a circadian rhythm, regulates IOP and modulates retinal circuits and vision."	( Lanzi, C; Lucarini, L; Masini, E; Sgambellone, S, 2021)
"Histamine is an important mediator of allergic reactions, and mucus hypersecretion is a major allergic symptom. "	( Cho, HJ; Choi, JY; Kang, JW; Kang, MJ; Kim, CH; Lee, HJ; Lee, SN; Lee, YH; Min, HJ; Namkung, W; Oh, R; Yoon, JH, 2017)
"Histamine (HA) is a biogenic amine that can accumulate to high concentration levels in food as a result of microbial activity and can cause toxic effects in consumers. "	( Beier, RC; Dong, XX; Lei, HT; Luo, L; Mao, C; Shen, YD; Sun, YM; Xu, ZL; Yang, JY; Zhang, YF, 2017)
"Histamine intolerance is a disorder in the homeostasis of histamine due to a reduced intestinal degradation of this amine, mainly caused by diamine oxidase (DAO) enzyme deficiency, which provokes its accumulation in plasma and the appearance of adverse health affects. "	( Bernacchia, R; Comas-Basté, O; Latorre-Moratalla, ML; Veciana-Nogués, MT; Vidal-Carou, MC, 2017)
"Histamine iontophoresis is a well-standardized in vivo model to quantitatively study the early stages of cutaneous inflammation with minimal impact on the skin barrier. "	( Falcone, D; Richters, R; Uzunbajakava, N; van de Kerkhof, PCM; van Erp, PEJ, 2017)
"Histamine is a toxic chemical and is the causative agent of food poisoning. "	( Huang, YL; Huang, YR; Kung, HF; Lee, YC; Su, YC; Tsai, YH, 2017)
"Histamine is a biogenic amine with extensive effects on many immune cell types. "	( Akdis, CA; Barcik, W; O'Mahony, L; Wawrzyniak, M, 2017)
"Histamine is an important chemical mediator in the development of allergic rhinitis and plays a key role in eliciting the nasal symptoms of the disorder. "	( Li, L; Tang, Y; Xia, Q; Yu, C, 2017)
"Histamine is a neurotransmitter that regulates diverse physiological functions including the sleep-wake cycle. "	( Iida, T; Kárpáti, A; Matsuzawa, T; Miura, Y; Mochizuki, T; Mogi, A; Naganuma, F; Nakamura, T; Okamura, N; Yanai, A; Yanai, K; Yoshikawa, T, 2017)
"Histamine is a widely distributed biogenic amine involved in the regulation of an array of biological processes. "	( Abudupataer, M; Chen, J; Ding, S; Ge, J; Hong, T; Li, H; Wang, TC; Xu, L; Yang, X; Zhang, S; Zhang, W; Zhou, Z; Zou, Y, 2018)
"Histamine is a well-known mediator involved in skin allergic responses through up-regulation of pro-inflammatory cytokines. "	( Abas, F; Ahmad, S; Lai, KS; Nazarudin, NA; Razali, NA, 2018)
"Histamine is a biogenic amine that influences many immune cells. "	( Jang, Y; Jin, M; Seo, SH, 2018)
"Histamine is a key biological signaling molecule. "	( Conejero-Muriel, M; Corral-Lugo, A; Gavira, JA; Hida, A; Kato, J; Krell, T; Martín-Mora, D; Matilla, MA; Mesa Torres, N; Oku, S; Silva Jiménez, H, 2018)
"Histamine is a heterocyclic amine formed by decarboxylation of the amino acid l-histidine. "	( Adam, V; Gagic, M; Jamroz, E; Kopel, P; Krizkova, S; Milosavljevic, V, 2019)
"Histamine is an important immunomodulator influencing both the innate and adaptive immune system. "	( Akdis, CA; Altunbulakli, C; Barcik, W; Brescó, MS; Ferstl, R; Frei, R; Groeger, D; Krawczyk, K; O'Mahony, L; Pugin, B; Rinaldi, A; Sokolowska, M; Van Elst, D; Wawrzyniak, M; Westermann, P, 2019)
"Histamine is a well-known mediator of inflammation that is released from mast cells and basophils. "	( Hirasawa, N, 2019)
"Histamine is an inflammatory factor."	( Khoushabi, A; Mahjour, M, 2020)
"Histamine is known to be a principal causative agent associated with marine food poisoning outbreaks worldwide, which is typically formed in the contaminated food by decarboxylation of histidine by bacterial histidine decarboxylase. "	( Nair, SS; Sai, VVR; Satija, J; Yadav, S, 2019)
"Histamine is a central mediator released from mast cells through allergic reactions."	( Ogasawara, M; Yamauchi, K, 2019)
"Histamine is an immune modulator, neuroprotective, and remyelinating agent, beneficially acting on skeletal muscles and promoting anti-inflammatory features in amyotrophic lateral sclerosis (ALS) microglia. "	( Amadio, S; Apolloni, S; Cavallaro, S; Fabbrizio, P; Ferri, A; Latagliata, EC; Madaro, L; Morello, G; Proietti, D; Puglisi-Allegra, S; Salvatori, I; Spampinato, AG; Volonté, C, 2019)
"Histamine is a crucial mediator in the development of anaphylaxis. "	( Hide, M; Ishii, K; Ohshimo, S; Shime, N; Yamaga, S; Yanase, Y, 2020)
"Histamine clearance is an essential process for avoiding excessive histaminergic neuronal activity. "	( Harada, R; Iida, T; Kasajima, A; Mohsen, AS; Naganuma, F; Nakamura, T; Sasano, H; Yanai, K; Yoshikawa, T, 2013)
"Histamine is a potent biogenic amine that mediates numerous physiological processes throughout the body, including digestion, sleep, and immunity. "	( Chuang, JC; Osborne-Lawrence, S; Park, WM; Perello, M; Sakata, I; Walker, AK; Zigman, JM, 2013)
"Histamine is an important mediator in the development of allergic reactions. "	( Alcañiz, L; Aroca, R; Bergstralh, DT; Blanca, M; Chacón, P; El Bekay, R; Monteseirin, J; Vega, A; Ventura, I, 2013)
"Histamine is a biogenic monoamine that plays a role in several physiological functions, including induction of inflammatory reactions, wound healing, and regeneration."	( Mirshafiey, A; Naddafi, F, 2013)
"Histamine (HA) is a key regulator of experimental allergic encephalomyelitis (EAE), the autoimmune model of multiple sclerosis. "	( Case, LK; del Rio, R; Noubade, R; Saligrama, N; Teuscher, C, 2013)
"Histamine acts as a modulatory neurotransmitter in the mammalian brain. "	( Nuutinen, S; Panula, P, 2013)
"histamine intolerance is a little known disease with a potentially relevant incidence. "	( Ferrés-Ramis, L; García-Teresa-García, E; Pérez-Esteban, G; Rosell-Camps, A; Vila-Vidal, M; Zibetti, S, 2013)
"Histamine is a major inflammatory mediator present in large quantities in asthmatic airways."	( Boudreau, HE; Leto, TL; Park, JJ; Rada, B, 2014)
"Histamine is a regulator of the microcirculation and is supplied by release from its stores and/or by de novo production via the induction of histidine decarboxylase (HDC)."	( Endo, Y; Kumamoto, H; Niijima-Yaoita, F; Ohtsu, H; Sasaki, K; Sugawara, S; Tadano, T; Tsuchiya, M; Watanbe, M; Yanai, K; Yoneda, H, 2013)
"Histamine is an important mediator of allergic diseases. "	( Glatzer, F; Gschwandtner, M; Gutzmer, R; Köther, B; Mommert, S; Stark, H; Werfel, T, 2014)
"Histamine is a biogenic amine with extensive effects on many cell types, mediated by the activation of its four receptors (H1R-H4R). "	( Crameri, R; Jutel, M; O'Mahony, L; Smolinska, S, 2014)
"Histamine (HA) is a neurotransmitter synthesized in most mammalian tissues exclusively by histidine decarboxylase enzyme. "	( Mondillo, C; Monzón, C; Pagotto, RM; Pereyra, EN; Pignataro, OP, 2014)
"Histamine is an inflammatory mediator that increases vascular permeability, and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24 h with 1 μM simvastatin and 100 μM aspirin on histamine responsiveness."	( Absi, M; Bruce, JI; Ward, DT, 2014)
"Histamine is an important modulatory agent of the sympathetic neurotransmission, but its exact action on the testicular capsule or rat vas deferens is not fully understood. "	( Caricati-Neto, A; da Silva Júnior, ED; de Souza, BP; Jurkiewicz, A; Jurkiewicz, NH; Rodrigues, JQ, 2014)
"Histamine is a potent mediator of inflammation and a regulator of innate and adaptive immune responses. "	( Dong, H; He, S; Hu, G; Zeng, X; Zhang, H; Zhang, S; Zhang, W, 2014)
"Histamine is a potent mediator of allergic inflammation, substantially involved in asthmatic pathophysiology."	( Horie, M; Jo, T; Kohyama, T; Mikami, Y; Nagase, T; Nakajima, J; Saito, A; Sakamoto, M; Takizawa, H; Yamauchi, Y, 2014)
"Histamine is an important immunomodulator involved in allergic reactions and inflammatory responses. "	( He, L; Jin, Y; Kuo, L; Muñoz-Garay, C; Peng, JM; Peng, X; Si, H; Zawieja, DC; Zhang, SL; Zheng, H; Zhou, MH; Zhou, Y, 2014)
"Histamine is a mast cell mediator released e.g. "	( Althaus, M; Bell, A; Diener, M, 2015)
"Histamine is an important mediator of anaphylactic reactions. "	( Chen, X; Hu, W; Liu, J; Wang, L; Zhong, D, 2014)
"Histamine is an important mediator in the pathophysiology of asthma. "	( Dai, H; Jones, BL; Raje, N; Vyhlidal, CA, 2015)
"Histamine is an important biogenic amine involved in regulating numerous physiological and pathophysiological processes in humans and animals. "	( Boyne, MT; Chimalakonda, KC; Howard, KE; Pang, E; Patel, V; Weaver, JL, 2015)
"Histamine is a well-known mammalian acid secretagogue and it stimulates acid secretion through H2 receptors."	( Alada, AR; Olatunji, LA; Usman, TO, 2015)
"Histamine is a physiological amine which initiates a multitude of physiological responses by binding to four known G-protein coupled histamine receptor subtypes as follows: histamine H1 receptor (H1 R), H2 R, H3 R, and H4 R. "	( Harada, R; Iida, T; Iwata, R; Matsuzawa, T; Miura, Y; Mohsen, AS; Naganuma, F; Nakamura, T; Yanai, K; Yoshikawa, T, 2015)
"Histamine is an important mediator in the pathogenesis of asthma. "	( Anvari, S; Dai, H; Jones, BL; Vyhlidal, CA, 2015)
"Histamine is a developmentally highly conserved autacoid found in most vertebrate tissues. "	( Chazot, PL; Cowart, M; Gutzmer, R; Haas, HL; Leurs, R; Liu, WL; Panula, P; Stark, H; Thurmond, RL, 2015)
"Histamine appears to be an important transmitter throughout the Animal Kingdom. "	( Croll, RP; Delgado, N; Habib, MR; Miller, MW; Mohamed, AH; Mossalem, HS; Osman, GY; Rolón-Martínez, S; Sharaf El-Din, AT; Torres, G, 2015)
"Histamine is a mediator of allergic inflammation released mainly from mast cells. "	( Ashina, K; Hori, M; Kobayashi, K; Murata, T; Nakamura, T; Omori, K; Ozaki, H; Tsubosaka, Y, 2015)
"Histamine is a biogenic amine that is widely distributed and has multiple functions, but the role it plays in acute myocardial infarction (AMI) remains unclear. "	( Chen, J; Deng, L; Ding, S; Ge, J; Hong, T; Huang, Z; Jia, J; Lin, J; Wang, TC; Yang, X; Zou, Y, 2015)
"Histamine (HA) is a small amine playing an important role in anaphylactic reactions. "	( Amé-Thomas, P; Bendavid, C; Gicquel, T; Laurichesse, M; Moreau, C; Morel, I; Tarte, K; Tribut, O, 2016)
"Histamine is an endogenous nitrogenous compound with extensive effects on immunologic cells and involved in many physiological functions. "	( Cheng, X; He, L; Jia, Y; Li, J; Li, Y; Yang, D, 2015)
"Histamine is an important pleiotropic factor in neuroimmune regulation."	( Aliev, G; Cacabelos, R; Fernández-Novoa, L; Torrellas, C, 2016)
"Histamine is an important chemical messenger that regulates multiple physiological processes in both vertebrate and invertebrate animals. "	( An, F; Borycz, J; Borycz, JA; Meinertzhagen, IA; Wang, T; Xu, Y, 2015)
"Histamine is a neurotransmitter crucial to the visual processing of Drosophila melanogaster. "	( Borman, RP; Denno, ME; Privman, E; Venton, BJ; Wolin, DC, 2016)
"Histamine is an imidazolic compound performing a crucial function in the pathogenesis of inflammation. "	( Barone, M; Di Leo, A; Girardi, B; Ierardi, E; Losurdo, G; Pricci, M; Principi, M, 2018)
"Histamine is a primordial signalling molecule, capable of activating cells in an autocrine or paracrine fashion via specific cell surface receptors, in a variety of pathways that probably predate its more recent role in innate and adaptive immunity. "	( Dreyer, HC; Ely, MR; Halliwill, JR; Hocker, AD; Luttrell, MJ; Mangum, JE; Romero, SA; Sieck, DC; Struck, AJ; Turnbull, DW, 2016)
"Histamine is a primordial signalling molecule, capable of activating cells in an autocrine or paracrine fashion via specific cell surface receptors. "	( Dreyer, HC; Ely, MR; Halliwill, JR; Hocker, AD; Luttrell, MJ; Mangum, JE; Romero, SA; Sieck, DC; Struck, AJ; Turnbull, DW, 2016)
"Histamine is a biogenic molecule that plays a role in many physiological pathways via binding to a specific receptor. "	( Cima, F; Franchi, N, 2016)
"Histamine is an important neurotransmitter that exerts its physiological actions through H1-4 metabotropic receptors in mammals. "	( Ernst, M; Fleck, MW; Hoerbelt, P; Hough, LB; Ramerstorfer, J; Sieghart, W; Thomson, JL, 2016)
"Histamine (HA) is a pleiotropic monoamine involved in several neurophysiological functions, neuroimmune regulation, and CNS pathogenesis."	( Cacabelos, R; Fernández-Novoa, L; López-Muñoz, F; Torrellas, C, 2016)
"Histamine is a potent vasodilator that has been found to increase during exercise. "	( Choi, HM; Doh, HW; Kim, JK; Nho, H; Park, J; Stebbins, CL, 2016)
"Histamine is an amine widely known as a peripheral inflammatory mediator and as a neurotransmitter in the central nervous system. "	( Alves, G; Bernardino, L; Cortes, L; Cristóvão, AC; Esteves, M; Ferreira, R; Je, G; Kim, YS; Klibanov, A; Rocha, SM; Santos, T; Saraiva, C; Saraiva, T; Valero, J, 2016)
"Histamine is a key immunoregulatory mediator in immediate-type hypersensitivity reactions and chronic inflammatory responses, in particular histamine suppresses proinflammatory responses to bacterial ligands, through histamine receptor 2 (H2R). "	( Akdis, CA; Ferstl, R; Frei, R; Groeger, D; Jutel, M; Konieczna, P; OʼMahony, L; Perez, NR; Schiavi, E; Smolinska, S, 2016)
"Low-histamine diet is a therapeutically useful, simple and cost-free tool to decrease symptoms and increase quality of life in CsU patients with gastrointestinal involvement. "	( Dirk, D; Mitzel, H; Peveling-Oberhag, A; Rady-Pizarro, U; Reese, I; Staubach, P; Wagner, N, 2017)
"Histamine is an aminergic neurotransmitter, which regulates wakefulness, arousal and attention in the central nervous system. "	( Andersson, R; Fisahn, A; Galter, D; Papadia, D, 2017)
"Histamine is a transmitter in the nervous system and a signaling molecule in the gut, the skin, and the immune system. "	( Haas, HL; Selbach, O; Sergeeva, OA, 2008)
"Histamine (HA) is an important neuro-modulator, contributing to a variety of physiological responses in the mammalian central nervous system (CNS). "	( Akaike, H; Akaike, N; Ito, Y; Ogawa, S; Wang, ZM; Watanabe, T; Yanai, K, 2009)
"Histamine (HA) is a biogenic amine with multiple activities in the immune system. "	( Diem, S; Dy, M; Leite-de-Moraes, MC; Michel, ML; Ohtsu, H; Schneider, E; Thurmond, RL, 2009)
"As histamine is a wake-promoting amine known to decrease during sleep, decreased histamine could either passively reflect or partially mediate daytime sleepiness in these pathologies."	( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009)
"Histamine is a recognized growth factor in melanoma, and exogenous histamine produces a dual effect on proliferation. "	( Bergoc, RM; Cricco, GP; Martín, GA; Massari, NA; Medina, VA; Rivera, ES, 2009)
"Histamine is a typical chemical mediator involved in allergic conjunctivitis and induces hyperemia."	( Fukushima, A; Tomita, T, 2009)
"Histamine is a biogenic amine that has been shown to contribute to several pathological conditions, such as allergic conditions, experimental encephalomyelitis, and malaria. "	( Arrang, JM; Beghdadi, W; Dubayle, D; Dy, M; Louis, J; Mécheri, S; Morisset, S; Peronet, R; Porcherie, A; Schneider, BS, 2009)
"Histamine is a key inflammatory mediator derived from L: -histidine that governs vital cellular processes beyond inflammation, while recent evidence implies additional actions in both prokaryotes and eukaryotes."	( Delitheos, B; Papamichael, K; Tiligada, E, 2010)
"Histamine is a potent mediator in allergic inflammatory processes and is released by basophils and mast cells. "	( Kamitani, S; Kawasaki, S; Kohyama, T; Nagase, T; Takizawa, H; Yamauchi, Y, 2010)
"Histamine intolerance is a clinically heterogeneous disease. "	( Herbst, RA; Peters, KP; Stolze, I, 2010)
"Histamine is a well known mediator of allergic skin diseases and, with the discovery of the histamine H(4) receptor, the role of histamine is re-evaluated. "	( Bäumer, W; Kietzmann, M; Leurs, R; Rossbach, K; Sander, K; Stark, H, 2009)
"Histamine is a powerful modulator that regulates blood vessels and blood flow. "	( Chen, XL; Liu, Y; Tian, YM; Yang, PB; Zhang, JF; Zhang, JS; Zhao, JJ, 2010)
"Histamine is an important biogenic amine, which acts with a group of four G-protein coupled receptors (GPCRs), namely H(1) to H(4) (H(1)R - H(4)R) receptors. "	( Brandt, CA; Fernandes, JP; Ferreira, EI; Pasqualoto, KF, 2011)
"As histamine is an important regulator of allergic inflammation we investigated the role of histamine receptors, particularly the most recently identified histamine H(4) receptor (H(4) R), in modulating the pro-inflammatory function of slanDC."	( Gschwandtner, M; Gutzmer, R; Schäkel, K; Werfel, T, 2011)
"Histamine is an endogenous biogenic amine that is synthesized from the basic amino acid histidine. "	( Coskun, M; Elpek, GO; Keles, N; Yavuz Arican, R, 2012)
"Histamine is a biological amine that plays an important role in allergic responses. "	( Fujimoto, S; Kagami, S; Karakawa, M; Komine, M; Ohtsuki, M; Saeki, H; Tada, Y; Tamaki, K; Uratsuji, H, 2011)
"Histamine is an important inflammatory mediator in allergic conjunctivitis. "	( Choi, SH; Chung, SH; Jeon, S; Seo, KY, 2011)
"Histamine is a neurotransmitter and inflammation mediator, which at physiological pH conditions is present mainly in monocationic form."	( Grdadolnik, J; Maksić, ZB; Mavri, J; Stare, J; Vianello, R; Zidar, J, 2011)
"Histamine is a ubiquitous inflammatory mediator intimately associated with the pathology of allergy. "	( Dunford, PJ; Holgate, ST, 2010)
"Histamine is a biogenic amine widely distributed throughout the body. "	( Darvas, Z; Falus, A; Pós, Z, 2010)
"Histamine is an important wake-promoting neurotransmitter that activates seven-transmembrane G-protein coupled histamine receptors. "	( Bianchi, MT; Clark, AG; Fisher, JL, 2011)
"Histamine is a biogenic amine with extensive effects on many cell types, including important immunologic cells, such as antigen-presenting cells, natural killer cells, epithelial cells, and T and B lymphocytes. "	( Akdis, CA; Akdis, M; O'Mahony, L, 2011)
"Histamine is a bioactive amine that exerts immunomodulatory functions, including many allergic symptoms. "	( Bryce, PJ; Smuda, C; Wechsler, JB, 2011)
"Histamine is an important allergic mediator, and studies have defined roles for both histamine 1 and 4 receptors in allergic airway inflammation. "	( Bryce, PJ; Byrne, AJ; Swartzendruber, JA, 2012)
"Histamine is a key mediator governing vital cellular processes in mammals beyond its decisive role in inflammation. "	( Kyriakidis, DA; Theodorou, MC; Tiligada, E, 2012)
"Histamine is a regulator of the microcirculation (which performs these exchanges), suggesting a possible involvement of histamine in exercise."	( Endo, Y; Niijima-Yaoita, F; Ohtsu, H; Sugawara, S; Tadano, T; Tsuchiya, M; Yanai, K, 2012)
"Histamine is an established growth factor for gastrointestinal malignancies. "	( Fang, Z; Li, J; Li, M; Liu, L; Wang, L; Wang, W; Xiong, Y; Yang, Y; Zhang, C, 2012)
"Histamine is a potent mediator in allergic inflammation with immunomodulatory properties. "	( Bäumer, W; Bunk, H; Gschwandtner, M; Gutzmer, R; Kietzmann, M; Köther, B; Thurmond, RL; Werfel, T, 2012)
"Histamine is a biogenic amine performing pleiotropic effects in humans, involving tasks within the immune and neuroendocrine systems, neurotransmission, gastric secretion, cell life and death, and development. "	( Melgarejo, E; Pino-Ángeles, A; Reyes-Palomares, A; Sánchez-Jiménez, F, 2012)
"Histamine is a mediator of inflammation in allergic disease and asthma. "	( Dandekar, RD; Khan, MM, 2012)
"Histamine is an essential factor in the ascending arousal system (AAS) during motivated behaviors. "	( Panula, P; Sundvik, M, 2012)
"Histamine is an important inflammatory mediator during the early phase of allergic response and antihistamine is known to have an ability to reduce mucus secretion in inflamed airways. "	( Kim, HM; Lee, CH; Rhee, CS, 2012)
"Histamine is a biogenic amine with fundamental roles in circulatory and immune systems. "	( Chang, YT; Kielland, N; Lavilla, R; Vendrell, M, 2012)
"Histamine contamination is a food safety issue with this product that is manufactured from tuna fish that has been temperature abused."	( Bremer, PJ; Fletcher, GC; Flint, S; Meerdink, G; Naila, A, 2012)
"Histamine is a biogenic amine that forms in a variety of foods and can cause food poisoning at high concentrations (>500 ppm). "	( Bremer, PJ; Fletcher, GC; Flint, S; Meerdink, G; Morton, RH; Naila, A, 2012)
"Histamine is an important non-neural mediator of asthma from mast cells."	( Fu, YS; Guo, JJ; Huang, HT; Huang, YH, 2013)
"Histamine is a biogenic amine that exerts its biological effects as a neurotransmitter and local mediator via four histamine receptor (HR) subtypes (H(x)Rs) - H(1)R, H(2)R, H(3)R, and H(4)R - belonging to the superfamily of G-protein-coupled receptors (GPCRs). "	( Buschauer, A; Schneider, EH; Seifert, R; Strasser, A; Wittmann, HJ, 2013)
"Histamine is a biogenic amine that is indispensable in the efficient functioning of various physiological systems. "	( Cleij, TJ; Ingebrandt, S; Mingels, RH; Peeters, M; Thoelen, R; Troost, FJ; van Grinsven, B; Vranken, T; Wagner, P; Welsch, T, 2013)
"Histamine is a potent vasoactive agent, bronchial smooth muscle constrictor, and stimulant of nociceptive itch nerves. "	( Baraniuk, JN; Repka-Ramirez, MS, 2002)
"Histamine is a primary mediator of anaphylaxis and signs and symptoms of anaphylaxis can be reproduced by histamine infusion."	( Lieberman, PL; Winbery, SL, 2002)
"Histamine is a potent bioamine with multiple activities in various pathological and physiological conditions. "	( Akdis, CA; Akdis, M; Blaser, K; Jutel, M; Watanabe, T, 2002)
"Histamine is an aminergic neurotransmitter that is localized in the CNS and in peripheral tissues. "	( Ishikawa, T; Kotani, H; Suwa, H; Takahashi, K, 2002)
"Histamine (HA), which acts as a neurotransmitter in the central nervous system, has also been shown to be involved in feeding and exerts an inhibitory effect through activation of H(1) receptors."	( Kjaer, A; Knigge, U; Toftegaard, CL; Warberg, J, 2003)
"Histamine acts as a neurotransmitter in the brain and regulates e.g. "	( Kukko-Lukjanov, TK; Panula, P, 2003)
"Histamine is an important mediator released from activated mast cells provoked by allergen and has a substantial role in the pathophysiology of asthma. "	( Appel, J; Buzás, E; Falus, A; Keszei, M; Komlósi, Z; Kozma, GT; Losonczy, G; Magyar, P; Pállinger, E; Szabó, T; Szalai, C, 2003)
"Histamine release is a well known side effect of polygeline and - to a lesser extent - also of albumin, but was a novel finding for hydroxyethyl starch."	( Celik, I; Duda, D; Gajek, H; Kimura, K; Lorenz, W; Stinner, B, 2003)
"Histamine signaling is a principal regulator in a variety of pathophysiological processes including inflammation, gastric acid secretion, neurotransmission, and tumor growth. "	( Diab, RM; Diks, SH; Hardwick, JC; Peppelenbosch, MP; Richel, DJ; van Deventer, SJ; van Santen, MM; Versteeg, HH, 2003)
"Histamine is a biogenic amine with multiple physiological functions. "	( Falus, A; Fülöp, AK; Hegyi, K; Monostory, K; Tamási, V, 2003)
"Histamine is a biogenic amine synthesized by the enzymatic decarboxylation of histidine. "	( Claret, EJ; Ouled-Diaf, J; Seguin, P, 2003)
"Histamine is a neurotransmitter with actions throughout the nervous system of vertebrates and invertebrates. "	( Beenhakker, MP; Christie, AE; Marder, E; Nusbaum, MP; Quinlan, JE; Stein, W, 2004)
"Histamine is an important mast cell- and basophil-derived mediator that has been implicated in the pathogenesis of asthma, resulting in smooth muscle contraction, mucus hypersecretion, and increased vascular permeability leading to mucosal edema."	( Walsh, GM, 2002)
"Histamine is a potent activator of human colon mast cells, which represents a novel and pivotal self-amplification mechanism of mast cell degranulation."	( He, SH; Xie, H, 2004)
"Histamine is a versatile mediator that, according to in vitro studies, affects the synthesis of inflammatory cytokines and acute-phase proteins. "	( Donászi-Ivanov, A; Falus, A; Fülöp, AK; Scharek, P, 2004)
"Histamine is a degradation product of the bacterial decarboxylation of the amino acid histidine, which is present in large amounts in fish tissues of the Clupeidae and Scombridae families and its presence is an indicator of good manufacturing practices and of the state of preservation of some food. "	( Baccelliere, R; Calì, A; Cinquina, AL; Cozzani, R; De Santis, L; Longo, F, 2004)
"Histamine is a downstream effector of leptin as its release, metabolism is enhanced by leptin and hypothalamic histamine reduces food intake."	( Falus, A; Fülöp, KA; Hegyi, K; Kovács, KJ; Tóth, S, 2004)
"Histamine is an important agent of innate immunity, transiently increasing the flux of immune-competent molecules from the vascular space to the tissues and then allowing rapid restoration of the integrity of the endothelial barrier. "	( Ries, DR; Shasby, DM; Shasby, SS; Winter, MC, 2004)
"Histamine is a potent stimulator of arginine vasopressin (AVP) release and therefore, the role of AVP was studied in the reversal of critical haemorrhagic hypotension induced by endogenous central histamine after inhibition of histamine N-methyltransferase (HNMT) activity in rats."	( Jochem, J, 2004)
"Histamine is a major inflammatory molecule released from the mast cell, and is known to activate endothelial cells. "	( B Filla, M; Dileepan, KN; Kabir, MH; Stechschulte, DJ; Talreja, J, 2004)
"Histamine is an inflammatory agent that contributes to bovine laminitis. "	( Garner, MR; Gronquist, MR; Russell, JB, 2004)
"Histamine acts as a neurotransmitter of photoreceptors in insects and other arthropods, where it directly activates a chloride channel and mediates rapid inhibitory responses. "	( Gisselmann, G; Hatt, H; Plonka, J; Pusch, H, 2004)
"Histamine is a multifunctional biogenic amine with relevant roles in intercellular communication, inflammatory processes and highly prevalent pathologies. "	( Medina, MA; Moya-Garcia, AA; Sánchez-Jiménez, F, 2005)
"Histamine is a key mediator of the allergic immediate reaction. "	( Riechelmann, H, 2005)
"Histamine is a central neurotransmitter, it increases arousal via H1 receptors. "	( Pérez-Ordaz, L; Poitevin, B; Ruiz-Vega, G, 2005)
"Histamine is an important mediator contributing to oedema formation after thermal injury. "	( Alhava, E; Härmä, M; Harvima, R; Lahtinen, T; Papp, A; Uusaro, A, 2005)
"Histamine is a major mediator in allergic diseases, and has multiple effects that are mediated by specific surface receptors on target cells."	( He, SH; Xie, H, 2005)
"Histamine is an inflammation mediator that is fundamental for the development of some allergic reactions and is also implied in several common dermatological affections. "	( Gaudy-Marqueste, C; Grob, JJ; Richard, MA, 2005)
"Histamine is an important mediator in airway inflammation. "	( Wilson, AM, 2006)
"Histamine is an essential mediator and marker of basophils and is highly up-regulated in CML."	( Agis, H; Aichberger, KJ; Bilban, M; Derdak, S; Esterbauer, H; Falus, A; Florian, S; Gleixner, KV; Krauth, MT; Mayerhofer, M; Pickl, WF; Sillaber, C; Sonneck, K; Valent, P; Vales, A, 2006)
"Histamine is a potent stimulator of nerve growth factor (NGF) production in the central nerve system and in the periphery as well. "	( Lipnik-Stangelj, M, 2006)
"Histamine is a well-known mediator of allergic, inflammatory, and neurological responses. "	( August, EM; Brown, M; Gautschi, E; Hopkins, J; Kabcenell, A; Kronkaitis, A; Patnaude, L; Rajotte, D; Shrutkowski, A; Studts, J, 2006)
"Histamine is a biogenic amine responsible for multiple biological actions including regulation of physiological functions of mammary gland. "	( Bergoc, R; Correa-Fiz, F; Cricco, G; Martín, G; Medina, V; Mohamad, N; Nuñez, M; Rivera, ES; Sanchez-Jimenez, F, 2006)
"Histamine is a well-known mediator eliciting a broad range of responses in different cell types. "	( Bayer, H; Idzko, M; Müller, T; Myrtek, D; Norgauer, J; Schneider, K; Sorichter, S; Zissel, G, 2006)
"Histamine is a low-molecular-weight amine, synthesized from l-histidine by histidine decarboxylase. "	( Ohtsu, H; Sasaguri, Y; Tanimoto, A, 2006)
"Histamine is a well-known inflammatory mediator exerting various immunomodulatory effects and affecting the development of antigen-specific immune responses. "	( Buzás, E; Falus, A; Hangya, B; Horváth, Z; Jelinek, I; László, V; Pállinger, E, 2007)
"Histamine is a potent mediator of itch in humans, yet histamine H(1) receptor antagonists have been shown to be of limited use in the treatment of certain chronic pruritic diseases. "	( Desai, PJ; Dunford, PJ; Karlsson, L; McQueen, D; Thurmond, RL; Williams, KN, 2007)
"Histamine is a bioactive amine acting as a neurotransmitter as well as a chemical mediator."	( Kikuzaki, H; Nitta, Y; Ueno, H, 2007)
"Histamine is an important mediator of inflammatory and allergic responses."	( Katoh, N; Kishimoto, S; Soga, F, 2007)
"Histamine is a major mediator in allergy acting mainly through the histamine H(1) receptor (H1R). "	( Das, AK; Dev, S; Fujimoto, K; Fukui, H; Horio, S; Kitamura, Y; Mishima, R; Mizuguchi, H; Takeda, N; Wakayama, Y; Yoshimura, S, 2007)
"As histamine is a key mediator of allergic reactions, we investigated whether histamine is involved in airway remodeling."	( Akdis, CA; Azzi, A; Blaser, K; Kramer, BW; Kunzmann, S; Schmidt-Weber, C; Speer, CP; Zingg, JM, 2007)
"Histamine is a primary mediator of the inflammatory response in mammals. "	( Baird, AW; Campion, DP; Collins, CB; McGrath, J, 2007)
"Histamine is a biogenic amine that occurs to various degrees in many foods."	( Maintz, L; Novak, N, 2007)
"The histamine H(3) receptor is a constitutively active G protein-coupled receptor for the neurotransmitter histamine that serves a negative feedback function. "	( Pfankuch, T; Raber, J; van Meer, P, 2007)
"Histamine is an important inflammatory mediator and associated with early phase allergic response. "	( Kim, SW; Kim, YM; Lee, CH; Min, YG; Rhee, CS; Won, TB, 2007)
"Histamine is a major mast cell mediator of immunoneural signalling in the gut and mast cells play a role in the pathophysiology of functional and inflammatory bowel diseases. "	( Breunig, E; Michel, K; Schemann, M; Seidl, S; Weyhern, CW; Zeller, F, 2007)
"Histamine is a known inducer of cAMP-responsive element binding protein (CREB), which plays a key role in initiation of adipogenesis. "	( Falus, A; Hegyi, K; Toth, S, 2007)
"Histamine is a neurotransmitter and neuromodulator within the central nervous system that affects the regulation of food intake and obesity. "	( Masaki, T; Yoshimatsu, H, 2007)
"Histamine is a major autacoid released during allergic reactions. "	( Taylor-Clark, TE, 2008)
"Histamine is an important mediator in immune responses, but it is unclear whether periodontal tissues express histamine receptors and are able to respond to histamine. "	( Endo, Y; Kuroishi, T; Minami, T; Ozawa, A; Shimauchi, H; Sugawara, S, 2007)
"Histamine is a key regulator of the immune system. "	( Buzas, E; Falus, A; Fazakas, F; Koncz, A; Mazan, M; Nagy, G; Pasztoi, M, 2007)
"Histamine is proved to be an important substance that controls body temperature and respiration in systemic anaphylaxis but its role in controlling blood pressure is minor."	( Ohtsu, H, 2008)
"Histamine is a putative neurotransmitter in mammals and molluscs, but its role in the nervous systems of other animals is not known. "	( Claiborne, BJ; Selverston, AI, 1984)
"Histamine is a potent mediator of immediate hypersensitivity reactions, and is stored primarily in mast cells and basophils. "	( Marquardt, DL, 1983)
"Histamine challenge is a satisfactory method of assessing the proective effect of a drug in asthmatic children."	( Martin, AJ; Pullan, CR, 1980)
"Histamine is an important amine within the lung. "	( Aroyave, CM; Newman, JH; Reeves, JT; Voelkel, NF, 1981)
"histamine infusion test is a useful model for the study of experimental vascular headache."	( Krabbe, AA; Olesen, J, 1980)
"The histamine H2 receptor is a member of the family of G-protein-coupled receptors, and has three extracellular potential sites for N-glycosylation (Asn-4, Asn-162 and Asn-168)."	( Asano, T; Fukushima, Y; Katagiri, H; Matsuhashi, N; Oka, Y; Saitoh, T; Sugano, K; Takata, K; van Breda, E; Yazaki, Y, 1995)
"Histamine is a known chromaffin cell secretagogue that induces Ca(2+) -dependent release of catecholamines. "	( Rodríguez Del Castillo, A; Trifaró, JM; Zhang, L, 1995)
"Histamine (HA) acts as a neurotransmitter and/or neuromodulator in mammalian brain. "	( Alvarez, XA; Cacabelos, R; Fernández-Novoa, L; Franco, A, 1994)
"Histamine is an accepted neurotransmitter and/or neuromodulator in the central nervous system (CNS). "	( Nowak, JZ, 1994)
"Histamine is a paracrine messenger in the communication network."	( Cooke, HJ; Frieling, T; Wood, JD, 1994)
"Histamine is a vasoactive amine which is endogenously produced in many organs including the penis."	( Carson, CC; Davies, MG; Hagen, PO; Kim, YC; Lee, TH, 1995)
"Histamine (HA) is a biogenic amine involved in the regulation of neurovegetative, cognitive, neuroendocrine and neuroimmune functions in the central nervous system (CNS). "	( Alvarez, XA; Cacabelos, R; Fernández-Novoa, L; Franco, A, 1994)
"Histamine (HA) is a known neurotransmitter with a wide spectrum of biological actions at the central and peripheral levels. "	( Alvarez, XA; Caamaño, J; Cacabelos, R; Fernández-Novoa, L; Franco-Maside, A, 1994)
"Histamine is a major mediator of the mast cells that are present between epithelial cells in asthma. "	( Bousquet, J; Campbell, AM; Chanez, P; Godard, P; Lacoste, P; Michel, FB; Vignola, AM, 1993)
"Histamine is a potent vasodilatory substance released during anaphylaxis. "	( Bedarida, G; Blaschke, TF; Dachman, WD; Hoffman, BB, 1994)
"Histamine is an important mediator of allergic inflammation and bronchial hyperresponsiveness (BHR), a hallmark of asthma. "	( Bury, T; Corhay, JL; Louis, R; Radermecker, MF, 1993)
"Histamine is a neuromodulator in the brain, and the hippocampus is one of the regions of the brain that is innervated by histaminergic neurons. "	( Bekkers, JM, 1993)
"Histamine poisoning is a foodborne chemical intoxication resulting from the ingestion of food products containing high levels of histamine. "	( Fonberg-Broczek, M; Sawilska-Rautenstrauch, D, 1995)
"Histamine is considered to be an activator of cells with suppressive capacity. "	( Arad, G; Kaempfer, R; Na'amad, M; Nussinovich, R, 1996)
"Histamine is an established growth factor for gastric and colorectal cancer. "	( Akhter, J; Morris, DL; Reynolds, JL, 1996)
"The histamine H2 receptor is a member of the family of G-protein-coupled receptors and is linked to the activation of adenylate cyclase phospholipase C (PLC). "	( Aihara, M; Anai, M; Asano, T; Fukushima, Y; Funaki, M; Inukai, K; Katagiri, H; Matsuhashi, N; Ogihara, T; Oka, Y; Saitoh, T; Sugano, K; Yazaki, Y, 1996)
"Histamine is a forceful stimulus for inducing ETIA. "	( Folgering, HT; Luijendijk, SC; Meessen, NE; van der Grinten, CP, 1996)
"Histamine serves as a neurotransmitter and neuromodulator in the brain."	( Linday, LA, 1997)
"Histamine is a mediator in allergic respiratory diseases."	( Janardhana Rao, G, 1997)
"Histamine is a potent activator of endothelial cells (EC): it induces the expression of P-selectin on the surface of endothelium and the secretion of IL-6 and IL-8."	( Czarlewski, W; Gosset, P; Lassalle, P; Molet, S; Tonnel, AB, 1997)
"Histamine is known to be a neurotransmitter in the brain, but it has not been clearly implicated in major diseases. "	( Eriksson, KS; Kalimo, H; Kuokkanen, K; Panula, P; Relja, M; Rinne, J; Sallmen, T, 1998)
"Histamine is a critical mediator of immediate hypersensitivity reactions. "	( Esteve, H; Hsieh, L; Knippenberg, R; Kudlacz, E; Logan, D; Maynard, G; Olsen, K; Shatzer, S, 1998)
"Histamine is an important mediator in allergic reactions, gastric acid secretions, and neurotransmission in the central nervous system. "	( Butterfield, JH; Maeda, K; Ohno, I; Ohtsu, H; Sakurai, E; Shirato, K; Taniguchi, H; Tanno, Y; Watanabe, T; Yamauchi, K, 1998)
"Histamine is a general dilator of rat blood vessels. "	( Adeagbo, AS; Oriowo, MA, 1998)
"Histamine is an important mediator released from activated mast cells in acute bronchoconstriction provoked by allergen, exercise, hypertonic stimuli and inhaled adenosine. "	( Holgate, ST, 1999)
"Histamine is an inflammatory mediator produced by mast cells that reside close to blood vessels. "	( Al-Naemi, H; Baldwin, AL, 1999)
"Histamine is a known secretagogue in adrenal chromaffin cells. "	( Currie, KP; Fox, AP, 2000)
"Histamine is a potent facilitating agent."	( Baredes, S; Chandrasekhar, SS; Connelly, PE; Gatz, M; Huang, E; Kwartler, JA; Rubinstein, RY, 2000)
"Thus histamine is a very important modulator of Th1 cytokine production in PBMCs and is quite unique in triggering IL-18-initiating cytokine cascade without inducing IL-12 production."	( Akagi, T; Iwagaki, H; Kobashi, K; Kohka, H; Nakaya, N; Nishibori, M; Saeki, K; Tanaka, N; Yoshino, T, 2000)
"Histamine is a central nervous system (CNS) neurotransmitter that has been implicated in the pathophysiology of schizophrenia. "	( Lachman, HM; Rice, SR; Sobell, JL; Szumlanski, CL; Weinshilboum, RM; Yan, L, 2000)
"Histamine is an inflammatory mediator present in mast cells, which are abundant in the wall of the gallbladder. "	( Firth, TA; Guarraci, FA; Hemming, JM; Jennings, LJ; Mawe, GM; Nelson, MT, 2000)
"Histamine is a cation at neutral pH, but chlorination eliminated the charge on the amino group and shifted the pKa of the imidazole ring, resulting in formation of neutral histamine-chloramines."	( Dabbous, MK; Jefferson, MM; King, CC; Learn, DB; Thomas, EL, 2000)
"Histamine is a neurotransmitter at arthropod photoreceptors. "	( Borycz, J; Meinertzhagen, IA; Tokarczyk, G; Vohra, M, 2000)
"Histamine is an important mediator in the pathogenesis of nasal allergy."	( Fujikura, T; Shimosawa, T; Yakuo, I, 2001)
"Histamine is a well known mediator of inflammation including the allergic reaction. "	( Kohka-Takahashi, H; Mori, S; Nishibori, M, 2001)
"Histamine is a classical, but still interesting inflammatory mediator. "	( Endo, Y, 2001)
"As histamine is a key inflammatory mediator in cattle, while serotonin takes on this role in rodents, the diversification of these tick proteins may reflect host adaptation."	( Nuttall, PA; Paesen, GC; Sangamnatdej, S; Slovak, M, 2002)
"Histamine is a well-known mediator of inflammatory and allergic reactions and has immunomodulatory capacities. "	( Gutzmer, R; Kapp, A; Langer, K; Lisewski, M; Mommert, S; Rieckborn, D; Werfel, T, 2002)
"Histamine also functions as a bioprotection system against various noxious and unfavorable stimuli (for examples, convulsion, nociception, drug sensitization, ischemic lesions, and stress)."	( Watanabe, T; Yanai, K, 2001)
"Histamine is a well-known mediator eliciting different responses in immune and nonimmune cells, but its role in modulating dendritic cell (DC) functions has been marginally investigated."	( Di Virgilio, F; Dichmann, S; Ferrari, D; Girolomoni, G; Herouy, Y; Idzko, M; la Sala, A; Mockenhaupt, M; Norgauer, J; Panther, E, 2002)
"The histamine H4 receptor is a novel G-protein-coupled receptor with a unique pharmacological profile. "	( Bayne, M; Coates, E; Monsma, FJ; Morse, KL; Murgolo, NJ; Shin, N; Strader, CD, 2002)
"Histamine is a ubiquitous biogenic amine involved in the regulation of numerous basic physiological and pathophysiological processes. "	( Falus, A; Fitzimons, CP; Igaz, P; Szalai, C, 2002)
"A histaminergic pathway is an attractive possibility to explain the excitatory response, because both pyrilamine and cimetidine inhibit the thyrotropin-releasing hormone induced response and the peptide has no further influence on antral motility after the tissue is exposed to a supramaximal concentration of histamine."	( Behsudi, FM; Bruce, LA; Fawcett, CP, 1979)
"Histamine is an important mediator of asthma. "	( Bousquet, J; Godard, P; Michel, FB, 1992)
"Histamine was found to be a potent stimulus for acid secretion in 1920. "	( Obrink, KJ, 1991)
"Histamine is thought to be a neuroactive substance in the brain and have various physiological functions such as biological rhythms and autonomic regulation. "	( Tamiya, R, 1991)
"Histamine is known to be a classical inducer of pruritus. "	( Behrendt, H; Ring, J, 1990)
"Histamine is known to be a mediator of inflammation. "	( Kajiyama, Y; Murayama, T; Nomura, Y, 1990)
"Histamine was found to be a potent activator of phospholipase C, leading to polyphosphoinositide hydrolysis and subsequent intracellular Ca2+ mobilization."	( de Laat, SW; Ladoux, A; Moolenaar, WH; Remorie, R; Tertoolen, LG; Tilly, BC; Verlaan, I, 1990)
"Histamine (HA), which acts as a neurotransmitter in the central nervous system, participates in the neuroendocrine regulation of prolactin (PRL) secretion. "	( Knigge, UP, 1990)
"Histamine release is a frequent event in the perioperative period. "	( Doenicke, A; Lorenz, W, 1985)
"Histamine is an important pro-inflammatory molecule mediating leukocyte margination, plasma extravasation and vasodilation, but its precise mode of action on vascular endothelium is unclear. "	( Bull, HA; Dowd, PM; Rustin, MH, 1989)
"Histamine (HA) is a neurotransmitter present in the brain. "	( Itoh, Y; Nishibori, M; Oishi, R; Saeki, K, 1985)
"Histamine is a 4-substituted imidazole and a preliminary study has shown it to be an inhibitor of rat liver microsomal drug oxidation."	( Crewe, HK; Harlow, JR; Lennard, MS; Morris, CQ; Tucker, GT; Woods, HF, 1989)
"Histamine is a major mediator of the allergic reactions. "	( Ruff, F; Santais, MC, 1988)
"Histamine is an impressive modulator of immune functions at least via its effects on lymphoid cells. "	( Bristow, MR; Goodman, M; Khan, MM; Marr-Leisy, D; Melmon, KL; Strober, S; Verlander, MS, 1986)
"Histamine is alleged to be a potential inducing factor for degrading enzymes."	( Dastych, J; Fogel, WA; Maśliński, C, 1988)
"Histamine is a widely distributed amine with many functions, both physiological and pathological. "	( Withington, DE, 1988)
"Histamine is a potent secretagogue for opioid pentapeptides (Met- and Leu-enkephalin) in adrenal chromaffin cells in vitro. "	( Bommer, M; Herz, A; Kley, N; Liebisch, D; Noble, E, 1987)

Effects

Excerpt	Reference
"Histamine has an impact on the gene expression profile of macrophages during compressive strain in vitro, most likely having an impairing effect on orthodontic tooth movement by upregulation of osteoprotegerin expression."	( Damanaki, A; Jantsch, J; Kirschneck, C; Petring, C; Proff, P; Schröder, A, 2022)
"The histaminergic system has a role in the treatment of brain disorders by the development of histamine receptor agonists, antagonists."	( Mirshafiey, A; Naddafi, F, 2013)
"Histamine has a selective affinity for H3 receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology."	( Barreto-Vizcaíno, S; Isais-Millán, S; Millán-Guerrero, RO; Rios-Madariaga, C; Rivera-Castaño, L, 2009)
"Histamine has a direct suppressive effect on IEL-derived cytokines via H(2)R, which would have a crucial role in the suppression of local immunoregulation in the intestinal epithelium."	( Furuta, T; Hamaya, Y; Hishida, A; Horio, Y; Ikuma, M; Osawa, S; Takagaki, K; Takayanagi, Y; Yamada, T, 2009)
"Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure. "	( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010)
"CSF histamine has a robust daily rhythm, with a mean of 24.9 ± 3.29 pg mL(-1) , amplitude of 31.7 ± 6.46 pg mL(-1) and a peak at 17:49 ± 70.3 min (lights on 07:00-19:00 hours)."	( Buckmaster, CL; Honda, Y; Kodama, T; Lyons, DM; Mignot, E; Nishino, S; Zeitzer, JM, 2012)
"Histamine has a variety of airway actions and is considered to be an important mediator in asthma. "	( Hattori, T; Ichinose, M; Ishigaki-Suzuki, S; Koarai, A; Kuramasu, A; Makabe-Kobayashi, Y; Ohtsu, H; Sakurai, E; Shirato, K; Sugiura, H; Watanabe, T; Yamagata, S, 2003)
"Histamine has a short-term, transient, stimulating effect on endothelial nitric oxide synthase (eNOS) activity; however, long-term effects on eNOS have not been described yet. "	( Brausch, I; Burkhardt, C; Förstermann, U; Heinrich, UR; Li, H; Xia, N, 2003)
"Histamine has an important role in the development of gastric ulcers and mast cell derived histamine might be essential in this process."	( Aboul-Enein, HY; Tunçel, M; Tunçel, N, 2003)
"Histamine has a recognised role in allergic and inflammatory reactions, and is reported to affect several aspects of chondrocyte behaviour."	( Tetlow, LC; Woolley, DE, 2005)
"Histamine has an important role in regulation of immune response which is mediated by differential expression of four distinct receptors, H1R-H4R. "	( Center, DM; Cross, L; Cruikshank, WW; Green, DS; Kornfeld, H; McAllister, B; Morgan, RK, 2007)
"Histamine has a selective affinity for H3-receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology. "	( Barreto-Vizcaíno, S; Garcia-Solorzano, A; Isais-Millán, R; López-Blanca, C; Membrila-Maldonado, M; Millán-Guerrero, RO; Muñoz-Solis, R; Rivera-Castaño, L, 2007)
"Histamine has a key role in allergic inflammatory conditions. "	( Dunford, PJ; Gelfand, EW; Thurmond, RL, 2008)
"Histamine has a selective affinity for H3 receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology."	( Baltazar, LM; Barreto-Vizcaíno, S; Gutiérrez, I; Isais-Millán, R; Millán-Guerrero, RO; Rivera-Castaño, L; Trujillo-Hernández, B, 2008)
"Histamine has a greater relaxant effect on mesenteric artery strips at 22 degrees than at 38 degrees, normally."	( Christiansen, VJ; Horst, MA; Robinson, C, 1983)
"Histamine has a trophic effect on at least two colorectal cancer cell lines in vivo and in vitro."	( Adams, WJ; Lawson, JA; Morris, DL, 1994)
"Histamine has a different effect causing an increase in serotonin immediately after treatment, which then returns to the control level after 24 h."	( Csaba, G; Kovács, P, 1994)
"Histamine has a marked secretagogue effect in the exocrine pancreas of several animal species but in many cases the secretory effect is gender-related."	( Pariente, JA; Salido, GM; Singh, J, 1997)
"Histamine has a long history of therapeutic use in many diseases, including multiple sclerosis (MS). "	( Ballasiotes, G; DeLack, E; Gillson, G; Wright, JV, 1999)
"Histamine has an antinociceptive effect in the brain and may be involved in opioid-induced analgesia."	( Eriksson, KS; Haas, HL; Stevens, DR, 2000)
"Histamine has a dual action on the isolated perfused ear preparation of the rabbit. "	( Ercan, ZS; Türker, RK, 1975)
"1 Histamine has a dual action on the in situ gall bladder of the guinea-pig: a spasmogenic and a relaxant effect mediated through H1- and H2-receptor stimulation respectively. "	( Impicciatore, M, 1978)
"Histamine has a positive inotropic action in humans. "	( Berlin, R; Borow, KM; Ehler, D; Neumann, A, 1992)
"Histamine has a similar, although less notable effect than histidine."	( Csaba, G; Darvas, Z, 1986)
"Histamine has multiple effects on cardiac physiology, mainly via the histamine 1 and 2 receptors, which on a simplified level have opposing effects on heart rate, force of contraction, and coronary vasculature function."	( Levick, SP, 2022)
"Histamine has long been accepted as an anorexigenic agent. "	( Chen, Z; Zheng, Y, 2022)
"Histamine has been implicated in urinary bladder dysfunction as an inflammatory mediator driving sensory nerve hypersensitivity. "	( Jones, BM; Mingin, GC; Tykocki, NR, 2022)
"Histamine has shown a possible role in the etiopathogenesis of migraine. "	( Agúndez, JAG; Alonso-Navarro, H; Amo, G; Calleja, M; García-Albea, E; García-Martín, E; García-Ruiz, R; Jiménez-Jiménez, FJ; Millán-Pascual, J; Navacerrada, F; Navarro-Muñoz, S; Plaza-Nieto, JF; Recio-Bermejo, M; Rodriguez, C; Serrador, M; Turpín-Fenoll, L, 2022)
"Histamine poisoning has been reported worldwide. "	( Hara-Kudo, Y; Toda, M; Tomaru, A, 2022)
"Histamine has been postulated to play a role in atopic dermatitis via histamine receptor 4, mediating pruritic and inflammatory effects. "	( Bäumer, W; Bruno, S; Delucis-Bronn, C; Fehlmann, D; Goetschy, JF; Hauchard, A; Kaupmann, K; Kempf, D; Raulf, F; Röhn, TA; Roussel, E; Stark, H; Uluckan, Ö; Urban, B; Wack, N; Wang, Y; Wilzopolski, J; Zerwes, HG, 2023)
"Histamine has been shown to play a series of pathophysiological roles by modulating immune and inflammatory responses in a number of disease conditions, whereas the mechanistic aspects underlying induced HDC expression remain elusive."	( Moriguchi, T; Takai, J, 2020)
"Antihistamine medications have been suggested to elicit clinical features of restless legs syndrome. "	( Alvente, S; Bastianini, S; Berteotti, C; Lin, JS; Lo Martire, V; Matteoli, G; Ohtsu, H; Silvani, A; Zoccoli, G, 2021)
"Histamine has an impact on the gene expression profile of macrophages during compressive strain in vitro, most likely having an impairing effect on orthodontic tooth movement by upregulation of osteoprotegerin expression."	( Damanaki, A; Jantsch, J; Kirschneck, C; Petring, C; Proff, P; Schröder, A, 2022)
"Histamine has been shown to modulate visual system and photic behavior in arthropods. "	( Denoroy, L; Parrot, S; Pavón Vergés, M; Perrot-Minnot, MJ, 2017)
"Histamine has been shown to regulate NF-κB activity, though not in hepatocytes."	( Haas, MJ; Hammoud, R; Jurado-Flores, M; Mooradian, AD; Onstead-Haas, L; Plazarte, G; Wong, NCW, 2018)
"Histamine has generally excitatory effects on target neurons, but paradoxically, histamine neurons may also release the inhibitory neurotransmitter GABA."	( Dauvilliers, Y; Franks, NP; Jackson, AC; Scammell, TE; Wisden, W, 2019)
"The histaminergic system has a role in the treatment of brain disorders by the development of histamine receptor agonists, antagonists."	( Mirshafiey, A; Naddafi, F, 2013)
"Anti-histaminergic drugs have been widely used in the clinical treatment of vestibular disorders and most studies concentrate on their presynaptic actions. "	( Peng, SY; Wang, JJ; Yu, L; Zhang, XY; Zhu, JN; Zhuang, QX, 2013)
"The histamine field has moved on rapidly in the last four years, with expansion in roles and clinical development, particularly in the newest two of four histamine receptors. "	( Chazot, PL, 2013)
"Histamine synthesis has been demonstrated in osteoclast precursors."	( Folwarczna, J; Wiercigroch, M, 2013)
"Histamine has been suggested to participate in seizure control."	( Fereidoni, J; Gholipoor, P; Roshan-Milani, S; Saboory, E, 2013)
"Histamine has been studied in both health and disease since the initial description a century ago. "	( Alstadhaug, KB, 2014)
"Histamine antagonism has been in common use to block its adverse effects."	( Kovacic, JP; Peters, LJ, 2009)
"Histamine has been implicated in the pathogenesis of migraine. "	( Agúndez, JA; Alonso-Navarro, H; Ayuso, P; García-Martín, E; Jiménez-Jiménez, FJ; Martínez, C; Navacerrada, F; Serrador, M, 2015)
"Histamine has previously been studied with FSCV; however, the lack of a robust Faradaic electrochemical signal makes it difficult to selectively identify histamine in complex media, as found in vivo."	( Abdalla, A; Hashemi, P; Robke, R; Samaranayake, S; Wood, KM; Zeqja, A, 2015)
"Low histamine metabolism has been suggested to play a role in the pathogenesis of allergy and migraine. "	( Ávila-Hernández, J; Espinosa-Padilla, S; López-Márquez, F; Meza-Velázquez, R; Rivera-Guillen, M; Rosales-González, M, 2017)
"Histamine has been reported to decrease the ultrafiltration coefficient, which inversely correlates with glomerular permselectivity, however the mechanism(s) underling this effect have never been investigated. "	( Chazot, PL; Fantozzi, R; Grange, C; Miglio, G; Moggio, A; Pini, A; Premoselli, F; Rosa, AC; Tiligada, K; Veglia, E, 2016)
"Histamine receptors have been the target of efforts to develop pro-cognitive drugs to treat disorders such as Alzheimer's disease and schizophrenia."	( Andersson, R; Fisahn, A; Galter, D; Papadia, D, 2017)
"Histamine has been proposed to be an excitatory transmitter between the carotid body (CB) chemoreceptor (glomus) cells and petrosal ganglion (PG) neurons. "	( Alcayaga, J; Del Rio, R; Fujiwara, K; Iturriaga, R; Koenig, CS; Moya, EA, 2008)
"Histamine has a selective affinity for H3 receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology."	( Barreto-Vizcaíno, S; Isais-Millán, S; Millán-Guerrero, RO; Rios-Madariaga, C; Rivera-Castaño, L, 2009)
"Histamine has various effects in physiological and pathological reactions, such as inflammation, cell growth, and neuro-transmission."	( Hong, SH; Jeong, HJ; Kang, IC; Kang, TH; Kim, HM; Kim, JJ; Kim, SJ; Moon, PD; Seo, JU; Um, JY, 2009)
"Histamine has a direct suppressive effect on IEL-derived cytokines via H(2)R, which would have a crucial role in the suppression of local immunoregulation in the intestinal epithelium."	( Furuta, T; Hamaya, Y; Hishida, A; Horio, Y; Ikuma, M; Osawa, S; Takagaki, K; Takayanagi, Y; Yamada, T, 2009)
"Histamine and tyramine have been affected by pyrogallol, catechol, starch, ascorbic and chlorogenic acids at different levels with different conditions."	( El-Din, AM; El-Din, LA; El-Hameed, AK; Mohamed, GG, 2010)
"Histamine has been proposed to be an important regulator of energy intake and expenditure. "	( Ding, Y; Guo, X; Hirano, K; Kohno, K; Sasaguri, Y; Tanimoto, A; Tsukada, H; Wang, KY; Watanabe, T; Yamada, S, 2010)
"Histamine has been demonstrated to be involved in cell proliferation, embryonic development, and tumour growth. "	( Alonso-Tejerina, E; Asumendi, A; Blaya, B; Boyano, MD; Burgos-Bretones, J; Jangi, SM; Nicolau-Galmés, F; Ortega-Martínez, I; Pérez-Yarza, G, 2010)
"Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure. "	( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010)
"Histamine has been shown to promote Th2 polarization by dendritic cells."	( Borrebaeck, CA; Broos, S; Greiff, L; Lindstedt, M; Lundberg, K, 2011)
"Histamine has been reported to play an important role in pathogenesis of bronchial asthma. "	( Kobayashi, H; Maeyama, K; Nakamura, Y; Ogasawara, M; Shikanai, T; Yamauchi, K, 2011)
"Histamine has been detected after controlled challenges with allergen and, when administered into the nasal cavity, elicits signs and symptoms similar to those elicited by allergen."	( Taylor-Clark, T, 2010)
"CSF histamine has a robust daily rhythm, with a mean of 24.9 ± 3.29 pg mL(-1) , amplitude of 31.7 ± 6.46 pg mL(-1) and a peak at 17:49 ± 70.3 min (lights on 07:00-19:00 hours)."	( Buckmaster, CL; Honda, Y; Kodama, T; Lyons, DM; Mignot, E; Nishino, S; Zeitzer, JM, 2012)
"Antihistamines have been classifed as first or second generation drugs, according to their pharmacokinetic properties, chemical structure and adverse effects. "	( Bartra, J; Dávila, I; del Cuvillo, A; Ferrer, M; Jáuregui, I; Montoro, J; Mullol, J; Sastre, J; Valero, A, 2011)
"Histamine has been recognized as a NANC factor in the early postprandial period in pythons, but the mechanism of its release has not been identified."	( Enok, S; Pedersen, SV; Simonsen, LS; Skovgaard, N; Wang, T, 2012)
"Histamine has been shown to induce melanogenesis via histamine receptor 2, suggesting the possibility of histamine as a repigmenting agent for the treatment of vitiligo."	( Kang, JH; Kim, HJ; Kim, HM; Kim, YL; Lee, AY; Lee, CH; Lee, EJ; Lee, HJ; Park, MK, 2012)
"Histamine has the ability to influence the activity of immune cells including neutrophils and plays a pivotal role in inflammatory processes, which are a complex network of cellular and humoral events. "	( Cíž, M; Lojek, A, 2013)
"Histamine has a variety of airway actions and is considered to be an important mediator in asthma. "	( Hattori, T; Ichinose, M; Ishigaki-Suzuki, S; Koarai, A; Kuramasu, A; Makabe-Kobayashi, Y; Ohtsu, H; Sakurai, E; Shirato, K; Sugiura, H; Watanabe, T; Yamagata, S, 2003)
"Histamine has pro-inflammatory effects on conjunctival fibroblasts, inducing the production of cytokines and the expression of ICAM-1. "	( De Paoli, M; DeFranchis, G; Fregona, I; Leonardi, A; Plebani, M; Secchi, A, 2002)
"Histamine has a short-term, transient, stimulating effect on endothelial nitric oxide synthase (eNOS) activity; however, long-term effects on eNOS have not been described yet. "	( Brausch, I; Burkhardt, C; Förstermann, U; Heinrich, UR; Li, H; Xia, N, 2003)
"Histamine has an important role in the development of gastric ulcers and mast cell derived histamine might be essential in this process."	( Aboul-Enein, HY; Tunçel, M; Tunçel, N, 2003)
"Histamine has been suggested to have roles as a neurotransmitter or a neuromodulator. "	( Kitanaka, J; Kitanaka, N; Takemura, M, 2003)
"Histamine has been referred to as an anorexic factor that decreases appetite and fat accumulation and affects feeding behavior. "	( Buzás, E; Falus, A; Földes, A; Fülöp, AK; Hegyi, K; Kleiber, M; Kovács, KJ; Miklós, IH; Nagy, A; Romics, L, 2003)
"Histamine has been shown to depress transmission through the perfused superior cervical ganglion of the cat when doses of 150 mug. "	( GERTNER, SB; KOHN, R, 1959)
"Histamine has been proposed to be an important modulator of developing neurons, but its mechanism of action remains unclear. "	( Catacuzzeno, L; Fioretti, B; Franciolini, F; Tata, AM, 2004)
"Histaminergic neurons have been strongly implicated in the regulation of wakefulness by activating cortical neurons. "	( Chu, M; Eguchi, N; Huang, ZL; Qu, WM; Urade, Y; Yao, MH, 2004)
"Histamine has many regulatory activities and is well recognised for its importance in allergic and inflammatory disorders. "	( Tetlow, LC; Woolley, DE, 2004)
"Histamine has been proven to be a major regulator of the immune system's T-helper cell subset balance and major shifts in this balance towards TH2 cytokines have contributed to diseases such as asthma, lupus and cancer."	( Kavekos, M, 2005)
"Histamine has a recognised role in allergic and inflammatory reactions, and is reported to affect several aspects of chondrocyte behaviour."	( Tetlow, LC; Woolley, DE, 2005)
"Histamine has been shown to have a key physiological role in the control of gastric acid secretion and a pathophysiological role in a range of allergic disorders."	( Ganellin, CR; Parsons, ME, 2006)
"Antihistamines have been shown to have bronchodilatory effects, effects on allergen-, exercise-, and adenosine-monophosphate-challenge testing, and also to prevent allergen-induced nonspecific airways hyperresponsiveness."	( Wilson, AM, 2006)
"Histamine and carnosine have been proposed as protective agents against such damage."	( Davies, MJ; Pattison, DI, 2006)
"Histamine has many physiological roles in the brain and periphery. "	( Kato, M; Nishiyama, S; Oreland, L; Sakurai, E; Watanabe, T; Yanai, K, 2006)
"Histamine has an important role in regulation of immune response which is mediated by differential expression of four distinct receptors, H1R-H4R. "	( Center, DM; Cross, L; Cruikshank, WW; Green, DS; Kornfeld, H; McAllister, B; Morgan, RK, 2007)
"Histamine has a selective affinity for H3-receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology. "	( Barreto-Vizcaíno, S; Garcia-Solorzano, A; Isais-Millán, R; López-Blanca, C; Membrila-Maldonado, M; Millán-Guerrero, RO; Muñoz-Solis, R; Rivera-Castaño, L, 2007)
"Histamine has a key role in allergic inflammatory conditions. "	( Dunford, PJ; Gelfand, EW; Thurmond, RL, 2008)
"Histamine has a selective affinity for H3 receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology."	( Baltazar, LM; Barreto-Vizcaíno, S; Gutiérrez, I; Isais-Millán, R; Millán-Guerrero, RO; Rivera-Castaño, L; Trujillo-Hernández, B, 2008)
"Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy."	( Ho, AD; Perz, JB, 2008)
"Histamine has neurotransmitter/neuromodulator functions in the adult brain, but its role during CNS development has been elusive. "	( Molina-Hernández, A; Velasco, I, 2008)
"Histamine has been shown to increase renal blood flow via H1- and H2-receptors. "	( Barker, LA; Robie, NW, 1983)
"Histamine release has been detected biologically after exposure of human right atrial biopsy samples to compound 48/80. "	( Gristwood, RW; Lincoln, JC; Owen, DA; Smith, IR, 1981)
"Histamine has been reported to attenuate adrenergic responses in cardiovascular tissues. "	( Bailey, WH; Chenouda, AA; Gross, SS; Guo, ZG; Levi, R, 1984)
"Histamine has a greater relaxant effect on mesenteric artery strips at 22 degrees than at 38 degrees, normally."	( Christiansen, VJ; Horst, MA; Robinson, C, 1983)
"Histamine has been shown to activate cyclic AMP synthesis in brain slices and homogenates of certain species, although less is known about species differences in brain homogenates. "	( Green, JP; Hough, LB, 1981)
"Histamine has been known as a cardiac stimulant for over 70 years. "	( McNeill, JH, 1984)
"Histamine receptors have been demonstrated on lymphocyte membranes by a variety of techniques. "	( Cohen, EB; McCaffrey, RP; Osband, ME; Shapiro, HM, 1980)
"Histamine has been shown to possess many neurotransmitter-like properties, and a variety of studies indicate that central histamine may function in modulating behavioral arousal. "	( Kalivas, PW, 1982)
"Histamine has been measured by an isotopic enzyme conversion assay in guinea pig bone marrow cultures under conditions which stimulate basophilopoiesis. "	( Befus, AD; Bienenstock, J; Denburg, JA; Goodacre, R, 1981)
"Histamine has been implicated in the pathogenesis of gastroduodenal ulcers. "	( Kitamura, Y; Maeyama, K; Miyano, Y; Shimada, M; Takahashi, Y; Tatsuta, M; Yamatodani, A; Yokoyama, M, 1980)
"Histamine has been investigated for its effect on gastric acid secretion and mucosal blood flow in man. "	( Knight, SE; McIsaac, RL; Rennie, CD, 1980)
"Histamine transport has been characterized in cultured astroglial cells of rat brain. "	( Huszti, Z; Imrik, P; Madarász, E, 1994)
"Histamine has a trophic effect on at least two colorectal cancer cell lines in vivo and in vitro."	( Adams, WJ; Lawson, JA; Morris, DL, 1994)
"Histamine has a different effect causing an increase in serotonin immediately after treatment, which then returns to the control level after 24 h."	( Csaba, G; Kovács, P, 1994)
"Histamine has numerous functions in the brain and has recently been shown to modulate responses of N-methyl-D-aspartate (NMDA) receptors on hippocampal neurons by a mechanism that does not involve classical histamine receptors. "	( Williams, K, 1994)
"Histamine has potent effects on cerebral blood vessels which include increased permeability and dilatation. "	( Schilling, L; Wahl, M, 1994)
"Histamine tachyphylaxis has been demonstrated after repeated challenges in mild asthmatics not using inhaled corticosteroid."	( Manning, PJ; O'Byrne, PM; Strban, M; Watson, RM, 1994)
"Histamine has previously been described as a possible substrate for the semicarbazide-sensitive amine oxidase activity (SSAO) of rat white adipose tissue (WAT). "	( Banchelli, G; Buffoni, F; Conforti, L; Ignesti, G; Pirisino, R; Raimondi, L, 1993)
"Histamine and IL-1 have been implicated in the pathogenesis of chronic inflammatory diseases, such as pulmonary allergic reactions and rheumatoid arthritis. "	( Dinarello, CA; Vannier, E, 1993)
"Histamine has arrhythmogenic, chronotropic, inotropic and vasoactive effects."	( Kaszaki, J; Nagy, S; Szabó, I; Vaage, J; Valen, G, 1993)
"Histamine has been implicated as a neuromodulator of secretion of gonadotropins in several species. "	( Alexander, BM; Moss, GE; Murdoch, WJ; Rose, JD; Van Kirk, EA, 1993)
"Histamine has recently been shown to be a growth factor for some gastric and colorectal cancer cells. "	( Adams, WJ; Lawson, JA; Morris, DL, 1996)
"The histamine H3 receptor has been shown to inhibit pentagastrin-induced gastric acid secretion in dogs. "	( Bertini, S; Garbarg, M; Intorre, L; Rouleau, A; Schwartz, JC; Soldani, G, 1996)
"Antihistamines have been compared on the basis of their ability to block the histamine-induced wheal and flare in the skin."	( Daly, AF; Monroe, EW; Shalhoub, RF, 1997)
"Histamine has been shown to be involved in atherosclerosis and coronary heart disease. "	( Angelin, B; Liao, W; Rudling, M, 1997)
"Histamine has been widely used experimentally to induce headache in healthy subjects and migraine in migraineurs. "	( Eichler, HG; Findl, O; Graselli, U; Kastner, J; Schmetterer, L; Simak, S; Singer, EA; Strenn, K; Wolzt, M, 1997)
"Histamine has important neuromodulatory influences on the central electrophysiology which underlies normal thalamocortical function."	( Sangalli, BC, 1997)
"Histamine has a marked secretagogue effect in the exocrine pancreas of several animal species but in many cases the secretory effect is gender-related."	( Pariente, JA; Salido, GM; Singh, J, 1997)
"Histamine has been found to stimulate growth of colorectal cancer in vitro and in vivo. "	( Adams, WJ; Akhter, J; Morris, DL; Reynolds, JL, 1997)
"Histamine has been well tolerated, and 21/22 CR patients have treated themselves at home throughout the trial."	( Brune, M; Carneskog, J; Celsing, F; Hellstrand, K; Kimby, E; Mellqvist, UH; Wallhult, E, 1997)
"Histamine has not been proved responsible for signs."	( Laroche, D, 1998)
"Histamine has been shown to affect circadian rhythms both in vivo and in vitro."	( Hall, AC; Harrington, ME; Meyer, JL, 1998)
"Histamine has long been suspected as one of the factors that is involved in implantation."	( Das, N; Das, SK; Dey, SK; Dileepan, KN; Paria, BC; Zhao, X, 1998)
"Histamine has been converted into a non-imidazole H3-receptor histamine antagonist by addition of a 4-phenylbutyl group at the N alpha-position followed by removal of the imidazole ring. "	( Arrang, JM; Ganellin, CR; Garbarg, M; Leurquin, F; Ligneau, X; Piripitsi, A; Schunack, W; Schwartz, JC, 1998)
"Histamine has been shown to increase the adhesion of leucocytes to the endothelium and to stimulate production of IL-6 and IL-8 by endothelial cells."	( Bachert, C, 1998)
"Histamine has been incriminated as having a responsibility for intolerance reaction to wines. "	( Bauza, T; Blaise, A; Cabanis, JC; Daumas, F; Frémont, S; Guillemin, F; Kanny, G; Moneret-Vautrin, DA; Nicolas, JP, 1999)
"Histamine has been proposed to play an important role in early inflammatory responses, based on studies documenting the effects of histamine on vasodilation and permeability of microvascular endothelium, as well as histamine-stimulated neutrophil adhesion to endothelial cells. "	( Neugebauer, E; Schaefer, U; Schmitz, V; Schneider, A, 1999)
"Histamine has direct effects on keratinocytes as well."	( Koizumi, H; Ohkawara, A, 1999)
"Histamine has a long history of therapeutic use in many diseases, including multiple sclerosis (MS). "	( Ballasiotes, G; DeLack, E; Gillson, G; Wright, JV, 1999)
"Histamine has an antinociceptive effect in the brain and may be involved in opioid-induced analgesia."	( Eriksson, KS; Haas, HL; Stevens, DR, 2000)
"Histamine has been reported to potentiate NMDA receptor-mediated events under a variety of conditions."	( Facci, L; Kee, WJ; Skaper, SD; Strijbos, PJ, 2001)
"Histamine has been suggested to be a immunomodulator."	( Kohka-Takahashi, H; Mori, S; Nishibori, M, 2001)
"Histamine has been shown to play a role in arthropod vision; it is the major neurotransmitter of arthropod photoreceptors. "	( Cully, DF; Hirschberg, B; Hunt, DC; Ludmerer, SW; Schmatz, DM; Wang, AP; Yuan, J; Zheng, Y, 2002)
"Histamine has also been shown to play a role in the regulation of sleep and feeding."	( Brown, RE; Eriksson, KS; Haas, HL; Sergeeva, O, 2001)
"Histamine has been shown to inhibit ROS formation and possibly synergize with cytokines to permit activation of natural killer cells and T cells."	( Agarwala, SS; Belt, R; Feun, L; Gehlsen, KR; Glaspy, J; Gonzalez, R; Gutheil, J; Hellstrand, K; Hersh, E; Kirkwood, JM; Meyskens, F; Mitchell, M; Naredi, P; O'Day, SJ; Whitman, E; Wood, D, 2002)
"Histamine has a dual action on the isolated perfused ear preparation of the rabbit. "	( Ercan, ZS; Türker, RK, 1975)
"1 Histamine has a dual action on the in situ gall bladder of the guinea-pig: a spasmogenic and a relaxant effect mediated through H1- and H2-receptor stimulation respectively. "	( Impicciatore, M, 1978)
"Histamine may have been released close to airway receptors, inducing bronchoconstriction, but in amounts undetectable in arterial plasma."	( Chiesa, A; Dain, D; Gold, WM; Kessler, GF; Meyers, GL, 1975)
"Histamine has been shown to inhibit a variety of immune responses including the antigen-induced, IgE mediated, release of histamine from sensitized human leucocytes and from sensitized monkey and dog mast cells. "	( Dulabh, R; Vickers, MR, 1978)
"Histamine has been measured in whole blood and in the plasma of twenty-three subjects following exercise testing of seventeen asthmatics and six normal controls. "	( Burge, PS; Cromwell, O; Harries, MG; O'Brien, I; Pepys, J, 1979)
"Histamine has been found biochemically in the mammalian vascular wall. "	( Brody, MJ; El-Ackad, TM, 1975)
"Histamine has been alleged to have a role in the vasoconstrictor response with generalized alveolar and thus systemic hypoxia, but the role for histamine is not clear in localized alveolar hypoxia."	( Hales, CA; Kazemi, H, 1975)
"Histamine release have been demonstrated in haemorrhagic shock. "	( Asakawa, H; Karácsonyi, S; Zöllei, I, 1992)
"Histamine has a positive inotropic action in humans. "	( Berlin, R; Borow, KM; Ehler, D; Neumann, A, 1992)
"Antihistamines have been reported to have antitussive actions in allergic rhinitis which may be due to an effect of the drug on the cough reflex. "	( Fuller, RW; Studham, J, 1992)
"Histamine has been reported to cause endothelium-dependent relaxation of vascular smooth muscle and vasodilation. "	( Bailly, DA; Gruetter, CA; Stewart, NL; Szarek, JL, 1992)
"Histamine has been shown to mediate features of pulmonary allergic reactions including increased tracheobronchial blood flow. "	( Brock, JM; Chung, KF; Colbert, SR; Howard, RS; Nichol, GM; Parsons, GH; Villablanca, AC, 1992)
"Histamine, which has long been implicated as a mediator of allergic airway disease, has multiple effects on airways which are mediated by at least three histamine receptors. "	( Barnes, PJ, 1991)
"Histamine has been proposed as a photoreceptor neurotransmitter in two major groups of arthropods, the insects and the crustacea. "	( Andrews, AW; Battelle, BA; Callaway, JC; Calman, BG; Grieco, FD; Mleziva, MB; Stuart, AE, 1991)
"Histamine, which has been found in middle ear effusions, is a potent pharmacological mediator released at an early stage of allergic reactions or general inflammatory process, increasing permeability of small blood vessels. "	( Esaki, Y; Furuya, H; Nakai, Y; Ohashi, Y; Ohno, Y; Okamoto, H; Sugiura, Y, 1991)
"Histamine antagonists have been in clinical use since 1942."	( Behrendt, H; Ring, J, 1990)
"Histamine has been determined by bioassay, chemically by different modification of a fluorometric method, by radioenzymatic methods, and, recently, by immunoassays."	( Brenna, E; Sandvik, AK; Schulze Søgnen, B; Waldum, HL, 1991)
"Histamine has been involved in the first minutes of the anaphylactic reaction and new-formed compounds in the subsequent response."	( Montaño, LM; Segura, P; Selman, M; Vanda, B; Vargas, MH, 1990)
"Histamine has remained a putative neurotransmitter for many years, partially because some of the criteria necessary to define it as a central nervous system neurotransmitter have not been established. "	( Clemens, JA; Henry, DP; Phebus, LA; Russell, WL, 1990)
"Histamine has been shown previously to cause dose-dependent systemic hypotension and concurrent alterations in the permeability of the blood-brain barrier of rats. "	( Boertje, SB; Le Beau, D; Williams, C, 1989)
"Histamine has generally been accepted to be an important mediator of immediate-type-allergic reactions. "	( Behrendt, H, 1985)
"Histamine H1 receptors have been demonstrated on adherent rheumatoid synovial cells using biochemical and radioligand binding assays in vitro. "	( Taylor, DJ; Woolley, DE, 1987)
"Histamine has been suggested as an important mediator of the cardiovascular abnormalities during septic shock. "	( Jacobs, R; Kaliner, M; Parrillo, JE; Shelhamer, JH, 1989)
"Histamine has a similar, although less notable effect than histidine."	( Csaba, G; Darvas, Z, 1986)
"Histamine has been shown to have both positive inotropic and chronotropic effects. "	( Lui, CY; McCall, D, 1986)
"Histamine has been compared with methacholine inhalation challenge in two samples of adults from a small town to determine which is the better agent for use in community studies."	( Britton, JR; Burney, PG; Chinn, S; Higgins, BG; Jones, TD; Tattersfield, AE; Vathenen, AS, 1988)
"Histamine has been found to activate three subtypes of receptors: the H1 subtype, which mediates a number of cellular events resulting in airway obstruction; the H2 subtype, which plays an unclear and perhaps variable role in mediating airway caliber changes; and the newly described H3 subtype, which has not yet been studied in relation to airway caliber."	( Casale, TB; Joad, J, 1988)
"Histamine (H) levels have been reported during various types of shock, but there is a paucity of such data during hemorrhagic shock. "	( Adamicza, A; Nagy, A; Nagy, S; Szabó, I; Tárnoky, K; Traub, A, 1986)
"Histamine has been claimed to be the final common chemical mediator of acid secretion."	( Ekelund, M; Håkanson, R; Vallgren, S, 1987)
"Histamine levels have been measured in plasma and synovial fluid (SF) obtained from patients with various arthritides, using a radioenzymatic assay procedure. "	( Cleland, LG; Frewin, DB; Jonsson, JR; Robertson, PW, 1986)
"Histamine levels have been measured using an HPLC procedure involving fluorimetric detection after fluorescamine derivatization."	( Angi, MR; Benassi, CA; Bettero, A; Galiano, F, 1985)
"Histamine, which has been associated with food poisoning in concentrations of 185 mg/100 g in Swiss cheese and 180 to 500 mg/100 g in fish, was found in concentrations above 500 mg/100 g in Swiss cheese."	( Ayres, JW; Chang, SF; Sandine, WE, 1985)
"Histamine levels have been determined in nine tissues of four kinds (W/Wv, Wv/+, W/+, +/+) of WBB6F1 male and female mice, and mast cells have been counted in the skin and the fundus of W/Wv and +/+ mice. "	( Burtin, C; Canu, P; Galoppin, L; Ponvert, C; Scheinmann, P, 1985)
"Histamine, which has recently been shown to increase leukocyte cyclic AMP, had a pronounced inhibitory effect on lysate-induced histamine release, producing 50% inhibition at a concentration of only 2.5 x 10(-12) M.Leukocytes, incubated with leukocyte lysates, were sampled at various times and assayed for free histamine released into the incubation mixture supernates, and for bound histamine associated with the leukocyte buttons after centrifugation."	( Kelly, MT; White, A, 1973)
"Histamine has positive inotropic and chronotropic effects on the heart which are not abolished by beta adrenergic-blocking agents. "	( Klein, I; Levey, GS, 1971)

Actions

Excerpt	Reference
"The histaminergic system plays a significant role in the maintenance of wakefulness, appetite regulation, cognition and arousal, which are severely affected in neuropsychiatric disorders."	( Chen, Z; Cheng, L; Liu, J, 2021)
"Histamine promotes cell transformation through redox-mediated alterations in the cell cycle, DNA repair, and immunological response."	( Aschner, M; Guijosa, A; Hernández-Mora, VM; Molina, A; Morales-Mulia, M; Ortega-Gómez, A; Prospero-García, O; Rodríguez-Flores, KL; Ruiz-García, E; Santamaría, A; Torres-Román, AL, 2023)
"Histamine plays pivotal role in normal physiology and dysregulated production of histamine or signaling through histamine receptors (HRH) can promote pathology. "	( Ball, RL; Blankenhorn, EP; Case, LK; Chen, Y; Chesler, EJ; Diehl, SA; Huang, R; Kost, J; Krementsov, DN; Li, D; Ma, R; Mahoney, JM; Philip, VM; Raza, A; Teuscher, C; Tyler, AL, 2023)
"Histamine plays a central role in its creation."	( Domokos, K; Sütő, B, 2023)
"Histamine plays a complex role and stands out as a promising drug for TNBC treatment, which deserves to be tested in clinical settings. "	( Cremaschi, GA; Formoso, K; Herrero Ducloux, MV; Martinel Lamas, D; Massari, NA; Medina, VA; Nicoud, MB; Sterle, HA; Táquez Delgado, MA, 2020)
"Histamine can cause foodborne intoxication."	( Boulom, S; Giavang, Y; Marui, J; Phouphasouk, S; Yialee, Y, 2021)
"Histamine can cause foodborne intoxication."	( Boulom, S; Giavang, Y; Marui, J; Phouphasouk, S; Yialee, Y, 2021)
"Histamine plays a central role in various allergic diseases, such as allergic asthma and allergic rhinitis. "	( Li, P; Wang, J; Wu, Z; Yang, Z; Zhou, E; Zhu, X, 2021)
"Histamine was found to activate S-type sensilla, which harbor bitter-sensing gustatory receptor neurons."	( Aryal, B; Lee, Y, 2021)
"The histamine-mediated increase of theta phase-locking of spikes and high gamma power is consistent with successful spatial recognition."	( Chen, Q; Gao, D; He, C; Hu, B; Hu, Z; Jiang, J; Liao, X; Luo, F; Xia, J; Xiao, Q; Yue, F; Zhang, J, 2018)
"Histamine plays an important role in physiology and pathophysiology of cardiovascular system."	( Fogel, WA; Gola, J; Kobos, J; Kraszewska, K; Mazurek, U; Mussur, M; Stark, H; Stasiak, A, 2018)
"Histamine plays a role in airway obstruction via smooth muscle contraction, bronchial secretion, and airway mucosal edema."	( Ogasawara, M; Yamauchi, K, 2019)
"Histamine plays an important role in neuromodulation and the biological immune response. "	( Lee, ST; Puthongkham, P; Venton, BJ, 2019)
"Histamine is known to increase vascular permeability and induce apoptosis, and these effects are closely associated with endothelial and mitochondrial dysfunction, respectively."	( Bin, J; Chen, B; Dai, M; Fukushima, Y; He, N; Huang, Q; Kitakaze, M; Liao, Y; Luo, T; Wu, B; Xu, D; Zeng, Z; Zhao, Z, 2013)
"Histamine plays an important role in the development of symptoms in allergic, infectious, neoplastic and other diseases. "	( Dauth, W; Hagel, AF; Hagel, E; Hagel, HJ; Hagel, WH; Kressel, J; Layritz, CM; Molderings, GJ; Neurath, MF; Raithel, M; Regnet, T; Rosenberg, A, 2013)
"Histamine is the main cause of sneezing and hypersecretion, while other mediators probably also play a role in nasal blockage."	( Mygind, N, 2014)
"Histamine plays a critical role in cancer cell proliferation, migration, and invasion."	( Ikeda, J; Jiang, Y; Morii, E; Ohtsu, H; Sato, A; Tian, T; Wang, Y, 2014)
"Histamine plays a key role in the morbidity and mortality associated with allergy, asthma, gastric ulcers, anaphylaxis, sepsis, hemorrhagic shock, anesthesia, surgery, cardiovascular disease, cancer, CNS disorders, and immune-mediated disease. "	( Kovacic, JP; Peters, LJ, 2009)
"Histamine plays a major role in the mediation of allergic reactions such as peripheral inflammation. "	( Abdalla, A; Hashemi, P; Robke, R; Samaranayake, S; Wood, KM; Zeqja, A, 2015)
"Histamine can cause histaminergic angioedema."	( Bouckaert, M; Feller, L; Khammissa, R; Lemmer, J; Wood, NH, 2014)
"Antihistamines inhibit histamine signaling by blocking histamine H1 receptor (H1R) or suppressing H1R signaling as inverse agonists. "	( Das, AK; Dev, S; Fukui, H; Kitamura, Y; Maeyama, K; Mizuguchi, H; Shahriar, M; Takeda, N, 2016)
"Histamine plays an important role as a neurotransmitter in diverse brain functions, and clearance of histamine is essential to avoid excessive histaminergic neuronal activity. "	( Yanai, K; Yoshikawa, T, 2017)
"Histamine promotes the development of eczematous lesions, elevates IgE serum levels, and induces scratching behavior in CACD."	( Ohtsu, H; Seike, M, 2017)
"The histamine plays a decisive role in acute and chronic inflammatory responses and is regulated through its four types of distinct receptors designated from H1 to H4. "	( Elden, BT; Kaliappan, I; Mariappanadar, V; Nagarajan, G; Tamizh, M, 2017)
"Histamine plays significant roles in the early-phase swelling via H1 receptors, and the late-phase swelling via H3/H4 receptors in this TPA-modified allergic dermatitis model."	( Hirasawa, N; Hong, J; Ishihara, K; Katoh, G; Ohsawa, Y; Ohuchi, K; Seyama, T; Shibata, K; Tamura, S, 2009)
"Histamine plays an important role in many physiological functions; and a change in cytosolic Ca(2+) ([Ca(2+)](i)) may be an early signal in these processes. "	( Chen, ZY; Dominic Chan, TW; Huang, Y; Kwan, HY; Wong, CO; Yao, X, 2009)
"As histamine plays a central role in allergic diseases, it is possible that SST affects the allergy-related histamine signaling."	( Das, AK; Dev, S; Fukui, H; Kitamura, Y; Kodama, M; Matsushita, C; Mizuguchi, H; Takeda, N; Umehara, H, 2009)
"Histamine was shown to increase the number of osteoclasts and osteoclast precursors whereas antagonists of histamine receptor-1 and -2 decreased both osteoclast recruitment and resorption."	( Baroukh, B; Biosse-Duplan, M; de Vernejoul, MC; Dy, M; Saffar, JL, 2009)
"Histamine plays important roles in eliciting AR symptoms."	( Fukui, H; Hattori, M; Horio, S; Kitamura, Y; Maeyama, K; Mizuguchi, H; Orimoto, N; Shahriar, M; Takeda, N; Umehara, H, 2009)
"Histamine plays an important role in allergy mainly through histamine H1 receptor (H1R). "	( Fujimoto, K; Fukui, H; Horio, S; Mizuguchi, H, 2010)
"Histamine is known to increase vascular permeability."	( Akhmedov, A; Becher, B; Borén, J; Hofmann, J; Johansen, P; Lüscher, TF; Mocharla, P; Rohrer, L; Rozenberg, I; Sluka, SH; Soliz, J; Steffel, J; Tanner, FC; Watanabe, T, 2010)
"Histamine promotes immune complex-induced vascular leakage in vivo, a critical and early event that leads to joint-specific autoimmune damage. "	( McMorrow, JP; Murphy, EP; Zocco, D, 2010)
"Histaminergic neurons enhance cognition and memory, suggesting that their degeneration may contribute to the cognitive decline of AD."	( Arrang, JM; Callebert, J; Motawaj, M; Peoc'h, K, 2010)
"Histamine plays an important role in morphine addiction and memory-dependent behavior. "	( Chen, Z; Feng, B; Gong, YX; Ohtsu, H; Shou, WT; Wang, HJ; Zhang, WP, 2010)
"Histamine plays significant roles in early-phase swelling via H₁ receptors and in late-phase swelling via H₃/H₄ receptors in this TPA-modified allergic dermatitis model."	( Hirasawa, N; Ohuchi, K, 2011)
"Histamine plays a major role in allergic rhinitis. "	( Taylor-Clark, T, 2010)
"Histamine plays major roles in allergic diseases and its action is mediated mainly by histamine H(1) receptor (H1R). "	( Choudhuri, MS; Fukui, H; Hattori, M; Maeyama, K; Mizuguchi, H; Mukherjee, PK; Nurul, IM; Shahriar, M; Takeda, N; Venkatesh, P, 2011)
"Histamine plays a role in several (patho) physiological processes that are commonly studied in mouse models. "	( Burhenne, H; Kaever, V; Neumann, D; Seifert, R; Zimmermann, AS, 2011)
"The histaminergic system plays an important role in memory and learning. "	( Fogel, WA; Kiec-Kononowicz, K; Lazewska, D; Mussur, M; Stasiak, A; Unzeta, M, 2011)
"Histamine increase in [Ca(2+)](i) was desensitized by repeated addition of agonist and blocked by a phospholipase C antagonist."	( Carozza, RB; Dartt, DA; Hodges, RR; Li, D; Shatos, MA, 2012)
"Histamine induced the increase of IP1 formation, but failed to cause an increase in extracellularly releasing of [3H]choline metabolites, or intracellular accumulation of [³H]phosphscholine."	( Wang, HL; Wang, LC; Wei, JW, 2013)
"Histamine produce a contractile response in isolated myometrial strips, in the majority of mammals, via H1 histamine receptors activation, but in some species e.g."	( Merwid-Lad, A; Szelag, A; Trocha, M, 2002)
"Histamine plays the role of neurotransmitter in the central nervous system, and histaminergic fibers are widely distributed in the brain."	( Adachi, N, 2002)
"Histamine plays an important role in modulating acquisition and retention in learning and memory process in experimental animals."	( Kamei, C; Nishiga, M, 2003)
"The histamine-induced increase in ICAM-1 expression was inhibited by emedastine but not by azelastine and levocabastine."	( De Paoli, M; DeFranchis, G; Fregona, I; Leonardi, A; Plebani, M; Secchi, A, 2002)
"Histamine induced an increase in serosal-to-mucosal chloride flux leading to a decrease of chloride net absorption."	( Ahrens, F; Aschenbach, JR; Gäbel, G; Garz, B, 2003)
"Thus histamine can increase as well as decrease muscle blood flow, according to local concentration."	( Madri, JA; Payne, GW; Segal, SS; Sessa, WC, 2003)
"Histamine plays an important role in the pathogenesis of atopic asthma through differential regulation of T helper lymphocytes."	( Khan, MM; Packard, KA, 2003)
"of histamine all produce contractions, giving tracings about 4 cm."	( VANE, JR, 1957)
"Histamine and serotonin cause the endothelial cells of certain vessels to separate, and thus to create discrete intercellular gaps."	( MAJNO, G; PALADE, GE; SCHOEFL, GI, 1961)
"Histamine plays an important role in upper and lower airway inflammation."	( Akdis, CA; Blaser, K, 2003)
"Histamine plays an important role in the regulation of gastric acid secretion; however, its role in maintenance of gastric morphology remains unclear. "	( Aihara, T; Furutani, K; Ichikawa, A; Jimbo, K; Kataoka, T; Nakamura, E; Ohtsu, H; Okabe, S; Tanaka, S, 2004)
"Histamine further promotes the immune response and stimulates gastric acid secretion."	( Buzás, E; Falus, A; Fülöp, AK; Gyulai, Z; Klausz, G; Mándi, Y; Scharek, P; Tiszlavicz, L, 2004)
"Histamine and thrombin cause phosphorylation and activation of endothelial NO-synthase (eNOS) on Ser1177. "	( Halldórsson, H; Thorgeirsson, G; Thors, B, 2004)
"Histamine release may cause anaphylactoid reactions. "	( Duda, D; Sattler, J; Sitter, H; Torossian, A, 2004)
"More histamine was needed to produce a wheal in Poland than in Libya: a 20-mm2 wheal required an injected histamine concentration of about 8.8 mg/ml in Libya, 29.5 mg/ml in Italy and 102.1 mg/ml in Poland."	( Al-Bousafy, A; Al-Tubuly, A; Barreto, M; Bohmerova, Z; Falasca, C; Haluszka, J; Lesiak-Bednarek, A; Martella, S; Ronchetti, R; Villa, MP; Zakrzewski, J, 2004)
"Histamine plays an initial central role in airway inflammation, further release of histamine by circulating basophils, and peripheral thrombotic events."	( Hoet, PH; Hoylaerts, MF; Nemery, B; Nemmar, A; Vermylen, J, 2004)
"Histamine plays an important role in the regulation of various immunological functions. "	( Buzás, E; Dobozy, A; Falus, A; Garaczi, E; Jánossy, T; Kemény, L; Koreck, A; Pivarcsi, A; Pos, Z; Széll, M, 2004)
"Histamine evoked an increase in mucin release to 3.9 +/- 0.4 microg/cm2/min (p < 0.01), protein output to 24.1 +/- 3.3 microg/cm2/min (p < 0.01) and viscosity to 12.8 +/- 1.1 (p < 0.05)."	( McCallum, RW; Namiot, Z; Sarosiek, J, 2004)
"Histamine plays an important role in the allergic inflammation. "	( Deichmann, K; Deindl, P; Heinzmann, A; Lau, S; Müller, S; Nickel, R; Niggemann, B; Peri-Jerkan, S; Sengler, C; Sommerfeld, C; Wahn, U, 2005)
"The histamine-induced increase in excitability was unaffected by K+ channel inhibitors; however, it was reduced by either blockage of voltage-gated Ca2+ channels with 200 microM Cd2+ or replacement of extracellular Ca2+ with Mg2+."	( Hardwick, JC; Kotarski, AF; Powers, MJ, 2006)
"Histamine plays a role as a neurotransmitter in the mammalian brain, and histamine release from nerve endings is enhanced in ischemia by facilitation of histaminergic activity."	( Adachi, N, 2005)
"The histamine-induced increase in I(sc) was blocked by the histamine H(1) antagonist, pyrilamine, but was resistant against the histamine H(2) antagonist, cimetidine."	( Diener, M; Hennig, B; Prinz, G; Schultheiss, G; Schunack, W, 2006)
"This histamine-induced increase in the number of citric acid-induced coughs was dose dependently and significantly reduced when animals were pretreated with fexofenadine, a histamine H1 receptor antagonist."	( Kamei, J; Takahashi, Y, 2006)
"Histamine plays an important role in vascular disease. "	( Akhmedov, A; Arnet, C; Iseli, SM; Lüscher, TF; Steffel, J; Tanner, FC, 2006)
"If histamine actually plays an inhibitory role in reward, then it would be expected that mice lacking histamine would be more sensitive to the behavioral effects of cocaine."	( Anaclet, C; Brabant, C; Lin, JS; Ohtsu, H; Quertemont, E; Tirelli, E, 2007)
"Histamine plays a central role in allergic responses. "	( Bousquet, J; Devillier, P, 2007)
"Histamine can inhibit the metastasis of melanoma B16 cells in C57BL/6 mice either through lymphatic or hemal route, and this partly because of its inhibitory effect on tumor growth."	( Li, L; Qin, YS; Yu, HL; Zhang, X, 2007)
"Histamine induced increase in histamine H(1) receptor gene expression in vitro, and the protein kinase C-delta isoform was suggested to mediate the gene expression."	( Fukui, H, 2008)
"Histamine also plays a role in inducing atherosclerosis in the mouse model."	( Ohtsu, H, 2008)
"Histamine tended to increase the released amount of radioactive arachidonic acid."	( Juan, H; Sametz, W, 1980)
"Histamine was able to suppress not only spontaneous GH secretion but also the antiserum-stimulated GH release."	( Guidobono, F; Netti, C; Olgiati, VR; Pagani, F; Pecile, A; Sibilia, V, 1984)
"The histamine-induced increase in nasal airway resistance was 52% inhibited by combined use of the two antihistamine sprays (p less than 0.05), 22% by chlorpheniramine alone (p less than 0.05), and 29% by ranitidine."	( Borum, P; Kirkegaard, J; Maansson, A; Mygind, N; Osterhammel, P; Secher, C, 1982)
"Histamine increase was blocked by alpha-fluoromethyl histidine (alpha FMH), acting after a significant lag period."	( Gomes, EL; Rothschild, AM, 1984)
"Histamine and VIP produce an elevation of cAMP production in gastric glands isolated from the human fetal stomach at 15 weeks gestation. "	( Dupont, C; Gespach, C; Rosselin, G, 1981)
"Histamine was shown to cause vascular leakage via an H1 receptor."	( Bemis, KG; Fleisch, JH; Rinkema, LE, 1984)
"The histamine-induced increase in serum corticosterone levels of stressed rats was considerably antagonized by prazosin, phenoxybenzamine, phentolamine and yohimbine, alpha 1 and alpha 2-adrenergic antagonists."	( Bugajski, J; Gadek, A, 1984)
"Histamine might increase either of these determinants of transport in the sheep lung."	( McNamee, JE, 1983)
"Histamine caused an increase in pulmonary resistance and a decrease in compliance: these effects were partially vagally mediated and partially due to a direct stimulation of smooth muscles by the drug."	( Aguggini, G; Clement, MG; Miserocchi, G, 1981)
"Histamine caused an increase in gastric blood flow and oxygen uptake."	( Granger, DN; Murphree, D; Perry, MA, 1982)
"Histamine plays no major role in AGBM-induced immune injury in the rat and does not prevent a reduction in nephron filtration rate."	( Blantz, RC; Gushwa, LC; Peterson, OW; Tucker, BJ; Wilson, CB, 1981)
"Histamine plays an important role in the control of gastric acid secretion by activating H2 receptors located on parietal cells. "	( Bali, JP; Hollande, F; Magous, R, 1993)
"The histamine-induced increase in rG-CSF binding appeared to be definitely through H2 receptors."	( Doi, M; Mio, M; Nakaya, N; Tasaka, K, 1994)
"Histamine is known to cause edema and excitation of small-diameter primary afferent neurons. "	( Amann, R; Donnerer, J; Lanz, I; Schuligoi, R, 1995)
"Histamine did not increase after antigen challenge."	( Baumgarten, CR; Petersson, G; Wihl, JA, 1995)
"Histamine plays an important role in the control of gastric acid secretion. "	( Asagoe, K; Kita, T; Murakami, M, 1995)
"Histamine is known to activate vasopressin neurons via a histamine receptor subtype 1 and to increase release of vasopressin, but effects on oxytocin neurons have been previously unexplored."	( Hatton, GI; Yang, QZ, 1994)
"Histamine can produce vasodilation of submucosal arterioles by two distinct mechanisms: activation of vascular H1 receptors resulting in release of nitric oxide from endothelium and activation of H3 receptors on sympathetic nerve terminals resulting in presynaptic inhibition of vasoconstrictor tone."	( Beyak, M; Vanner, S, 1995)
"Histamine induced increase in IL-5 production was inhibited by histamine H2-receptor antagonists, but remained unaffected by H1- or H3-receptor antagonists."	( Fleissner, S; Heimann-Weitschat, I; Lindstaedt, R; Schmidt, J; Szelenyi, I, 1994)
"Histamine was chosen because it is one of the naturally occurring inflammatory mediators."	( Chan, KH; Swarts, JD; Tan, L, 1994)
"Histamine elicited an increase in cAMP content in bone marrow stromal cells."	( Mio, M; Nakaya, N; Shimazawa, M; Tasaka, K, 1993)
"Histamine plays a major part in food and wine intolerance."	( Götz, M; Jarisch, R; Wantke, F, 1993)
"Histamine did not increase isometric tension."	( Bodmer, J; Giaever, I; Kamath, J; Keese, C; Moy, AB; Shasby, DM; Shasby, S; Van Engelenhoven, J, 1996)
"Histamine did not cause any major effects on testicular blood flow."	( Bergh, A; Collin, O; Damber, JE, 1996)
"Histamine was shown to increase afferent impulse activity of the small intestine's mesenteric nerves in a dose-dependent manner, the effect being reduced by antagonists of the H1 and H2 histamine receptors. "	( Akoev, GN; Filippova, LV; Sherman, NO, 1996)
"The histamine-induced increase in [Ca2+]i was attenuated completely by chlorpheniramine, an H1 antagonist, but not by cimetidine, an H2 antagonist."	( Furuyama, S; Niisato, N; Ogata, Y; Sugiya, H, 1996)
"Histamine plays a critical role in the pathogenesis of bronchial asthma. "	( Yamauchi, K, 1996)
"Histamine did not increase eosinophil transendothelial migration."	( Hamano, N; Hiruma, K; Isikawa, K; Konno, A; Sirotori, K; Terada, N; Togawa, K, 1996)
"Histamine caused RL to increase at all ages."	( Agani, FH; Dreshaj, IA; Haxhiu, MA; Martin, RJ; Potter, CF, 1996)
"A histamine-induced increase in short-circuit current was also significantly reduced by inhibitors of the cyclooxygenase pathway indicating the involvement of prostaglandin E2 in its action."	( Burakoff, R; Homaidan, FR; Tripodi, J; Zhao, L, 1997)
"Histamine did not cause superoxide anion production by equine neutrophils."	( Cunningham, FM; Foster, AP, 1997)
"Histamine plays an important part in the cutaneous weal and flare response which underlies many allergic skin conditions. "	( Bennett, AR; Church, MK; Clough, GF, 1998)
"The histamine-induced increase in [Ca2+]i transient was significantly inhibited by chlorpheniramine, but not by cimetidine."	( Hattori, Y; Houzen, H; Kanno, M; Yasuda, K; Yoshimoto, K, 1998)
"The histamine-evoked increase was prevented by the H1-receptor antagonist, mepyramine (2 microM)."	( Bunn, SJ; Powis, DA; Zerbes, M, 1998)
"Histamine was found to produce less response in mice to PCl."	( Cao, J; Cheng, X; Lu, J; Wu, F; Xu, Q, 1999)
"Histamine may also activate additional pathways for Ca2+ entry."	( Marley, PD; O'Farrell, M, 1999)
"Histamine did not increase myosin light chain phosphorylation of control or transfected ECV304 cells."	( Chen, YT; Kamath, AM; Ries, DR; Shasby, DM; Shasby, SS; Winter, MC, 1999)
"Histamine plays a key role in the pathogenesis of chronic urticaria (CU). "	( Feldman, L; Gueant, JL; Kanny, G; Mallie, JP; Moneret-Vautrin, DA; Schohn, H, 1993)
"Histamine induced an increase in c-jun mRNA in human embryonic kidney cells stably transfected with the hH(2)R (maximal effect: 554.6 +/- 86.8% of control)."	( del Valle, J; Grand, E; Todisco, A; Wang, LD; Wang, M, 2000)
"Histamine induced an increase in tyrosine phosphorylation in four main clusters of proteins with apparent molecular weights of 25, 35, 65 and 150 kDa."	( Akaishi, Y; Hattori, Y; Kanno, M; Kitabatake, A; Yasuda, K; Yoshimoto, K, 2000)
"The histamine induced increase of acid output in the Heidenhain pouch dog was blocked by 71% 150 min after oral administration of enteric-coated IY-81149 at a dose of 3 mg/kg, and omeprazole showed similar effects."	( Chae, JB; Cho, KD; Huh, IH; Kim, DY; Kim, EJ; Kim, YS; Kwon, D; Lee, SM; Park, CW, 2001)
"Histamine plays a role in various cellular functions, including cell differentiation."	( Falus, A; László, V; Orsó, E; Pállinger, E; Pós, Z; Rothe, G; Schmitz, G; Szeberényi, JB; Szeberényi, S; Zsinkó, M, 2001)
"Histamine plays fundamental roles in numerous immune reactions. "	( Falus, A; Héninger, E; Horváth, B; Igaz, P; Lázaár, E; Novák, I, 2001)
"Histamine failed to increase ([Ca2+](i)) in Ca2+-free medium after cells were pretreated with thapsigargin (an endoplasmic reticulum Ca2+ pump inhibitor)."	( Chen, YC; Cheng, JS; Jan, CR; Lee, KC; Lo, YK; Lu, CH; Tseng, LL; Wang, JL; Wang, JW, 2001)
"Histamine plays important biological roles in cell-to-cell communication; it is a mediator in allergic responses, a regulator of gastric acid secretion, a messenger in bronchial asthma, and a neurotransmitter in the central nervous system. "	( Cheng, X; Horton, JR; Nishibori, M; Sawada, K; Zhang, X, 2001)
"Histamine also plays important roles in bioprotection against various noxious or unfavorable stimuli (convulsion, nociception, drug sensitization, ischemic lesions, stress and so on)."	( Watanabe, T, 2001)
"The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein."	( Ghosh, AK; Hirasawa, N; Ohuchi, K, 2001)
"The histamine-induced increase in intranasal pressure was significantly augmented after repeated antigen challenge, indicating that nasal hyperresponsiveness was achieved. "	( Chiba, Y; Matsuo, K; Misawa, M; Saitoh, N, 2002)
"The histamine-induced increase in cGMP appeared to be mediated through calcium: the increase in cGMP required the presence of calcium in the extracellular medium, and the calcium ionophore A23187 caused a calcium-dependent increase in cGMP."	( Greengard, P; Study, RE, 1978)
"Histamine was found to inhibit cytolysis reversibly and to increase lymphoid cell cyclic AMP levels."	( Henney, CS; Lichtenstein, LM; Plaut, M, 1975)
"The histamine-induced increase in respiration was inhibited when the atropine concentration was raised to 10 (-4) M."	( Berglindh, T, 1977)
"histamine-induced increase of intractracheal pressure and the effect was longer-lasting."	( Bianco, S; Ceserani, R; Gandolfi, C; Marotta, F; Orlando, N; Usardi, MM, 1979)
"Histamine is known to enhance left ventricular contractility in the guinea-pig heart by interacting with H2-receptors. "	( Levi, R; Zavecz, JH, 1978)
"Histamine is known to cause a substantial increase in the permeability of venules to both water and proteins. "	( Baldwin, AL; Wu, NZ, 1992)
"No histamine increase was seen following saline SPT."	( Bindslev-Jensen, C; Petersen, LJ; Skov, PS; Søndergaard, J, 1992)
"Histamine can cause the release of catecholamines from bovine adrenal medullary chromaffin cells by a mechanism distinct from that of the depolarizing agents nicotine or high K+ buffer. "	( Bunn, SJ; Dunkley, PR; Harrison, SM, 1992)
"Histamine is known to increase permeability of venules and to cause formation of gaps between endothelial cells. "	( Baldwin, AL; Wu, NZ, 1992)
"The histamine-induced increase in intracellular calcium was not blocked by the H1 or H2 antagonists pyrilamine or cimetidine (10(-4) M), respectively; however, the response to 10(-6) M histamine was completely blocked by the specific H3 antagonist thioperamide (10(-6) M)."	( Cardillo, R; DiMuzio, J; Post, TJ; Raible, DG; Schulman, ES, 1992)
"Histamine did not inhibit the release of marker proteins from specific or gelatinase containing granules by neutrophils in suspension."	( Boxer, LA; Francis, JW; Petty, HR; Todd, RF, 1991)
"Histamine did not increase adenosine 3',5'-cyclic monophosphate at any doses tested but induced a rapid increase in the cytoplasmic free calcium concentration ([Ca2+]c)."	( Kojima, I; Mine, T; Ogata, E, 1991)
"The histamine-induced increase in Isc was dose-dependent with the maximal increase from the baseline value and EC50 being 4.4 +/- 0.5 microA/cm2 and 10(-6) M, respectively."	( Isono, K; Kanemura, T; Sakai, N; Takeuchi, S; Takeyama, K; Takizawa, T; Tamaoki, J, 1991)
"Histamine was shown to suppress the in vitro generation of secondary syngeneic tumour-specific Ly-2+, L3T4- cytotoxic T cells from Ly-2+, L3T4- precursor cells. "	( Laatikainen, A, 1989)
"Histamine caused an increase of respiratory resistance (Rrs) at lower frequencies and a frequency dependence of Rrs."	( Polko, AH; Visser, BF; Wouters, EF, 1989)
"The histamine increase in the postanaphylactic phase was accompanied by the increase of histidine decarboxylase activity in inflammatory tissues."	( Hirasawa, N; Ohuchi, K; Tsurufuji, S; Watanabe, M, 1987)
"Histamine at lower concentrations between about 5 x 10(-8) and 10(-6) M caused a dose-dependent deceleration of the rhythm of spontaneous contractions."	( Kawai, Y; Ohhashi, T; Watanabe, N, 1988)
"Histamine was shown to suppress to a similar extent the production of interleukin 2 (IL-2) and gamma interferon (IFN-gamma) by Leu 3+, Leu 3+8+, and Leu 3+8- cell subsets."	( Carlsson, R; Dohlsten, M; Hedlund, G; Sjögren, HO, 1988)
"(Histamine levels were lower in one subject and were only 50% higher in another subject than the corresponding baseline value.) Histamine levels and symptom scores were maximal at the same dose of allergen in only four of seven clinical responders."	( Castells, M; Schwartz, LB, 1988)
"The histamine-induced increase in [Ca2+]i was not markedly diminished when the extracellular calcium was bound by excess ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)."	( Avdonin, PV; Danilov, SM; Popov, EG; Posin, EY; Ryan, US; Tkachuk, VA, 1988)
"Histamine was found to produce a marked release of both amines from rat cerebral cortex at concentrations between 0.1 and 1 mM."	( Hill, SJ; Mason, R; Young, CS, 1988)
"Histamine did not produce any marked changes of the duration of a TEA-broadened somatic action potential of B18."	( Chiel, HJ; Kupfermann, I; Weiss, KR, 1988)
"The histamine-induced increase in myocardial oxygen extraction was accompanied by a significant increase in MVO2 in the presence of diphenhydramine."	( Fisher, H; Kang, YH; Merrill, GF; Wei, HM, 1987)
"Histamine stimulated an increase in [Ca2+]i from a resting level of 111 +/- 4 nM (mean +/- SEM, n = 10) to micromolar levels; maximal and half-maximal responses were elicited by 10(-4) M and 5 X 10(-6) M histamine, respectively."	( Gallin, JI; Rotrosen, D, 1986)
"The histamine content was lower in all parts of the upper gastrointestinal tract in duodenal ulcer patients than in controls and was raised again in all regions after selective proximal vagotomy."	( Lorenz, W; Ohmann, C; Rohde, H; Röher, HD; Thon, KP; Weber, D, 1985)
"The histamine-induced increase in RL was blocked by pretreatment with the histamine H1 receptor antagonist, chlorpheniramine, whereas the histamine-induced elevation in Qbr was prevented by the H2 antagonist, metiamide."	( Abraham, WM; el Fawal, H; Eyre, P; Long, WM; Sprung, CL; Wanner, A; Yerger, LD, 1985)
"Histamine failed to enhance responses of the muscle to electrical stimulation of either the muscle, directly, or its motor nerve.7."	( Block, AJ; Reit, E, 1973)

Treatment

Excerpt	Reference
"Histamine treatment (5 mg kg"	( Cremaschi, GA; Formoso, K; Herrero Ducloux, MV; Martinel Lamas, D; Massari, NA; Medina, VA; Nicoud, MB; Sterle, HA; Táquez Delgado, MA, 2020)
"Histamine treatment upregulated VEGF and IL-6 and downregulated PEDF expression in ARPE-19 cells cultivated under hyperglycemic conditions."	( Byeon, HE; Che, JH; Cho, CS; Kim, JH; Kim, YH; Kwon, JW; Lee, BJ; Lee, K; Seok, SH, 2020)
"Histamine levels of HPP-treated loins were in the range of 3.08 to 3.35 μg/g, identical to that of steam-treated loin."	( Berends, P; Devahastin, S; Jiranuntakul, W; Kasemsuwan, T; Nakwiang, N; Saetung, T, 2018)
"Histamine treatment decreased the extracellular glutamate content and alleviated neuronal cell death induced by exogenous glutamate challenge."	( Chen, Z; Fang, Q; Hu, WW; Jin, MM; Lou, GD; Shen, Y; Wang, XF; Xu, TL; Yan, HJ; Yang, Y; Zeng, WZ; Zhang, SH, 2014)
"Histamine treatment had extensive effects on keratinocytes, including effects on proinflammatory responses and cellular functions promoting wound healing. "	( Gutowska-Owsiak, D; Ogg, GS; Salimi, M; Selvakumar, TA; Taylor, S, 2014)
"Histamine treatment failed to produce gastric lesions, but when it was combined with ischemia, the widespread gastric lesions in the corpus mucosa, but not in the antrum, were observed. "	( Brzozowski, T; Konturek, PC; Konturek, SJ; Neurath, MF; Raithel, M; Sliwowski, Z, 2010)
"Histamine treatment substantially reduced the grade of aplasia, the oedema and vascular damage induced by ionising radiation on bone marrow of mice and rats. "	( Bergoc, RM; Carabajal, E; Croci, M; Medina, VA; Rivera, ES, 2010)
"Histamine treatment inhibited significantly exploration of the lesser fear-inducing arms of the labyrinth but its effect was more pronounced when histamine microinjection was in the left BLA."	( Alvarez, EO; Banzan, AM, 2011)
"Histamine-5 Gy and untreated-5 Gy groups were irradiated with a single dose of whole-body Cesium-137 irradiation."	( Bergoc, RM; Carabajal, E; Croci, M; Elverdin, JC; Medina, VA; Prestifilippo, JP; Rivera, ES, 2011)
"Histamine treatment partially reversed the methacholine-induced salivation reduction produced by EP while preventing SMG histological damage. "	( Carabajal, E; Croci, M; Elverdin, JC; Fernández-Solari, J; Medina, VA; Prestifilippo, JP; Rivera, ES, 2012)
"Histamine-5Gy and untreated-5Gy groups were irradiated with a dose of whole-body Cesium-137 irradiation."	( Bergoc, RM; Carabajal, E; Croci, M; Martinel Lamas, DJ; Massari, N; Medina, VA; Prestifilippo, JP; Rivera, ES, 2012)
"Histamine treatment also decreased mRNA expression of ob gene in epididymal white adipose tissue and up-regulated uncoupling protein 1 mRNA expression in brown adipose tissue."	( Chiba, S; Kakuma, T; Masaki, T; Noguchi, H; Sakata, T; Yasuda, T; Yoshimatsu, H; Yoshimichi, G, 2003)
"Histamine treatment of iDC significantly increased the IL-12 p40 mRNA and protein levels compared to histamine untreated iDC."	( Iwabuchi, K; Kikuchi, K; Onoé, K; Pavlinkova, G; Yanagawa, Y, 2003)
"Histamine treatment (0.5 or 5.0 mg/kg, twice daily) protected against this liver injury as evident by normal serum transaminase levels and significantly reduced liver pathology scores."	( Gehlsen, KR; Haaparanta, T; Hornyak, SC, 2003)
"Antihistamine treatment inhibited but did not prevent leucocyte recruitment in the skin flaps post-surgery in +/+ and Wistar rats."	( Guo, Y; Hedqvist, P; Raud, J; Törkvist, L, 2003)
"Histamine treatment for 30 min resulted in an approx."	( Carmosino, M; Mannucci, R; Procino, G; Svelto, M; Tamma, G; Valenti, G, 2007)
"The histamine-treated cells showed increased cytoplasmic staining for MUC5AC compared to cells treated with media alone, and cells pretreated with chlorpheniramine or NFA before histamine treatment."	( Kim, SW; Kim, YM; Lee, CH; Min, YG; Rhee, CS; Won, TB, 2007)
"Histamine-10 Gy and untreated-10 Gy groups were irradiated with a single dose on whole-body using Cesium-137 source (7 Gy/min) and were sacrificed 3 days after irradiation."	( Bergoc, RM; Crescenti, EJ; Cricco, GP; Croci, M; Garbarino, G; Martín, GA; Massari, N; Medina, VA; Mohamad, NA; Núñez, MA; Rivera, ES, 2007)
"Histamine treatment reduced mucosal atrophy, edema and preserved villi, crypts and nuclear and cytoplasmic characteristics of small intestine after radiation exposure. "	( Bergoc, RM; Crescenti, EJ; Cricco, GP; Croci, M; Garbarino, G; Martín, GA; Massari, N; Medina, VA; Mohamad, NA; Núñez, MA; Rivera, ES, 2007)
"Histamine treatment resulted in loss of response of the adenylate cyclase to histamine in purified plasma membranes, but had no effect on basal, vasoactive intestinal peptide (VIP)- or NaF-stimulated enzyme activities."	( Emami, S; Gespach, C; Prost, A, 1984)
"Histamine treatment accelerated tumor growth, but only in normal animals and had little effect on tumor growth in immunocompromised hosts."	( Askenase, PW; Nordlund, JJ, 1983)
"In histamine-treated and in serotonin-treated mice, histological studies of the tumours showed large and numerous foci of haemorrhagic necrosis."	( Burtin, C; Canu, P; Lespinats, G; Salomon, JC; Scheinmann, P, 1982)
"Histamine pretreatment significantly inhibited 5-HT and insulin-derived growth factor-1-induced MAP kinase activation."	( Abe, MK; Chao, TS; Gomes, I; Hershenson, MB; Kelleher, MD; Rosner, MR; Solway, J, 1995)
"Histamine pretreatment (0.1 mM, 10-120 min) failed to modify the inositol phosphate response to a subsequent NaF or thrombin challenge."	( Hall, IP; Hill, SJ; McCreath, G, 1994)
"Two histamine-treated patients showed complete resolution of extensive liver metastasis."	( Asztély, M; Hafström, L; Hellstrand, K; Hermodsson, S; Lindner, P; Lundholm, K; Naredi, P; Rudenstam, CM, 1994)
"Antihistamine pretreatment increased mean baseline measurements of forced expiratory volume in 1 second (FEV1) between 2.58% and 9.28% compared with placebo, which was significant for all drugs except brompheniramine and clemastine. "	( Holgate, ST; Wood-Baker, R, 1993)
"Histamine pretreatment did not affect cell surface high affinity TNF-alpha receptors, as determined by ligand binding and immunodetection, and did not induce KC TNF-alpha production."	( Mitra, RS; Nickoloff, BJ; Shimizu, Y, 1993)
"2. Histamine pretreatment desensitized guinea-pig cortex slices to a subsequent challenge with histamine, which was observed as a reduction in the best-fit maximum response to 182 +/- 32% over basal accumulation."	( Bajusz, I; Banford, PC; Bristow, DR; Vedat, A; Young, JM, 1993)
"3. Histamine (10(-4) M) pretreatment of HeLa cells for 30 min desensitized the subsequent histamine-induced IPn accumulation."	( Bristow, DR; Zamani, MR, 1993)
"With histamine in seven BDP-treated and in five placebo-treated patients, decrease in FEV1 > or = 20 percent from saline solution was paralleled by a significant decrease in tidal volume (VT), inspiratory time (Ti), and expiratory time (Te), and increase in respiratory frequency (RF)."	( Duranti, R; Fanelli, A; Gorini, M; Maggi, E; Scano, G; Stendardi, L, 1993)
"4. Histamine pretreatment in nominal (zero calcium + 0.2 mM EGTA) or in low (0.3 mM) extracellular calcium did not induce histamine receptor desensitization, supporting a role for extracellular calcium in the homologous H1 receptor desensitization process."	( Bristow, DR; Zamani, MR, 1996)
"Antihistamine treatment significantly reduced the increase in plasma histamine levels after the first histamine injection but did not alter the levels after subsequent histamine injections."	( Doenicke, A; Hoernecke, R; Lorenz, W; Moss, J; Ostwald, P; Toledano, A, 1997)
"Histamine treatment did not result in iNOS mRNA expression or detectable NO synthesis."	( Basclain, KA; Garlepp, MJ; Peroni, DJ; Thompson, PJ; Watkins, DN, 1997)
"Histamine pretreatment of non-IBD control tissues reduced anti-IgE responses to levels seen in IBD colon but had no effect in small intestine."	( Crowe, SE; Luthra, GK; Perdue, MH, 1997)
"Antihistamine pretreatment significantly decreased the incidence and severity of the reactions."	( Finn, HA; Laroche, D; Lynch, JP; Moss, J; Renz, CL; Thisted, R; Thurn, JD, 1998)
"Histamine or thrombin treatment also caused IL-8-containing granules to rapidly disappear from HIMEC."	( Bakka, A; Brandtzaeg, P; Haraldsen, G; Jahnsen, FL; Utgaard, JO, 1998)
"Histamine treatment (10-5 M) increased the release of IL-10 from unstimulated (2.2-fold) and LPS-stimulated (1."	( Bissonnette, EY; Ménard, G; Moses, AS; Sirois, J, 2000)
"Histamine treatment induced a similar adhesion phenomenon."	( André, P; Denis, CV; Hynes, RO; Ruggeri, ZM; Saffaripour, S; Wagner, DD; Ware, J, 2000)
"Histamine treatment reduced body fat weight, ob gene expression, and serum leptin concentration more in the model mice than in pair-fed controls."	( Chiba, S; Masaki, T; Sakata, T; Watanabe, T; Yoshimatsu, H, 2001)
"Histamine or serotonin treatment of HFL-1 augmented the expression of eotaxin mRNA."	( Haniuda, M; Koyama, S; Numanami, H; Okubo, Y; Sato, E; Takashi, S; Tsukadaira, A; Ushiyama, T, 2002)
"histamine, whereas pretreatment with p-chlorophenylalanine, a selective depletor of serotonin stores, had no effect."	( Donin, L; Gori, E; Massi, P; Parolaro, D; Patrini, G; Rubino, T, 1992)
"Histamine treatment restored the dopamine response of desensitized tracheal muscle with resensitization of the adrenoceptors."	( Chen, CJ; Shue, CH, 1992)
"Histamine-treated cells showed marked increases in expressions of steady-state c-fos mRNA, with a time course of mRNA induction similar to cells exposed to platelet-derived growth factor or serum, known smooth muscle and fibroblast cell mitogens."	( Kelly, AM; Kotlikoff, MI; Panettieri, RA; Rubinstein, NA; Yadvish, PA, 1990)
"Histamine treatment significantly reduced both the large vessel and middle compartment compliances before and during low venous pressure elevation."	( Barman, SA; Taylor, AE, 1990)
"Histamine treatment increased free cytosolic calcium levels, but not those of adenosine 3',5'-cyclic monophosphate (cAMP) or guanosine 3',5'-cyclic monophosphate (cGMP)."	( Barrett, KE; Beuerlein, G; Dharmsathaphorn, K; Huott, PA; Kagnoff, MF; Wasserman, SI, 1988)
"Treatment with histamine (100 µM) in U&LP of juvenile animals caused increases in baseline tension by 47.84 ± 6.52 mN/g (p < 0.001, n = 51) and by 50.76 ± 4.10 mN/g (p < 0.001, n = 55) in adult animals."	( Chess-Williams, R; Moro, C; Stromberga, Z, 2020)
"Pretreatment with histamine receptor-1 antagonist, azelastine prevented the early effect of nasal secretions of AR patients on epithelial integrity."	( Akdis, CA; Boeckxstaens, G; Boon, L; Bullens, DM; Ceuppens, JL; Farré, R; Hellings, PW; Kortekaas Krohn, I; Raap, U; Seys, SF; Steelant, B; Talavera, K; Van Gerven, L; Van Woensel, M; Wawrzyniak, P, 2018)
"Pretreatment with histamine significantly prevented the cell damage and rescued the expression of GS in a concentration-dependent manner."	( Chen, Z; Gao, JQ; Hou, WW; Hu, WW; Li, J; Shen, Y; Shi, XJ; Tan, L; Tian, YY; Wang, XF; Yan, HJ, 2013)
"pre-treatment with histamine H1 receptor antagonist chlorpheniramine (50 nmol)."	( Altinbas, B; Giuliani, D; Guarini, S; Jochem, J; Kasperska-Zajac, A; Ottani, A; Savci, V; Yalcin, M, 2016)
"treatment with histamine increased the phosphorylation of the NR1 subunit of N-methyl-D-aspartate (NMDA) receptors."	( Iwata, Y; Katsuyama, S; Komatsu, T; Mizoguchi, H; Onodera, K; Orito, T; Sakurada, S; Sakurada, T; Watanabe, C; Watanabe, H; Yonezawa, A, 2011)
"Co-treatment with histamine and the histamine receptor-1 agonist trifluoromethyl toluidide did not inhibit the vacuolation."	( Chen, Z; Hu, WW; Shen, Z; Wang, GH; Wang, Z; Yang, Y; Zhang, XN, 2012)
"Pretreatment with histamine at a concentration of 1 mM induced MUC2 mRNAand protein production, which was equivalent to that caused by 10 µg/ml LPS, but less than that of 0.5 µM PMA."	( Kim, HM; Lee, CH; Rhee, CS, 2012)
"Pretreatment with histamine ameliorated the GalN/LPS-induced necrotic and apoptotic changes in the hepatocytes and inhibited the elevation of serum AST and ALT levels."	( Chiba, S; Endo, M; Kakuma, T; Masaki, T; Noguchi, H; Seike, M; Tatsukawa, H; Watanabe, T; Yoshimatsu, H, 2005)
"Treatment with histamine led to significant dose-dependent reductions in proteinuria compared to the control antibody-injected group and markedly decreased the number of crescentic glomeruli and macrophage infiltration of the glomeruli."	( Adachi, N; Hatta, T; Kameyama, H; Kimura, T; Kishimoto, N; Kusaba, T; Matsubara, H; Mori, Y; Okigaki, M; Sado, Y; Sasaki, S; Sonomura, K; Takeda, K; Tamagaki, K; Tanda, S, 2007)
"Treatment with histamine stimulated the phagocytotic activity of the Tetrahymena to a measurable degree, which was still demonstrable after a week (about 40 generations). "	( Csaba, G; Darvas, Z; László, V, 1983)
"Pigs treated with histamine (2 micrograms/kg/minute for 60 minutes) had significantly higher blood flow to the gastric mucosa (P less than 0.025), particularly to the region of the proper gastric (fundic) glands (P less than 0.01), than did the saline-treated pigs."	( Gallagher, L; Johnson, P; Reddy, VK; Zamora, CS, 1981)
"Pretreatment with histamine significantly potentiated the increases in RL caused by vagal stimulation but the potentiation of the increases in RL produced by histamine and acetylcholine were not significant."	( Dixon, M; Jackson, DM; Richards, IM, 1980)
"Treatment with histamine increased P1CP production in keloid fibroblasts, although it did not change that in the controls."	( Kadono, T; Kikuchi, K; Takehara, K, 1995)
"Treatment with histamine (0.1, 0.2, 0.4 mumol/rat, i.c.v.) 150 min after intraplantar carrageenin (0.1 ml of 1% solution) caused a significant increase of paw pressure thresholds in inflamed (but not in non-inflamed) paws."	( Braga, PC; Guidobono, F; Netti, C; Pecile, A; Sibilia, V; Villani, P, 1994)
"Pretreatment with histamine inhibited IL-2 mRNA expression and secretion in cells activated with anti-CD3 or PMA, but not in cells activated with PMA + ionomycin."	( Huggler, GK; Khan, MM; Patterson, EB; Poluektova, LY, 1999)
"Pretreatment by histamine perfusion (10(-5) M final concentration) increased this value to 30 +/- 9% (p < 0.001), and pretreatment by Ca2+-free buffer perfusion increased it to 67 +/- 8% (p < 0.001)."	( Chossat, N; Haddada, H; Hatem, SN; Heimburger, M; Logeart, D; Mercadier, JJ; Névo, N; Perricaudet, M; Rücker-Martin, C, 2000)
"treatment with histamine thus makes it possible to partially restore the distorted energy intake and expenditure in leptin-resistant mice."	( Chiba, S; Masaki, T; Sakata, T; Watanabe, T; Yoshimatsu, H, 2001)
"Also treatment with histamine markedly reduced ulcer area evoked by WRS."	( Brzozowski, T; Ceranowicz, P; Dembiński, A; Dembiński, M; Konturek, SJ; Stachura, J; Warzecha, Z, 2001)
"1 Treatment with histamine H2-receptor antagonists, which inhibit basal acid secretion was found to activate rat stomach histidine decarboxylase. "	( Häkanson, R; Hedenbro, J; Liedberg, G; Rehfeld, JF; Stadil, F, 1975)
"Pretreatment with histamine had no effect on rat gastric tissue or gastric secretion, under identical conditions of stimulation."	( Kowalewski, K, 1976)
"Treatment with histamine (10(-4) M) of cultured non-pigmented human ciliary epithelial cells led to a biphasic elevation of free intracellular calcium mediated by H1-receptors. "	( Stahl, F; Strauss, O; Wiederholt, M, 1992)
"Treatment with histamine only did not affect the level of specific IgE antibody."	( Nakazawa, T; Umegae, Y, 1992)
"Pretreatment with histamine H2 receptor antagonist cimetidine significantly reduced the extravasation of both the tracers and thwarted the increase of brain water content as compared to the untreated group."	( Cervós-Navarro, J; Sharma, HS, 1991)
"The treatment of histamine type 2 (H2) agonist showed decreased PFC responses in the mouse as well as histamine did."	( Abe, T; Furusawa, S; Okitsu-Negishi, S; Yoshino, K, 1988)

Pathways (110)

histamine is involved in 110 pathway(s), involving a total of 1086 unique proteins and 1546 unique compounds

Role	Description
neurotransmitter	An endogenous compound that is used to transmit information across the synapse between a neuron and another cell.
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
aralkylamino compound	An organic amino compound in which an aminoalkyl group is linked to an arene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism	44	85
Histidine Metabolism	17	35
Histidinemia	17	35
Esomeprazole Action Pathway	10	13
Omeprazole Action Pathway	10	14
Lansoprazole Action Pathway	10	12
Pantoprazole Action Pathway	10	13
Rabeprazole Action Pathway	10	13
Ranitidine Action Pathway	10	12
Famotidine Action Pathway	10	12
Cimetidine Action Pathway	10	12
Nizatidine Action Pathway	10	12
Pirenzepine Action Pathway	10	12
Intracellular Signalling Through Histamine H2 Receptor and Histamine	9	7
Fc Epsilon Receptor I Signaling in Mast Cells	42	11
Gastric Acid Production	10	11
Roxatidine Acetate Action Pathway	10	12
Metiamide Action Pathway	10	12
Betazole Action Pathway	10	12
Lafutidine H2-Antihistamine Action	10	12
Chlorphenamine H1-Antihistamine Action	8	7
Pheniramine H1-Antihistamine Action	8	7
Dexchlorpheniramine H1-Antihistamine Action	8	7
Brompheniramine H1-Antihistamine Action	8	7
Dexbrompheniramine H1-Antihistamine Action	8	7
Triprolidine H1-Antihistamine Action	8	7
Dimetindene H1-Antihistamine Action	8	7
Mepyramine H1-Antihistamine Action	8	7
Antazoline H1-Antihistamine Action	8	7
Chloropyramine H1-Antihistamine Action	8	7
Talastine H1-Antihistamine Action	8	7
Tripelennamine H1-Antihistamine Action	8	7
Histapyrrodine H1-Antihistamine Action	8	7
Methapyrilene H1-Antihistamine Action	8	7
Thonzylamine H1-Antihistamine Action	8	7
Diphenhydramine H1-Antihistamine Action	8	7
Carbinoxamine H1-Antihistamine Action	8	7
Doxylamine H1-Antihistamine Action	8	7
Orphenadrine H1-Antihistamine Action	8	7
Bromodiphenhydramine H1-Antihistamine Action	8	7
Clemastine H1-Antihistamine Action	8	7
Chlorphenoxamine H1-Antihistamine Action	8	7
Diphenylpyraline H1-Antihistamine Action	8	7
Phenyltoloxamine H1-Antihistamine Action	8	7
Cyclizine H1-Antihistamine Action	8	7
Chlorcyclizine H1-Antihistamine Action	8	7
Hydroxyzine H1-Antihistamine Action	8	7
Meclizine H1-Antihistamine Action	8	7
Buclizine H1-Antihistamine Action	8	7
Oxatomide H1-Antihistamine Action	8	7
Cetirizine H1-Antihistamine Action	8	7
Cinnarizine H1-Antihistamine Action	8	7
Levocetirizine H1-Antihistamine Action	8	7
Promethazine H1-Antihistamine Action	8	7
Alimemazine H1-Antihistamine Action	8	7
Cyproheptadine H1-Antihistamine Action	8	7
Phenbenzamine H1-Antihistamine Action	8	7
Fenethazine H1-Antihistamine Action	8	7
Hydroxyethylpromethazine H1-Antihistamine Action	8	7
Isothipendyl H1-Antihistamine Action	8	7
Mequitazine H1-Antihistamine Action	8	7
Methdilazine H1-Antihistamine Action	8	7
Oxomemazine H1-Antihistamine Action	8	7
Azatadine H1-Antihistamine Action	8	7
Ketotifen H1-Antihistamine Action	8	7
Doxepin H1-Antihistamine Action	8	7
Acrivastine H1-Antihistamine Action	8	7
Astemizole H1-Antihistamine Action	8	7
Bepotastine H1-Antihistamine Action	8	7
Bilastine H1-Antihistamine Action	8	7
Loratadine H1-Antihistamine Action	8	7
Desloratadine H1-Antihistamine Action	8	7
Ebastine H1-Antihistamine Action	8	7
Terfenadine H1-Antihistamine Action	8	7
Fexofenadine H1-Antihistamine Action	8	7
Levocabastine H1-Antihistamine Action	8	7
Mizolastine H1-Antihistamine Action	8	7
Rupatadine H1-Antihistamine Action	8	7
Olopatadine H1-Antihistamine Action	8	7
Azelastine H1-Antihistamine Action	8	7
Thiazinamium H1-Antihistamine Action	8	7
Quifenadine H1-Antihistamine Action	8	7
Betahistine H1-Antihistamine Action	8	7
Emedastine H1-Antihistamine Action	8	7
Flunarizine H1-Antihistamine Action	8	7
Mebhydrolin H1-Antihistamine Action	8	7
Phenindamine H1-Antihistamine Action	8	7
Epinastine H1-Antihistamine Action	8	7
Tolpropamine H1-Antihistamine Action	8	7
Embramine H1-Antihistamine Action	8	7
Latrepirdine H1-Antihistamine Action	8	7
Thenyldiamine H1-Antihistamine Action	8	7
Propiomazine H1-Antihistamine Action	8	7
Clocinizine H1-Antihistamine Action	8	7
Homochlorcyclizine H1-Antihistamine Action	8	7
Temelastine H1-Antihistamine Action	8	7
Alcaftadine H1-Antihistamine Action	8	7
Bamipine H1-Antihistamine Action	8	7
Deptropine H1-Antihistamine Action	8	7
Quetiapine H1-Antihistamine Action	8	7
Mirtazapine H1-Antihistamine Action	8	7
Pimethixene H1-Antihistamine Action	8	7
Pyrrobutamine H1-Antihistamine Action	8	7
Thenalidine H1-Antihistamine Action	8	7
Tritoqualine H1-Antihistamine Action	8	7
Histamine H1 Receptor Activation	8	6
Histidine degradation ( Histidine degradation )	23	26
CCL18 signaling pathway	96	2
Biochemical pathways: part I	0	466
Amino acid metabolism	0	94

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	5.6234	0.0032	45.4673	12,589.2998	AID2517
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	3,162.2800	0.0447	17.8581	100.0000	AID485294
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	23.7781	0.1000	20.8793	79.4328	AID488772
phosphopantetheinyl transferase	Bacillus subtilis	Potency	12.9244	0.1413	37.9142	100.0000	AID1490
USP1 protein, partial	Homo sapiens (human)	Potency	44.6684	0.0316	37.5844	354.8130	AID504865
GALC protein	Homo sapiens (human)	Potency	0.7079	28.1838	28.1838	28.1838	AID1159614
GLS protein	Homo sapiens (human)	Potency	0.2818	0.3548	7.9355	39.8107	AID624146
AR protein	Homo sapiens (human)	Potency	26.8325	0.0002	21.2231	8,912.5098	AID743035; AID743063
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	5.0119	0.7079	12.1943	39.8107	AID720542
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	31.6228	0.0013	18.0743	39.8107	AID926; AID938
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	10.6213	0.5318	15.4358	37.6858	AID504845
EWS/FLI fusion protein	Homo sapiens (human)	Potency	14.6921	0.0013	10.1577	42.8575	AID1259252; AID1259253
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	79.4328	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	8.4368	0.0355	20.9770	89.1251	AID504332
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	28.1838	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	33.4915	0.0003	23.4451	159.6830	AID743065
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.8913	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 3	Homo sapiens (human)	Ki	140.0000	0.1200	0.1200	0.1200	AID681689
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1449628
Macrophage migration inhibitory factor	Homo sapiens (human)	IC50 (µMol)	73.6000	0.0380	3.0910	9.8000	AID1877334
Macrophage migration inhibitory factor	Homo sapiens (human)	Ki	62.0000	0.0380	2.2256	5.5500	AID1877338
Histamine H2 receptor	Homo sapiens (human)	Ki	13.7162	0.0006	2.1973	10.0000	AID1249559; AID1661702; AID1756648; AID1830579; AID1895194; AID548984; AID88468
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	Ki	12.5892	0.0026	1.7832	10.0000	AID87062
Histamine H1 receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1585	0.0000	0.3227	1.2589	AID87362
Histamine H1 receptor	Rattus norvegicus (Norway rat)	Ki	15,848,899,584.0000	0.0007	1.5440	6.5000	AID87372
Metabotropic glutamate receptor 5	Rattus norvegicus (Norway rat)	Ki	0.0052	0.0005	0.1964	3.7600	AID479096
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	0.1585	0.0000	0.4436	5.1768	AID87362
Histamine H1 receptor	Homo sapiens (human)	Ki	1,440,809,168.8762	0.0000	0.5110	10.0000	AID1249556; AID1756647; AID1895193; AID500222; AID500223; AID500224; AID500225; AID500226; AID500227; AID500228; AID87372
Histamine H3 receptor	Mus musculus (house mouse)	Ki	0.0680	0.0006	0.0181	0.0680	AID426166
Histamine N-methyltransferase	Rattus norvegicus (Norway rat)	Ki	0.0144	0.0144	0.0144	0.0144	AID90040
Glutaminyl-peptide cyclotransferase	Homo sapiens (human)	Ki	850.0000	0.2620	2.9358	7.0000	AID1796109
Solute carrier family 22 member 1	Rattus norvegicus (Norway rat)	Ki	770.5000	0.1300	2.3785	6.9000	AID679214; AID681375
Histamine H4 receptor	Rattus norvegicus (Norway rat)	Ki	0.0996	0.0024	0.9296	8.5110	AID1249563; AID549011
Histamine H4 receptor	Mus musculus (house mouse)	Ki	0.0607	0.0026	0.6978	5.1250	AID1249562; AID549008
Histamine H4 receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0060	0.0060	0.3309	1.0715	AID1249561
Histamine H4 receptor	Homo sapiens (human)	Ki	0.0144	0.0006	0.4787	10.0000	AID1249557; AID1249560; AID1323898; AID1693528; AID1756650; AID1798265; AID1895197; AID239984; AID327691; AID404336; AID462453; AID483141; AID548981; AID549005; AID586694; AID632452; AID638337; AID90040
Histamine H3 receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0001	0.0001	0.0030	0.0126	AID86442
Solute carrier family 22 member 2	Rattus norvegicus (Norway rat)	Ki	280.5000	0.3900	2.3295	9.4000	AID679638; AID681368
Histamine H3 receptor	Homo sapiens (human)	Ki	0.0801	0.0001	0.3399	8.5110	AID1249558; AID1323901; AID1558682; AID1558712; AID1693529; AID1756649; AID1798266; AID1829881; AID1829899; AID1895195; AID479096; AID548987; AID586693; AID632451; AID86614; AID86619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, CARBONIC ANHYDRASE II	Homo sapiens (human)	Kd	125.0000	125.0000	125.0000	125.0000	AID977611
Chain A, Protein (female-specific Histamine Binding Protein 2)	Rhipicephalus appendiculatus	Kd	0.0017	0.0017	0.0017	0.0017	AID977611
Histamine H2 receptor	Homo sapiens (human)	EC50 (µMol)	1.8055	0.1148	1.7769	5.4954	AID1661706; AID1756656; AID1756658; AID1830576; AID1830581; AID1830582; AID1830584; AID1895209; AID1895211; AID270367; AID345033; AID414924; AID471096; AID478880; AID88336
Histamine H2 receptor	Homo sapiens (human)	Kd	0.0122	0.0122	0.0919	0.2512	AID1895194
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	0.1622	0.0026	0.5334	1.2020	AID86921
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	Kd	0.0008	0.0008	0.1228	0.9550	AID86904
Histamine H1 receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	4.4668	0.1585	1.8255	4.4668	AID87543
Metabotropic glutamate receptor 5	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.6400	0.0015	1.6537	10.0000	AID479097
Histamine H1 receptor	Homo sapiens (human)	EC50 (µMol)	0.1511	0.0004	0.1881	0.7943	AID1300592; AID270366; AID345031; AID414923; AID471095; AID478884; AID548979; AID87232
Histamine H1 receptor	Homo sapiens (human)	Kd	0.0045	0.0001	0.4021	5.4000	AID1895193
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	0.8074	0.0003	0.5719	1.2023	AID1756654; AID1895213; AID1895214; AID345035; AID478882
Histamine H4 receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	14.1624	0.0026	1.0668	3.7153	AID1540383; AID1540405; AID1540407; AID546820
Histamine H4 receptor	Rattus norvegicus (Norway rat)	Kd	0.1340	0.1340	0.1340	0.1340	AID1540380
Histamine H4 receptor	Mus musculus (house mouse)	EC50 (µMol)	2.8596	0.0024	2.0716	8.7096	AID1300595; AID1540382; AID1540401; AID1540403; AID549009
Histamine H4 receptor	Mus musculus (house mouse)	Kd	0.0420	0.0420	0.0420	0.0420	AID1540379
Histamine H4 receptor	Homo sapiens (human)	EC50 (µMol)	0.1124	0.0074	0.6016	10.0000	AID1272169; AID1300588; AID1300593; AID1540381; AID1540397; AID1540399; AID270369; AID345039; AID414926; AID452998; AID453000; AID471098; AID478888; AID548982; AID548993; AID549006; AID586696; AID89895; AID90034; AID90035
Histamine H4 receptor	Homo sapiens (human)	Kd	0.0105	0.0040	0.0194	0.0702	AID1540378; AID1895197
Histamine H3 receptor	Homo sapiens (human)	EC50 (µMol)	0.0615	0.0000	0.0947	3.1623	AID1300585; AID1558683; AID1558686; AID1558713; AID1690423; AID1690426; AID270368; AID345037; AID414925; AID471097; AID478886; AID479097; AID548991; AID586697; AID86450; AID86477; AID86478
Histamine H3 receptor	Homo sapiens (human)	Kd	0.0030	0.0001	0.0138	0.0631	AID1895195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
aryl hydrocarbon receptor nuclear translocator	Homo sapiens (human)	AC50	23.0800	0.1900	23.3694	115.5100	AID651703
transforming acidic coiled-coil-containing protein 3	Homo sapiens (human)	AC50	23.0800	0.1900	24.2333	115.5100	AID651703
Solute carrier family 22 member 2	Homo sapiens (human)	Km	1,300.0000	0.0289	1.0407	2.6000	AID679157
Solute carrier family 22 member 1	Homo sapiens (human)	Activity	3,007.0000	0.7100	5.3017	9.7000	AID681117
Carbonic anhydrase 12	Homo sapiens (human)	KA	27.9250	0.2400	0.8192	1.6700	AID1186310; AID1815483; AID318346; AID431566
Carbonic anhydrase 1	Homo sapiens (human)	Ka	1.9738	0.0200	1.7219	7.4000	AID1186307; AID1331203; AID1397319; AID1435058; AID1537221; AID1815474; AID268620; AID291061; AID293051; AID318343; AID365827; AID409984; AID431557; AID462829; AID50346; AID50347; AID50348; AID50358; AID609368; AID691713; AID725228
Carbonic anhydrase 2	Homo sapiens (human)	Ka	117.8913	0.0110	1.4273	7.8000	AID1186308; AID1331204; AID1397320; AID1435059; AID1537222; AID1815475; AID268621; AID291063; AID293052; AID318344; AID365828; AID409986; AID414329; AID431558; AID462830; AID464319; AID47752; AID47753; AID47897; AID47907; AID609369; AID691714; AID725229
Plasma kallikrein	Homo sapiens (human)	KA	3.5200	0.0440	1.3974	4.3800	AID305777
Carbonic anhydrase 3	Homo sapiens (human)	Ka	36.9250	0.0910	0.7285	1.1200	AID1815476; AID365829; AID409993; AID431559
Carbonic anhydrase 4	Homo sapiens (human)	KA	24.7043	0.0790	4.4560	7.3000	AID1537223; AID1815477; AID257047; AID293053; AID365830; AID375786; AID431560
Carbonic anhydrase 6	Homo sapiens (human)	KA	14.2750	1.2000	5.8276	9.5400	AID1537224; AID1815480; AID431563; AID462831
Adenosine receptor A1	Rattus norvegicus (Norway rat)	KA	125.0000	0.0110	1.3233	7.8000	AID691714
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	KA	125.0000	0.0110	1.3233	7.8000	AID691714
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	KA	0.6325	0.0100	2.7926	9.8100	AID1815478; AID293054; AID305776; AID431561
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Carbonic anhydrase 7	Homo sapiens (human)	KA	31.4000	0.7100	3.8756	10.0000	AID1186309; AID1768134; AID1815481; AID291065; AID293055; AID431564
Carbonic anhydrase	Saccharomyces cerevisiae S288C	Ka	20.4000	0.9500	5.1250	9.3000	AID414331; AID464321
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Carbonic anhydrase 9	Homo sapiens (human)	KA	35.0667	0.0090	4.2493	9.7100	AID1815482; AID318345; AID431565
Carbonic anhydrase-like protein, putative	Trypanosoma cruzi strain CL Brener	KA	2.7300	0.1400	2.8050	7.5400	AID1397322
Carbonic anhydrase	Candida albicans SC5314	KA	18.4000	0.9600	3.9533	8.4000	AID458784
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Solute carrier family 22 member 1	Rattus norvegicus (Norway rat)	Km	199.3000	0.2700	5.6950	10.0000	AID678817; AID679822
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ka	27.4000	7.1000	8.3000	9.5000	AID464322
Carbonic anhydrase 13	Homo sapiens (human)	KA	4.6000	0.0500	1.1133	4.6000	AID1815484
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Carbonic anhydrase 15	Mus musculus (house mouse)	KA	18.5000	4.0000	7.6857	9.5000	AID375787
Carbonic anhydrase 13	Mus musculus (house mouse)	KA	4.6000	0.0130	1.5140	4.6000	AID268622; AID431567
Carboxylic ester hydrolase	Rattus norvegicus (Norway rat)	KA	32.7000	0.8800	0.8950	0.9100	AID1186309; AID1186310
Solute carrier family 22 member 2	Rattus norvegicus (Norway rat)	Km	409.0000	9.4000	9.4000	9.4000	AID678807; AID681589
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	KA	37.5000	0.7100	3.7900	9.7400	AID291065
Carbonic anhydrase 14	Homo sapiens (human)	Ka	0.3880	0.0100	2.2894	7.2100	AID1186311; AID1815485; AID291067; AID293056; AID431568
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	KA	3.5133	0.0440	2.1205	10.0000	AID1815479; AID305777; AID431562
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
Factor XII activation	Plasma kallikrein	Homo sapiens (human)
proteolysis	Plasma kallikrein	Homo sapiens (human)
blood coagulation	Plasma kallikrein	Homo sapiens (human)
zymogen activation	Plasma kallikrein	Homo sapiens (human)
plasminogen activation	Plasma kallikrein	Homo sapiens (human)
fibrinolysis	Plasma kallikrein	Homo sapiens (human)
positive regulation of fibrinolysis	Plasma kallikrein	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
prostaglandin biosynthetic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of cytokine production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of mature B cell apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
inflammatory response	Macrophage migration inhibitory factor	Homo sapiens (human)
cell surface receptor signaling pathway	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of cell population proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of gene expression	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of macrophage chemotaxis	Macrophage migration inhibitory factor	Homo sapiens (human)
carboxylic acid metabolic process	Macrophage migration inhibitory factor	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of cell migration	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of B cell proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathway	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of myeloid cell apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
regulation of macrophage activation	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
innate immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive chemotaxis	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of protein metabolic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of prostaglandin secretion involved in immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
protein homotrimerization	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Macrophage migration inhibitory factor	Homo sapiens (human)
cellular senescence	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of cellular senescence	Macrophage migration inhibitory factor	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
gastric acid secretion	Histamine H2 receptor	Homo sapiens (human)
immune response	Histamine H2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H2 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H2 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of locomotion	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
inflammatory response	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
memory	Histamine H1 receptor	Homo sapiens (human)
visual learning	Histamine H1 receptor	Homo sapiens (human)
regulation of vascular permeability	Histamine H1 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H1 receptor	Homo sapiens (human)
regulation of synaptic plasticity	Histamine H1 receptor	Homo sapiens (human)
cellular response to histamine	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H1 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H1 receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
protein modification process	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
histamine metabolic process	Equilibrative nucleoside transporter 4	Homo sapiens (human)
neurotransmitter transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
serotonin transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
organic cation transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
monoamine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
dopamine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
norepinephrine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
adenosine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
xenobiotic transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
epinephrine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
histamine transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
serotonin uptake	Equilibrative nucleoside transporter 4	Homo sapiens (human)
histamine uptake	Equilibrative nucleoside transporter 4	Homo sapiens (human)
norepinephrine uptake	Equilibrative nucleoside transporter 4	Homo sapiens (human)
epinephrine uptake	Equilibrative nucleoside transporter 4	Homo sapiens (human)
dopamine uptake	Equilibrative nucleoside transporter 4	Homo sapiens (human)
monoatomic cation transmembrane transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
export across plasma membrane	Equilibrative nucleoside transporter 4	Homo sapiens (human)
transport across blood-brain barrier	Equilibrative nucleoside transporter 4	Homo sapiens (human)
nucleoside transmembrane transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
organic acid transmembrane transport	Equilibrative nucleoside transporter 4	Homo sapiens (human)
cellular detoxification	Equilibrative nucleoside transporter 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 13	Homo sapiens (human)
inflammatory response	Histamine H4 receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Histamine H4 receptor	Homo sapiens (human)
biological_process	Histamine H4 receptor	Homo sapiens (human)
regulation of MAPK cascade	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H4 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H4 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H4 receptor	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
neurotransmitter secretion	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H3 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H3 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
serine-type endopeptidase activity	Plasma kallikrein	Homo sapiens (human)
protein binding	Plasma kallikrein	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
protease binding	Macrophage migration inhibitory factor	Homo sapiens (human)
dopachrome isomerase activity	Macrophage migration inhibitory factor	Homo sapiens (human)
cytokine activity	Macrophage migration inhibitory factor	Homo sapiens (human)
cytokine receptor binding	Macrophage migration inhibitory factor	Homo sapiens (human)
protein binding	Macrophage migration inhibitory factor	Homo sapiens (human)
chemoattractant activity	Macrophage migration inhibitory factor	Homo sapiens (human)
identical protein binding	Macrophage migration inhibitory factor	Homo sapiens (human)
phenylpyruvate tautomerase activity	Macrophage migration inhibitory factor	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
histamine receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H2 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
selenol Se-methyltransferase activity	Histamine N-methyltransferase	Rattus norvegicus (Norway rat)
protein binding	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
zinc ion binding	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
glutaminyl-peptide cyclotransferase activity	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
nucleoside transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
organic acid transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
monoatomic cation transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
monoamine transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
organic cation transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
efflux transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
toxin transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Equilibrative nucleoside transporter 4	Homo sapiens (human)
protein binding	Carbonic anhydrase 13	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 13	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 13	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Bos taurus (cattle)
histamine receptor activity	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H4 receptor	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
histamine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular region	Plasma kallikrein	Homo sapiens (human)
extracellular space	Plasma kallikrein	Homo sapiens (human)
plasma membrane	Plasma kallikrein	Homo sapiens (human)
extracellular exosome	Plasma kallikrein	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
extracellular region	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular space	Macrophage migration inhibitory factor	Homo sapiens (human)
nucleoplasm	Macrophage migration inhibitory factor	Homo sapiens (human)
cytoplasm	Macrophage migration inhibitory factor	Homo sapiens (human)
cytosol	Macrophage migration inhibitory factor	Homo sapiens (human)
plasma membrane	Macrophage migration inhibitory factor	Homo sapiens (human)
cell surface	Macrophage migration inhibitory factor	Homo sapiens (human)
vesicle	Macrophage migration inhibitory factor	Homo sapiens (human)
secretory granule lumen	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular exosome	Macrophage migration inhibitory factor	Homo sapiens (human)
ficolin-1-rich granule lumen	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular space	Macrophage migration inhibitory factor	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
synapse	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
dendrite	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
cytosol	Histamine N-methyltransferase	Rattus norvegicus (Norway rat)
extracellular region	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
specific granule lumen	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
extracellular exosome	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
tertiary granule lumen	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
ficolin-1-rich granule lumen	Glutaminyl-peptide cyclotransferase	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Equilibrative nucleoside transporter 4	Homo sapiens (human)
basolateral plasma membrane	Equilibrative nucleoside transporter 4	Homo sapiens (human)
apical plasma membrane	Equilibrative nucleoside transporter 4	Homo sapiens (human)
presynapse	Equilibrative nucleoside transporter 4	Homo sapiens (human)
plasma membrane	Equilibrative nucleoside transporter 4	Homo sapiens (human)
cytosol	Carbonic anhydrase 13	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 13	Homo sapiens (human)
intracellular membrane-bounded organelle	Carbonic anhydrase 13	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 13	Homo sapiens (human)
cytosol	Carbonic anhydrase 13	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
side of membrane	Carbonic anhydrase 4	Bos taurus (cattle)
plasma membrane	Histamine H4 receptor	Homo sapiens (human)
plasma membrane	Histamine H4 receptor	Homo sapiens (human)
dendrite	Histamine H4 receptor	Homo sapiens (human)
synapse	Histamine H4 receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
presynapse	Histamine H3 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
synapse	Histamine H3 receptor	Homo sapiens (human)
dendrite	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (598)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346017	Rat H3 receptor (Histamine receptors)	2001	Biochemical and biophysical research communications, Jan-12, Volume: 280, Issue:1	The rat H3 receptor: gene organization and multiple isoforms.
AID1346107	Human H3 receptor (Histamine receptors)	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID1346037	Human H1 receptor (Histamine receptors)	2004	European journal of biochemistry, Jul, Volume: 271, Issue:13	Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor.
AID1346107	Human H3 receptor (Histamine receptors)	2000	British journal of pharmacology, Dec, Volume: 131, Issue:7	Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain.
AID1346133	Rat H2 receptor (Histamine receptors)	1997	British journal of pharmacology, Nov, Volume: 122, Issue:5	Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells.
AID1346107	Human H3 receptor (Histamine receptors)	2002	European journal of pharmacology, Oct-18, Volume: 453, Issue:1	Characteristics of recombinantly expressed rat and human histamine H3 receptors.
AID1346017	Rat H3 receptor (Histamine receptors)	2000	British journal of pharmacology, Dec, Volume: 131, Issue:7	Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain.
AID1346037	Human H1 receptor (Histamine receptors)	2006	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 317, Issue:1	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines.
AID1346107	Human H3 receptor (Histamine receptors)	2000	The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3	Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
AID1346107	Human H3 receptor (Histamine receptors)	2001	Molecular pharmacology, Mar, Volume: 59, Issue:3	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
AID1346055	Human H4 receptor (Histamine receptors)	2001	The Journal of pharmacology and experimental therapeutics, Mar, Volume: 296, Issue:3	Cloning and characterization of a novel human histamine receptor.
AID1346037	Human H1 receptor (Histamine receptors)	1994	European journal of biochemistry, Sep-01, Volume: 224, Issue:2	Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene.
AID1346017	Rat H3 receptor (Histamine receptors)	2000	The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3	Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
AID1346088	Mouse H3 receptor (Histamine receptors)	2003	European journal of pharmacology, Apr-25, Volume: 467, Issue:1-3	Molecular and pharmacological characterization of the mouse histamine H3 receptor.
AID1346044	Mouse H4 receptor (Histamine receptors)	2001	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1	Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346055	Human H4 receptor (Histamine receptors)	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID1346055	Human H4 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1346107	Human H3 receptor (Histamine receptors)	2001	The Biochemical journal, Apr-15, Volume: 355, Issue:Pt 2	Genomic organization and characterization of splice variants of the human histamine H3 receptor.
AID1346055	Human H4 receptor (Histamine receptors)	2001	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1	Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346055	Human H4 receptor (Histamine receptors)	2006	British journal of pharmacology, Apr, Volume: 147, Issue:7	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
AID1346028	Rat H4 receptor (Histamine receptors)	2001	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1	Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346037	Human H1 receptor (Histamine receptors)	2003	The Journal of pharmacology and experimental therapeutics, Jun, Volume: 305, Issue:3	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor.
AID1346055	Human H4 receptor (Histamine receptors)	2001	Molecular pharmacology, Mar, Volume: 59, Issue:3	Cloning, expression, and pharmacological characterization of a novel human histamine receptor.
AID1346088	Mouse H3 receptor (Histamine receptors)	2004	Journal of neurochemistry, Sep, Volume: 90, Issue:6	Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms.
AID1346037	Human H1 receptor (Histamine receptors)	2002	The Journal of pharmacology and experimental therapeutics, Jul, Volume: 302, Issue:1	A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors.
AID1346055	Human H4 receptor (Histamine receptors)	2001	Molecular pharmacology, Mar, Volume: 59, Issue:3	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346107	Human H3 receptor (Histamine receptors)	2001	Molecular pharmacology, Mar, Volume: 59, Issue:3	Discovery of a novel member of the histamine receptor family.
AID1346055	Human H4 receptor (Histamine receptors)	2000	The Journal of biological chemistry, Nov-24, Volume: 275, Issue:47	Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes.
AID1346055	Human H4 receptor (Histamine receptors)	2001	Molecular pharmacology, Mar, Volume: 59, Issue:3	Discovery of a novel member of the histamine receptor family.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID500231	Inverse agonist activity at human wild-type histamine H1 receptor N7.45C mutant assessed as NF-kappaB activation at 0.1 mM after 48 hrs by luciferase reporter gene assay	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID478883	Selectivity ratio of EC50 for human histamine 5HT2 to EC50 for guinea pig 5HT2 receptor	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID193680	Maximum rate of rise of the left ventricular isovolumetric pressure (dP/dt, an index of cardiac inotropism in mmHg/sec)in anesthetized rats by i.v. administration	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Further hypotensive metabolites from Verbesina caracasana.
AID444825	Cytotoxicity against human U937 cells after 3 days by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID50343	Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 uM	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID1756649	Displacement of [3H]UR-P129 from human histamine H3 receptor expressed in sf9 insect cell membranes co-expressing Galphai2/Gbeta1gamma2 incubated for 60 mins by microbeta scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID88336	Inhibition of human Histamine H2 receptor using [3H]tiotidine	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
AID1210315	Increase of human PMAT-mediated drug uptake expressed in Xenopus laevis oocytes in NaCl buffer at pH 6 at 100 uM after 60 mins relative to control	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID86574	Maximum response (E max) against Histamine H1 receptor in rat aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID1768134	Activation of human carbonic anhydrase VII by stopped flow CO2 hydrase assay	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Quantum mechanical study on the activation mechanism of human carbonic anhydrase VII cluster model with bis-histamine schiff bases and bis-spinaceamine derivatives.
AID462829	Activation of human recombinant CA1 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines.
AID86754	Relative potency against Histamine H1 receptor of guinea pig aorta	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1540401	Agonist activity at mouse H4R expressed in HEK293-SF-mH4R-His6-CRE-Luc cells incubated for 5 hrs by luciferase reporter gene assay
AID1877340	Non-competitive inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition by Lineweaver-Burk plot anlysis	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID500223	Displacement of [3H]mepyramine from human histamine H1 receptor S3.36A mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID318344	Activation of human recombinant CA2 by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
AID458784	Activation of Candida albicans beta-carbonic anhydrase Nce103 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID431560	Activation of human recombinant carbonic anhydrase 4 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID1815477	Activation of human carbonic anhydrase 4 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID87232	Inhibition of human Histamine H1 receptor using [3H]pyrilamine	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
AID1895194	Displacement of [3H]UR-DE257 from human histamine H2 receptor stably expressed in baculovirus infected Sf9 cell membrane co-expressing RG-Salpha S incubated for 60 mins by scintillation counting analysis
AID47753	Tested in vitro for activation of Human cloned isozyme carbonic anhydrase II (hCA II)	2002	Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8	Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID86894	Compound was evaluated for mepyramine antagonism effects in guinea pig aorta (contraction) at a mepyramine concentration of 100 nM	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID549010	Agonist activity at mouse histamine H4 receptor by luciferase reporter gene assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID546823	Binding affinity to dog histamine H4 receptor expressed in COS7 cells by radioligand displacement assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID781325	pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID609369	Activation of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives.
AID1397320	Activation of human CA2 by stopped-flow CO2 hydration assay
AID168741	Intrinsic activity was reported in endothelium-denuded guinea pig aortic segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID1397322	Activation of Trypanosoma cruzi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay
AID478888	Activity at human recombinant GAIP-fused histamine H4 receptor expressed in Sf9 cells coexpressing Galphai, Gbeta1gamma2 by steady-state GTPase activity assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID80595	The compound was evaluated for intrinsic activity in relaxed rat aortic rings with intact endothelium, submaximally precontracted with 15.8 nM U-46,619	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID26967	concentration of mepyramine was determined	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID1323898	Binding affinity to histamine H4 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
AID86921	Effective concentration against histamine H1 receptor in endothelium-Denuded rings of guinea pig Aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID586693	Displacement of [3H]N-alpha-methylhistamine from human histamine H3 receptor expressed in HEK293 cells after 60 mins by liquid scintillation counting	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
AID88560	In vivo percent change in mean arterial pressure in guinea pig was determined at a dose of 1 mg/kg/h	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1815484	Activation of human carbonic anhydrase 13 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID90040	Inhibition of [3H]-histamine binding to membranes of SK-N-MC cells expressing the human Histamine H4 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID1815476	Activation of human carbonic anhydrase 3 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID88558	In vivo percent change in airway overflow in guinea pig was determined at a dose of 1 mg/kg/h	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID90060	Relative potency in guinea pig myocardium (GPM) by adenylate cyclase stimulation assay, H2 receptor response	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID86602	H1-Histamine receptor agonism on Guinea pig ileum was evaluated as Intrinsic activity given as 1.0 (paired 't'test;p>0.05)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID1756650	Displacement of [3H]histamine from human histamine H4 receptor expressed in sf9 insect cell membranes co-expressing Galphai2/Gbeta1gamma2 incubated for 60 mins by microbeta scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID1895197	Displacement of [3H]-histamine from human histamine H4 receptor stably expressed in baculovirus infected Sf9 cell membrane co-expressing G-alphai2 and G-beta1gamma2 incubated for 60 mins by scintillation counting analysis
AID681368	TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells	2001	Pharmaceutical research, Nov, Volume: 18, Issue:11	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID73677	Compound was evaluated for mepyramine antagonism effects in guinea pig ileum (contraction) at a mepyramine concentration of 100 nM	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID1210305	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 6 to 8.5 by two-microelectrode voltage-clamp method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID88004	Intrinsic activity against histamine H2 receptor in guinea pig right atrium	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID87852	Evaluated for activity at Histamine H2 receptor in guinea pig ileum	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID47727	Maximal activatory effect against human carbonic anhydrase II (hCA II)	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID404336	Displacement of [3H]histamine from human histamine H4 receptor expressed in SK-NM-C cells	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
AID1249557	Binding affinity to histamine H4 receptor (unknown origin)	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID86778	Agonistic activity, Histamine H3 receptor dependent activation of G-proteins with GTP gamma-[35S] autoradiography of rat cortical tissue sections. at 10e-5 M conc.; maximal response	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID183687	Relative inhibition of [3H]histamine release from pre-loaded slices of rat cerebral cortex	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID1756653	Selectivity ratio of Ki for displacement of displacement of [3H]histamine from human histamine H4 receptor expressed in sf9 insect cell membranes co-expressing Galphai2/Gbeta1gamma2 to Ki for displacement of [3H]UR-DE257 from human histamine H2 receptor e	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID365830	Activation of human recombinant truncated CA4 at 10 uM by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines.
AID90034	Inhibition of the forskolin-stimulated cAMP production in SK-N-MC cells expressing human Histamine H4 receptor	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
AID549009	Agonist activity at mouse histamine H4 receptor by luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID345031	Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID414328	Activity at yeast recombinant CA expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID87077	Evaluated for agonistic activity at Histamine H1 receptor of guinea pig ileum and is represented as potency	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID293046	Activity of human recombinant CA2 at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID409988	Activation of Methanobacterium thermoautotrophicum beta-class CA by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID1249560	Binding affinity to human histamine H4 receptor	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID681987	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Histamine: 1000 uM) in OCT2A-expressing HEK293 cells	2002	Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID576507	Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID86761	Relative potency against Histamine H1 receptor in guinea pig ileum	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID193759	Change in heart rate after iv administration of 0.044 uM/kg in anesthetized rats	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1186307	Activation of cytosolic human carbonic anhydrase-1 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators.
AID546820	Agonist activity at rat histamine H4 receptor by luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1830579	Displacement of [3H]UR-DE257 from Gsalphas-coupled human H2R expressed in Sf9 cell membranes by competitive binding assay
AID1895214	Agonist activity at histamine H2 receptor in spontaneous beating guinea pig right atrium assessed as increase in heart beat
AID1830585	Agonist activity at human H2 receptor expressed in HEK293T-ARRB2 cells assessed as stimulation of beta-arrestin 2 recruitment by measuring maximum efficacy
AID86477	Inhibition of the forskolin-stimulated cAMP production in SK-N-MC cells expressing human Histamine H3 receptor	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
AID177148	In vivo effect on gastric acid secretion in rat was determined after subcutaneous administration	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1877338	Inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition by Lineweaver-Burk plot anlysis	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID431561	Activation of human recombinant carbonic anhydrase 5A by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID681988	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Histamine: 1000 uM) in OCT2-expressing HEK293 cells	2002	Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID478881	Agonist activity at GsalphaS-fused guinea pig histamine H2 receptor expressed in Sf9 cells by [35S]GTPgammaS binding assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID168743	Relative potency in guinea pig ileal whole segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID725229	Activation of human recombinant CA2 by stopped flow CO2 hydrase method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	The extremo-α-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines.
AID26616	Acid dissociation constant was determined for the compound	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID431558	Activation of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID1895215	Agonist activity at histamine H2 receptor in spontaneous beating guinea pig right atrium assessed as increase in heart beat at 30 uM relative to histamine
AID47752	Inhibition of human Carbonic anhydrase II, using histamine as standard	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties.
AID48116	Tested in vitro for activation of carbonic anhydrase IV (bCA IV), purified from bovine lung microsomes	2002	Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8	Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID86478	Inhibitory activity determined by the inhibition of cAMP- stimulated beta-galactosidase transcription in SK-N-MC cells expressing the human Histamine H3 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID1815475	Activation of human carbonic anhydrase 2 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID293055	Activation of human recombinant CA7 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID170660	Tested for the change in diastolic blood pressure administered at 0.044 ug/kg intravenously in anesthetized rats	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1186310	Activation of cytosolic human carbonic anhydrase-12 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators.
AID87543	Effective concentration against histamine H1 receptor in rat aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID50346	Inhibition of human Carbonic anhydrase I, using histamine as standard	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties.
AID72706	Concentration of compound which gives 20% increase in the force contraction in ferret papillary muscle.	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID375786	Activation of human recombinant carbonic anhydrase 4 lacking 20 amino terminal residues by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines.
AID197352	Effective concentration for agonism activity in relaxed rat aortic rings with intact endothelium, submaximally precontracted with 15.8 nM U-46,619	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID345039	Activity at human recombinant histamine H4 receptor-RGS4 fusion protein expressed in Sf9 cells coexpressing Galphai2 and G-beta-1-gamma-2 by steady-state GTPase activity assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID464316	Activity at archaea Methanobacterium thermoautotrophicum recombinant carbonic anhydrase	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID88468	Binding affinity against human H2 receptor by the displacement of [125I]iodoaminopotentidine, bound to membranes of CHO cells.	1995	Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2	Homologs of histamine as histamine H3 receptor antagonists: a new potent and selective H3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole.
AID464317	Activity at Saccharomyces cerevisiae recombinant Nce103p	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID1244806	Antibacterial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by serial microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
AID1540397	Agonist activity at human H4R expressed in HEK293-SF-hH4R-His6-CRE-Luc cells incubated for 5 hrs by luciferase reporter gene assay
AID1540383	Agonist activity at rat H4R by [35S]-GTPgammaS-binding assay
AID1300588	Agonist activity at human histamine H4 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 incubated for 90 mins by [35S]GTPgammaS binding assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID73893	In vitro H1 agonistic activity by taking guinea pig ileum contraction	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID1331210	Activation of Burkholderia pseudomallei gamma carbonic anhydrase assessed as Kcat at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydration assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines.
AID500226	Displacement of [3H]mepyramine from human histamine H1 receptor N7.45C mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID1210314	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current in NMDG chloride buffer at pH 6 to 7.5 at -10 to -30 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID638337	Displacement of [3H]histamine from human H4 receptor expressed in HEK cell membranes	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
AID345037	Activity at human recombinant histamine H3 receptor expressed in Sf9 cells coexpressing Galphai, G-beta-1-gamma-2 and RGS4 by steady-state GTPase activity assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID409986	Activation of human recombinant CA2 by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID548994	Agonist activity at human histamine H4 receptor expressed in human SK-N-MC cells by CRE-beta galactosidase reporter gene assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID86749	Contractile effect on isolated guinea pig aorta is a measure of H1 (histamine) receptor agonistic activity relative to histamine	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID345033	Activity at human recombinant histamine H2 receptor-Gsalpha fusion protein expressed in Sf9 cells by steady-state GTPase activity assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID86452	Efficacy was measured for human Histamine H3 receptor	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
AID87851	Evaluated for agonistic (intrinsic) activity at Histamine H2 receptor of guinea pig atrium and is represented as intrinsic activity	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID632452	Displacement of [3H]histamine from human H4 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
AID478878	Agonist activity at histamine H2 receptor in spontaneously beating guinea pig atrium assessed as increase in heart rate as relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1186309	Activation of cytosolic human carbonic anhydrase-7 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators.
AID725228	Activation of human recombinant CA1 by stopped flow CO2 hydrase method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	The extremo-α-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines.
AID414923	Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.
AID1249559	Binding affinity to histamine H2 receptor (unknown origin)	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID1300593	Agonist activity at human SF-His6-tagged histamine H4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated response incubated for 5 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID50348	In vitro carbonic anhydrase activation in human cloned Carbonic anhydrase I (hCA I)	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID193699	Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Further hypotensive metabolites from Verbesina caracasana.
AID77707	The compound was evaluated for intrinsic activity i.e. maximum histamine controls relative to contraction evoked by 10 uM PGF2-alpha in Endothelium-Denuded guinea pig aortic segment(pre contracted with PGF-2 alpha)	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID86904	Compound was tested for the contractile effects antagonized by mepyramine (1-1000 nM) against Histamine H1 receptor of guinea pig aorta.	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1829881	Binding affinity in Nluc-hH3R assessed in HEK293 cells by NanoBRET binding assay	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	A Versatile Sub-Nanomolar Fluorescent Ligand Enables NanoBRET Binding Studies and Single-Molecule Microscopy at the Histamine H
AID1895198	Selectivity ratio of Ki for human histamine H4 receptor to Ki for human histamine H2 receptor incubated for 60 mins by scintillation counting analysis
AID548991	Agonist activity at human histamine H3 receptor expressed in human SK-N-MC cells by CRE-beta galactosidase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1895211	Agonist activity at human histamine H2 receptor stably expressed in HEK293T cells co-expressing NlucN-mGs/hH2R-NlucC assessed as induction of mini-Gi protein recruitment using furimazine as substrate measured for 45 mins by luminescence assay
AID89895	Inhibition of human Histamine H4 receptor	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
AID414924	Agonist activity at human H2 receptor expressed in insect Sf9 cells co-expressing GsalphaS fusion protein assessed as gamma[32P]GTP binding by liquid scintillation counting	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.
AID681375	TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells	2001	Pharmaceutical research, Nov, Volume: 18, Issue:11	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID464322	Activation of Candida glabrata recombinant carbonic anhydrase by stopped flow CO2 hydration method	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID1435058	Activation of recombinant human carbonic anhydrase 1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5	Carbonic anhydrases activation with 3-amino-1H-1,2,4-triazole-1-carboxamides: Discovery of subnanomolar isoform II activators.
AID80722	Relative potency was recorded in relaxed rat aortic rings with intact endothelium, submaximally precontracted with 15.8 nM U-46,619	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID86620	Selectivity is the ratio of inhibitory activity against Histamine H3 receptor to that of Histamine H4 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID89554	Intrinsic activity against H3 receptor in rat brain cortex	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID318345	Activation of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
AID86910	Relative potency against Histamine H1 receptor in endothelium-Denuded rings of guinea pig Aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID86257	Evaluated for activity at Histamine H1 receptor in guinea pig ileum	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID1300595	Agonist activity at mouse SF-His6-tagged histamine H4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated response incubated for 5 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID1830582	Agonist activity at NlucN/mini-Gi protein-fused human H2R stably expressed in HEK293T cells assessed as induction of mini-Gi protein recruitment using furimazine as substrate measured for 45 mins by luminescence assay
AID26824	Acid dissociation constant was determined for the compound	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID1186311	Activation of transmembrane human carbonic anhydrase-14 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators.
AID89730	Binding affinity for Histamine H3 receptor	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID86307	Tested in vitro for antagonist activity against H3 receptor of guinea pig jejunum.	1995	Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2	Homologs of histamine as histamine H3 receptor antagonists: a new potent and selective H3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole.
AID50358	In vitro binding affinity against human carbonic anhydrase I (hCA-I human cloned isozyme).	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties.
AID86783	Agonistic activity, Histamine H3 receptor dependent activation of G-proteins with GTP gamma-[35S] autoradiography of rat striatal tissue sections. at 10e-5 M conc.; maximal response	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID431567	Activation of mouse recombinant carbonic anhydrase 13 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID678807	TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells	1999	Molecular pharmacology, Jul, Volume: 56, Issue:1	Selective substrates for non-neuronal monoamine transporters.
AID1249562	Binding affinity to mouse histamine H4 receptor	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID1558713	Agonist activity at human H3R expressed on SK-N-MC cells assessed as inhibition of forskolin-induced beta galactosidase activity preincubated with forskolin for 6 hrs followed compound addition by CRE-luciferase reporter gene assay
AID1661709	Selectivity index, ratio of Ki for human H4R expressed in baculovirus infected Sf9 cells to Ki for Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Fluorescent H
AID86926	H1-Histamine receptor agonism on Guinea pig aorta was evaluated (SEM 0.03-0.18)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID305776	Activation of human recombinant carbonic anhydrase 5A by stopped-flow CO2 hydrase method	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines.
AID268622	Activation of mouse recombinant CA13 by CO2 hydrase method	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines.
AID86425	Partial agonist activity against Histamine H1 receptor in guinea pig ileum.	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1756648	Displacement of [3H]UR-DE257 from human histamine H2 receptor expressed in sf9 insect cell membranes co-expressing GSalphaS incubated for 60 mins by microbeta scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID90058	Effect on histamine type 1 receptor mediated contraction of the isolated rabbit aorta was determined; + means Histamine-like pharmacological effect was retained	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID222158	Ex vivo carbonic anhydrase activation after 30 min incubation of human erythrocytes with 5 uM activator Histamine	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID431564	Activation of human recombinant carbonic anhydrase 7 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID452998	Agonist activity at human histamine H4 receptor expressed in Sf9 cells co-expressing Galphai2 and Gbeta1gamma2 assessed as stimulation of [35S]GTPgammaS binding	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID1661708	Selectivity index, ratio of Ki for human H3R expressed in baculovirus infected Sf9 cells to Ki for Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Fluorescent H
AID1186308	Activation of cytosolic human carbonic anhydrase-2 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators.
AID1244834	Antibacterial activity against Staphylococcus epidermidis ATCC 49134 after 18 hrs by serial microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
AID462455	Agonist activity at human histamine H4 receptor expressed in HEK293T cells by CRE-beta-galactosidase assay	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H4 receptor inverse agonists.
AID87372	Inhibitory activity against human Histamine H1 receptor	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
AID86753	Relative potency against Histamine H1 receptor in guinea pig ileum.	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1661706	Antagonist activity at Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells incubated for 60 mins in presence of histamine by GTPgammaS binding assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Fluorescent H
AID1690423	Agonist activity at human H3 receptor stably transfected in CHO-DUKX cells assessed as increase in cAMP accumulation by measuring reduction in forskolin level by HitHunter-cAMP assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Novel pyrrolidinone derivative lacks claimed histamine H
AID86922	Effective concentration against histamine H1 receptor in guinea pig ileum	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID1148741	Retardation factor of the compound using EtOCH2CH2OH-HCl(11N)-H2O at ratio of 8:1:1 as solvent system by thin layer chromatography	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID305777	Activation of human recombinant carbonic anhydrase 5B by stopped-flow CO2 hydrase method	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines.
AID1323901	Binding affinity to histamine H3 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
AID86420	Partial agonist activity with mepyramine against Histamine H1 receptor in guinea pig ileum.	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID478882	Agonist activity at GsalphaS-fused guinea pig histamine H2 receptor expressed in Sf9 cells by [35S]GTPgammaS binding assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1830584	Agonist activity at human H2 receptor expressed in HEK293T-ARRB1 cells assessed as stimulation of beta-arrestin 1 recruitment
AID1830576	Agonist activity at human H2 receptor expressed in HEK293T-ARRB2 cells assessed as stimulation of beta-arrestin 2 recruitment
AID87535	Relative potency against H1 receptor in rat aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID231384	Activity ratio of H2 receptor pD2 at pH 7.8 / pD2 at pH 7.4	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID548987	Displacement of [3H]Nalpha-methylhistamine from human histamine H3 receptor expressed in human SK-N-MC cells	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID231383	Activity ratio of H2 receptor pD2 at pH 7.4 / pD2 at pH 7.0	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID1830578	Agonist activity at NlucN/mini-Gi protein-fused human H2R stably expressed in HEK293T cells assessed as induction of mini-Gi protein recruitment by measuring maximum efficacy using furimazine as substrate measured for 45 mins by luminescence assay
AID50347	Tested in vitro for activation of Human cloned isozyme carbonic anhydrase I (hCA I)	2002	Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8	Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID1815479	Activation of human carbonic anhydrase 5B by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID88164	Agonistic activity of guinea pig Histamine H2 receptor expressed as pD2 at pH 7.4	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID86785	Agonistic activity, H3-receptor dependent activation of G-proteins with GTP gamma-[35S] autoradiography of rat striatal tissue sections. at 10e-5 M conc.; maximal response	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID1895212	Agonist activity at human histamine H2 receptor stably expressed in HEK293T cells co-expressing NlucN-mGs/hH2R-NlucC assessed as induction of mini-Gi protein recruitment by measuring maximum efficacy at 100 uM using furimazine as substrate measured for 45
AID88034	Intrinsic activity against histamine H2 receptor	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles.
AID1815480	Activation of human carbonic anhydrase 6 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID87541	Relative potency against Histamine H1 receptor in rat aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID549007	Agonist activity at human recombinant histamine H4 receptor expressed in human SK-N-MC cells co-expressing SRE-Luc by luciferase reporter gene assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID79823	Effective concentration for agonism activity in guinea pig ileal whole segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID691715	Activity of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant CA expressed in Escherichia coli BL21(DE3) after 15 mins by phenol red staining based stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable α-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines.
AID88305	In vitro functional Histamine H2 receptor assay was measured on guinea pig atrium.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
AID1272169	Antagonist activity at human histamine 4 receptor expressed in Sf9 cell membranes co-expressing Galphai2 and Gbeta1gamma2 assessed as [35S]GTPgammaS binding by scintillation counting	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.
AID88002	Histamine H2 receptor agonism activity was determined on the isolated Guinea pig Atrium was determined as Intrinsic activity with respect to Histamine	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID1895195	Displacement of [3H]Nalpha-methylhistamine from human histamine H3 receptor stably expressed in baculovirus infected Sf9 cell membrane co-expressing G-alphai2 and G-beta1gamma2 incubated for 60 mins by scintillation counting analysis
AID462453	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293T cells	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H4 receptor inverse agonists.
AID414935	Agonist activity at histamine H2 receptor in guinea pig atrium assessed as increase in heart rate	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.
AID409984	Activation of human recombinant CA1 by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID1249558	Binding affinity to histamine H3 receptor (unknown origin)	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID79499	Full pA2 value of compound at 0.3-100 nM concentration of mepyramine in guinea pig ileum	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID1756647	Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 insect cell membranes co-expressing RGS4 incubated for 60 mins by microbeta scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID1300592	Agonist activity at human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 or RGS9 assessed as increase in 32Pi level incubated for 20 mins by liquid scintillation counting in presence of [gamma32P]GTP	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID1244813	Antibacterial activity against Staphylococcus aureus ATCC 4163 after 18 hrs by serial microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
AID478884	Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1210313	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current in NaCl buffer at pH 6 to 7.5 at -10 to -30 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID87227	Intrinsic activity was determined	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
AID86455	Intrinsic activity determined towards Histamine H3 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID231579	Receptor selectivity is the ratio between activity and active species (7.8 / 7.4)	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID478886	Activity at human recombinant histamine H3 receptor expressed in Sf9 cells coexpressing Galphai, Gbeta1gamma2 and RGS4 by steady-state GTPase activity assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1895193	Displacement of [3H] mepyramine from human histamine H1 receptor stably expressed in baculovirus infected Sf9 cell membrane co-expressing RGS4 incubated for 60 mins by scintillation counting analysis
AID431568	Activation of human recombinant carbonic anhydrase 14 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID318346	Activation of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
AID1895209	Agonist activity at human histamine H2 receptor stably expressed in HEK293T cells co-expressing ARRB2 incubated for 60 mins by beta-arrestin2 recruitment assay
AID1331206	Activation of Burkholderia pseudomallei gamma carbonic anhydrase at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydration assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines.
AID1435059	Activation of recombinant human carbonic anhydrase 2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5	Carbonic anhydrases activation with 3-amino-1H-1,2,4-triazole-1-carboxamides: Discovery of subnanomolar isoform II activators.
AID87362	Inhibitory activity against human Histamine H1 receptor	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
AID471098	Agonist activity at human histamine H4 receptor expressed in Sf9 cells coexpressing RGS19 protein by steady-state GTPase assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
AID345035	Activity at guinea pig recombinant histamine H2 receptor-Gsalpha fusion protein expressed in Sf9 cells by steady-state GTPase activity assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID50342	Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 mM	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID293048	Activity of human recombinant CA5A at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID88166	Histamine H2 receptor agonistic activity in guinea pig right atrium	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles.
AID409990	Activation of Methanosarcina thermophila Zinc(2)-derived gamma-class CA by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID1537223	Activation of human CA-4 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	α-Carbonic anhydrases are strongly activated by spinaceamine derivatives.
AID48127	In vitro inhibitory activity against bovine carbonic anhydrase IV (bCA IV) purified from lung microsomes.	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties.
AID293050	Activity of human recombinant CA14 at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID293049	Activity of human recombinant CA7 at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID479098	Agonist activity at human recombinant histamine H3 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding at 10 nM after 1 hr by liquid scintillation counting relative to (R)-alpha-methylhistamine	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
AID1210308	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current in NaCl buffer at pH 6 to 7.5 at -10 to -150 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID546821	Agonist activity at rat histamine H4 receptor by luciferase reporter gene assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID293047	Activity of human recombinant CA4 at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID444826	Induction of dendrite out growth in IL-4/GMCSF-stimulated mouse P19 cells assessed as dendrite length at 100 nM after 48 hrs by light microscopy	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID409992	Activation of Methanosarcina thermophila cobalt(2)-derived gamma-class CA by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID78839	In vitro contractile response of histamine at 0.5 ug/mL in guinea pig ileum	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1281542	Activation of Malassezia globosa beta-carbonic anhydrase assessed as catalytic rate at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydrase method (Rvb = 9.2 +/- 0.1 x 10'5 /s)	2016	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5	Carbonic anhydrase activators: Activation of the β-carbonic anhydrase from Malassezia globosa with amines and amino acids.
AID365827	Activation of human recombinant CA1 at 10 uM by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines.
AID1815474	Activation of human carbonic anhydrase 1 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID90061	Effect on accumulation of intracellular cAMP in murine lymphocytes for the H2 receptor response was determined; + means Histamine-like pharmacological effect was retained	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID90062	Relative potency by cAMP assay in natural suppressor cells.	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID458786	Activation of Cryptococcus neoformans beta-carbonic anhydrase Can2 assessed as enzyme catalytic rate at 10 uM by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID1331203	Activation of recombinant human carbonic anhydrase 1 at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydration assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines.
AID414925	Agonist activity at human H3 receptor expressed in insect Sf9 cells co-expressing Gialpha2, Gbeta1gamma2 and RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.
AID725227	Activation of Sulfurihydrogenibium yellowstonense recombinant CA by stopped flow CO2 hydrase method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	The extremo-α-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines.
AID414926	Agonist activity at human H4 receptor expressed in insect Sf9 cells co-expressing RGS19 fusion protein and Gialpha2, Gbeta1gamma2 assessed as gamma[32P]GTP binding by liquid scintillation counting	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.
AID1815478	Activation of human carbonic anhydrase 5A by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID1895213	Agonist activity at guinea pig histamine H2 receptor stably transfected in HEK293T cells co-expressing NlucN-mGs/gpH2R-NlucC by mini-G protein recruitment assay
AID549005	Binding affinity to human recombinant histamine H4 receptor expressed in human SK-N-MC cells by radioligand displacement assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1210304	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 7.5 by two-microelectrode voltage-clamp method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID679638	TP_TRANSPORTER: inhibition of MPP+ uptake in OCT2-expressing HEK293 cells	1999	Molecular pharmacology, Jul, Volume: 56, Issue:1	Selective substrates for non-neuronal monoamine transporters.
AID87056	Contractile effects on guinea pig aorta as histamine H1 receptor agonism	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID471097	Agonist activity at human histamine H3 receptor expressed in Sf9 cells coexpressing Gialpha-2-Gbeta-1-gamma-2 and RGS4 proteins protein by steady-state GTPase assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
AID222156	Ex vivo carbonic anhydrase activation was measured after 30 min of incubation of lysed human erythrocyte	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties.
AID72705	In vitro inotropy blocking studies in ferret papillary muscle in the presence of 100 uM nadolol; NB-Not Blocked	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID270369	Agonist activity at human H4 receptor expressed in 293-EBNA cells by luciferase reporter gene assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
AID1558712	Displacement of [3H]-N-alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells incubated for 40 min by liquid scintillation counting analysis
AID464315	Activity at human recombinant carbonic anhydrase isozyme 2	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID458785	Activity of Cryptococcus neoformans beta-carbonic anhydrase Can2 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID1249563	Binding affinity to rat histamine H4 receptor	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID90057	Effect on peripheral vasculature of the rabbit as percentage change in contractility.	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID1210309	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current in NMDG chloride buffer at pH 6 to 7.5 at -10 to -150 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID291063	Activation of human recombinant CA2 by CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
AID1815481	Activation of human carbonic anhydrase 7 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID1249561	Binding affinity to guinea pig histamine H4 receptor	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID1693528	Displacement of [3H]-Histamine from human histamine 4 receptor transfected in HEK293T cells incubated for 16 hrs by liquid scintillation counter analysis
AID500233	Inverse agonist activity at human wild-type histamine H1 receptor N7.45S mutant assessed as NF-kappaB activation at 0.1 mM after 48 hrs by luciferase reporter gene assay	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID431563	Activation of human recombinant carbonic anhydrase 6 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID89870	In vitro binding affinity was measured against Histamine H3 receptor on rat cerebral cortex.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
AID73894	In vitro H2 agonistic activity by taking spontaneously beating guinea pig right atrium	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID679157	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	1998	Molecular pharmacology, Aug, Volume: 54, Issue:2	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
AID1300585	Agonist activity at human histamine H3 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 incubated for 90 mins by [35S]GTPgammaS binding assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID79729	Effect on H1 receptor mediated enhanced suppressor activity of natural suppressor cells; + means Histamine-like pharmacological effect was retained	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID500227	Displacement of [3H]mepyramine from human histamine H1 receptor N7.45Q mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID1210306	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current at 2.5 mM in NaCl buffer at pH 6 to 7.5 at -50 to -150 mV of membrane potential by two-microelectrode voltage-clamp method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID168740	Compound was evaluated for mepyramine antagonism effects in guinea pig ileum (contraction) at a mepyramine concentration of 100 nM	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID291061	Activation of human recombinant CA1 by CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
AID1895199	Selectivity ratio of Ki for human histamine H1 receptor to Ki for human histamine H2 receptor incubated for 60 mins by scintillation counting analysis
AID479096	Displacement of [3H[N-alpha-methylhistamine form human recombinant histamine H3 receptor expressed in CHO cells after 1 hr by liquid scintillation counting	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
AID1537224	Activation of human CA-6 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	α-Carbonic anhydrases are strongly activated by spinaceamine derivatives.
AID1756656	Agonist activity at human histamine receptor expressed in sf9 insect cell membranes co-exprssing GsalphaS incubated for 90 mins [35S]GTPgammaS binding based microbeta scintillation counting analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID87058	The H1 receptor-mediated nature of the ileum contractionhas been verified by competition experiments with the H1 receptor antagonist mepyramine	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID444824	Induction of dendrite out growth in IL-4/GMCSF-stimulated human U937 cells assessed as dendrite length at 100 nM after 48 hrs by light microscopy	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID231201	Active species ratio of pD2 at pH 7.4 / pD2 at pH 7.0	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID548982	Agonist activity at human recombinant histamine H4 receptor expressed in Sf9 cells coexpressing RGS19, Galphai2, Gbeta1gamma2 by steady-state GTPase activity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID47907	In vitro binding affinity against human carbonic anhydrase II (hCA-II human cloned isozyme).	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties.
AID1829899	Binding affinity in Nluc-hH3R assessed in HEK293T cells by NanoBRET binding assay	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	A Versatile Sub-Nanomolar Fluorescent Ligand Enables NanoBRET Binding Studies and Single-Molecule Microscopy at the Histamine H
AID678817	TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes	1996	FEBS letters, Oct-21, Volume: 395, Issue:2-3	Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1.
AID1210311	Binding affinity to human PMAT expressed in Xenopus laevis oocytes in NaCl buffer at pH 6 to 7.5 at -50 to -150 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID1756651	Selectivity ratio of Ki for displacement of displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 insect cell membranes co-expressing RGS4 to Ki for displacement of [3H]UR-DE257 from human histamine H2 receptor expressed in sf9	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID1210310	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current in NMDG chloride buffer at pH 7.5 at -10 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID1558714	Intrinsic activity at human H3R expressed in forskolin-stimulated SK-N-MC cells preincubated with forskolin for 6 hrs followed compound addition by CRE-luciferase reporter gene assay
AID192795	Maximum rate of rise of the left ventricular isovolumetric pressure administered at 0.044 uM/kg iv in anesthetized rats	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID86450	Inhibition of human Histamine H3 receptor using [3H]N-alpha-methyl histamine	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
AID268621	Activation of human recombinant CA2 by CO2 hydrase assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines.
AID431559	Activation of human recombinant carbonic anhydrase 3 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID681589	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	2001	American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3	Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID1537221	Activation of human CA-1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	α-Carbonic anhydrases are strongly activated by spinaceamine derivatives.
AID471096	Agonist activity at human histamine H2 receptor expressed in Sf9 cells coexpressing GsalphaS protein by steady-state GTPase assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
AID1815482	Activation of human carbonic anhydrase 9 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID270367	Agonist activity at human H2 receptor expressed in 293-EBNA cells by luciferase reporter gene assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
AID90035	Inhibitory activity determined by the inhibition of cAMP- stimulated beta-galactosidase transcription in SK-N-MC cells expressing the human Histamine H4 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID462832	Activation of Stylophora pistillata carbonic anhydrase STPCA by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines.
AID86256	Evaluated for agonistic (intrinsic) activity at Histamine H1 receptor of guinea pig ileum and is represented as intrinsic activity	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID478877	Agonist activity at histamine H2 receptor in spontaneously beating guinea pig atrium	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID458550	Activity of Candida albicans beta-carbonic anhydrase Nce103 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID500222	Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID691714	Activity of human recombinant CA2 cytosolic isoform after 15 mins by phenol red staining based stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable α-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines.
AID548984	Displacement of [125I]iodoaminopotentidine from human histamine H2 receptor expressed in CHO cells	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID679822	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	2001	American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3	Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID80154	Relative potency was recorded in endothelium-denuded guinea pig aortic segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID478879	Agonist activity at GsalphaS-fused human histamine H2 receptor expressed in Sf9 cells by [35S]GTPgammaS binding assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID293045	Activity of human recombinant CA1 at 10 uM by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID257047	Activation constant against recombinant human CA IV isozyme by the esterase method	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators.
AID483141	Displacement of [3H]histamine from human recombinant histamine H4 receptor	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.
AID239984	Binding affinity towards human histamine H4 receptor was determined by [3H]Na-methylhistamine binding to SK-N-MC cell membranes	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID549011	Binding affinity to rat histamine H4 receptor expressed in human SK-N-MC cells by radioligand displacement assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID431562	Activation of human recombinant carbonic anhydrase 5B by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID197301	Changes in systolic blood pressure following iv administration at (0.044 umol/kg)anesthetized rats	2001	Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18	Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID500225	Displacement of [3H]mepyramine from human histamine H1 receptor S3.36T mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID47897	In vitro carbonic anhydrase activation in human cloned Carbonic anhydrase II (hCA II)	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID680539	TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Histamine: 5000 uM) in OCTN2-expressing HEK293 cells	2001	Molecular pharmacology, Feb, Volume: 59, Issue:2	Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID453000	Agonist activity at human histamine H4 receptor expressed in Sf9 cells co-expressing Galphai2 and Gbeta1gamma2 assessed as stimulation of GTPase by [gamma-32P]GTP spontaneous degradation assay	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1210312	Binding affinity to human PMAT expressed in Xenopus laevis oocytes in NMDG chloride buffer at pH 6 to 7.5 at -50 to -150 mV of membrane potential by Michaelis-Menten equation analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID293052	Activation of human recombinant CA2 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID86901	Contractile effects antagonized by mepyramine (0.3-100 nM) against Histamine H1 receptor in guinea pig ileum	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1815485	Activation of human carbonic anhydrase 14 by stopped flow CO2 hydrase assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID222159	Ex vivo carbonic anhydrase activation after 60 min incubation of human erythrocytes with 5 uM activator Histamine	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID1815483	Activation of human carbonic anhydrase 12 by stopped flow assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases.
AID1540407	Agonist activity at rat H4R expressed in HEK293T-beta-arr2-rH4R cells by beta-arrestin2 recruitment assay
AID1756652	Selectivity ratio of Ki for displacement of displacement of [3H]UR-P129 from human histamine H3 receptor expressed in sf9 insect cell membranes co-expressing Galphai2/Gbeta1gamma2 to Ki for displacement of [3H]UR-DE257 from human histamine H2 receptor exp	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID1693529	Displacement of [3H]-Histamine from human histamine 3 receptor transfected in HEK293T cells incubated for 16 hrs by liquid scintillation counter analysis
AID1537222	Activation of human CA-2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	α-Carbonic anhydrases are strongly activated by spinaceamine derivatives.
AID1249556	Binding affinity to histamine H1 receptor (unknown origin)	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID86598	H1-Histamine receptor agonism on Guinea pig aorta was evaluated as Intrinsic activity given as 1.0 with respect to histamine (paired 't'test;p>0.05)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID691713	Activity of human recombinant CA1 cytosolic isoform after 15 mins by phenol red staining based stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable α-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines.
AID231578	Receptor selectivity is the ratio between activity and active species (7.4 / 7.0)	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID87869	Effect on Histamine H2 receptor-mediated adenylate cyclase stimulation of the guinea pig myocardium was determined; + means Histamine-like pharmacological effect was retained	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Congener derivatives and conjugates of histamine: synthesis and tissue and receptor selectivity of the derivatives.
AID232997	dp/dt value of the compound	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1281543	Activation of Malassezia globosa beta-carbonic anhydrase incubated for 15 mins prior to testing by stopped flow CO2 hydrase method	2016	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5	Carbonic anhydrase activators: Activation of the β-carbonic anhydrase from Malassezia globosa with amines and amino acids.
AID462831	Activation of human full length CA6 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines.
AID414327	Activity at Methanothermobacter thermautotrophicus recombinant Cab	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID345023	Agonist activity at histamine H2 receptor in guinea pig spontaneously beating right atrium assessed as positive chronotropic activity	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID78482	In vitro chronotropic effect of histamine at 5 ug/mL in guinea pig atrium	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1331205	Activation of recombinant Methanosarcina thermophila gamma carbonic anhydrase at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydration assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines.
AID88172	Evaluated for agonistic activity at Histamine H2 receptor of guinea pig atrium and is represented as potency	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID478880	Agonist activity at GsalphaS-fused human histamine H2 receptor expressed in Sf9 cells by [35S]GTPgammaS binding assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1540380	Binding affinity to rat H4R
AID681117	TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells	2003	Molecular pharmacology, Mar, Volume: 63, Issue:3	Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID87062	Binding affinity against H1 receptor of guinea pig by the displacement of [3H]mepyramine, bound to membranes of CHO cells	1995	Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2	Homologs of histamine as histamine H3 receptor antagonists: a new potent and selective H3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole.
AID548981	Displacement of [3H]-histamine from human histamine H4 receptor expressed in Sf9 cells coexpressing RGS19, Galphai2, Gbeta1gamma2	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1397319	Activation of human CA1 by stopped-flow CO2 hydration assay
AID293056	Activation of human recombinant CA14 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID86304	In vitro functional Histamine H3 receptor assay was measured on guinea pig jejunum.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
AID86423	Compound was tested for its partial antagonist activity in the presence of mepyramine (1-1000 nM) against Histamine H1 receptor of guinea pig aorta.	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID1756654	Agonist activity at guinea pig right atrium histamine H2 receptor assessed as increase in heart rate incubated for 30 mins in presence of cimetidine	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID431557	Activation of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID1244827	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by serial microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
AID86750	Contractile effect on isolated guinea pig ileal segments is a measure of H1 (histamine) receptor agonistic activity relative to histamine.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID681689	TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HEK293 cells	1999	Molecular pharmacology, Jul, Volume: 56, Issue:1	Selective substrates for non-neuronal monoamine transporters.
AID171673	Change in systolic blood pressure after iv administration of 0.044 uM/kg in anesthetized rats	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID101738	Compound was tested for its agonist activity against M3-acetylcholine receptor of guinea pig ileum; ND = Not determined	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID180828	Tested for change in heart rate administered at 0.044 uM/kg iv in anesthetized rats	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID293051	Activation of human recombinant CA1 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID548979	Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID22108	concentration of mepyramine was determined	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID586696	Agonist activity at human histamine H4 receptor expressed in HEK293 cells assessed by forskolin induced cAMP response element activation by luciferase reporter gene assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
AID478887	Activity at human recombinant histamine H3 receptor expressed in Sf9 cells coexpressing Galphai, Gbeta1gamma2 and RGS4 by steady-state GTPase activity assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1558686	Agonist activity at human H3R expressed on HEK293T cells by [35S]GTPgammaS binding assay
AID471095	Agonist activity at human histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
AID549008	Binding affinity to mouse histamine H4 receptor expressed in human SK-N-MC cells by radioligand displacement assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID293053	Activation of human recombinant CA4 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID170824	Tested for the change in systolic blood pressure administered at 0.044 ug/kg intravenously in anesthetized rats	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID86443	Binding affinity towards histamine H3 receptor using [3H](R)-alpha-methylhistamine as radioligand in guinea pig ileum LMMP homogenates	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.
AID462830	Activation of human recombinant CA2by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines.
AID464320	Activation of archaea Methanobacterium thermoautotrophicum recombinant carbonic anhydrase by stopped flow CO2 hydration method	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID88324	Compound is evaluated for histamine H2 receptor agonistic activity in guinea pig cerebral cortex using [3H]tiotidine as radioligand	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles.
AID464319	Activation of human recombinant carbonic anhydrase isoenzyme 2 by stopped flow CO2 hydration method	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID1830577	Agonist activity at human H2 receptor expressed in HEK293T-ARRB1 cells assessed as stimulation of beta-arrestin 1 recruitment by measuring maximum efficacy
AID365828	Activation of human recombinant CA2 at 10 uM by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines.
AID268620	Activation of human recombinant CA1 by CO2 hydrase assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines.
AID89731	In vitro functional Histamine H3 receptor assay was measured on rat cerebral cortex.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
AID431565	Activation of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID86917	Contractile effect on isolated guinea pig ileal segments by H1 (histamine) receptor agonism.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID180032	The compound was evaluated for intrinsic activity in relaxed rat aortic rings with intact endothelium, submaximally precontracted with 15.8 nM U-46,619	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID168744	Relative potency was recorded in Endothelium-Denuded guinea pig aortic segment(pre contracted with PGF-2 alpha)	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID171640	Change in diastolic blood pressure after iv administration of 0.044 uM/kg in anesthetized rats	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1540399	Agonist activity at human H4R expressed in HEK293T-beta-arr2-hH4R cells by beta-arrestin2 recruitment assay
AID175839	In vitro H3 agonistic activity against K+ induced histamine in slices of rat brain cortex.	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID48115	Bovine Carbonic anhydrase IV activity using histamine as standard	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties.
AID1895210	Agonist activity at human histamine H2 receptor stably expressed in HEK293T cells co-expressing ARRB2 assessed as maximum efficacy at 100 uM incubated for 60 mins by beta-arrestin2 recruitment assay relative to histamine
AID73676	Compound was evaluated for mepyramine antagonism effects in guinea pig aorta (relaxation) at a mepyramine concentration of 100 nM	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID87388	Maximum response (E max) against Histamine H1 receptor endothelium-Denuded rings of guinea pig Aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID86614	Histamine H3 receptor competition binding using [3H]Na-methylhistamine	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
AID479097	Agonist activity at human recombinant histamine H3 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr by liquid scintillation counting	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
AID500224	Displacement of [3H]mepyramine from human histamine H1 receptor S3.36C mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID260225	Agonist activity at histamine H1 receptor in guinea pig ileum	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Side-chain modified analogues of histaprodifen: asymmetric synthesis and histamine H1-receptor activity.
AID77700	Intrinsic activity was reported in guinea pig ileal whole segment.	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID500232	Inverse agonist activity at human wild-type histamine H1 receptor N7.45Q mutant assessed as NF-kappaB activation at 0.1 mM after 48 hrs by luciferase reporter gene assay	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID444827	Cytotoxicity against mouse P19 cells after 3 days by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID632451	Displacement of [3H]histamine from human H3 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
AID548993	Agonist activity at human histamine H4 receptor expressed in human SK-N-MC cells by CRE-beta galactosidase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1877333	Inhibition of inhibition of MIF tautomerase (unknown origin) in MIF-induced mouse RAW264.7 cells assessed as reduction in cell migration relative to control	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID86440	Maximum response (E max) against Histamine H1 receptor endothelium-Denuded rings of guinea pig Aorta	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID586694	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293 cells after 60 mins by liquid scintillation counting	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
AID609368	Activation of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives.
AID1877336	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability up to 100 uM by CCK8 assay	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1895200	Selectivity ratio of Ki for human histamine H3 receptor to Ki for human histamine H2 receptor incubated for 60 mins by scintillation counting analysis
AID478885	Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID725226	Activation of Sulfurihydrogenibium azorense recombinant alpha carbonic anhydrase by stopped flow CO2 hydrase method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	The extremo-α-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines.
AID86442	Binding affinity towards histamine H3 receptor using [3H](R)-alpha-methylhistamine as radioligand in guinea pig cortical homogenates	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.
AID1540381	Agonist activity at human H4R by [35S]-GTPgammaS-binding assay
AID478889	Activity at human recombinant GAIP-fused histamine H4 receptor expressed in Sf9 cells coexpressing Galphai, Gbeta1gamma2 by steady-state GTPase activity assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
AID1148743	Retardation factor of the compound using MeOH-NH4OH-H2O at ratio of 6:1:1 as solvent system by thin layer chromatography	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID414326	Activity at human recombinant CA2	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID500228	Displacement of [3H]mepyramine from human histamine H1 receptor N7.45S mutant expressed in COS-7 cells by liquid scintillation counting	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Linking agonist binding to histamine H1 receptor activation.
AID222157	Ex vivo carbonic anhydrase activation was measured after 60 min of incubation of lysed human erythrocyte	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties.
AID1877334	Inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID86757	Maximum response (E max) against Histamine H1 receptor in guinea pig ileum	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
AID375787	Activation of membrane associated mouse recombinant carbonic anhydrase 15 isoform by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines.
AID86619	Inhibitory activity measured by [3H]- N alpha- methyl-histamine binding to membranes of SK-N-MC cells expressing the human Histamine H3 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID1830583	Agonist activity at human H2 receptor expressed in Sf9 cell membranes co-exprssing GsalphaS assessed as stimulation of [35S]GTPgammaS binding by measuring maximum efficacy incubated for 90 mins by scintillation counting analysis
AID79985	Compound was tested for inhibition of histamine H3-receptor mediated neurogenic contractions in the isolated guinea pig ileum assay; Full agonist	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.
AID231202	Active species ratio of pD2 at pH 7.8 / pD2 at pH 7.4	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID1540403	Agonist activity at mouse H4R expressed in HEK293T-beta-arr2-mH4R cells by beta-arrestin2 recruitment assay
AID193688	Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Further hypotensive metabolites from Verbesina caracasana.
AID1661702	Displacement of [3H]UR-DE257 from Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells incubated for 60 mins by scintillation counting method	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Fluorescent H
AID1397321	Activation of Leishmania donovani chagasi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay
AID88163	Agonistic activity of guinea pig Histamine H2 receptor expressed as pD2 at pH 7.0	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID548992	Agonist activity at human histamine H3 receptor expressed in human SK-N-MC cells by CRE-beta galactosidase reporter gene assay relative to histamine	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID1540382	Agonist activity at mouse H4R by [35S]-GTPgammaS-binding assay
AID72703	In vitro inotropy blocking studies in ferret papillary muscle in the presence of 10 uM cimetidine; B-Blocked	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID408970	Inverse agonist activity at human histamine H4 receptor expressed in HEK293T cells by CRE-beta-galactosidase assay	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.
AID409993	Activation of human recombinant CA3 by stopped-flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines.
AID464321	Activation of Saccharomyces cerevisiae recombinant Nce103p by stopped flow CO2 hydration method	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID192740	Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 0.044 uM/kg in anesthetized rats	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID365829	Activation of human recombinant CA3 at 10 uM by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines.
AID1558683	Agonist activity at human H3R expressed on HEK293T cells assessed as inhibition of forskolin-induced CRE-driven luciferase activity co-incubated with forskolin for 6 hrs and measured after 30 mins by CRE-luciferase reporter gene assay
AID414331	Activation of yeast recombinant CA by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID679214	TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells	1999	Molecular pharmacology, Jul, Volume: 56, Issue:1	Selective substrates for non-neuronal monoamine transporters.
AID270366	Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
AID86424	Partial agonist activity against Histamine H1 receptor in guinea pig aorta	1998	Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18	N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.
AID197187	Evaluated for inhibition of [3H]-histamine release from rat cerebral cortex.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID89539	Antagonistic activity, Histamine H3 receptor dependent activation of G-proteins with GTP gamma-[35S] autoradiography of rat cortical tissue sections. at 10e-6 M conc.; maximal response	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID1210303	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 6 by two-microelectrode voltage-clamp method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID1210307	Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as increase of inwardly directed H+ gradient current at 2.5 mM in NMDG chloride buffer at pH 6 to 7.5 at -50 to -150 mV of membrane potential by two-microelectrode voltage-clamp	2012	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6	Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID193687	Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Further hypotensive metabolites from Verbesina caracasana.
AID426166	Displacement of 3-([1,1,1-3H]methyl)-2-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-4(3H)-quinazolinone from mouse histamine H3 receptor expressed in HEK293 cells	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.
AID464318	Activity at Candida glabrata recombinant carbonic anhydrase	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids.
AID89899	Intrinsic activity for human Histamine H4 receptor	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
AID25362	Compound was evaluated for the ionization constant (pKa) by using potentiometric titration (ionization of end group)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	(Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists.
AID291067	Activation of of human recombinant CA14 by CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
AID86604	Intrinsic activity against histamine H1 receptor in guinea pig ileum	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (alpha R, beta S)-alpha,beta-dimethylhistamine, a novel high potent histamine H3 receptor agonist.
AID458783	Activation of Candida albicans beta-carbonic anhydrase Nce103 assessed as enzyme catalytic rate at 10 uM by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID1540378	Binding affinity to human H4R
AID458787	Activation of Cryptococcus neoformans beta-carbonic anhydrase Can2 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.
AID270368	Agonist activity at human H3 receptor expressed in 293-EBNA cells by luciferase reporter gene assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
AID327691	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293T cells	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.
AID25363	Compound was evaluated for the ionization constant (pKa) by using potentiometric titration (ionization of imidazole group)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	(Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists.
AID414329	Activation of human recombinant CA2 by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID79822	Effective concentration for agonism activity in Endothelium-Denuded guinea pig aortic segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID197292	Changes in diastolic blood pressure following iv administration at (0.044 umol/Kg)anesthetized rats	2001	Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18	Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID293054	Activation of human recombinant CA5A by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.
AID48117	In vitro carbonic anhydrase IV activation in bovine lung microsomes.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID1540405	Agonist activity at rat H4R expressed in HEK293-SF-rH4R-His6-CRE-Luc cells incubated for 5 hrs by luciferase reporter gene assay
AID414330	Activation of Methanothermobacter thermautotrophicus recombinant Cab by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids.
AID168742	Effective concentration for agonism activity in endothelium-denuded guinea pig aortic segment	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
AID1830581	Agonist activity at human H2 receptor expressed in Sf9 cell membranes co-exprssing GsalphaS assessed as stimulation of [35S]GTPgammaS binding incubated for 90 mins by scintillation counting analysis
AID1690426	Agonist activity at human H3 receptor expressed in CHO cells assessed as increase in cAMP accumulation by measuring reduction in forskolin level incubated for 4 hrs by CRE/MRE-luciferase reporter gene assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Novel pyrrolidinone derivative lacks claimed histamine H
AID86920	In vitro functional Histamine H1 receptor assay was measured on guinea pig jejunum.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
AID1558682	Displacement of [3H]NAMH from human H3R expressed in HEK293T cells incubated for 2 hrs by microbeta scintillation counting analysis
AID1756658	Agonist activity at human histamine H2 receptor expressed in HEK293T cells co-expressing ELucC by beta arrestin2 recruitment assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
AID1244820	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by serial microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
AID318343	Activation of human recombinant CA1 by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
AID680330	TP_TRANSPORTER: uptake in OCT3-expressing HEK293 cells	1999	Molecular pharmacology, Jul, Volume: 56, Issue:1	Selective substrates for non-neuronal monoamine transporters.
AID1331204	Activation of recombinant human carbonic anhydrase 2 at 10 uM incubated for 15 mins prior to testing by stopped flow CO2 hydration assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines.
AID1895206	Agonist activity at guinea pig histamine H2 receptor stably transfected in HEK293T cells co-expressing NlucN-mGs/gpH2R-NlucC assessed as maximum efficacy at 100 uM by mini-G protein recruitment assay relative to histamine
AID88165	Agonistic activity of guinea pig Histamine H2 receptor expressed as pD2 at pH 7.8	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.
AID1540379	Binding affinity to mouse H4R
AID1877335	Reversal inhibition of MIF tautomerase (unknown origin) at 0.5 mM using 4-HPP as substrate preincubated for 30 min followed by 100 fold dilution by dilution assay	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID586697	Agonist activity at human histamine H3 receptor expressed in HEK293 cells assessed by forskolin induced cAMP response element activation by luciferase reporter gene assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
AID291065	Activation of human recombinant CA7 by CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
AID88562	In vivo percent change in total acid secretion in guinea pig was determined at a dose of 1 mg/kg/h	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID549006	Agonist activity at human recombinant histamine H4 receptor expressed in human SK-N-MC cells co-expressing SRE-Luc by luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Histamine H4 receptor agonists.
AID431566	Activation of human recombinant carbonic anhydrase 12 catalytic domain by stopped flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	1999	Molecular cell, May, Volume: 3, Issue:5	Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure.
AID1811	Experimentally measured binding affinity data derived from PDB	1999	Molecular cell, May, Volume: 3, Issue:5	Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1796109	QC Inhibition Testing from Article 10.1074/jbc.M309077200: \\Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.\\	2003	The Journal of biological chemistry, Dec-12, Volume: 278, Issue:50	Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.
AID1798266	H3R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1798265	H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1811	Experimentally measured binding affinity data derived from PDB	1997	Biochemistry, Aug-26, Volume: 36, Issue:34	Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	1997	Biochemistry, Aug-26, Volume: 36, Issue:34	Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	21504 (60.86)	18.7374
1990's	6129 (17.35)	18.2507
2000's	3900 (11.04)	29.6817
2010's	2835 (8.02)	24.3611
2020's	966 (2.73)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,372 (3.64%)	5.53%
Reviews	2,039 (5.41%)	6.00%
Case Studies	371 (0.98%)	4.05%
Observational	15 (0.04%)	0.25%
Other	33,921 (89.93%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation[NCT03673384]		50 participants (Actual)	Interventional	2015-03-02	Completed
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch[NCT03943407]		0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to The Imiquimod 3.75% was ineffective)
Skin Prick Test of KeraStat® Cream[NCT04058054]		22 participants (Actual)	Interventional	2019-07-29	Completed
Effect of Intradermal Morphine Application on Histaminergic and Non-histaminergic Itch and Related TRPV1 and Antihistamine Treatments (2nd Sub-project)[NCT04700007]		26 participants (Actual)	Interventional	2021-01-18	Completed
A Phase I/II Trial of Peri- and Postoperative Treatment With Histamine Dihydrochloride and Low-dose Interleukin-2 in Patients With Primary Resectable Pancreatic Cancer[NCT05810792]	Phase 2	50 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)[NCT03050866]	Phase 2	140 participants (Anticipated)	Interventional	2017-02-21	Active, not recruiting
Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.[NCT01730638]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2013-01-31	Completed
A Multicenter, Randomized, Double Blind, Active Controlled, Parallel Group, Clinical Study, to Evaluate the Safety and Efficacy of Apitox vs Histamine in Subjects With Refractory Osteoarthritis Pain and Inflammation of the Knee[NCT01112722]	Phase 3	363 participants (Actual)	Interventional	2013-12-31	Completed
Effects of Halophyte-based Cream Skin Application in a Human Experimental Model of Pain and Itch[NCT04635254]		32 participants (Actual)	Interventional	2020-11-12	Completed
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients[NCT03710655]	Phase 3	468 participants (Anticipated)	Interventional	2019-04-30	Not yet recruiting
Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission[NCT01347996]	Phase 4	84 participants (Actual)	Interventional	2009-07-31	Completed
Nerve Excitability Testing Protocol to Efficiently Induce Itch[NCT05195177]		20 participants (Anticipated)	Interventional	2021-11-25	Enrolling by invitation
Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.[NCT00630383]	Phase 2	0 participants (Actual)	Interventional	2008-02-29	Withdrawn(stopped due to superceded by another similar study)
En Mekanistisk undersøgelse af Interaktioner Imellem Det Thermoceptive og Det Pruriceptive Sensoriske System[NCT03576053]		59 participants (Actual)	Interventional	2018-07-01	Completed
Repetitive Applications of Pruritogens and Effects of a Cutaneous-induced Pain Stimulation on Nonhistaminergic Itch Perception[NCT06154824]		30 participants (Anticipated)	Interventional	2023-12-15	Recruiting
Investigation of the Effects of Sleep Provocations on Itch and Pain Sensitivity[NCT06081946]		30 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
A Phase I and Phase II Study of the Efficacy and Safety of Maintenance Treatment With Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Who Achieved Hematological Response to Azacitidine[NCT01324960]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2011-03-31	Withdrawn
A Mechanistic Study on Morphine-induced Orthogonal Neural Plasticity for Itch and Pain Processing in Humans (a Relation of Morphine-induced Itch and Pain Processing)[NCT04115462]		24 participants (Actual)	Interventional	2020-01-15	Completed
Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up[NCT00795496]		50 participants (Actual)	Observational	2008-11-30	Completed
A Mechanistic Evaluation of the Nociceptive Desensitization Induced by Repeated Administration of Topical Local Anaesthetic Mixture of Lidocaine and Prilocaine (EMLA) in a Model of Histaminergic and Non-histaminergic Itch.[NCT04076865]		26 participants (Actual)	Interventional	2019-10-15	Completed
In Vivo Functional Assessment of Histamine Pharmacodynamics in Children[NCT00809692]		0 participants (Actual)	Interventional	2007-09-30	Withdrawn(stopped due to Study withdrawn and combined with a new protocol)
Can Low Histamine Diet Reduce Symptoms of Patients With Idiopathic Urticaria?[NCT02047136]		8 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to Unable to recruit subjects, patients want active treatment instead of placebo.)
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis[NCT02555852]		4,238,504 participants (Actual)	Observational	2011-09-30	Completed
Are Technicians Showing Bronchial Hyperreactivity Able to Safely Perform Bronchial Provocation Tests?[NCT01937494]		13 participants (Actual)	Interventional	2013-05-31	Completed
Investigation of the Effects of Sleep Provocations on Itch and Pain Sensitivity[NCT06081998]		30 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Leukotriene D4 Nasal Provocation Test: Rationale, Methodology, Diagnostic Value and Its Impact on Airway Inflammation in Allergic Rhinitis With or Without Asthma[NCT01963741]		60 participants (Actual)	Interventional	2012-11-30	Completed
Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests[NCT01989897]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2013-03-31	Withdrawn(stopped due to Funding for the trial was lost so study was ended. No participants were enrolled.)
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of TOLAMBA™ in Ragweed-Allergic Rhinitis Adults[NCT00387738]	Phase 2	738 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.)
Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch[NCT04588532]		24 participants (Actual)	Interventional	2020-10-01	Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma[NCT04674137]	Phase 2	70 participants (Actual)	Interventional	2020-12-16	Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Optimal Dose of XC8 in Patients With Partly Controlled Bronchial Asthma Receiving Stable Treatment With Low Doses of Inhaled Corticosteroids With or Wi[NCT03450434]	Phase 2	120 participants (Actual)	Interventional	2016-09-20	Completed
Double-blind, Randomized, Dose-escalating, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8 After Single and Multiple Oral Doses in Healthy Volunteers[NCT02882217]	Phase 1	32 participants (Actual)	Interventional	2016-08-31	Completed
An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy Participants[NCT04676763]		37 participants (Actual)	Interventional	2021-03-02	Completed
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick[NCT04399213]		13 participants (Actual)	Interventional	2019-01-15	Completed
Histaminergic Basis of Fatigue in Multiple Sclerosis[NCT04764383]	Phase 2	0 participants (Actual)	Interventional	2022-01-01	Withdrawn(stopped due to Withdrawn as more data drug analysis is recommended before the study.)
Randomized Evaluation of Ten Allergy Skin Prick Test Devices[NCT03509766]		24 participants (Actual)	Interventional	2014-01-31	Completed
A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers[NCT01292070]	Early Phase 1	4 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Futility)
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor[NCT04711044]		20 participants (Actual)	Interventional	2021-02-01	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of TOLAMBA™ in the Control of Symptoms of Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model[NCT00537355]	Phase 2	271 participants (Actual)	Interventional	2007-09-30	Completed
A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Me[NCT00039234]	Phase 3	0 participants	Interventional	2002-09-30	Active, not recruiting
Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leuk[NCT00003991]	Phase 3	360 participants (Anticipated)	Interventional	1998-07-31	Completed
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]		228 participants (Actual)	Interventional	2012-01-31	Completed
Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency[NCT01507792]		22 participants (Actual)	Interventional	2002-01-31	Completed
Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1[NCT01719133]	Phase 1	20 participants (Actual)	Interventional	2008-02-29	Completed
Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expr[NCT01730612]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2012-12-31	Completed
Role of the Central Nervous System in Allergic Rhinitis: Activation of Different Brain Regions After a Nasal Histamine Provocation in Healthy and Allergic Patients[NCT01777464]		14 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to analysing images ongoing)
Immunologic Profile of Chronically Photodamaged Skin[NCT02889159]	Phase 4	40 participants (Anticipated)	Interventional	2016-06-06	Recruiting
En undersøgelse af Mekanismerne Bag Nociceptiv Desensibilisering forårsaget af Topikal Capsaicin[NCT03587220]		44 participants (Actual)	Interventional	2018-08-01	Completed
A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma[NCT00005038]	Phase 2	0 participants	Interventional	1999-06-30	Active, not recruiting
Evaluation of Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts as an Adjuvant[NCT02506998]	Phase 2	30 participants (Actual)	Interventional	2013-08-31	Completed
Middle Ear Pressure Regulation in Health and Disease -- Gas Supply, Demand and Middle Ear Gas Balance -- Specific Aim 2[NCT01925729]	Phase 1	84 participants (Actual)	Interventional	2013-10-01	Completed
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor[NCT04554888]		20 participants (Actual)	Interventional	2022-03-01	Completed
Inter-arm and Inter-period Reproducability of the Dermal Blood Flow Response After a Histamine Skin Prick.[NCT04396977]		14 participants (Actual)	Interventional	2019-02-28	Completed
Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes[NCT05921097]		50 participants (Anticipated)	Observational	2023-06-17	Enrolling by invitation
A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)[NCT03040401]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2017-02-15	Recruiting
A Randomized, Double-Blinded, Negative- and Positive-Controlled Study for Evaluation of the Allergenicity of Amphadase® in Healthy Volunteers Using Intradermal Skin Test[NCT01689363]	Phase 2	253 participants (Actual)	Interventional	2012-09-30	Completed
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)[NCT03441373]	Phase 2/Phase 3	320 participants (Actual)	Interventional	2016-02-03	Completed
Use of the Modified PUQE ( Pregnancy -Unique Quantification of Emesis ) Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment[NCT04785911]		200 participants (Actual)	Observational	2021-09-05	Completed
A Double-blind, Randomized, Placebo-controlled Study of the Safety and Tolerability of Increasing Doses of XC8 After Single and Repeated Oral Administration in Healthy Volunteers[NCT03441815]	Phase 1	28 participants (Actual)	Interventional	2015-02-14	Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]		101 participants (Actual)	Interventional	2012-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mm (Mean)
KeraStat® Cream	0
KeraStat® Gel	0.32
Biafine	0.23
Histamine	6.73
Saline	0

Intervention	percentage of tests true positive (Number)
Skin Testing	95.8

Intervention	ratio (Mean)
1 Versus 6mg	1

Intervention	mm (Mean)
Skin Testing	6.8

Intervention	participants (Number)
Histamine-2 Receptor Antagonist Group	106
Placebo Group	101

Intervention	mm (Mean)
Arm H	2.1
Arm N	0.1
Arm P	34.0

Intervention	mm (Mean)
Arm H	1.1
Arm N	0.0
Arm P	44.1

Intervention	mm (Mean)
Arm H	0.5
Arm N	0.0
Arm P	11.5

Intervention	mm (Mean)
Arm H	0.1
Arm N	0.0
Arm P	15.2

Intervention	percentage of participants (Number)
Arm H	53.8
Arm N	11.1
Arm P	97.6

Intervention	percentage of participants (Number)
Arm H	51.4
Arm N	8.7
Arm P	100.0

Intervention	percentage of participants (Number)
Arm H	10.3
Arm N	1.6
Arm P	79.1

Intervention	percentage of participants (Number)
Arm H	7.7
Arm N	1.1
Arm P	100.0

Intervention	mm (Mean)
Arm H	5.4
Arm N	0.9
Arm P	41.5

Intervention	mm (Mean)
Arm H	4.3
Arm N	0.6
Arm P	44.4

Intervention	mm (Mean)
Arm H	1.5
Arm N	1.7
Arm P	14.1

Intervention	mm (Mean)
Arm H	1.1
Arm N	1.7
Arm P	15.3

Intervention	participants (Number)
Intent-to-Treat Population (ITT)	7

Intervention	participants (Number)
Per-Protocol Population (PPP)	0

Intervention	participants (Number)
Proton Pump Inhibitor Group	1
Histamine-2 Receptor Antagonist Group	7

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
tele-methylhistamine	[no description available]	medium	1	0
dimaprit	[no description available]	medium	256	0	imidothiocarbamic ester
dimaprit	[no description available]	medium	256	1	imidothiocarbamic ester
impromidine	[no description available]	medium	97	0
impromidine	[no description available]	medium	97	1
sk&f 91486	[no description available]	medium	5	0
n-methylhistamine	[no description available]	medium	8	0	aralkylamine
cimetidine	[no description available]	high	1,127	41	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cimetidine	[no description available]	high	1,127	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
tele-methylhistamine	[no description available]	high	111	0	imidazoles; primary amino compound	human metabolite; mouse metabolite
pyrilamine	[no description available]	medium	885	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
pyrilamine	[no description available]	medium	885	9	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
ranitidine	[no description available]	medium	4	0	aralkylamine
dexchlorpheniramine	[no description available]	medium	10	0	chlorphenamine
dexchlorpheniramine	[no description available]	medium	10	1	chlorphenamine
4-methylhistamine	[no description available]	medium	83	0	aralkylamino compound; imidazoles	histamine agonist; metabolite
4-methylhistamine	[no description available]	medium	83	1	aralkylamino compound; imidazoles	histamine agonist; metabolite
tiotidine	[no description available]	medium	48	0	thiazoles
2-methylhistamine	[no description available]	medium	42	0	aralkylamino compound; imidazoles	histamine agonist; metabolite
2-methylhistamine	[no description available]	medium	42	1	aralkylamino compound; imidazoles	histamine agonist; metabolite
alpha-methylhistamine	[no description available]	medium	21	0	aralkylamino compound; imidazoles	H3-receptor agonist
dexchlorpheniramine	[no description available]	medium	2	0	chlorphenamine
metiamide	[no description available]	high	312	2	imidazoles
metiamide	[no description available]	high	312	0	imidazoles
burimamide	[no description available]	high	107	1	imidazoles
burimamide	[no description available]	high	107	0	imidazoles
thioperamide	[no description available]	medium	189	0	primary aliphatic amine
(2S)-1-(1H-imidazol-5-yl)-2-propanamine	[no description available]	medium	7	0	aralkylamine
histamine trifluoromethyl-toluidide	[no description available]	medium	11	0	(trifluoromethyl)benzenes
mifentidine	[no description available]	medium	7	0
betahistine	[no description available]	medium	33	0	aminoalkylpyridine; secondary amino compound	H1-receptor agonist; vasodilator agent
betahistine	[no description available]	medium	33	1	aminoalkylpyridine; secondary amino compound	H1-receptor agonist; vasodilator agent
2-(2-aminoethyl)thiazole	[no description available]	medium	36	0	1,3-thiazoles
2-(3-trifluoromethylphenyl)histamine	[no description available]	medium	12	0
imetit	[no description available]	medium	39	0	imidazoles; imidothiocarbamic ester	H3-receptor agonist; H4-receptor agonist
imidazolyl-4-propylamine	[no description available]	medium	6	0
4-(1h-imidazol-4-ylmethyl)piperidine	[no description available]	medium	29	0	piperidines
impentamine	[no description available]	medium	6	0
4-(1h-imidazol-4-yl)butanamine	[no description available]	medium	6	0
cetirizine	[no description available]	medium	164	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
cetirizine	[no description available]	medium	164	79	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
cyproheptadine	[no description available]	medium	112	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
cyproheptadine	[no description available]	medium	112	19	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
triprolidine	[no description available]	medium	59	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
triprolidine	[no description available]	medium	59	12	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
clonidine	[no description available]	medium	90	0	clonidine; imidazoline
clonidine	[no description available]	medium	90	5	clonidine; imidazoline
guanethidine	[no description available]	medium	75	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanethidine	[no description available]	medium	75	1	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
papaverine	[no description available]	medium	212	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
papaverine	[no description available]	medium	212	1	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
reserpine	[no description available]	medium	390	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
reserpine	[no description available]	medium	390	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
hexamethonium chloride	[no description available]	medium	4	0
quinidine	[no description available]	medium	29	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
quinine	[no description available]	medium	18	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
iodoaminopotentidine	[no description available]	medium	8	0
ranitidine	[no description available]	medium	310	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
ranitidine	[no description available]	medium	310	20	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
amantadine	[no description available]	medium	11	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
memantine	[no description available]	medium	6	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
memantine	[no description available]	medium	6	1	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
1-methyl-4-phenylpyridinium	[no description available]	medium	13	0	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin
clobenpropit	[no description available]	medium	57	0	imidazoles; imidothiocarbamic ester; organochlorine compound	H3-receptor antagonist; H4-receptor agonist
iodoproxyfan	[no description available]	medium	10	0
histidinol	[no description available]	high	3	0	amino alcohol; imidazoles	EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitor; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
proxyfan	[no description available]	medium	9	0	benzyl ether
gt 2331	[no description available]	medium	2	0
choline	[no description available]	high	111	3	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
choline	[no description available]	high	111	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
guanidine	[no description available]	medium	13	0	carboxamidine; guanidines; one-carbon compound
tetraethylammonium	[no description available]	medium	40	0	quaternary ammonium ion
isoproterenol	[no description available]	medium	992	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoproterenol	[no description available]	medium	992	7	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
agmatine	[no description available]	high	13	0	guanidines; primary amino compound	Escherichia coli metabolite; mouse metabolite
galegine	[no description available]	medium	1	0	guanidines
methylhistaprodifen	[no description available]	medium	8	0
histaprodifen	[no description available]	medium	18	0
clozapine	[no description available]	medium	24	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
ciproxifan	[no description available]	medium	24	0	aromatic ketone
alpha-ketoglutaric acid	[no description available]	medium	2	0	oxo dicarboxylic acid	fundamental metabolite
thiamine	[no description available]	high	14	1	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thiamine	[no description available]	high	14	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
p-aminohippuric acid	[no description available]	medium	3	0	N-acylglycine	Daphnia magna metabolite
verapamil	[no description available]	medium	146	0	aromatic ether; nitrile; polyether; tertiary amino compound
verapamil	[no description available]	medium	146	3	aromatic ether; nitrile; polyether; tertiary amino compound
diphenhydramine	[no description available]	medium	523	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
diphenhydramine	[no description available]	medium	523	14	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
lidocaine	[no description available]	medium	107	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
lidocaine	[no description available]	medium	107	16	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
procainamide	[no description available]	medium	16	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
n-methylnicotinamide	[no description available]	medium	5	0	pyridinecarboxamide	metabolite
acetylcarnitine	[no description available]	medium	1	0	O-acetylcarnitine; saturated fatty acyl-L-carnitine	human metabolite; Saccharomyces cerevisiae metabolite
desipramine	[no description available]	medium	45	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
desipramine	[no description available]	medium	45	1	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
probenecid	[no description available]	medium	12	0	benzoic acids; sulfonamide	uricosuric drug
corticosterone	[no description available]	high	196	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
tetramethylammonium chloride	[no description available]	medium	2	0	organic molecular entity
tetrapropylammonium	[no description available]	medium	3	0	quaternary ammonium ion
tetrabutylammonium	[no description available]	medium	4	0	quaternary ammonium ion
metiprenaline	[no description available]	medium	1	0
cyanine 863	[no description available]	medium	1	0
chlorpheniramine	[no description available]	medium	335	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpheniramine	[no description available]	medium	335	26	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
disopyramide	[no description available]	medium	8	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
imipramine	[no description available]	medium	55	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
acecainide	[no description available]	medium	5	0	acetamides; benzamides	anti-arrhythmia drug
amiloride	[no description available]	medium	34	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
amiloride	[no description available]	medium	34	1	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
tetrapentylammonium	[no description available]	medium	3	0	quaternary ammonium ion
histidine	[no description available]	high	760	3	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
histidine	[no description available]	high	760	0	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
carnosine	[no description available]	high	64	0	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
alanine	[no description available]	medium	29	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
aspartic acid	[no description available]	high	42	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
aspartyl-aspartic acid	[no description available]	medium	1	0	dipeptide	Mycoplasma genitalium metabolite
alanylalanine	[no description available]	medium	1	0	dipeptide zwitterion; dipeptide	Mycoplasma genitalium metabolite
alpha-aspartylalanine	[no description available]	medium	1	0	dipeptide	metabolite
doxepin hydrochloride	[no description available]	medium	2	0
1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene	[no description available]	medium	1	0
zidovudine	[no description available]	medium	5	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
grepafloxacin	[no description available]	medium	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
nicotine	[no description available]	medium	284	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
nicotine	[no description available]	medium	284	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
levofloxacin	[no description available]	medium	6	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
chlorpromazine	[no description available]	medium	144	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
pindolol	[no description available]	medium	21	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
tyramine	[no description available]	high	332	3	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
tyramine	[no description available]	high	332	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
gentian violet	[no description available]	medium	1	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
arpromidine	[no description available]	medium	6	0
citalopram	[no description available]	medium	11	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
citalopram	[no description available]	medium	11	1	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
fluoxetine	[no description available]	medium	19	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
phenylalanine	[no description available]	high	54	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
sertraline	[no description available]	medium	3	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
benzimidazole	[no description available]	medium	2	0	benzimidazole; polycyclic heteroarene
aminoimidazole carboxamide	[no description available]	high	2	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
2-aminobenzimidazole	[no description available]	medium	1	0	benzimidazoles	marine xenobiotic metabolite
n-acetylimidazole	[no description available]	medium	2	0	N-acylimidazole
1-(trimethylsilyl)-1h-imidazole	[no description available]	medium	1	0	imidazoles; N-silyl compound	chromatographic reagent
dazoxiben	[no description available]	medium	3	0
3-methylhistamine	[no description available]	medium	26	0
n-acetylhistamine	[no description available]	high	12	0	acetamides; imidazoles	human metabolite
1-(3-aminopropyl)imidazole	[no description available]	medium	1	0	imidazoles
4-[3-(1H-imidazol-5-yl)propyl]piperidine	[no description available]	medium	1	0	aralkylamine
tripelennamine	[no description available]	medium	156	0	aromatic amine
2-(2-aminoethyl)pyridine	[no description available]	medium	113	0	aminoalkylpyridine; primary amine	histamine agonist; metabolite
levocetirizine	[no description available]	medium	21	0	diarylmethane
levocetirizine	[no description available]	medium	21	9	diarylmethane
jnj 7777120	[no description available]	medium	47	0
jnj 10191584	[no description available]	medium	6	0	benzimidazoles
octoclothepine	[no description available]	medium	1	0	dibenzothiepine
amoxapine	[no description available]	medium	4	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
ebastine	[no description available]	medium	22	0	organic molecular entity
ebastine	[no description available]	medium	22	11	organic molecular entity
fexofenadine	[no description available]	medium	46	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fexofenadine	[no description available]	medium	46	18	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
hydroxyzine	[no description available]	medium	77	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hydroxyzine	[no description available]	medium	77	33	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
loratadine	[no description available]	medium	95	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
loratadine	[no description available]	medium	95	45	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
loxapine	[no description available]	medium	3	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
azatadine	[no description available]	medium	7	0	benzocycloheptapyridine; tertiary amine	anti-allergic agent; H1-receptor antagonist
azatadine	[no description available]	medium	7	3	benzocycloheptapyridine; tertiary amine	anti-allergic agent; H1-receptor antagonist
mizolastine	[no description available]	medium	11	0	benzimidazoles
mizolastine	[no description available]	medium	11	6	benzimidazoles
amthamine	[no description available]	medium	18	0	thiazoles
aminopotentidine	[no description available]	medium	5	0	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist
triptorelin	[no description available]	medium	6	0	organoiodine compound
famotidine	[no description available]	medium	3	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
4-(1H-imidazol-5-ylmethyl)pyridine	[no description available]	medium	2	0	pyridines
methimepip	[no description available]	medium	3	0
histidine methyl ester	[no description available]	medium	3	0	histidine derivative
levodopa	[no description available]	high	36	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
tryptophan	[no description available]	high	99	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
aminoethylpiperazine	[no description available]	medium	17	0
D-tryptophan	[no description available]	medium	17	0	D-alpha-amino acid; tryptophan zwitterion; tryptophan	bacterial metabolite
2-(aminomethyl)pyridine	[no description available]	medium	16	0	pyridines
copper histidine	[no description available]	medium	17	0	D-alpha-amino acid; histidine; polar amino acid zwitterion	Saccharomyces cerevisiae metabolite
phenylalanine	[no description available]	medium	17	0	D-alpha-amino acid zwitterion; D-alpha-amino acid; phenylalanine
D-dopa	[no description available]	medium	16	0	amino acid zwitterion; D-tyrosine derivative; dopa
4-2-Aminoethyl-morpholine	[no description available]	medium	16	0	morpholines
tyrosine	[no description available]	medium	97	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
4-aminophenylalanine	[no description available]	medium	16	0	4-aminophenylalanine; amino acid zwitterion
epitrate	[no description available]	medium	11	0	4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
n-methylquipazine	[no description available]	medium	1	0	aminoquinoline; N-alkylpiperazine; N-arylpiperazine	serotonergic agonist
6,7-dichloro 3-(4-methylpiperazin-1-yl)quinoxalin-2(1h)-one	[no description available]	medium	3	0
vuf10166	[no description available]	medium	1	0
normetanephrine	[no description available]	medium	18	0	catecholamine
phenytoin	[no description available]	medium	14	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acebutolol	[no description available]	medium	4	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen	[no description available]	medium	17	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetaminophen	[no description available]	medium	17	2	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
theophylline	[no description available]	medium	324	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
theophylline	[no description available]	medium	324	16	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amitriptyline	[no description available]	medium	29	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amsacrine	[no description available]	medium	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
antipyrine	[no description available]	medium	17	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
arcaine	[no description available]	medium	1	0	guanidines
aspirin	[no description available]	medium	296	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
aspirin	[no description available]	medium	296	18	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol	[no description available]	medium	12	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine	[no description available]	high	10	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azathioprine	[no description available]	high	10	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen	[no description available]	medium	15	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
buspirone	[no description available]	medium	6	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
caffeine	[no description available]	high	175	4	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
caffeine	[no description available]	high	175	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
candesartan	[no description available]	medium	3	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine	[no description available]	medium	8	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carisoprodol	[no description available]	medium	3	0	carbamate ester	muscle relaxant
celecoxib	[no description available]	medium	6	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chloroquine	[no description available]	medium	88	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chloroquine	[no description available]	medium	88	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorzoxazone	[no description available]	medium	3	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
clomipramine	[no description available]	medium	7	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clotrimazole	[no description available]	high	6	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
eflornithine	[no description available]	medium	3	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
diazepam	[no description available]	medium	37	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazepam	[no description available]	medium	37	3	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diclofenac	[no description available]	medium	12	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
valproic acid	[no description available]	medium	9	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
valproic acid	[no description available]	medium	9	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
doxazosin	[no description available]	medium	1	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
felodipine	[no description available]	medium	4	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
felodipine	[no description available]	medium	4	1	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate	[no description available]	medium	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fentanyl	[no description available]	medium	28	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fentanyl	[no description available]	medium	28	5	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fluphenazine	[no description available]	medium	5	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluorouracil	[no description available]	medium	11	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
flutamide	[no description available]	medium	3	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
furosemide	[no description available]	medium	26	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
furosemide	[no description available]	medium	26	4	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin	[no description available]	medium	4	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
glipizide	[no description available]	medium	2	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide	[no description available]	medium	22	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
haloperidol	[no description available]	medium	39	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hydralazine	[no description available]	medium	14	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide	[no description available]	medium	11	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
ibuprofen	[no description available]	medium	21	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
ketoconazole	[no description available]	high	5	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoconazole	[no description available]	high	5	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen	[no description available]	medium	7	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketoprofen	[no description available]	medium	7	1	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
loperamide	[no description available]	medium	5	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
meclizine	[no description available]	medium	8	0	diarylmethane
metaproterenol	[no description available]	high	35	3	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metaproterenol	[no description available]	high	35	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin	[no description available]	medium	6	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
metoclopramide	[no description available]	medium	15	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metoprolol	[no description available]	medium	10	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metoprolol	[no description available]	medium	10	1	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
mianserin	[no description available]	medium	10	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
ofloxacin	[no description available]	medium	7	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
ondansetron	[no description available]	medium	6	0	carbazoles
ondansetron	[no description available]	medium	6	3	carbazoles
orphenadrine	[no description available]	medium	3	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxprenolol	[no description available]	medium	4	0	aromatic ether
oxybutynin	[no description available]	medium	5	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
oxybutynin	[no description available]	medium	5	1	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
phenobarbital	[no description available]	medium	29	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine	[no description available]	medium	169	0	aromatic amine
phenoxybenzamine	[no description available]	medium	169	1	aromatic amine
prazosin	[no description available]	medium	43	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prazosin	[no description available]	medium	43	2	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prochlorperazine	[no description available]	medium	7	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
prochlorperazine	[no description available]	medium	7	1	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
promazine	[no description available]	medium	8	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine	[no description available]	medium	197	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
promethazine	[no description available]	medium	197	5	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone	[no description available]	medium	5	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol	[no description available]	medium	24	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propofol	[no description available]	medium	24	3	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol	[no description available]	medium	527	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
propranolol	[no description available]	medium	527	13	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
risperidone	[no description available]	medium	6	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
sotalol	[no description available]	medium	15	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
sulfasalazine	[no description available]	medium	3	0
terazosin	[no description available]	medium	3	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline	[no description available]	medium	79	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terbutaline	[no description available]	medium	79	23	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine	[no description available]	medium	149	0	diarylmethane
terfenadine	[no description available]	medium	149	69	diarylmethane
tinidazole	[no description available]	medium	2	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
ultram	[no description available]	medium	2	0	aromatic ether; tertiary alcohol; tertiary amino compound
trihexyphenidyl	[no description available]	medium	2	0	amine
trimethoprim	[no description available]	medium	5	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimipramine	[no description available]	medium	6	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
troglitazone	[no description available]	medium	5	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thyroxine	[no description available]	high	53	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
spironolactone	[no description available]	medium	2	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
prednisone	[no description available]	medium	44	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
prednisone	[no description available]	medium	44	6	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
pilocarpine	[no description available]	medium	138	0	pilocarpine	antiglaucoma drug
pilocarpine	[no description available]	medium	138	1	pilocarpine	antiglaucoma drug
chloramphenicol	[no description available]	medium	16	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
apomorphine	[no description available]	medium	18	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
cysteamine	[no description available]	high	44	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
androstenedione	[no description available]	high	4	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
colchicine	[no description available]	medium	43	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
ampicillin	[no description available]	medium	10	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol	[no description available]	medium	34	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
mannitol	[no description available]	medium	34	1	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
mepenzolate bromide	[no description available]	medium	3	0	diarylmethane
ergotamine	[no description available]	medium	58	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
ergotamine	[no description available]	medium	58	2	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
neostigmine bromide	[no description available]	medium	2	0	bromide salt
nandrolone	[no description available]	high	4	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid	human metabolite
acetylcysteine	[no description available]	high	11	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin	[no description available]	medium	12	0	cyclic ketone; erythromycin
vinblastine	[no description available]	medium	3	0
vancomycin	[no description available]	medium	18	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
vancomycin	[no description available]	medium	18	8	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
clodronic acid	[no description available]	medium	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
clemastine	[no description available]	medium	49	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
clemastine	[no description available]	medium	49	15	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
cephalexin	[no description available]	medium	3	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
timolol	[no description available]	medium	11	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
timolol	[no description available]	medium	11	1	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
paclitaxel	[no description available]	high	15	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
paclitaxel	[no description available]	high	15	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide	[no description available]	medium	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
methyldopa	[no description available]	medium	39	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
diltiazem	[no description available]	medium	28	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
diltiazem	[no description available]	medium	28	1	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
captopril	[no description available]	medium	33	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
captopril	[no description available]	medium	33	3	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
bucindolol	[no description available]	medium	2	0
bucindolol	[no description available]	medium	2	1
simvastatin	[no description available]	medium	7	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
pravastatin	[no description available]	medium	2	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
esmolol	[no description available]	medium	4	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
esmolol	[no description available]	medium	4	2	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
zanamivir	[no description available]	medium	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
efavirenz	[no description available]	medium	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
repaglinide	[no description available]	medium	1	0	piperidines
2-methoxyestradiol	[no description available]	medium	2	0	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
methotrexate	[no description available]	medium	14	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
atropine	[no description available]	medium	987	0
atropine	[no description available]	medium	987	14
melagatran	[no description available]	medium	1	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
glucosamine	[no description available]	high	15	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
pancuronium	[no description available]	medium	15	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
pancuronium	[no description available]	medium	15	4	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
acarbose	[no description available]	medium	1	0	amino cyclitol; glycoside
clindamycin	[no description available]	medium	3	0
chlorprothixene	[no description available]	medium	3	0	chlorprothixene
methimazole	[no description available]	medium	7	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
sulindac	[no description available]	medium	2	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
digoxin	[no description available]	medium	13	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
digoxin	[no description available]	medium	13	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tamoxifen	[no description available]	medium	12	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
pulmicort	[no description available]	medium	46	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
pulmicort	[no description available]	medium	46	23	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
flupenthixol	[no description available]	medium	1	0	flupenthixol	dopaminergic antagonist
codeine	[no description available]	medium	57	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
codeine	[no description available]	medium	57	16	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine	[no description available]	medium	2	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
cyproterone	[no description available]	medium	2	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; chlorinated steroid; tertiary alpha-hydroxy ketone	androgen antagonist
morphine	[no description available]	medium	271	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
morphine	[no description available]	medium	271	14	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
denopamine	[no description available]	medium	2	0	dimethoxybenzene
naltrexone	[no description available]	medium	19	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
naltrexone	[no description available]	medium	19	2	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
indinavir sulfate	[no description available]	medium	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
enalapril	[no description available]	medium	9	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
enalapril	[no description available]	medium	9	1	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
scopolamine hydrobromide	[no description available]	medium	77	0
scopolamine hydrobromide	[no description available]	medium	77	2
taurocholic acid, monosodium salt	[no description available]	medium	1	0	bile salt
tetracycline	[no description available]	medium	16	0
warfarin	[no description available]	medium	30	0	benzenes; hydroxycoumarin; methyl ketone
warfarin	[no description available]	medium	30	2	benzenes; hydroxycoumarin; methyl ketone
acyclovir	[no description available]	medium	3	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
folic acid	[no description available]	high	19	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin	[no description available]	medium	6	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
rifampin	[no description available]	medium	6	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
ganciclovir	[no description available]	medium	2	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
allopurinol	[no description available]	medium	39	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
sildenafil citrate	[no description available]	medium	3	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
sildenafil citrate	[no description available]	medium	3	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
putrescine	[no description available]	medium	186	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine	[no description available]	medium	100	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermidine	[no description available]	medium	100	1	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine	[no description available]	medium	88	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
cholesterol alpha-oxide	[no description available]	medium	2	0	3beta-hydroxy steroid; epoxy steroid; oxysterol
tretinoin	[no description available]	high	21	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
tretinoin	[no description available]	high	21	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
docosahexaenoate	[no description available]	medium	1	0	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical
adenine	[no description available]	high	53	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
adenine	[no description available]	high	53	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine	[no description available]	medium	36	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
benzyl alcohol	[no description available]	medium	2	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
betaine	[no description available]	medium	4	0	amino-acid betaine; glycine derivative	fundamental metabolite
lactic acid	[no description available]	medium	36	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
lactic acid	[no description available]	medium	36	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
glycine	[no description available]	high	78	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol	[no description available]	high	44	6	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
glycerol	[no description available]	high	44	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
alpha-glycerophosphoric acid	[no description available]	medium	1	0	glycerol monophosphate	algal metabolite; human metabolite
inositol	[no description available]	medium	25	0	cyclitol; hexol
niacin	[no description available]	high	50	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
succinic acid	[no description available]	medium	8	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
methacholine	[no description available]	medium	1	0	acetate ester; quaternary ammonium ion	bronchoconstrictor agent; cholinergic agonist; epitope; muscarinic agonist; vasodilator agent
albendazole	[no description available]	medium	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
ambroxol	[no description available]	medium	4	0	aromatic amine
ambroxol	[no description available]	medium	4	1	aromatic amine
aminoglutethimide	[no description available]	medium	4	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
amiodarone	[no description available]	medium	5	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
antazoline	[no description available]	medium	23	0	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
barbital	[no description available]	medium	3	0	barbiturates	drug allergen
bendroflumethiazide	[no description available]	medium	3	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzamide	[no description available]	medium	1	0	benzamides
benzquinamide	[no description available]	medium	3	0	monocarboxylic acid amide	antiemetic; antipsychotic agent; H1-receptor antagonist; muscarinic antagonist; sedative
bepridil	[no description available]	medium	2	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
bethanidine	[no description available]	medium	2	0	guanidines	adrenergic antagonist; antihypertensive agent
betaxolol	[no description available]	medium	4	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bisacodyl	[no description available]	medium	5	0	diarylmethane
bromhexine	[no description available]	medium	2	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bunitrolol	[no description available]	medium	1	0	aromatic ether
bupranolol	[no description available]	medium	2	0	aromatic ether
butalbital	[no description available]	medium	1	0	barbiturates	analgesic; sedative
metrizoate	[no description available]	medium	1	0	monocarboxylic acid	radioopaque medium
carbazochrome	[no description available]	medium	1	0
carbinoxamine	[no description available]	medium	2	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carmustine	[no description available]	medium	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
chlorcyclizine	[no description available]	medium	2	0	diarylmethane
chlorothiazide	[no description available]	medium	6	0	benzothiadiazine	antihypertensive agent; diuretic
chloroxine	[no description available]	medium	1	0	monohydroxyquinoline; organochlorine compound	antibacterial agent; antifungal drug; antiseborrheic
chlorpropamide	[no description available]	medium	5	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
ciprofibrate	[no description available]	medium	2	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
clioquinol	[no description available]	medium	2	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clofazimine	[no description available]	medium	2	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
cyclandelate	[no description available]	medium	2	0	carboxylic ester; secondary alcohol	vasodilator agent
cyclofenil	[no description available]	medium	1	0	organic molecular entity
debrisoquin	[no description available]	high	3	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
amphetamine	[no description available]	medium	41	0	primary amine
dichlorphenamide	[no description available]	medium	3	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
diphenidol	[no description available]	medium	1	0	benzenes; piperidines; tertiary alcohol	antiemetic
doxylamine	[no description available]	medium	4	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
dyphylline	[no description available]	medium	3	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
profenamine	[no description available]	medium	2	0	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist
ethyl loflazepate	[no description available]	medium	1	0	organic molecular entity
etizolam	[no description available]	medium	1	0	organic molecular entity
brl 42810	[no description available]	medium	1	0	2-aminopurines; acetate ester	antiviral drug; prodrug
fenfluramine	[no description available]	medium	6	0	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
fenoprofen	[no description available]	medium	2	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
berotek	[no description available]	medium	31	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
berotek	[no description available]	medium	31	7	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
flavoxate	[no description available]	medium	2	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide	[no description available]	medium	3	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
flucytosine	[no description available]	medium	2	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flufenamic acid	[no description available]	medium	14	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flufenamic acid	[no description available]	medium	14	1	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluphenazine depot	[no description available]	medium	1	0	decanoate ester; N-alkylpiperazine; organofluorine compound; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug; prodrug
fluphenazine enanthate	[no description available]	medium	1	0	phenothiazines
flurazepam	[no description available]	medium	2	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
flutazolam	[no description available]	medium	1	0	hemiaminal ether; organic molecular entity
gemfibrozil	[no description available]	medium	2	0	aromatic ether	antilipemic drug
gliclazide	[no description available]	medium	3	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
hexylresorcinol	[no description available]	medium	1	0	resorcinols
homochlorocyclizine	[no description available]	medium	2	0	diarylmethane
hydroflumethiazide	[no description available]	medium	3	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
amrinone	[no description available]	medium	10	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
iodamide	[no description available]	medium	2	0	benzoic acids; organoiodine compound	radioopaque medium
iothalamic acid	[no description available]	medium	15	0	organic molecular entity
iothalamic acid	[no description available]	medium	15	1	organic molecular entity
iodipamide	[no description available]	medium	8	0	benzoic acids; organoiodine compound; secondary carboxamide	radioopaque medium
isoniazid	[no description available]	medium	35	0	carbohydrazide	antitubercular agent; drug allergen
isopropamide iodide	[no description available]	medium	1	0	diarylmethane
isoxsuprine	[no description available]	medium	2	0	alkylbenzene
ketotifen	[no description available]	medium	81	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
ketotifen	[no description available]	medium	81	11	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol	[no description available]	medium	7	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
labetalol	[no description available]	medium	7	1	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
leflunomide	[no description available]	medium	3	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
lorazepam	[no description available]	medium	2	0	benzodiazepine
maprotiline	[no description available]	medium	6	0	anthracenes
vitamin k 3	[no description available]	medium	2	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
mesoridazine	[no description available]	medium	2	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
methapyrilene	[no description available]	medium	11	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methocarbamol	[no description available]	medium	3	0	aromatic ether; carbamate ester; secondary alcohol
methyprylon	[no description available]	medium	1	0	organic molecular entity
metronidazole	[no description available]	high	12	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metronidazole	[no description available]	high	12	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone	[no description available]	medium	13	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
midazolam	[no description available]	medium	11	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midazolam	[no description available]	medium	11	4	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
modafinil	[no description available]	medium	10	0	monocarboxylic acid amide; sulfoxide
moxisylyte	[no description available]	medium	5	0	monoterpenoid
moxisylyte	[no description available]	medium	5	1	monoterpenoid
nalidixic acid	[no description available]	medium	3	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
nefazodone	[no description available]	medium	3	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nimetazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative
nimodipine	[no description available]	medium	7	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nitrazepam	[no description available]	medium	2	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine	[no description available]	medium	11	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitrendipine	[no description available]	medium	11	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nomifensine	[no description available]	medium	2	0	isoquinolines	dopamine uptake inhibitor
nortriptyline	[no description available]	medium	5	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
omeprazole	[no description available]	medium	135	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
omeprazole	[no description available]	medium	135	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
oxamniquine	[no description available]	medium	2	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
oxolinic acid	[no description available]	medium	1	0	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
pargyline	[no description available]	medium	57	0	aromatic amine
pentobarbital	[no description available]	medium	85	0	barbiturates	GABAA receptor agonist
pentoxifylline	[no description available]	medium	8	0	oxopurine
perhexiline	[no description available]	medium	4	0	piperidines	cardiovascular drug
perphenazine	[no description available]	medium	8	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacemide	[no description available]	medium	2	0	acetamides
phenacetin	[no description available]	medium	6	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenazopyridine	[no description available]	medium	2	0	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic
phenindione	[no description available]	medium	2	0	aromatic ketone; beta-diketone	anticoagulant
pheniramine	[no description available]	medium	35	0	pyridines; tertiary amino compound
pheniramine	[no description available]	medium	35	2	pyridines; tertiary amino compound
phenolphthalein	[no description available]	medium	2	0	phenols
phentermine	[no description available]	medium	2	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
pyranoprofen	[no description available]	medium	2	0	pyridochromene
proglumide	[no description available]	medium	7	0	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
propiomazine	[no description available]	medium	1	0	aromatic ketone; phenothiazines; tertiary amino compound	dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; sedative; serotonergic antagonist
protriptyline	[no description available]	medium	2	0	carbotricyclic compound	antidepressant
proxyphylline	[no description available]	medium	2	0	oxopurine
rizatriptan	[no description available]	medium	1	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib	[no description available]	medium	3	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
salicylsalicylic acid	[no description available]	medium	3	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
secobarbital	[no description available]	medium	1	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
ipodate	[no description available]	medium	1	0
succinylcholine	[no description available]	medium	32	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
succinylcholine	[no description available]	medium	32	4	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulfadimethoxine	[no description available]	medium	4	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamethoxazole	[no description available]	medium	4	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfobromophthalein	[no description available]	medium	5	0	2-benzofurans; organobromine compound; organosulfonic acid; phenols	dye
sumatriptan	[no description available]	medium	9	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suramin	[no description available]	medium	4	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
thalidomide	[no description available]	medium	5	0	phthalimides; piperidones
thioridazine	[no description available]	medium	8	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
tiaramide	[no description available]	medium	1	0	benzothiazoles
ticlopidine	[no description available]	medium	2	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone	[no description available]	medium	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tiopronin	[no description available]	medium	4	0	N-acyl-amino acid
tizanidine	[no description available]	medium	1	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
tolperisone	[no description available]	medium	1	0	aromatic ketone
trichlormethiazide	[no description available]	medium	2	0	benzothiadiazine; sulfonamide antibiotic	antihypertensive agent; diuretic
trifluperidol	[no description available]	medium	3	0	aromatic ketone
trimebutine	[no description available]	medium	2	0	trihydroxybenzoic acid
trimethadione	[no description available]	medium	2	0	oxazolidinone	anticonvulsant; geroprotector
delavirdine	[no description available]	medium	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
venlafaxine	[no description available]	medium	3	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
lysergic acid diethylamide	[no description available]	medium	71	0	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
phentolamine	[no description available]	high	291	1	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
phentolamine	[no description available]	high	291	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol	[no description available]	high	19	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
floxuridine	[no description available]	medium	2	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
norethindrone acetate	[no description available]	medium	1	0	3-oxo-Delta(4) steroid; acetate ester; terminal acetylenic compound	progestin; synthetic oral contraceptive
cyclobarbital	[no description available]	medium	1	0	barbiturates
norethandrolone	[no description available]	medium	1	0	corticosteroid hormone
oxandrolone	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
desoxycorticosterone acetate	[no description available]	medium	6	0	corticosteroid hormone
lysine	[no description available]	high	62	4	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
lysine	[no description available]	high	62	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
ethinyl estradiol	[no description available]	medium	10	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
bretylium tosylate	[no description available]	medium	3	0	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
leucine	[no description available]	high	24	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
gallamine triethiodide	[no description available]	medium	17	0
cytarabine	[no description available]	medium	6	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
4-hydroxypropiophenone	[no description available]	medium	2	0	acetophenones
methandrostenolone	[no description available]	medium	1	0	organic molecular entity
quinethazone	[no description available]	medium	1	0	quinazolines	antihypertensive agent; diuretic
tribromoethanol	[no description available]	medium	1	0	alcohol; organobromine compound
carbromal	[no description available]	medium	1	0	N-acylurea
triparanol	[no description available]	medium	1	0	stilbenoid	anticoronaviral agent
pantothenic acid	[no description available]	medium	9	0	pantothenic acid; vitamin B5	antidote to curare poisoning; geroprotector; human blood serum metabolite
cyclizine	[no description available]	medium	8	0	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
buclizine	[no description available]	medium	1	0	monochlorobenzenes; N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; histamine antagonist; local anaesthetic
thiopropazate	[no description available]	medium	1	0	acetate ester; N-alkylpiperazine; organochlorine compound; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug
acetrizoic acid	[no description available]	medium	3	0	aminobenzoic acid
penicillin v	[no description available]	medium	5	0	penicillin allergen; penicillin
pseudoephedrine	[no description available]	medium	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
propylparaben	[no description available]	medium	4	0	benzoate ester; paraben; phenols	antifungal agent; antimicrobial agent
propylparaben	[no description available]	medium	4	2	benzoate ester; paraben; phenols	antifungal agent; antimicrobial agent
methylparaben	[no description available]	medium	2	0	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite
methylparaben	[no description available]	medium	2	1	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite
estradiol dipropionate	[no description available]	medium	1	0	steroid ester
paramethadione	[no description available]	medium	1	0	oxazolidinone	anticonvulsant
framycetin	[no description available]	medium	18	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
anileridine	[no description available]	medium	1	0	ethyl ester; piperidinecarboxylate ester; substituted aniline	opioid analgesic; opioid receptor agonist
ditiocarb	[no description available]	medium	4	0	dithiocarbamic acids	chelator; copper chelator
sulfalene	[no description available]	medium	1	0	pyrazines; sulfonamide antibiotic; sulfonamide
propantheline bromide	[no description available]	medium	3	0	xanthenes
ephedrine	[no description available]	medium	58	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
ephedrine	[no description available]	medium	58	7	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
chlormadinone acetate	[no description available]	medium	2	0	corticosteroid hormone
norchlorcyclizine	[no description available]	medium	1	0
evans blue	[no description available]	medium	59	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
opipramol	[no description available]	medium	3	0	dibenzoazepine
carbutamide	[no description available]	medium	1	0	benzenes; sulfonamide
glymidine	[no description available]	medium	1	0	diether; pyrimidines; sulfonamide	hypoglycemic agent
N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine	[no description available]	medium	1	0	aromatic amine
prenylamine	[no description available]	medium	7	0	diarylmethane
thiazolidine-4-carboxylic acid	[no description available]	medium	1	0	alpha-amino acid zwitterion; non-proteinogenic alpha-amino acid; sulfur-containing amino acid; thiazolidinemonocarboxylic acid	antidote; antioxidant; hepatoprotective agent
chlorphentermine	[no description available]	medium	4	0	amphetamines
dextropropoxyphene	[no description available]	medium	6	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
lucanthone	[no description available]	medium	1	0	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug
dichloralantipyrine	[no description available]	medium	1	0
emetine	[no description available]	medium	2	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
emetine	[no description available]	medium	2	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
dihydralazine	[no description available]	medium	2	0	phthalazines
methallenestril	[no description available]	medium	1	0	naphthalenes
androstenediol	[no description available]	medium	1	0	17beta-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid	androgen; human metabolite; mouse metabolite; radiation protective agent
levocarnitine	[no description available]	medium	1	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
decamethonium dibromide	[no description available]	medium	1	0
thiphenamil	[no description available]	medium	1	0	diarylmethane
metahexamide	[no description available]	medium	1	0	benzenes; sulfonamide
phenindamine	[no description available]	medium	8	0	indene
2-amino-2-methyl-1-propanol	[no description available]	medium	1	0
phendimetrazine	[no description available]	medium	1	0
trimetozine	[no description available]	medium	2	0	morpholines
butaperazine	[no description available]	medium	1	0	phenothiazines
oxolamine	[no description available]	medium	1	0	oxadiazole; ring assembly
ethylestrenol	[no description available]	medium	1	0	17beta-hydroxy steroid; tertiary alcohol	anabolic agent
dehydroepiandrosterone acetate	[no description available]	medium	1	0	steroid ester
metaxalone	[no description available]	medium	1	0	aromatic ether
spectinomycin	[no description available]	medium	1	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
paraquat	[no description available]	medium	5	0	organic cation	geroprotector; herbicide
clothiapine	[no description available]	medium	1	0	dibenzothiazepine
azaribine	[no description available]	medium	2	0	acetate ester; N-glycosyl-1,2,4-triazine	antipsoriatic; prodrug
sulfadoxine	[no description available]	medium	2	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
acetophenazine	[no description available]	medium	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
cephaloglycin	[no description available]	medium	1	0	beta-lactam antibiotic allergen; cephalosporin	antimicrobial agent
streptomycin	[no description available]	medium	25	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
noxiptilin	[no description available]	medium	1	0	organic tricyclic compound
benorilate	[no description available]	medium	1	0	carbonyl compound
metocurine	[no description available]	medium	2	0	isoquinolines
floxacillin	[no description available]	medium	2	0	penicillin allergen; penicillin	antibacterial drug
clomacran	[no description available]	medium	1	0	acridines
iprindole	[no description available]	medium	3	0	indoles
isometheptene	[no description available]	medium	1	0	secondary amino compound
olsalazine	[no description available]	medium	1	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
molindone	[no description available]	medium	1	0	indoles
hexocyclium	[no description available]	medium	1	0	amine
ancitabine	[no description available]	medium	1	0	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug
clortermine	[no description available]	medium	1	0	amphetamines
nicofuranose	[no description available]	medium	1	0	organooxygen compound
apazone	[no description available]	medium	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
cloforex	[no description available]	medium	1	0	amphetamines
selegiline	[no description available]	medium	8	0	selegiline; terminal acetylenic compound	geroprotector
levamisole	[no description available]	medium	16	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
clobutinol	[no description available]	medium	1	0	benzenes; organic amino compound
thiamphenicol	[no description available]	medium	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
isosorbide-5-mononitrate	[no description available]	medium	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
razoxane	[no description available]	medium	2	0	N-alkylpiperazine
fludarabine phosphate	[no description available]	medium	1	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
proquazone	[no description available]	medium	1	0	pyrimidines
halazepam	[no description available]	medium	1	0	organic molecular entity
ripazepam	[no description available]	medium	1	0	benzenes
amoxicillin	[no description available]	medium	8	0	penicillin allergen; penicillin	antibacterial drug
amoxicillin	[no description available]	medium	8	2	penicillin allergen; penicillin	antibacterial drug
indoramin	[no description available]	medium	2	0	tryptamines
moricizine	[no description available]	medium	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
feprazone	[no description available]	medium	1	0	organic molecular entity
tobramycin	[no description available]	medium	2	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
tobramycin	[no description available]	medium	2	1	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
halofantrine	[no description available]	medium	1	0	phenanthrenes
etidocaine	[no description available]	medium	1	0	amino acid amide	local anaesthetic
ribavirin	[no description available]	medium	2	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin	[no description available]	medium	1	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
epirubicin	[no description available]	medium	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
prenalterol	[no description available]	medium	5	0	aromatic ether
lorcainide	[no description available]	medium	1	0	acetamides
idarubicin	[no description available]	medium	2	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
atracurium	[no description available]	medium	36	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
atracurium	[no description available]	medium	36	12	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
pergolide	[no description available]	medium	1	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
doxofylline	[no description available]	medium	1	0	oxopurine	anti-asthmatic drug; antitussive; bronchodilator agent
alfentanil	[no description available]	medium	3	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
alfentanil	[no description available]	medium	3	1	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
cefotetan	[no description available]	medium	1	0
quinapril	[no description available]	medium	2	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
tiagabine	[no description available]	medium	1	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
lamivudine	[no description available]	medium	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
ziprasidone	[no description available]	medium	3	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
adenosine	[no description available]	high	332	3	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
adenosine	[no description available]	high	332	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
ceftezole	[no description available]	medium	1	0	cephalosporin; thiadiazoles
hexestrol bis(diethylaminoethyl ether)	[no description available]	medium	1	0	stilbenoid
disobutamide	[no description available]	medium	1	0	acetamides
dipropylacetamide	[no description available]	medium	1	0	fatty amide	geroprotector; metabolite; teratogenic agent
clociguanil	[no description available]	medium	2	0
lividomycin	[no description available]	medium	1	0	lividomycins	metabolite
gentamicin c1	[no description available]	medium	1	0
2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide	[no description available]	medium	1	0
clarithromycin	[no description available]	medium	5	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
moexipril	[no description available]	medium	1	0	peptide
sennoside B	[no description available]	medium	1	0	oxo dicarboxylic acid; sennosides
dimethacrine	[no description available]	medium	1	0	acridines
perindopril	[no description available]	medium	1	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
5-hydroxydopamine	[no description available]	medium	1	0	catecholamine
tazobactam	[no description available]	medium	1	0	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
xylose	[no description available]	medium	8	0	D-xylose
clofibride	[no description available]	medium	1	0	monocarboxylic acid
aminopterin	[no description available]	medium	2	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
l 694,458	[no description available]	medium	2	0
carbocysteine	[no description available]	medium	2	0	L-cysteine thioether; non-proteinogenic L-alpha-amino acid	mucolytic
dromostanolone propionate	[no description available]	medium	1	0	3-oxo-5alpha-steroid; steroid ester	antineoplastic agent
phenethicillin	[no description available]	medium	3	0	penicillin allergen; penicillin
bekanamycin	[no description available]	medium	1	0	kanamycins
strychnine	[no description available]	medium	20	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
griseofulvin	[no description available]	medium	3	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
netilmicin	[no description available]	medium	1	0
hetacillin	[no description available]	medium	1	0	penicillin	antibacterial drug
medigoxin	[no description available]	medium	1	0	cardenolide glycoside
betamethasone acetate	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; fluorinated steroid; steroid ester; tertiary alpha-hydroxy ketone
retinol	[no description available]	high	15	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
zithromax	[no description available]	medium	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
melphalan	[no description available]	medium	8	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
dibekacin	[no description available]	medium	1	0	kanamycins	antibacterial agent; protein synthesis inhibitor
riboflavin	[no description available]	high	8	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
flavin mononucleotide	[no description available]	medium	1	0	flavin mononucleotide; vitamin B2	bacterial metabolite; coenzyme; cofactor; human metabolite; mouse metabolite
mezlocillin	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug
mitobronitol	[no description available]	medium	1	0	alcohol; organobromine compound
prednisolone hemisuccinate	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; hemisuccinate; tertiary alpha-hydroxy ketone	anti-inflammatory drug
octotropine methylbromide	[no description available]	medium	2	0
nsc 4347	[no description available]	medium	2	0
etomidate	[no description available]	high	7	2	ethyl ester; imidazoles	intravenous anaesthetic; sedative
etomidate	[no description available]	high	7	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine	[no description available]	medium	5	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
mercaptopurine	[no description available]	medium	5	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
lobeline	[no description available]	medium	1	0
thiothixene	[no description available]	medium	3	0	N-methylpiperazine	anticoronaviral agent
benztropine	[no description available]	medium	4	0	diarylmethane
thiouracil	[no description available]	medium	7	0	nucleobase analogue; thiocarbonyl compound	antithyroid drug; metabolite
terbinafine	[no description available]	medium	2	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
1,4-benzoquinone guanylhydrazone thiosemicarbazone	[no description available]	medium	1	0
zeranol	[no description available]	medium	2	0	macrolide
thiopental	[no description available]	medium	38	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
thiopental	[no description available]	medium	38	1	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
toremifene	[no description available]	medium	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
albutoin	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
iodothiouracil	[no description available]	medium	1	0	organohalogen compound; pyrimidines
tolcapone	[no description available]	medium	2	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
bilirubin	[no description available]	high	8	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprost	[no description available]	high	215	5	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
dinoprost	[no description available]	high	215	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
calcitriol	[no description available]	high	6	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
beta carotene	[no description available]	high	3	0	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
clavulanic acid	[no description available]	medium	1	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
eprosartan	[no description available]	medium	1	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ethchlorvynol	[no description available]	medium	3	0
rokitamycin	[no description available]	medium	1	0	organic molecular entity
etretinate	[no description available]	medium	3	0	enoate ester; ethyl ester; retinoid	keratolytic drug
misoprostol	[no description available]	medium	15	0
misoprostol	[no description available]	medium	15	4
epoprostenol	[no description available]	medium	1	0	prostaglandins I	mouse metabolite
natamycin	[no description available]	medium	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
cloprednol	[no description available]	medium	1	0	21-hydroxy steroid
estropipate	[no description available]	medium	1	0	piperazinium salt; steroid sulfate
hydroxystilbamidine	[no description available]	medium	1	0
levetiracetam	[no description available]	medium	2	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
meprednisone	[no description available]	medium	1	0	21-hydroxy steroid
oxymorphone	[no description available]	medium	5	0	morphinane alkaloid
oxymorphone	[no description available]	medium	5	1	morphinane alkaloid
acepreval	[no description available]	medium	1	0	corticosteroid hormone
proscillaridin	[no description available]	medium	1	0	organic molecular entity
fluvoxamine	[no description available]	medium	2	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
stilbamidine	[no description available]	medium	3	0
butorphanol	[no description available]	medium	4	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
butorphanol	[no description available]	medium	4	1	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefixime	[no description available]	medium	2	0	cephalosporin	antibacterial drug; drug allergen
zimeldine	[no description available]	medium	2	0	styrenes
ceftriaxone	[no description available]	medium	1	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
ceftazidime	[no description available]	medium	1	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril	[no description available]	medium	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
nitrofurantoin	[no description available]	medium	3	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
fosinopril	[no description available]	medium	1	0
abt-770	[no description available]	medium	1	0
9-n-(1-propyl)erythromyclamine	[no description available]	medium	1	0
azacosterol	[no description available]	medium	1	0
homatropine methylbromide	[no description available]	medium	1	0
vindesine	[no description available]	medium	1	0
amodiaquine hydrochloride	[no description available]	medium	1	0
novobiocin	[no description available]	medium	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
chlortetracycline	[no description available]	medium	8	0
bephenium hydroxynaphthoate	[no description available]	medium	1	0
phenprocoumon	[no description available]	medium	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
viomycin	[no description available]	medium	3	0	heterodetic cyclic peptide; peptide antibiotic	antitubercular agent
dacarbazine	[no description available]	medium	3	0	dacarbazine
dacarbazine	[no description available]	medium	3	1	dacarbazine
olanzapine	[no description available]	medium	10	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
D-tyrosine	[no description available]	medium	6	0	D-alpha-amino acid zwitterion; D-alpha-amino acid; tyrosine	Escherichia coli metabolite
ethylisopropylamiloride	[no description available]	medium	3	0	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
astemizole	[no description available]	medium	34	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
astemizole	[no description available]	medium	34	9	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
bufexamac	[no description available]	medium	2	0	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
hycanthone	[no description available]	medium	3	0	thioxanthenes	mutagen; schistosomicide drug
mefloquine hydrochloride	[no description available]	medium	1	0	organofluorine compound; piperidines; quinolines; secondary alcohol
nizatidine	[no description available]	medium	1	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
periciazine	[no description available]	medium	2	0	hydroxypiperidine; nitrile; phenothiazines	adrenergic antagonist; first generation antipsychotic; sedative
sulfamerazine	[no description available]	medium	3	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen
vincristine	[no description available]	medium	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
quinacrine monohydrochloride	[no description available]	medium	1	0
apomorphine hydrochloride, anhydrous	[no description available]	medium	1	0
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide	[no description available]	medium	1	0
antimycin a	[no description available]	medium	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
clobetasol propionate	[no description available]	medium	2	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; fluorinated steroid; glucocorticoid	anti-inflammatory drug
ranitidine hydrochloride	[no description available]	medium	1	0
chloroquine diphosphate	[no description available]	medium	2	0
telmisartan	[no description available]	medium	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
5-(n-methyl-n-isobutyl)amiloride	[no description available]	medium	1	0
amperozide	[no description available]	medium	1	0	diarylmethane; monofluorobenzenes; N-alkylpiperazine; secondary carboxamide; ureas	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
amperozide hydrochloride	[no description available]	medium	1	0	hydrochloride	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
atovaquone	[no description available]	medium	1	0	hydroxy-1,2-naphthoquinone
cinchonine	[no description available]	medium	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
sk&f 95282	[no description available]	medium	20	0	piperidines
3',4'-dichlorobenzamil	[no description available]	medium	3	0	guanidines; pyrazines
ici 162846	[no description available]	medium	2	0	fatty amide
cloperastine hydrochloride	[no description available]	medium	1	0	diarylmethane
mometasone furoate	[no description available]	medium	11	0	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
mometasone furoate	[no description available]	medium	11	1	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
quinidine sulfate	[no description available]	medium	1	0
artesunate	[no description available]	medium	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
artenimol	[no description available]	medium	1	0
quinine sulfate	[no description available]	medium	1	0	hydrate
vuf 8430	[no description available]	medium	9	0
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	[no description available]	medium	3	0	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
carnitine	[no description available]	high	11	2	amino-acid betaine	human metabolite; mouse metabolite
carnitine	[no description available]	high	11	0	amino-acid betaine	human metabolite; mouse metabolite
coumarin	[no description available]	medium	6	0	coumarins	fluorescent dye; human metabolite; plant metabolite
bupropion	[no description available]	medium	2	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
guaiacol	[no description available]	medium	3	0	guaiacols	disinfectant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; expectorant; plant metabolite
acetanilide	[no description available]	medium	1	0	acetamides; anilide	analgesic
pyridoxine	[no description available]	high	20	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
enprofylline	[no description available]	medium	8	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
enprofylline	[no description available]	medium	8	2	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
oxyquinoline	[no description available]	medium	4	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
oxyquinoline	[no description available]	medium	4	1	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
tacrine	[no description available]	medium	8	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acetarsol	[no description available]	medium	2	0	acetamides; anilide
ethacridine	[no description available]	medium	1	0	acridines
4-(acetylamino)benzeneacetic acid	[no description available]	medium	1	0	acetamides; anilide
adiphenine	[no description available]	medium	1	0	diarylmethane
aklomide	[no description available]	medium	1	0	carbonyl compound; organohalogen compound
albuterol	[no description available]	medium	215	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
albuterol	[no description available]	medium	215	53	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
altretamine	[no description available]	medium	2	0	triamino-1,3,5-triazine
amlodipine	[no description available]	medium	2	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amodiaquine	[no description available]	medium	22	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
amprolium	[no description available]	medium	1	0	pyridinium ion	coccidiostat
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol	[no description available]	medium	1	0	aporphine alkaloid
arecoline	[no description available]	medium	14	0	enoate ester; methyl ester; pyridine alkaloid; tetrahydropyridine	metabolite; muscarinic agonist
benserazide	[no description available]	medium	4	0	carbohydrazide; catechols; primary alcohol; primary amino compound	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzocaine	[no description available]	medium	5	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzocaine	[no description available]	medium	5	1	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzothiazide	[no description available]	medium	4	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzothiazide	[no description available]	medium	4	1	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
bethanechol	[no description available]	medium	62	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bretylium	[no description available]	medium	3	0	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
seratrodast	[no description available]	medium	10	0	organic molecular entity
seratrodast	[no description available]	medium	10	1	organic molecular entity
bumetanide	[no description available]	medium	19	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bumetanide	[no description available]	medium	19	2	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
busulfan	[no description available]	medium	5	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
butacaine	[no description available]	medium	2	0	benzoate ester
butamben	[no description available]	medium	2	0	amino acid ester; benzoate ester; primary amino compound; substituted aniline	local anaesthetic
carbamylcholine	[no description available]	medium	1	0
carteolol	[no description available]	medium	1	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
chloroxylenol	[no description available]	medium	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
aricine	[no description available]	medium	1	0	cinchona alkaloid
ciprofloxacin	[no description available]	medium	6	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
ciprofloxacin	[no description available]	medium	6	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clomiphene	[no description available]	medium	1	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
cloxyquin	[no description available]	medium	1	0	organochlorine compound; quinolines
cromolyn	[no description available]	medium	1	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
cyclobenzaprine	[no description available]	medium	2	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
dapsone	[no description available]	medium	3	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
diazoxide	[no description available]	medium	12	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
dibenzothiophene	[no description available]	medium	1	0	dibenzothiophenes; mancude organic heterotricyclic parent	keratolytic drug
dibucaine	[no description available]	medium	13	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
dicyclomine	[no description available]	medium	3	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
dilacor xr	[no description available]	medium	1	0	acetate ester; aromatic ether; benzothiazepine; lactam; tertiary amino compound
dimethadione	[no description available]	medium	1	0	oxazolidinone
diphenylpyraline	[no description available]	medium	2	0	piperidines; tertiary amine	cholinergic antagonist; H1-receptor antagonist
disulfiram	[no description available]	medium	9	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
donepezil	[no description available]	medium	6	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
droperidol	[no description available]	medium	12	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyclonine	[no description available]	medium	3	0	aromatic ketone; piperidines	topical anaesthetic
dyclonine	[no description available]	medium	3	1	aromatic ketone; piperidines	topical anaesthetic
ebselen	[no description available]	medium	7	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
econazole	[no description available]	high	3	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
ethosuximide	[no description available]	medium	3	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin	[no description available]	medium	1	0	imidazolidine-2,4-dione	anticonvulsant
etidronate	[no description available]	medium	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
felbamate	[no description available]	medium	2	0	carbamate ester	anticonvulsant; neuroprotective agent
fenoldopam	[no description available]	medium	4	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
flumazenil	[no description available]	medium	6	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flurbiprofen	[no description available]	medium	19	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flurbiprofen	[no description available]	medium	19	8	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
glafenine	[no description available]	medium	1	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
glimepiride	[no description available]	medium	1	0	sulfonamide
guaifenesin	[no description available]	medium	92	0	methoxybenzenes
guaifenesin	[no description available]	medium	92	4	methoxybenzenes
hexoprenaline	[no description available]	medium	4	0
hexamethylene bisacetamide	[no description available]	medium	2	0	acetamides
phenelzine	[no description available]	medium	7	0	primary amine
indapamide	[no description available]	medium	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin	[no description available]	medium	595	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
indomethacin	[no description available]	medium	595	12	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoquinol	[no description available]	medium	1	0	monohydroxyquinoline; organoiodine compound	antiamoebic agent; antibacterial agent; antiprotozoal drug; antiseptic drug
iproniazid	[no description available]	medium	43	0	carbohydrazide; pyridines
isoetharine	[no description available]	medium	1	0	catecholamine
letrozole	[no description available]	medium	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
losartan	[no description available]	high	4	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
ly 171883	[no description available]	medium	6	0	acetophenones; aromatic ether; phenols; tetrazoles	anti-asthmatic drug; leukotriene antagonist
meclofenamic acid	[no description available]	medium	19	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mephenesin	[no description available]	medium	2	0	aromatic ether; glycerol ether
mephenytoin	[no description available]	medium	1	0	imidazolidine-2,4-dione	anticonvulsant
benzoic acid [2-methyl-2-(propylamino)propyl] ester	[no description available]	medium	1	0	benzoate ester
mesalamine	[no description available]	medium	4	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
mesalamine	[no description available]	medium	4	1	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
miconazole	[no description available]	high	3	0	dichlorobenzene; ether; imidazoles
minoxidil	[no description available]	medium	6	0	dialkylarylamine; tertiary amino compound
mitotane	[no description available]	medium	1	0	diarylmethane
nadolol	[no description available]	medium	1	0	tetralins
nafronyl	[no description available]	medium	2	0	naphthalenes
naftopidil	[no description available]	medium	1	0	piperazines
naphazoline	[no description available]	medium	9	0	naphthalenes
neostigmine	[no description available]	medium	68	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine	[no description available]	medium	3	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine	[no description available]	medium	13	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine	[no description available]	high	111	9	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nifedipine	[no description available]	high	111	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilvadipine	[no description available]	medium	2	0	dihydropyridine; isopropyl ester; methyl ester; nitrile
nitromide	[no description available]	medium	1	0
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one	[no description available]	medium	1	0	isoquinolines
nylidrin	[no description available]	medium	2	0	alkylbenzene
oxethazaine	[no description available]	medium	1	0	amino acid amide
oxibendazole	[no description available]	medium	1	0	benzimidazoles; carbamate ester
benoxinate	[no description available]	medium	3	0	amino acid ester; benzoate ester; substituted aniline; tertiary amino compound	drug allergen; local anaesthetic; topical anaesthetic
benoxinate	[no description available]	medium	3	1	amino acid ester; benzoate ester; substituted aniline; tertiary amino compound	drug allergen; local anaesthetic; topical anaesthetic
pentamidine	[no description available]	medium	4	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate	[no description available]	medium	1	0	pyrroloindole
pinacidil	[no description available]	medium	15	0	pyridines
pioglitazone	[no description available]	medium	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam	[no description available]	medium	5	0	organonitrogen compound; organooxygen compound
pirenzepine	[no description available]	medium	41	0	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
pirenzepine	[no description available]	medium	41	1	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
piretanide	[no description available]	medium	2	0	aromatic ether
practolol	[no description available]	medium	21	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
duodote	[no description available]	medium	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
praziquantel	[no description available]	medium	5	0	isoquinolines
primaquine	[no description available]	medium	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
proadifen	[no description available]	medium	4	0	diarylmethane
probucol	[no description available]	medium	2	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
procaine	[no description available]	medium	103	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
procaine	[no description available]	medium	103	3	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
pyrimethamine	[no description available]	medium	41	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
riluzole	[no description available]	medium	2	0	benzothiazoles
roxarsone	[no description available]	medium	1	0	2-nitrophenols; organoarsonic acid	agrochemical; animal growth promotant; antibacterial drug; coccidiostat
salicylamide	[no description available]	medium	2	0	phenols; salicylamides	antirheumatic drug; non-narcotic analgesic
sulfadiazine	[no description available]	medium	3	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfadiazine	[no description available]	medium	3	1	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
spiperone	[no description available]	medium	5	0	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
imatinib	[no description available]	medium	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
succinylsulfathiazole	[no description available]	medium	1	0	1,3-thiazoles
sulfacetamide	[no description available]	medium	3	0	N-sulfonylcarboxamide; substituted aniline	antibacterial drug; antiinfective agent; antimicrobial agent; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethazine	[no description available]	medium	3	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfamethizole	[no description available]	medium	2	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfisoxazole	[no description available]	medium	2	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulpiride	[no description available]	medium	13	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
telenzepine	[no description available]	medium	3	0	benzodiazepine
tetracaine	[no description available]	medium	23	0	benzoate ester; tertiary amino compound	local anaesthetic
tetrahydroxy-1,4-quinone	[no description available]	medium	1	0	hydroxybenzoquinone	keratolytic drug
thiabendazole	[no description available]	medium	3	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
2-thiosalicylic acid	[no description available]	medium	1	0	sulfanylbenzoic acid	antipyretic; non-narcotic analgesic
thiotepa	[no description available]	medium	1	0	aziridines
tolazamide	[no description available]	medium	2	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolazoline	[no description available]	high	38	0	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent
tolbutamide	[no description available]	high	6	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolnaftate	[no description available]	medium	2	0	monothiocarbamic ester	antifungal drug
trapidil	[no description available]	medium	2	0	triazolopyrimidines
trifluoperazine	[no description available]	medium	18	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluoperazine	[no description available]	medium	18	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
triflupromazine	[no description available]	medium	2	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
trimeprazine	[no description available]	medium	4	0	phenothiazines
trioxsalen	[no description available]	medium	1	0	psoralens	dermatologic drug; photosensitizing agent
tropicamide	[no description available]	medium	1	0	acetamides
tulobuterol	[no description available]	medium	2	0	organochlorine compound
urapidil	[no description available]	medium	1	0	piperazines
urethane	[no description available]	medium	38	0	carbamate ester	fungal metabolite; mutagen
xylazine	[no description available]	medium	7	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
xylometazoline	[no description available]	medium	8	0	alkylbenzene
prednisolone	[no description available]	medium	105	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
prednisolone	[no description available]	medium	105	13	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
estriol	[no description available]	high	8	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
piperonyl butoxide	[no description available]	medium	1	0	benzodioxoles	pesticide synergist
estrone	[no description available]	high	21	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
penicillin g	[no description available]	medium	11	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
penicillin g	[no description available]	medium	11	1	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
metaraminol	[no description available]	medium	9	0	phenylethanolamines	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
pentylenetetrazole	[no description available]	medium	34	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
ethopabate	[no description available]	medium	1	0	amidobenzoic acid
acepromazine	[no description available]	medium	6	0	aromatic ketone; methyl ketone; phenothiazines; tertiary amino compound	phenothiazine antipsychotic drug
acepromazine	[no description available]	medium	6	1	aromatic ketone; methyl ketone; phenothiazines; tertiary amino compound	phenothiazine antipsychotic drug
methoxamine	[no description available]	medium	39	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
methoxamine	[no description available]	medium	39	1	amphetamines	alpha-adrenergic agonist; antihypotensive agent
cloxacillin	[no description available]	medium	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
zoxazolamine	[no description available]	medium	2	0	benzoxazole
berlition	[no description available]	medium	1	0	dithiolanes; heterocyclic fatty acid; lipoic acid; thia fatty acid	cofactor; nutraceutical; prosthetic group
desoxycorticosterone	[no description available]	high	33	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
norethindrone	[no description available]	medium	5	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
norethindrone	[no description available]	medium	5	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
cycloserine	[no description available]	medium	3	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
trifluridine	[no description available]	medium	3	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
trifluridine	[no description available]	medium	3	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
sulfachlorpyridazine	[no description available]	medium	1	0	organochlorine compound; pyridazines; sulfonamide	antibacterial drug; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
methylprednisolone	[no description available]	medium	37	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
methylprednisolone	[no description available]	medium	37	10	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
phensuximide	[no description available]	medium	1	0	pyrrolidines
dimethisoquin	[no description available]	medium	1	0	isoquinolines
synephrine	[no description available]	medium	8	0	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite
pyridostigmine bromide	[no description available]	medium	3	0	pyridinium salt
benzonatate	[no description available]	medium	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
phenformin	[no description available]	medium	4	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
cinchophen	[no description available]	medium	9	0	quinolines
chloroprocaine	[no description available]	medium	3	0	benzoate ester; monochlorobenzenes	central nervous system depressant; local anaesthetic; peripheral nervous system drug
chloroprocaine	[no description available]	medium	3	1	benzoate ester; monochlorobenzenes	central nervous system depressant; local anaesthetic; peripheral nervous system drug
yohimbine	[no description available]	medium	38	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
fluorometholone	[no description available]	medium	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone	anti-inflammatory drug
dimenhydrinate	[no description available]	medium	6	0	diarylmethane
4-(benzoylamino)-2-hydroxybenzoic acid	[no description available]	medium	1	0	benzamides
megestrol acetate	[no description available]	medium	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
docosanol	[no description available]	medium	1	0	docosanol; long-chain primary fatty alcohol	antiviral drug; plant metabolite
tetramethylpyrazine	[no description available]	medium	2	0	alkaloid; pyrazines	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
flurandrenolone	[no description available]	medium	2	0	21-hydroxy steroid
pimozide	[no description available]	medium	11	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
flumethasone	[no description available]	medium	5	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-inflammatory drug
dicloxacillin	[no description available]	medium	1	0	dichlorobenzene; penicillin	antibacterial drug
tranylcypromine	[no description available]	medium	32	0	2-phenylcyclopropan-1-amine
beclomethasone	[no description available]	medium	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
(1S,2R)-tranylcypromine	[no description available]	medium	1	0	2-phenylcyclopropan-1-amine
parbendazole	[no description available]	medium	1	0	benzimidazoles; carbamate ester
danazol	[no description available]	medium	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
metergoline	[no description available]	medium	8	0	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
metergoline	[no description available]	medium	8	1	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
fenclozic acid	[no description available]	medium	1	0
capobenic acid	[no description available]	medium	2	0	benzamides
diftalone	[no description available]	medium	1	0
carbimazole	[no description available]	medium	3	0	1,3-dihydroimidazole-2-thiones; carbamate ester	antithyroid drug; prodrug
ursodeoxycholic acid	[no description available]	high	3	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
rose bengal b disodium salt	[no description available]	medium	1	0
carbidopa	[no description available]	medium	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
dobutamine	[no description available]	medium	10	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
bezafibrate	[no description available]	medium	3	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
benoxaprofen	[no description available]	medium	2	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
torsemide	[no description available]	medium	1	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
piperacillin	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug
indalpine	[no description available]	medium	1	0	indoles
lidamidine	[no description available]	medium	1	0	ureas
talniflumate	[no description available]	medium	1	0	benzofurans
nedocromil	[no description available]	medium	23	0	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
nedocromil	[no description available]	medium	23	9	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
tolrestat	[no description available]	medium	2	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
remoxipride	[no description available]	medium	3	0	dimethoxybenzene
alpidem	[no description available]	medium	2	0	imidazoles
dopexamine	[no description available]	medium	2	0	catecholamine
lonapalene	[no description available]	medium	1	0	naphthalenes; organochlorine compound
ipsapirone	[no description available]	medium	1	0	N-arylpiperazine
sematilide	[no description available]	medium	1	0
zileuton	[no description available]	medium	10	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
zileuton	[no description available]	medium	10	3	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
remacemide	[no description available]	medium	1	0	stilbenoid
valsartan	[no description available]	medium	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
paroxetine hydrochloride	[no description available]	medium	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
verapamil hydrochloride	[no description available]	medium	2	0
fenclofenac	[no description available]	medium	1	0	aromatic ether
proxicromil	[no description available]	medium	2	0
torbafylline	[no description available]	medium	2	0
enrofloxacin	[no description available]	medium	2	0	cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone	antibacterial agent; antimicrobial agent; antineoplastic agent
uk 68798	[no description available]	medium	2	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
mepindolol	[no description available]	medium	1	0	indoles
fpl 52791	[no description available]	medium	1	0
epanolol	[no description available]	medium	1	0	acetamides
methotrimeprazine	[no description available]	medium	9	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
methotrimeprazine	[no description available]	medium	9	2	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
rosiglitazone	[no description available]	medium	2	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
rosiglitazone	[no description available]	medium	2	1	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
levcromakalim	[no description available]	medium	2	0	1-benzopyran
hexylcaine hydrochloride	[no description available]	medium	1	0
imipenem, anhydrous	[no description available]	medium	1	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
sr141716	[no description available]	medium	3	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous	[no description available]	medium	3	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
fpl 55712	[no description available]	medium	46	0	aromatic ketone
fpl 55712	[no description available]	medium	46	1	aromatic ketone
sivelestat	[no description available]	medium	1	0	N-acylglycine; pivalate ester
fpl-52694	[no description available]	medium	9	0
ramatroban	[no description available]	medium	8	0	organic molecular entity
ramatroban	[no description available]	medium	8	1	organic molecular entity
xaliproden	[no description available]	medium	1	0	(trifluoromethyl)benzenes; naphthalenes; tertiary amino compound; tetrahydropyridine	serotonergic agonist
n-isobutyrylcysteine	[no description available]	medium	1	0
dexpanthenol	[no description available]	medium	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
quilostigmine	[no description available]	medium	1	0	pyrroloindole
imiloxan	[no description available]	medium	1	0	benzodioxine
aspartame	[no description available]	medium	2	0	carboxylic acid; dipeptide zwitterion; dipeptide; methyl ester	apoptosis inhibitor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; environmental contaminant; micronutrient; nutraceutical; sweetening agent; xenobiotic
tempol	[no description available]	medium	1	0	aminoxyls; hydroxypiperidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; catalyst; hepatoprotective agent; nephroprotective agent; neuroprotective agent; radical scavenger
vatalanib	[no description available]	medium	1	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
moxifloxacin	[no description available]	medium	3	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
clevidipine	[no description available]	medium	1	0	dihydropyridine
hyoscyamine	[no description available]	medium	2	0	tropane alkaloid
naproxen	[no description available]	medium	5	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
lactitol	[no description available]	medium	2	0	glycosyl alditol	cathartic; excipient; laxative
fpl 52757	[no description available]	medium	1	0
paromomycin	[no description available]	medium	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
fpl 59257	[no description available]	medium	1	0
ropivacaine	[no description available]	medium	2	0	piperidinecarboxamide; ropivacaine	local anaesthetic
ropivacaine	[no description available]	medium	2	1	piperidinecarboxamide; ropivacaine	local anaesthetic
erlotinib	[no description available]	medium	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
zeneca zd 6169	[no description available]	medium	2	0
sibenadet	[no description available]	medium	2	0
latrepirdine	[no description available]	medium	3	0	methylpyridines; pyridoindole	geroprotector
ramelteon	[no description available]	medium	1	0	indanes
lapatinib	[no description available]	medium	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib	[no description available]	medium	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
cortisone	[no description available]	high	138	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
ouabain	[no description available]	medium	119	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
ouabain	[no description available]	medium	119	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
salicin	[no description available]	medium	1	0	aromatic primary alcohol; aryl beta-D-glucoside; benzyl alcohols	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
digitoxin	[no description available]	medium	8	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
linezolid	[no description available]	medium	2	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
(S)-bicalutamide	[no description available]	medium	1	0	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
devazepide	[no description available]	medium	7	0	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug
halcinonide	[no description available]	medium	1	0	organic molecular entity	SMO receptor agonist
metrizamide	[no description available]	medium	2	0	amino sugar
methylthiouracil	[no description available]	medium	6	0	pyrimidone
crotamiton	[no description available]	medium	1	0
flunarizine	[no description available]	medium	6	0	diarylmethane
capsaicin	[no description available]	medium	282	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
capsaicin	[no description available]	medium	282	16	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
ethionamide	[no description available]	medium	3	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
scopolamine	[no description available]	medium	1	0	3-hydroxy carboxylic acid
almokalant	[no description available]	medium	1	0
vx-745	[no description available]	medium	1	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
deracoxib	[no description available]	medium	1	0	organofluorine compound; pyrazoles; sulfonamide	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
dasatinib	[no description available]	medium	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
2-aminohippuric acid	[no description available]	medium	1	0	N-acylglycine
rs-130830	[no description available]	medium	1	0
sitagliptin	[no description available]	medium	1	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
dinoprostone	[no description available]	high	452	9	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprostone	[no description available]	high	452	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
vitamin k semiquinone radical	[no description available]	medium	14	0
vitamin k semiquinone radical	[no description available]	medium	14	1
pheniramine maleate	[no description available]	medium	1	0	organic molecular entity
homatropine	[no description available]	medium	1	0	tropane alkaloid
naloxone	[no description available]	medium	92	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
naloxone	[no description available]	medium	92	2	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
sirolimus	[no description available]	medium	8	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
sirolimus	[no description available]	medium	8	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate	[no description available]	medium	4	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
topiramate	[no description available]	medium	4	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
ar c67085mx	[no description available]	medium	1	0
desoximetasone	[no description available]	medium	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
sb 223412	[no description available]	medium	1	0
su 11248	[no description available]	medium	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
enalaprilat anhydrous	[no description available]	medium	3	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
tiotropium	[no description available]	medium	1	0
guanabenz	[no description available]	medium	1	0	dichlorobenzene
nw 1029	[no description available]	medium	1	0
ici d1542	[no description available]	medium	1	0
gavestinel	[no description available]	medium	1	0
1-methyl-d-lysergic acid butanolamide	[no description available]	medium	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
dantrolene	[no description available]	medium	1	0
tipredane	[no description available]	medium	1	0	3-hydroxy steroid	androgen
bentiromide	[no description available]	medium	1	0	dipeptide	diagnostic agent; indicator; reagent
gemifloxacin	[no description available]	medium	1	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
utibapril	[no description available]	medium	1	0
zd 9379	[no description available]	medium	1	0
ly 450139	[no description available]	medium	1	0	peptide
cangrelor	[no description available]	medium	1	0	adenosine 5'-phosphate; aryl sulfide; nucleoside triphosphate analogue; organochlorine compound; organofluorine compound; secondary amino compound	P2Y12 receptor antagonist; platelet aggregation inhibitor
sch 527123	[no description available]	medium	1	0
linaprazan	[no description available]	medium	2	0
lecozotan	[no description available]	medium	1	0
ar c155858	[no description available]	medium	1	0
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	[no description available]	medium	1	0	methoxybenzenes; substituted aniline
azd 7545	[no description available]	medium	1	0	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
clavulanate potassium	[no description available]	medium	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
cytomel	[no description available]	medium	1	0	organic sodium salt
a 967079	[no description available]	medium	1	0
pht 427	[no description available]	medium	1	0
dicumarol	[no description available]	medium	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist
sildenafil	[no description available]	medium	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
leucovorin	[no description available]	medium	1	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
carbadox	[no description available]	medium	1	0	quinoxaline derivative
fenobam	[no description available]	medium	1	0	ureas
gamma-aminobutyric acid	[no description available]	high	252	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
gamma-aminobutyric acid	[no description available]	high	252	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetic acid	[no description available]	medium	43	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetic acid	[no description available]	medium	43	1	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
beta-alanine	[no description available]	high	19	0	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
benzoic acid	[no description available]	medium	4	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
benzoic acid	[no description available]	medium	4	1	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
formic acid	[no description available]	medium	2	0	monocarboxylic acid	antibacterial agent; astringent; metabolite; protic solvent; solvent
salicylic acid	[no description available]	medium	18	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
salicylic acid	[no description available]	medium	18	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
gallic acid	[no description available]	medium	15	0	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
dihydroxyphenylalanine	[no description available]	high	62	0	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
4-aminobenzoic acid	[no description available]	medium	5	0	aminobenzoic acid; aromatic amino-acid zwitterion	allergen; Escherichia coli metabolite; plant metabolite
picolinic acid	[no description available]	medium	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
propionic acid	[no description available]	medium	2	0	saturated fatty acid; short-chain fatty acid	antifungal drug
pyridoxamine	[no description available]	high	2	0	aminoalkylpyridine; hydroxymethylpyridine; monohydroxypyridine; vitamin B6	Escherichia coli metabolite; human metabolite; iron chelator; mouse metabolite; nephroprotective agent; plant metabolite; Saccharomyces cerevisiae metabolite
trimethylamine	[no description available]	medium	5	0	methylamines; tertiary amine	Escherichia coli metabolite; human xenobiotic metabolite
tryptophan	[no description available]	medium	1	0	alpha-amino acid; amino acid zwitterion; aminoalkylindole; aromatic amino acid; polar amino acid	Daphnia magna metabolite
2,4-dichlorophenoxyacetic acid	[no description available]	medium	1	0	chlorophenoxyacetic acid; dichlorobenzene	agrochemical; defoliant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; environmental contaminant; phenoxy herbicide; synthetic auxin
alprenolol	[no description available]	medium	7	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
dan 2163	[no description available]	medium	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
azelastine	[no description available]	medium	46	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
azelastine	[no description available]	medium	46	17	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
bisoprolol	[no description available]	medium	2	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carbidopa	[no description available]	medium	1	0	benzenes; monocarboxylic acid
carvedilol	[no description available]	medium	4	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celiprolol	[no description available]	medium	3	0	aromatic ketone
cinoxacin	[no description available]	medium	2	0	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
diflunisal	[no description available]	medium	2	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
domperidone	[no description available]	medium	3	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
ethacrynic acid	[no description available]	medium	5	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
fendiline	[no description available]	medium	1	0	diarylmethane
fleroxacin	[no description available]	medium	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
flumequine	[no description available]	medium	2	0	3-oxo monocarboxylic acid; organofluorine compound; pyridoquinoline; quinolone antibiotic
fluspirilene	[no description available]	medium	1	0	diarylmethane
mephentermine	[no description available]	medium	7	0	amphetamines
ketorolac	[no description available]	medium	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
lomefloxacin	[no description available]	medium	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
mefenamic acid	[no description available]	medium	15	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mefenamic acid	[no description available]	medium	15	1	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
meperidine	[no description available]	medium	24	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
meperidine	[no description available]	medium	24	1	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
methoxyphenamine	[no description available]	medium	2	0	amphetamines	beta-adrenergic agonist; bronchodilator agent
3-Hydroxy-alpha-methyl-DL-tyrosine	[no description available]	medium	1	0	benzenes; monocarboxylic acid
mexiletine	[no description available]	medium	3	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mexiletine	[no description available]	medium	3	1	aromatic ether; primary amino compound	anti-arrhythmia drug
mirtazapine	[no description available]	medium	3	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
norfloxacin	[no description available]	medium	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
oxotremorine	[no description available]	medium	20	0	N-alkylpyrrolidine
aminosalicylic acid	[no description available]	medium	5	0	aminobenzoic acid; phenols	antitubercular agent
suprofen	[no description available]	medium	2	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
gatifloxacin	[no description available]	medium	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tolmetin	[no description available]	medium	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
trazodone	[no description available]	medium	3	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
dextroamphetamine	[no description available]	medium	19	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
penicillamine	[no description available]	medium	15	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
isonicotinic acid	[no description available]	medium	1	0	pyridinemonocarboxylic acid	algal metabolite; human metabolite
physostigmine	[no description available]	medium	121	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
ethylamine	[no description available]	medium	4	0	primary aliphatic amine	human metabolite
tromethamine	[no description available]	medium	7	0	primary amino compound; triol	buffer
brompheniramine	[no description available]	medium	18	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
phenylpiperazine	[no description available]	medium	1	0
2-naphthoic acid	[no description available]	medium	1	0	naphthoic acid	mouse metabolite; xenobiotic metabolite
mecoprop	[no description available]	medium	2	0	aromatic ether; monocarboxylic acid; monochlorobenzenes
deanol	[no description available]	medium	2	0	ethanolamines; tertiary amine	curing agent; radical scavenger
4-methylmorpholine	[no description available]	medium	2	0
n-butylamine	[no description available]	medium	1	0	primary aliphatic amine
piperidine	[no description available]	medium	4	0	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
morpholine	[no description available]	medium	1	0	morpholines; saturated organic heteromonocyclic parent	NMR chemical shift reference compound
hexahydroazepine	[no description available]	medium	1	0	azacycloalkane; azepanes; saturated organic heteromonocyclic parent
n-methylpyrrolidine	[no description available]	medium	1	0
triethylamine	[no description available]	medium	1	0	tertiary amine
meglumine	[no description available]	medium	11	0	hexosamine; secondary amino compound
aziridine	[no description available]	medium	1	0	azacycloalkane; aziridines; saturated organic heteromonocyclic parent	alkylating agent
dibenzepin	[no description available]	medium	1	0	dibenzodiazepine
galantamine	[no description available]	medium	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
trifluoroethylamine	[no description available]	medium	1	0
2-fluoroethylamine	[no description available]	medium	1	0
arecaidine	[no description available]	medium	1	0	citraconoyl group
azetidine	[no description available]	medium	1	0	azacycloalkane; azetidines; saturated organic heteromonocyclic parent
gluconic acid	[no description available]	medium	2	0	gluconic acid	chelator; Penicillium metabolite
methamphetamine	[no description available]	medium	29	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
aminopenicillanic acid	[no description available]	medium	2	0	amino acid zwitterion; penicillanic acids	allergen
glycyl-glycyl-glycine	[no description available]	medium	1	0	tripeptide zwitterion; tripeptide
n,n-dimethylethylamine	[no description available]	medium	1	0
diethylmethylamine	[no description available]	medium	1	0
glycine ethyl ester	[no description available]	medium	2	0
n-methylpiperidine	[no description available]	medium	1	0
benzydamine	[no description available]	medium	1	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
tempidon	[no description available]	medium	1	0	piperidones
clopyralid	[no description available]	medium	1	0	organochlorine pesticide; pyridines	herbicide
dimethylaminopropionitrile	[no description available]	medium	1	0
5-phenylvaleric acid	[no description available]	medium	1	0	benzenes; monocarboxylic acid
cyclacillin	[no description available]	medium	1	0	penicillin	antibacterial drug
pyrrolidine	[no description available]	medium	2	0	azacycloalkane; pyrrolidines; saturated organic heteromonocyclic parent
metipranolol	[no description available]	medium	1	0	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
propamocarb	[no description available]	medium	1	0	carbamate ester; carbamate fungicide; tertiary amino compound	antifungal agrochemical; environmental contaminant; xenobiotic
phenyl-2-aminoethyl sulfide	[no description available]	medium	1	0
tolamolol	[no description available]	medium	1	0
sq-11725	[no description available]	medium	3	0
sufentanil	[no description available]	medium	5	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
sufentanil	[no description available]	medium	5	2	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
Flamprop	[no description available]	medium	1	0	benzamides
paroxetine	[no description available]	medium	3	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
atomoxetine	[no description available]	medium	1	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
atorvastatin	[no description available]	medium	3	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
atorvastatin	[no description available]	medium	3	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
irinotecan	[no description available]	medium	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
d-lactic acid	[no description available]	medium	1	0	2-hydroxypropanoic acid	Escherichia coli metabolite; human metabolite
trovafloxacin	[no description available]	medium	1	0
thiamorpholine	[no description available]	medium	1	0	saturated organic heteromonocyclic parent; thiomorpholines
glycyl-glycyl-glycyl-glycine	[no description available]	medium	1	0
nebivolol	[no description available]	medium	1	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
carazolol	[no description available]	medium	1	0	carbazoles
oleandomycin	[no description available]	medium	1	0	oleandomycins
phenylalanyl-phenylalanyl-phenylalanine	[no description available]	medium	1	0	oligopeptide
3-(4-methoxybenzoyl)propionic acid	[no description available]	medium	1	0
dimethylaminopropanol	[no description available]	medium	1	0
rivastigmine	[no description available]	medium	1	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
4-phenylbutylamine	[no description available]	medium	1	0	benzenes; phenylalkylamine; primary amino compound
glycinexylidide	[no description available]	medium	1	0	amino acid amide	drug metabolite
Trp-Trp	[no description available]	medium	1	0	dipeptide	Mycoplasma genitalium metabolite
kampirone	[no description available]	medium	1	0	N-arylpiperazine
isopelletierine	[no description available]	medium	1	0	citraconoyl group
fenpropimorph	[no description available]	medium	1	0	alkylbenzene
1-(2-pyridinyl)piperazine	[no description available]	medium	1	0
l-lactic acid	[no description available]	medium	1	0	(2S)-2-hydroxy monocarboxylic acid; 2-hydroxypropanoic acid	Escherichia coli metabolite; human metabolite
ibuprofen, (r)-isomer	[no description available]	medium	1	0	ibuprofen
deramciclane	[no description available]	medium	1	0
norpseudoephedrine	[no description available]	medium	1	0	amphetamines; phenethylamine alkaloid	central nervous system stimulant; plant metabolite; psychotropic drug
tolterodine	[no description available]	medium	1	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
vinpocetine	[no description available]	medium	6	0	alkaloid	geroprotector
e-z cinnamic acid	[no description available]	medium	1	0	cinnamic acid	plant metabolite
cocaine	[no description available]	high	122	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
cefamandole	[no description available]	medium	1	0	cephalosporin; semisynthetic derivative	antibacterial drug
sorbic acid	[no description available]	medium	3	0	alpha,beta-unsaturated monocarboxylic acid; sorbic acid
4-methylumbelliferyl glucoside	[no description available]	medium	1	0	beta-D-glucoside; coumarins; monosaccharide derivative	chromogenic compound
tylosin	[no description available]	medium	1	0	aldehyde; disaccharide derivative; enone; leucomycin; macrolide antibiotic; monosaccharide derivative	allergen; bacterial metabolite; environmental contaminant; xenobiotic
alprostadil	[no description available]	high	94	5	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
alprostadil	[no description available]	high	94	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
isotretinoin	[no description available]	medium	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
dihydrocodeine	[no description available]	medium	1	0	morphinane alkaloid
oxycodone	[no description available]	medium	3	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxycodone	[no description available]	medium	3	2	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid	[no description available]	medium	1	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
codeine phosphate	[no description available]	medium	1	0
dihydromorphine	[no description available]	medium	1	0	morphinane alkaloid
morphine-6-glucuronide	[no description available]	medium	1	0	morphinane alkaloid
heroin	[no description available]	medium	5	0	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
heroin	[no description available]	medium	5	1	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
normorphine	[no description available]	medium	1	0	morphinane alkaloid
morphine-3-glucuronide	[no description available]	medium	1	0	morphinane alkaloid
1,2-dielaidoylphosphatidylethanolamine	[no description available]	medium	1	0
rosaramicin	[no description available]	medium	1	0	aldehyde; enone; epoxide; macrolide antibiotic; monosaccharide derivative	bacterial metabolite
roxithromycin	[no description available]	medium	1	0	roxithromycin	environmental contaminant; xenobiotic
cefdinir	[no description available]	medium	1	0	cephalosporin; ketoxime	antibacterial drug
phenylalanylphenylalanine	[no description available]	medium	1	0	dipeptide; L-aminoacyl-L-amino acid zwitterion	human blood serum metabolite; Mycoplasma genitalium metabolite
norcodeine	[no description available]	medium	1	0	morphinane alkaloid
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride	[no description available]	medium	1	0
decanoylcarnitine	[no description available]	medium	1	0	decanoate ester; O-acylcarnitine	human urinary metabolite
norclozapine	[no description available]	medium	1	0	dibenzodiazepine; organochlorine compound; piperazines	delta-opioid receptor agonist; metabolite; serotonergic antagonist
pf-3893787	[no description available]	medium	1	0
4-fluorobenzylamine	[no description available]	medium	1	0
sodium perchlorate	[no description available]	medium	1	0	inorganic sodium salt
lithium perchlorate	[no description available]	medium	1	0
9-xylosyladenine	[no description available]	medium	2	0	purine nucleoside
malic acid	[no description available]	medium	6	0	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
phosphonoacetic acid	[no description available]	medium	1	0	monocarboxylic acid; phosphonic acids	antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
naringenin	[no description available]	medium	1	0	4'-hydroxyflavanones; trihydroxyflavanone
niacinamide	[no description available]	high	26	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
pyrazinamide	[no description available]	medium	1	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyrazinoic acid	[no description available]	medium	1	0	pyrazinecarboxylic acid	antitubercular agent; drug metabolite
1,10-phenanthroline	[no description available]	medium	2	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1,3-dipropyl-8-cyclopentylxanthine	[no description available]	medium	6	0	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
2,2'-dipyridyl	[no description available]	medium	4	0	bipyridine	chelator; ferroptosis inhibitor
ro 5-4864	[no description available]	medium	2	0
4-aminopyridine	[no description available]	medium	23	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
5,8,11,14-eicosatetraynoic acid	[no description available]	medium	15	0	long-chain fatty acid
5-fluoroindole-2-carboxylic acid	[no description available]	medium	1	0	indolyl carboxylic acid
etofylline	[no description available]	medium	1	0	oxopurine
7-nitroindazole	[no description available]	medium	3	0
aa 861	[no description available]	medium	8	0	1,4-benzoquinones; acetylenic compound; primary alcohol	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor
acetazolamide	[no description available]	medium	43	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
aniracetam	[no description available]	medium	1	0	N-acylpyrrolidine; pyrrolidin-2-ones
anisindione	[no description available]	medium	1	0	aromatic ketone; beta-diketone	anticoagulant; vitamin K antagonist
azelaic acid	[no description available]	medium	2	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite
azelaic acid	[no description available]	medium	2	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite
bay-k-8644	[no description available]	medium	44	0	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
benzbromarone	[no description available]	medium	1	0	1-benzofurans; aromatic ketone	uricosuric drug
bay h 4502	[no description available]	medium	2	0	biphenyls; imidazoles
brimonidine	[no description available]	medium	1	0	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
chlorambucil	[no description available]	medium	3	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorthalidone	[no description available]	medium	2	0	isoindoles; monochlorobenzenes; sulfonamide
cilostazol	[no description available]	medium	6	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide	[no description available]	medium	1	0	sulfonamide
deferiprone	[no description available]	medium	1	0	4-pyridones	iron chelator; protective agent
dichlorophen	[no description available]	medium	1	0	bridged diphenyl fungicide; diarylmethane
dipyridamole	[no description available]	medium	16	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
dipropizine	[no description available]	medium	2	0	piperazines
ellipticine	[no description available]	medium	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
epirizole	[no description available]	medium	8	0	aromatic ether
myambutol	[no description available]	medium	1	0	amino alcohol
ethoxzolamide	[no description available]	medium	2	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
etodolac	[no description available]	medium	3	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
4-biphenylylacetic acid	[no description available]	medium	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
fenbufen	[no description available]	medium	1	0	4-oxo monocarboxylic acid; biphenyls	non-steroidal anti-inflammatory drug
fluorometholone	[no description available]	medium	1	0
1-(5-isoquinolinesulfonyl)-2-methylpiperazine	[no description available]	medium	36	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
harmaline	[no description available]	medium	5	0	harmala alkaloid	oneirogen
hexachlorophene	[no description available]	medium	3	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
hexachlorophene	[no description available]	medium	3	1	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
indoprofen	[no description available]	medium	1	0	gamma-lactam; isoindoles; monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
ipriflavone	[no description available]	medium	2	0	aromatic ether; isoflavones	bone density conservation agent
itraconazole	[no description available]	medium	1	0	piperazines
khellin	[no description available]	medium	7	0	furanochromone; organic heterotricyclic compound; oxacycle	anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent
lamotrigine	[no description available]	medium	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole	[no description available]	medium	10	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
edaravone	[no description available]	medium	2	0	pyrazolone	antioxidant; radical scavenger
meclofenamate sodium anhydrous	[no description available]	medium	1	0	organic sodium salt
methazolamide	[no description available]	medium	1	0	sulfonamide; thiadiazoles
moclobemide	[no description available]	medium	1	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
nabumetone	[no description available]	medium	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nialamide	[no description available]	medium	20	0	organonitrogen compound; organooxygen compound
niflumic acid	[no description available]	medium	11	0	aromatic carboxylic acid; pyridines
nimesulide	[no description available]	medium	8	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimesulide	[no description available]	medium	8	2	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
cm 7116	[no description available]	medium	1	0	benzodiazepine
4-phenylbutyric acid	[no description available]	medium	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phenylbutazone	[no description available]	medium	87	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
pipemidic acid	[no description available]	medium	1	0	amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
pirenperone	[no description available]	medium	1	0	aromatic ketone
primidone	[no description available]	medium	1	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
pf 5901	[no description available]	medium	9	0	quinolines
ritanserin	[no description available]	medium	3	0	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
rolipram	[no description available]	medium	39	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ronidazole	[no description available]	medium	1	0	C-nitro compound; carbamate ester; imidazoles	antiparasitic agent; antiprotozoal drug
aldactazide	[no description available]	medium	1	0	steroid lactone
streptonigrin	[no description available]	medium	1	0	pyridines; quinolone	antimicrobial agent; antineoplastic agent
sulfabenzamide	[no description available]	medium	1	0	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug
sulfamethoxypyridazine	[no description available]	medium	1	0	pyridazines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
tegafur	[no description available]	medium	1	0	organohalogen compound; pyrimidines
vesamicol	[no description available]	medium	1	0	piperidines
zopiclone	[no description available]	medium	1	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
hydrocortisone acetate	[no description available]	medium	1	0	cortisol ester; tertiary alpha-hydroxy ketone
oxyphenonium bromide	[no description available]	medium	1	0
neostigmine methylsulfate	[no description available]	medium	1	0	arylammonium sulfate salt	EC 3.1.1.8 (cholinesterase) inhibitor
prednisolone acetate	[no description available]	medium	1	0	corticosteroid hormone
trichlorfon	[no description available]	medium	1	0	organic phosphonate; organochlorine compound; phosphonic ester	agrochemical; anthelminthic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; insecticide
androsterone	[no description available]	high	2	0	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid	androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone
promazine hydrochloride	[no description available]	medium	1	0	hydrochloride
azauridine	[no description available]	medium	1	0	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite
pilocarpine hydrochloride	[no description available]	medium	1	0	hydrochloride
dimethylphenylpiperazinium iodide	[no description available]	medium	36	0	N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt	nicotinic acetylcholine receptor agonist
benzyltrimethylammonium chloride	[no description available]	medium	1	0
promethazine hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative
uridine	[no description available]	high	8	0	uridines	drug metabolite; fundamental metabolite; human metabolite
tolazoline hydrochloride	[no description available]	medium	1	0	benzenes
acetylcholine chloride	[no description available]	medium	1	0	quaternary ammonium salt
methoxamine hydrochloride	[no description available]	medium	1	0	dimethoxybenzene
papaverine hydrochloride	[no description available]	medium	1	0
methacholine chloride	[no description available]	medium	433	0	quaternary ammonium salt
methacholine chloride	[no description available]	medium	433	60	quaternary ammonium salt
fluocinolone acetonide	[no description available]	medium	8	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
fluocinolone acetonide	[no description available]	medium	8	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
norethynodrel	[no description available]	medium	1	0	oxo steroid
17-alpha-hydroxyprogesterone	[no description available]	medium	1	0	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin
chlorpromazine hydrochloride	[no description available]	medium	1	0	hydrochloride; phenothiazines	anticoronaviral agent; phenothiazine antipsychotic drug
cytarabine hydrochloride	[no description available]	medium	1	0
medroxyprogesterone acetate	[no description available]	medium	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
mestranol	[no description available]	medium	3	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
lidocaine hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-arrhythmia drug; local anaesthetic
triamcinolone acetonide	[no description available]	medium	9	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
triamcinolone acetonide	[no description available]	medium	9	2	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
dehydrocholic acid	[no description available]	medium	4	0	12-oxo steroid; 3-oxo-5beta-steroid; 7-oxo steroid; oxo-5beta-cholanic acid	gastrointestinal drug
9,10-phenanthrenequinone	[no description available]	medium	1	0	phenanthrenes
phenothiazine	[no description available]	medium	22	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
2-methyl-4-chlorophenoxyacetic acid	[no description available]	medium	1	0	chlorophenoxyacetic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; synthetic auxin
arsanilic acid	[no description available]	medium	1	0	organoarsonic acid
3-aminobenzoic acid	[no description available]	medium	1	0	aminobenzoic acid
thiodipropionic acid	[no description available]	medium	1	0	dicarboxylic acid
imipramine hydrochloride	[no description available]	medium	1	0	hydrochloride	antidepressant
edrophonium chloride	[no description available]	medium	1	0	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
maltol	[no description available]	medium	1	0	4-pyranones	metabolite
methapyrilene hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
phenazopyridine hydrochloride	[no description available]	medium	1	0	hydrochloride	carcinogenic agent; local anaesthetic; non-narcotic analgesic
tetrracaine hydrochloride	[no description available]	medium	1	0	benzoate ester
protocatechualdehyde	[no description available]	medium	1	0	dihydroxybenzaldehyde
20-alpha-dihydroprogesterone	[no description available]	medium	1	0	20-hydroxypregn-4-en-3-one	human metabolite; mouse metabolite
2-chloroadenosine	[no description available]	medium	20	0	purine nucleoside
diphenhydramine hydrochloride	[no description available]	medium	17	0	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
diphenhydramine hydrochloride	[no description available]	medium	17	2	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
quinestrol	[no description available]	medium	1	0	17-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tripelennamine hydrochloride	[no description available]	medium	1	0
ethamivan	[no description available]	medium	1	0	methoxybenzenes; phenols
pargyline hydrochloride	[no description available]	medium	1	0
orphenadrine hydrochloride	[no description available]	medium	1	0	hydrochloride	antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
fluocinonide	[no description available]	medium	1	0	organic molecular entity
xanthinol niacinate	[no description available]	medium	2	0
glycyrrhetinic acid	[no description available]	medium	1	0	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
podophyllotoxin	[no description available]	medium	4	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
medroxyprogesterone	[no description available]	medium	5	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
tetrahydrozoline hydrochloride	[no description available]	medium	1	0	hydrochloride	nasal decongestant; sympathomimetic agent; vasoconstrictor agent
1,2-naphthoquinone	[no description available]	medium	1	0	1,2-naphthoquinones	aryl hydrocarbon receptor agonist; carcinogenic agent
amitriptyline hydrochloride	[no description available]	medium	1	0	organic tricyclic compound
naphazoline hydrochloride	[no description available]	medium	1	0	organic molecular entity
4,4'-bipyridyl	[no description available]	medium	1	0	bipyridine
doxylamine succinate	[no description available]	medium	3	0	organic molecular entity
monoacetyldapsone	[no description available]	medium	1	0	acetamides; anilide; secondary carboxamide; sulfone
formestane	[no description available]	medium	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
chlorotrianisene	[no description available]	medium	1	0	chloroalkene	antineoplastic agent; estrogen receptor modulator; xenoestrogen
aminacrine	[no description available]	medium	1	0
isoxsuprine hydrochloride	[no description available]	medium	1	0	alkylbenzene
bethanechol chloride	[no description available]	medium	1	0	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist
2-hydroxyacetanilide	[no description available]	medium	1	0	acetamides; phenols	anti-inflammatory agent; antineoplastic agent; antirheumatic drug; apoptosis inducer; platelet aggregation inhibitor; xenobiotic metabolite
clopamide	[no description available]	medium	1	0	sulfonamide
phosmet	[no description available]	medium	1	0	organic thiophosphate; organothiophosphate insecticide; phthalimides	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor
levonorgestrel	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
malononitrile dimer	[no description available]	medium	1	0
diphenyl disulfide	[no description available]	medium	1	0	benzenes
cyproheptadine hydrochloride (anhydrous)	[no description available]	medium	1	0	hydrochloride
estradiol valerate	[no description available]	medium	1	0	steroid ester
2,2'-dipyridylamine	[no description available]	medium	1	0
pregnenolone carbonitrile	[no description available]	medium	1	0	aliphatic nitrile
diethylcarbamazine citrate	[no description available]	medium	1	0	piperazinecarboxamide
azacyclonol	[no description available]	medium	1	0	diarylmethane
5 alpha-androstane-3 alpha,17 beta-diol	[no description available]	medium	1	0	androstane-3alpha,17beta-diol	Daphnia magna metabolite; human metabolite
guaiacoxyacetic acid	[no description available]	medium	1	0
methylene diphosphonate	[no description available]	medium	1	0	1,1-bis(phosphonic acid)	bone density conservation agent; chelator
amiloride hydrochloride, anhydrous	[no description available]	medium	1	0	hydrochloride	diuretic; sodium channel blocker
hydrocortisone hemisuccinate	[no description available]	medium	1	0	dicarboxylic acid monoester; hemisuccinate; tertiary alpha-hydroxy ketone
antazoline hydrochloride	[no description available]	medium	1	0
mebeverine hydrochloride	[no description available]	medium	1	0
stavudine	[no description available]	medium	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
clidinium bromide	[no description available]	medium	1	0
diloxanide furoate	[no description available]	medium	1	0	carboxylic ester; furans; organochlorine compound; tertiary carboxamide	antiamoebic agent; prodrug
nitroxoline	[no description available]	medium	1	0	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
cladribine	[no description available]	medium	2	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
alverine citrate	[no description available]	medium	1	0	citrate salt; organoammonium salt	antispasmodic drug; cholinergic antagonist
cyclogyl	[no description available]	medium	1	0
metoclopramide hydrochloride	[no description available]	medium	1	0
isoetharine mesylate	[no description available]	medium	1	0
6-nitroindazole	[no description available]	medium	1	0
hydrocortisone-17-butyrate	[no description available]	medium	1	0	butyrate ester; cortisol ester; primary alpha-hydroxy ketone	dermatologic drug; drug allergen
benserazide hydrochloride	[no description available]	medium	1	0	hydrochloride	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
pentamethylmelamine	[no description available]	medium	1	0
eedq	[no description available]	medium	2	0
ornidazole	[no description available]	medium	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
tetridamin	[no description available]	medium	1	0
thymolphthalein	[no description available]	medium	1	0	terpene lactone
frentizole	[no description available]	medium	1	0
eterobarb	[no description available]	medium	1	0	barbiturates
oxcarbazepine	[no description available]	medium	1	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
moricizine hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-arrhythmia drug
proroxan hydrochloride	[no description available]	medium	1	0
etomidate	[no description available]	medium	1	0	imidazoles
buspirone hydrochloride	[no description available]	medium	1	0	hydrochloride	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
propafenone hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-arrhythmia drug
picobenzide	[no description available]	medium	1	0
flecainide acetate	[no description available]	medium	1	0	acetate salt	anti-arrhythmia drug
nicardipine hydrochloride	[no description available]	medium	1	0	dihydropyridine	geroprotector
triadimenol	[no description available]	medium	1	0	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
terazosin hydrochloride anhydrous	[no description available]	medium	1	0
pergolide mesylate	[no description available]	medium	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
cerm-1978	[no description available]	medium	1	0	hydrochloride
dazoxiben hydrochloride	[no description available]	medium	1	0
lovastatin	[no description available]	medium	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
mifepristone	[no description available]	medium	7	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
tobramycin sulfate	[no description available]	medium	1	0
benzylaminopurine	[no description available]	medium	1	0	6-aminopurines	cytokinin; plant metabolite
fluoxetine hydrochloride	[no description available]	medium	1	0	hydrochloride; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
diltiazem hydrochloride	[no description available]	medium	1	0	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent
trazodone hydrochloride	[no description available]	medium	17	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
doxazosin mesylate	[no description available]	medium	1	0	methanesulfonate salt	geroprotector
amantadine hydrochloride	[no description available]	medium	1	0	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist
norharman	[no description available]	medium	1	0	beta-carbolines; mancude organic heterotricyclic parent	fungal metabolite; marine metabolite
desipramine hydrochloride	[no description available]	medium	1	0	hydrochloride	drug allergen
ticlopidine hydrochloride	[no description available]	medium	1	0	hydrochloride
dopamine hydrochloride	[no description available]	medium	1	0	catecholamine
sulconazole, mononitrate, (+-)-isomer	[no description available]	medium	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt
acetylcholine bromide	[no description available]	medium	1	0	bromide salt; quaternary ammonium salt
aloxistatin	[no description available]	medium	1	0	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
tryptamide	[no description available]	medium	1	0
trihexyphenidyl hydrochloride	[no description available]	medium	1	0	aralkylamine
oxyphencyclimine hydrochloride	[no description available]	medium	1	0	pyrimidines
thioridazine hydrochloride	[no description available]	medium	1	0	hydrochloride	first generation antipsychotic; geroprotector
diphenylpyraline hydrochloride	[no description available]	medium	1	0	hydrochloride	cholinergic antagonist; H1-receptor antagonist
procainamide hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-arrhythmia drug
siquil	[no description available]	medium	1	0	hydrochloride	anticoronaviral agent
mepivacaine hydrochloride	[no description available]	medium	1	0	hydrochloride; piperidinecarboxamide	local anaesthetic
oxymetazoline hydrochloride	[no description available]	medium	1	0	hydrochloride	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
diphenidol hydrochloride	[no description available]	medium	1	0	diarylmethane
alprenolol hydrochloride	[no description available]	medium	1	0	hydrochloride
edoxudin	[no description available]	medium	1	0	pyrimidine 2'-deoxyribonucleoside
6-ketoestradiol	[no description available]	medium	1	0
17 beta-estradiol hemisuccinate	[no description available]	medium	1	0
amizyl	[no description available]	medium	1	0
salicylhydroxamic acid	[no description available]	medium	1	0	hydroxamic acid; phenols	antibacterial drug; EC 1.11.2.2 (myeloperoxidase) inhibitor; EC 3.5.1.5 (urease) inhibitor; trypanocidal drug
1,7-phenanthroline	[no description available]	medium	12	0	phenanthroline
1,7-phenanthroline	[no description available]	medium	12	1	phenanthroline
3-fluoro-4-hydroxyphenylacetic acid	[no description available]	medium	1	0
dyclonine hydrochloride	[no description available]	medium	1	0	hydrochloride	topical anaesthetic
clomipramine hydrochloride	[no description available]	medium	1	0	hydrochloride	anticoronaviral agent; antidepressant; serotonergic antagonist; serotonergic drug
prazosin hydrochloride	[no description available]	medium	1	0	hydrochloride
mianserin hydrochloride	[no description available]	medium	1	0	hydrochloride	geroprotector
miconazole nitrate	[no description available]	medium	1	0
econazole nitrate	[no description available]	medium	1	0
2,4-dimethoxybenzaldehyde	[no description available]	medium	1	0
clobetasone butyrate	[no description available]	medium	2	0	organic molecular entity
clobetasone butyrate	[no description available]	medium	2	1	organic molecular entity
loxapine succinate	[no description available]	medium	1	0	succinate salt	geroprotector
guanfacine hydrochloride	[no description available]	medium	1	0	acetamides	geroprotector
labetalol hydrochloride	[no description available]	medium	1	0	salicylamides
diflorasone diacetate	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; fluorinated steroid; glucocorticoid	anti-inflammatory drug; antipruritic drug
acecainide hydrochloride	[no description available]	medium	1	0
loperamide hydrochloride	[no description available]	medium	1	0	hydrochloride	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
maprotiline hydrochloride	[no description available]	medium	1	0	anthracenes
hydroxyzine dihydrochloride	[no description available]	medium	1	0
betamipron	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
secnidazole	[no description available]	medium	1	0	C-nitro compound; imidazoles; secondary alcohol	epitope
ergocornine	[no description available]	medium	1	0	ergot alkaloid
pramoxine hydrochloride	[no description available]	medium	1	0	aromatic ether
butyrylcholine chloride	[no description available]	medium	1	0
1-benzylimidazole	[no description available]	medium	1	0
chloropyramine hydrochloride	[no description available]	medium	1	0
6-aminoindazole	[no description available]	medium	1	0	indazoles
5-aminoindazole	[no description available]	medium	1	0
phentolamine mesylate	[no description available]	medium	1	0
oxybutynin hydrochloride	[no description available]	medium	1	0	hydrochloride
2-methylhippuric acid	[no description available]	medium	1	0	N-acylglycine	metabolite
prilocaine hydrochloride	[no description available]	medium	1	0	hydrochloride	local anaesthetic
meclizine hydrochloride	[no description available]	medium	1	0
11-hydroxyprogesterone, (11alpha)-isomer	[no description available]	medium	1	0	11alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid
malic acid, (r)-isomer	[no description available]	medium	1	0	malic acid
21-deoxycortisol	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy-C21-steroid; deoxycortisol; tertiary alpha-hydroxy ketone	human blood serum metabolite; mouse metabolite
estrone 3-methyl ether	[no description available]	medium	1	0
e-250	[no description available]	medium	1	0
rac-glycerol 1-monodecanoate	[no description available]	medium	1	0	rac-1-monoacylglycerol
nipecotic acid amide	[no description available]	medium	1	0	piperidinecarboxamide
tachistin	[no description available]	medium	1	0
cortisol octanoate	[no description available]	medium	1	0	corticosteroid hormone
armepavine	[no description available]	medium	1	0
n(6)-phenyladenosine	[no description available]	medium	1	0	purine nucleoside
mizoribine	[no description available]	medium	1	0	imidazoles	anticoronaviral agent
alphaxalone	[no description available]	medium	2	0	corticosteroid hormone
alphaxalone	[no description available]	medium	2	1	corticosteroid hormone
bicuculline methiodide	[no description available]	medium	2	0
beta-carboline-3-carboxylic acid ethyl ester	[no description available]	medium	3	0	beta-carbolines
tryptoline	[no description available]	medium	1	0	beta-carbolines
gamma-fagarine	[no description available]	medium	1	0	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
betaxolol hydrochloride	[no description available]	medium	1	0	hydrochloride	antihypertensive agent; beta-adrenergic antagonist
Zearalanone	[no description available]	medium	1	0	macrolide; resorcinols
butethamate citrate	[no description available]	medium	1	0
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol	[no description available]	medium	1	0	piperidines
gallopamil hydrochloride	[no description available]	medium	1	0
histamine dihydrochloride	[no description available]	medium	1	0
1,3-dimethylbenzimidazoline-2-thione	[no description available]	medium	1	0
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine	[no description available]	medium	1	0	leucine derivative
desloratadine	[no description available]	medium	25	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
desloratadine	[no description available]	medium	25	9	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer	[no description available]	medium	1	0
dichloro-1,2-diaminocyclohexane platinum complex	[no description available]	medium	1	0
1,4-di(2'-thienyl)-1,4-butadione	[no description available]	medium	1	0
idazoxan hydrochloride	[no description available]	medium	1	0
methyl 5-aminolevulinate hydrochloride	[no description available]	medium	1	0	hydrochloride	antineoplastic agent; dermatologic drug; photosensitizing agent; prodrug
antazoline phosphate	[no description available]	medium	1	0
pridinol mesylate	[no description available]	medium	1	0
17 alpha-hydroxyprogesterone caproate	[no description available]	medium	1	0	corticosteroid hormone
5-fluorotryptamine monohydrochloride	[no description available]	medium	1	0
piribedil mesylate	[no description available]	medium	1	0
serc	[no description available]	medium	1	0
procyclidine hydrochloride	[no description available]	medium	1	0	hydrochloride
(7R)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one	[no description available]	medium	1	0	macrolide
equilin	[no description available]	medium	1	0	17-oxo steroid; 3-hydroxy steroid
adrenosterone	[no description available]	medium	1	0	11-oxo steroid; 17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; human urinary metabolite; marine metabolite
gossypol acetic acid	[no description available]	medium	1	0
epinastine	[no description available]	medium	1	0	corticosteroid hormone
benzatropine methanesulfonate	[no description available]	medium	1	0
4',6-dihydroxy-5,7-dimethoxyflavone	[no description available]	medium	1	0	dihydroxyflavone; dimethoxyflavone
2-hydroxyestradiol	[no description available]	medium	1	0	17beta-hydroxy steroid; 2-hydroxy steroid	carcinogenic agent; human metabolite; metabolite; mouse metabolite; prodrug
medrysone	[no description available]	medium	2	0	corticosteroid hormone
medrysone	[no description available]	medium	2	1	corticosteroid hormone
artisone acetate	[no description available]	medium	1	0	corticosteroid hormone
chondocurine (1beta)-(+-)-isomer	[no description available]	medium	3	0	aromatic ether
4-methoxyxanthone	[no description available]	medium	1	0
2-methyl-N-[4-(propan-2-ylamino)phenyl]-2-propenamide	[no description available]	medium	1	0	amine
mandelic acid, (s)-isomer	[no description available]	medium	1	0	(2S)-2-hydroxy monocarboxylic acid; mandelic acid
tosylphenylalanyl chloromethyl ketone	[no description available]	medium	2	0	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
cortodoxone	[no description available]	high	2	0	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
acebutolol hydrochloride	[no description available]	medium	1	0	hydrochloride	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
amiodarone hydrochloride	[no description available]	medium	1	0	aromatic ketone
dicyclomine hydrochloride	[no description available]	medium	1	0	hydrochloride	antispasmodic drug; muscarinic antagonist
nortriptyline hydrochloride	[no description available]	medium	1	0	organic tricyclic compound	geroprotector
difluprednate	[no description available]	medium	1	0	butyrate ester; corticosteroid hormone
dironyl	[no description available]	medium	1	0	organic molecular entity
amcinonide	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; corticosteroid; fluorinated steroid; spiroketal	anti-inflammatory drug
flumethasone pivalate	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; pivalate ester; tertiary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
dihydroergocristine monomesylate	[no description available]	medium	1	0	methanesulfonate salt	alpha-adrenergic antagonist; geroprotector; vasodilator agent
resveratrol	[no description available]	medium	8	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
adenosine-5'-(n-ethylcarboxamide)	[no description available]	medium	14	0	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
histidyl-proline diketopiperazine	[no description available]	medium	1	0	dipeptide; homodetic cyclic peptide; imidazoles; pyrrolopyrazine	anti-inflammatory agent; dopamine uptake inhibitor; human blood serum metabolite
afimoxifene	[no description available]	medium	3	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
ketoconazole	[no description available]	medium	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
aphidicolin	[no description available]	medium	2	0	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite
azaserine	[no description available]	medium	1	0	carboxylic ester; diazo compound; L-serine derivative; non-proteinogenic L-alpha-amino acid	antifungal agent; antimetabolite; antimicrobial agent; antineoplastic agent; glutamine antagonist; immunosuppressive agent; metabolite
maltitol	[no description available]	medium	1	0	alpha-D-glucoside; glycosyl alditol	laxative; metabolite; sweetening agent
chalcone	[no description available]	medium	4	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
thermospine	[no description available]	medium	1	0
dibenzylidene acetone	[no description available]	medium	1	0
4-methoxy-1,3-dimethyl-6-thiophen-2-yl-8-cyclohepta[c]furanone	[no description available]	medium	1	0	cycloheptafuran
5-[(5-methoxycarbonyl-2-methyl-3-furanyl)methoxy]-2-methyl-3-benzofurancarboxylic acid 2-methoxyethyl ester	[no description available]	medium	1	0	2-methoxyethyl ester; benzofurans
5,6,7-trimethoxy-1-methyl-2-indolecarboxylic acid	[no description available]	medium	1	0	indolyl carboxylic acid
haplamine	[no description available]	medium	1	0	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
diethylstilbestrol dipropionate	[no description available]	medium	1	0
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	[no description available]	medium	1	0	alkylbenzene
glycerylphosphorylcholine	[no description available]	medium	1	0	phosphocholines; sn-glycerol 3-phosphates	Escherichia coli metabolite; human metabolite; mouse metabolite; neuroprotective agent; parasympatholytic; Saccharomyces cerevisiae metabolite
n-methylscopolamine nitrate	[no description available]	medium	1	0
propylthiouracil	[no description available]	medium	6	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
phenytoin sodium	[no description available]	medium	1	0
ipratropium bromide anhydrous	[no description available]	medium	1	0
4-methoxy-N1,N3-bis(3-pyridinyl)benzene-1,3-dicarboxamide	[no description available]	medium	1	0	benzamides
methamilane methiodide	[no description available]	medium	1	0
physostigmine salicylate	[no description available]	medium	1	0	azaheterocycle salicylate salt; salicylates
pilocarpine nitrate	[no description available]	medium	1	0
n(6)-cyclopentyladenosine	[no description available]	medium	8	0
methylatropine nitrate	[no description available]	medium	1	0
1-[1-oxo-2-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxy]ethyl]-4-piperidinecarboxylic acid	[no description available]	medium	1	0	coumarins
prothionamide	[no description available]	medium	1	0	pyridines
2-(2,3,4-trimethoxyphenyl)-2,3-dihydro-1,3-benzoxazin-4-one	[no description available]	medium	1	0	benzoxazine
dienestrol	[no description available]	medium	1	0
4-methoxy-N-(3-pyridinylmethyl)benzamide	[no description available]	medium	1	0	benzamides
caffeic acid	[no description available]	medium	7	0	caffeic acid	geroprotector; mouse metabolite
5-methyl-4-[(2-oxo-1-benzopyran-7-yl)oxymethyl]-2-furancarboxylic acid methyl ester	[no description available]	medium	1	0	coumarins
2-(1,3-dioxo-2-isoindolyl)-N-(3-nitrophenyl)acetamide	[no description available]	medium	1	0	phthalimides
urocanic acid	[no description available]	high	14	0	urocanic acid	human metabolite
2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone	[no description available]	medium	1	0	stilbenoid
3-(4-methoxyphenyl)-5-(2-phenylethyl)-1,2,4-oxadiazole	[no description available]	medium	1	0	oxadiazole; ring assembly
3-(3,5-dimethyl-7-oxo-6-furo[3,2-g][1]benzopyranyl)propanoic acid	[no description available]	medium	1	0	psoralens
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione	[no description available]	medium	1	0	pyrimidotriazine
curcumin	[no description available]	medium	8	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
curcumin	[no description available]	medium	8	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
9-hydroxy-4-[1-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-[1]benzopyrano[3,4-b]pyridin-5-one	[no description available]	medium	1	0	pyridochromene
5-bromo-3-pyridinecarboxylic acid [3-(3-methylphenoxy)-4-oxo-1-benzopyran-7-yl] ester	[no description available]	medium	1	0	chromones
5-methyl-4-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxymethyl]-2-furancarboxylic acid	[no description available]	medium	1	0	coumarins
4-methyl-3-(phenylmethyl)-7-[(3,4,5-trimethoxyphenyl)methoxy]-1-benzopyran-2-one	[no description available]	medium	1	0	coumarins
[2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]-(4-morpholinyl)methanone	[no description available]	medium	1	0	quinolines
5-(3,3-dimethyl-2-oxobutoxy)-3,4,7-trimethyl-1-benzopyran-2-one	[no description available]	medium	1	0	coumarins
N-[4-(4-morpholinyl)phenyl]-5-(2-nitrophenyl)-2-furancarboxamide	[no description available]	medium	1	0	aromatic amide; furans
2-(8-methoxy-2-methyl-4-oxo-1-quinolinyl)-N-(2-methoxyphenyl)acetamide	[no description available]	medium	1	0	quinolines
N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-N-propan-2-yl-2-furancarboxamide	[no description available]	medium	1	0	quinolines
cinnarizine	[no description available]	medium	9	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
cinnarizine	[no description available]	medium	9	1	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
2-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)ethanone	[no description available]	medium	1	0	stilbenoid
1-cyclohexyl-3-(6-ethoxy-1,3-benzothiazol-2-yl)urea	[no description available]	medium	1	0	benzothiazoles
N-[(3,5-dimethoxyphenyl)methyl]-1-(2,3,4-trimethoxyphenyl)methanamine	[no description available]	medium	1	0	dimethoxybenzene
2-[[5-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]-4-oxo-2-phenyl-1-benzopyran-7-yl]oxy]acetic acid tert-butyl ester	[no description available]	medium	1	0	flavones; tert-butyl ester
ethylenethiourea	[no description available]	medium	1	0	imidazolidines
tacrine hydrochloride	[no description available]	medium	1	0
p-aminosalicylic acid monosodium salt	[no description available]	medium	1	0	organic molecular entity
mecysteine hydrochloride	[no description available]	medium	1	0	alpha-amino acid ester
2-(2-furanyl)-4-thiazolidinecarboxylic acid	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
dihydrosamidine	[no description available]	medium	1	0
N-(2-methoxycyclohexyl)-3,4-dimethylaniline	[no description available]	medium	1	0	methylbenzene
eskazine	[no description available]	medium	1	0
2-(3,4-dimethylphenyl)-5-ethyl-5-phenyl-1,2,4-triazolidine-3-thione	[no description available]	medium	1	0	methylbenzene
2-[3-oxo-1-[[[oxo(thiophen-2-yl)methyl]amino]-sulfanylidenemethyl]-2-piperazinyl]acetic acid propan-2-yl ester	[no description available]	medium	1	0	isopropyl ester; piperazines
monooctanoin	[no description available]	medium	1	0	1-monoglyceride; octanoate ester; rac-1-monoacylglycerol
trimethoprim	[no description available]	medium	1	0
4-hydroxy-1-[1-oxo-2-(phenylmethoxycarbonylamino)propyl]-2-pyrrolidinecarboxylic acid	[no description available]	medium	1	0	peptide
N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(2,3-dimethoxyphenyl)acetamide	[no description available]	medium	1	0	dimethoxybenzene
3-acetyl-6-methyl-1H-quinolin-4-one	[no description available]	medium	1	0	quinolines
3-(phenylthio)-1-(1-pyrrolidinyl)-1-propanone	[no description available]	medium	1	0	aryl sulfide
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide	[no description available]	medium	1	0	imidazolidines
Anthraniloyllycoctonine	[no description available]	medium	1	0	diterpene alkaloid
N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide	[no description available]	medium	1	0	aromatic amide
1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid	[no description available]	medium	1	0	harmala alkaloid
diclofenac sodium	[no description available]	medium	1	0	organic sodium salt
biochanin a	[no description available]	medium	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
prostaglandin b1	[no description available]	medium	1	0	prostaglandins B	human metabolite
prostaglandin f1	[no description available]	medium	3	0	prostaglandins Falpha	human metabolite
timolol maleate	[no description available]	medium	1	0	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
brompheniramine maleate	[no description available]	medium	1	0	maleate salt	anti-allergic agent
zearalenone	[no description available]	medium	1	0	macrolide; resorcinols	fungal metabolite; mycoestrogen
estriol 17-glucuronide	[no description available]	medium	1	0	steroid saponin
tranilast	[no description available]	medium	15	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
4-hydroxyestradiol	[no description available]	medium	1	0	4-hydroxy steroid	metabolite
menatetrenone	[no description available]	medium	1	0	menaquinone	anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent
xylometazoline hydrochloride	[no description available]	medium	1	0
ketotifen fumarate	[no description available]	medium	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
dinoprost tromethamine	[no description available]	medium	1	0	organic molecular entity
hydrocortisone valerate	[no description available]	medium	2	0	cortisol ester; glucocorticoid; primary alpha-hydroxy ketone; valerate ester
prostaglandin f2 methyl ester	[no description available]	medium	1	0	prostanoid
2-bromoergocryptine mesylate	[no description available]	medium	1	0
perhexiline maleate	[no description available]	medium	1	0
phenoxybenzamine hydrochloride	[no description available]	medium	1	0	organic molecular entity
phenylephrine hydrochloride	[no description available]	medium	67	0	hydrochloride
phenylephrine hydrochloride	[no description available]	medium	67	14	hydrochloride
mepyramine maleate	[no description available]	medium	1	0
ethisterone	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	drug metabolite; progestin
nalmefene	[no description available]	medium	2	0	morphinane alkaloid
6alpha-hydroxy-17beta-estradiol	[no description available]	medium	1	0	6alpha-hydroxy steroid
cytochalasin b	[no description available]	medium	21	0	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
u-44619	[no description available]	medium	1	0
furazolidone	[no description available]	medium	1	0
tyrphostin ag 555	[no description available]	medium	1	0
nifuroxazide	[no description available]	medium	1	0	benzoic acids
molsidomine	[no description available]	medium	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
rg 13022	[no description available]	medium	1	0
styrylquinoline	[no description available]	medium	1	0	2-styrylquinoline
kavain	[no description available]	medium	1	0	racemate	glycine receptor antagonist
enalapril maleate	[no description available]	medium	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
trimebutine maleate salt	[no description available]	medium	1	0	trihydroxybenzoic acid
vinblastine sulfate	[no description available]	medium	1	0
vincristine sulfate	[no description available]	medium	1	0
3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one	[no description available]	medium	1	0	isoflavones
(2R)-2-[[(2R,3R,4R)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-2-[(2S,3R,4S,5S)-5-(2,4-dioxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]acetic acid	[no description available]	medium	1	0	peptide
n-methylscopolamine bromide	[no description available]	medium	1	0
naltrexone hydrochloride	[no description available]	medium	1	0	hydrochloride	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
guanabenz acetate	[no description available]	medium	1	0	dichlorobenzene	geroprotector
nylidrin hydrochloride	[no description available]	medium	1	0	alkylbenzene
triprolidine hydrochloride anhydrous	[no description available]	medium	1	0	hydrochloride	H1-receptor antagonist
phentolamine	[no description available]	medium	1	0
fendiline hydrochloride	[no description available]	medium	1	0
tiapridex	[no description available]	medium	1	0	benzamides
nab-365	[no description available]	medium	1	0	hydrochloride	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
dithiazanine iodide	[no description available]	medium	1	0	benzothiazoles; organic iodide salt	anthelminthic drug; fluorochrome
sinequan	[no description available]	medium	1	0	dibenzooxazepine
buflomedil hydrochloride	[no description available]	medium	1	0	aromatic ketone
moxisylyte hydrochloride	[no description available]	medium	1	0	monoterpenoid
dirithromycin	[no description available]	medium	1	0	macrolide antibiotic	prodrug
fluphenazine	[no description available]	medium	1	0
homochlorocyclizine monohydrochloride	[no description available]	medium	1	0
butoxamine hydrochloride	[no description available]	medium	1	0
scopolamine hydrobromide	[no description available]	medium	1	0
protriptyline hydrochloride	[no description available]	medium	1	0	hydrochloride	antidepressant
emetine hydrochloride	[no description available]	medium	1	0
epinephrine bitartrate	[no description available]	medium	1	0
bicuculline methobromide	[no description available]	medium	1	0
6 beta-hydroxycortisol	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mammalian metabolite; probe
butylscopolammonium bromide	[no description available]	medium	2	0
androst-16-en-3-one	[no description available]	medium	1	0	3-oxo steroid; androstanoid	mammalian metabolite; pheromone
butaclamol hydrochloride	[no description available]	medium	1	0
dihydroouabain	[no description available]	medium	1	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; radiosensitizing agent
LSM-6455	[no description available]	medium	1	0	peptide ergot alkaloid
estradiol 17-acetate	[no description available]	medium	1	0	steroid ester
(3aR,6aR)-5-(3-methoxyphenyl)-3-[oxo(2-pyrazinyl)methyl]-3a,6a-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione	[no description available]	medium	1	0	pyrrolidines
3-morpholino-sydnonimine monohydrochloride	[no description available]	medium	1	0
cefotaxime sodium	[no description available]	medium	1	0	organic sodium salt
N-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)-4-pyrazolyl]methyl]-2-(2-pyridinyl)ethanamine	[no description available]	medium	1	0	pyrazoles; ring assembly
bucladesine	[no description available]	medium	231	0	3',5'-cyclic purine nucleotide
ampicillin sodium	[no description available]	medium	1	0	organic sodium salt
penicillin g potassium	[no description available]	medium	1	0	organic potassium salt
piperacillin sodium	[no description available]	medium	1	0	organic sodium salt
cefoxitin sodium	[no description available]	medium	1	0	organic molecular entity
nafcillin sodium	[no description available]	medium	1	0	organic sodium salt
cefamandole nafate	[no description available]	medium	1	0	organic sodium salt	antibacterial drug
sodium diatrizoate	[no description available]	medium	1	0	organic sodium salt; organoiodine compound	radioopaque medium
estrone sulfate, potassium salt	[no description available]	medium	1	0
cefazolin sodium	[no description available]	medium	1	0	organic sodium salt
naproxen sodium	[no description available]	medium	1	0	organic sodium salt	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
oxytetracycline, anhydrous	[no description available]	medium	2	0
piroxicam	[no description available]	medium	8	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
acenocoumarol	[no description available]	medium	1	0	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
mobic	[no description available]	medium	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex	[no description available]	medium	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
demeclocycline hydrochloride	[no description available]	medium	1	0
inosine	[no description available]	high	16	0	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
kf38789	[no description available]	medium	1	0
pralidoxime iodide	[no description available]	medium	1	0	organic iodide salt; pyridinium salt	cholinergic drug; cholinesterase reactivator
pralidoxime chloride	[no description available]	medium	1	0	organic chloride salt; pyridinium salt	cholinergic drug; cholinesterase reactivator
glutamine	[no description available]	high	33	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
asparagine	[no description available]	high	11	0	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
d-glutamate	[no description available]	medium	1	0	D-alpha-amino acid; glutamic acid	Escherichia coli metabolite; mouse metabolite
glutamic acid	[no description available]	high	97	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
pitolisant	[no description available]	medium	6	0	organochlorine compound
pitolisant	[no description available]	medium	6	1	organochlorine compound
sk&f 94482	[no description available]	medium	1	0
quinpirole	[no description available]	medium	9	0	pyrazoloquinoline	dopamine agonist
pramipexole	[no description available]	medium	1	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
jnj-5207852	[no description available]	medium	1	0
porphobilinogen	[no description available]	high	1	0	aralkylamino compound; dicarboxylic acid; pyrroles	Escherichia coli metabolite; metabolite; mouse metabolite
esculetin	[no description available]	medium	5	0	hydroxycoumarin	antioxidant; plant metabolite; ultraviolet filter
esculin	[no description available]	medium	1	0	beta-D-glucoside; hydroxycoumarin	antioxidant; metabolite
beta-escin	[no description available]	medium	29	0
astragaloside a	[no description available]	medium	1	0
silver	[no description available]	medium	16	2	copper group element atom; elemental silver	Escherichia coli metabolite
clozapine n-oxide	[no description available]	medium	1	0	dibenzodiazepine
piperidines	[no description available]	medium	419	32
angiotensin ii	[no description available]	medium	336	3	amino acid zwitterion; angiotensin II	human metabolite
bradykinin	[no description available]	medium	1,332	46	oligopeptide	human blood serum metabolite; vasodilator agent
ovalbumin	[no description available]	medium	609	4
cirsilineol	[no description available]	medium	1	0	dihydroxyflavone; trimethoxyflavone	antineoplastic agent; plant metabolite
prostaglandin d2	[no description available]	medium	183	19	prostaglandins D	human metabolite; mouse metabolite
leukotriene c4	[no description available]	medium	74	4	leukotriene	bronchoconstrictor agent; human metabolite; mouse metabolite
adenosine diphosphate	[no description available]	medium	67	2	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
cadaverine	[no description available]	medium	121	0	alkane-alpha,omega-diamine	Daphnia magna metabolite; Escherichia coli metabolite; mouse metabolite; plant metabolite
pyrogallol	[no description available]	medium	10	0	benzenetriol; phenolic donor	plant metabolite
procyanidin	[no description available]	medium	5	0	proanthocyanidin
carbostyril	[no description available]	medium	20	2	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
quinolinic acid	[no description available]	medium	2	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
nitrites	[no description available]	medium	49	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
thiourea	[no description available]	medium	369	4	one-carbon compound; thioureas; ureas	antioxidant; chromophore
olopatadine hydrochloride	[no description available]	medium	24	5	dibenzooxazepine
thyronines	[no description available]	medium	6	0	thyronine
3-iodothyronamine	[no description available]	medium	2	0	aromatic ether
3-iodothyroacetic acid	[no description available]	medium	3	0
allyl isothiocyanate	[no description available]	medium	3	0	alkenyl isothiocyanate; isothiocyanate	antimicrobial agent; antineoplastic agent; apoptosis inducer; lachrymator; metabolite
oxymatrine	[no description available]	medium	1	0
gold	[no description available]	medium	42	2	copper group element atom; elemental gold
orabase	[no description available]	medium	1	0
mocetinostat	[no description available]	medium	97	10	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
cysteine	[no description available]	medium	66	3	cysteinium	fundamental metabolite
malondialdehyde	[no description available]	medium	29	0	dialdehyde	biomarker
rupatadine	[no description available]	medium	10	2	benzocycloheptapyridine
vasoactive intestinal peptide	[no description available]	medium	131	6
neuromedin b	[no description available]	medium	2	0
neurokinin b	[no description available]	medium	6	0	polypeptide
natriuretic peptide, brain	[no description available]	medium	7	0	polypeptide
osthol	[no description available]	medium	8	0	botanical anti-fungal agent; coumarins	metabolite
substance p	[no description available]	medium	449	15	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
famotidine	[no description available]	medium	96	4	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
dexmedetomidine	[no description available]	medium	3	3	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
resolvin d2	[no description available]	medium	2	0	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; anti-obesity agent; estrogen receptor agonist; human xenobiotic metabolite; rat metabolite
resolvin d1	[no description available]	medium	3	0	hydroxy polyunsaturated fatty acid; resolvin; triol	anti-inflammatory agent
menthol	[no description available]	medium	10	2	p-menthane monoterpenoid; secondary alcohol	volatile oil component
catechin	[no description available]	medium	20	0	catechin	antioxidant; plant metabolite
epigallocatechin gallate	[no description available]	medium	8	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
imidazole	[no description available]	medium	30	0	imidazole
n-acetylneuraminic acid	[no description available]	medium	6	0	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
phenethylamine	[no description available]	medium	23	0	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
phenethylamine	[no description available]	medium	23	1	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
tryptamine	[no description available]	high	39	0	aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines	human metabolite; mouse metabolite; plant metabolite
gingerol	[no description available]	medium	1	0	beta-hydroxy ketone; guaiacols	antineoplastic agent; plant metabolite
1-hexadecyl-2-acetyl-glycero-3-phosphocholine	[no description available]	medium	374	13	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
doxepin	[no description available]	medium	20	7	dibenzooxepine; tertiary amino compound	antidepressant
tetrodotoxin	[no description available]	medium	179	0	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
dibutyl phthalate	[no description available]	medium	3	0
oligonucleotides	[no description available]	medium	9	0
tetrabromobisphenol a	[no description available]	medium	1	0	brominated flame retardant; bromobisphenol
cyclic gmp	[no description available]	medium	239	2	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
18-crown-6	[no description available]	medium	2	0	crown ether; saturated organic heteromonocyclic parent	phase-transfer catalyst
uridine triphosphate	[no description available]	medium	17	0	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
remifentanil	[no description available]	medium	4	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
fluticasone	[no description available]	medium	20	9	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; fluorinated steroid; thioester	anti-allergic agent; anti-asthmatic drug
nadp	[no description available]	medium	18	0
3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one	[no description available]	medium	1	0	coumarins	geroprotector
cadmium	[no description available]	medium	15	0	cadmium molecular entity; zinc group element atom
lactose	[no description available]	medium	13	4	lactose
diminazene	[no description available]	medium	3	0	carboxamidine; triazene derivative	antiparasitic agent; trypanocidal drug
edetic acid	[no description available]	medium	88	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
nafamostat	[no description available]	medium	5	0	benzoic acids; guanidines
n-oleoylethanolamine	[no description available]	medium	7	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
durapatite	[no description available]	medium	2	0
chlorhexidine	[no description available]	medium	1	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
n-hydroxy-2-aminopyrene	[no description available]	medium	1	0
carcinine	[no description available]	medium	18	0	beta-alanine derivative; imidazoles; monocarboxylic acid amide; organonitrogen compound; organooxygen compound	antioxidant; crustacean metabolite
kojic acid	[no description available]	medium	1	0	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
1-anilino-8-naphthalenesulfonate	[no description available]	medium	27	1	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
quercetin	[no description available]	medium	19	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
glycyrrhizic acid	[no description available]	medium	4	0	enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin	EC 3.4.21.5 (thrombin) inhibitor; plant metabolite
ascorbic acid	[no description available]	medium	129	8	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
glycogen	[no description available]	medium	67	0
alpha-asarone	[no description available]	medium	3	0	asarone	anticonvulsant; GABA modulator
cholecystokinin	[no description available]	medium	123	1
cromolyn sodium	[no description available]	medium	248	37	organic sodium salt	anti-asthmatic drug; drug allergen
aripiprazole	[no description available]	medium	2	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
pseudouridine	[no description available]	medium	1	0	pseudouridines	fundamental metabolite
benzofurans	[no description available]	medium	41	0
valencene	[no description available]	medium	1	0	carbobicyclic compound; polycyclic olefin; sesquiterpene
sesquiterpenes	[no description available]	medium	17	1
edetic acid	[no description available]	medium	1	0
hydroxyproline	[no description available]	medium	18	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
chondroitin sulfates	[no description available]	medium	18	0
creatine	[no description available]	medium	19	0	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
pantoprazole	[no description available]	medium	3	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
coenzyme a	[no description available]	medium	5	0	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
methionine	[no description available]	medium	34	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
arginine	[no description available]	medium	141	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
carbachol	[no description available]	medium	957	3	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
leukotriene d4	[no description available]	medium	75	4	dipeptide; leukotriene; organic sulfide	bronchoconstrictor agent; human metabolite; mouse metabolite
brine	[no description available]	medium	1	0
zolpidem	[no description available]	medium	5	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
adenosine monophosphate	[no description available]	medium	80	24	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
interleukin-8	[no description available]	medium	107	11
thiazoles	[no description available]	medium	150	2	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
isoleucine	[no description available]	medium	7	0	aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
threonine	[no description available]	medium	11	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
methane	[no description available]	medium	11	2	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
phenyl acetate	[no description available]	medium	144	8	benzenes; phenyl acetates
aluminum sulfate	[no description available]	medium	2	0	aluminium sulfate
eicosapentaenoic acid	[no description available]	medium	10	2	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
docosapentaenoic acid	[no description available]	medium	1	0	docosapentaenoic acid; omega-3 fatty acid	algal metabolite; human metabolite
thromboplastin	[no description available]	medium	13	0
n-glycolylneuraminic acid	[no description available]	medium	1	0	N-acylneuraminic acid
elastin	[no description available]	medium	3	0	oligopeptide
p-methoxy-n-methylphenethylamine	[no description available]	medium	802	21	aromatic ether; secondary amino compound	metabolite
diacerein	[no description available]	medium	1	0	anthraquinone
rhein	[no description available]	medium	1	0	dihydroxyanthraquinone
tannins	[no description available]	medium	7	0
dimethindene	[no description available]	medium	30	14	indene
cadmium oxide	[no description available]	medium	1	0
clay	[no description available]	medium	1	0
fibrinogen	[no description available]	medium	43	2	iditol	fungal metabolite
berbamine	[no description available]	medium	3	0	phenylpropanoid
palmidrol	[no description available]	medium	3	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
bufotalin	[no description available]	medium	1	0	steroid lactone
dinitrofluorobenzene	[no description available]	medium	19	0	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
dictamnine	[no description available]	medium	1	0	alkaloid antibiotic; organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
carbene	[no description available]	medium	1	0	carbene; methanediyl
tocopherols	[no description available]	medium	2	0
d-alpha tocopherol	[no description available]	medium	26	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
dansyl chloride	[no description available]	medium	6	0	aminonaphthalene; sulfonic acid derivative
chlorine	[no description available]	medium	344	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
vilazodone hydrochloride	[no description available]	medium	1	0	hydrochloride	antidepressant; serotonergic agonist; serotonin uptake inhibitor
dihydroergotamine	[no description available]	medium	12	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
biotin	[no description available]	medium	8	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
diminazene aceturate	[no description available]	medium	1	0	N-acetylglycinate salt	antiparasitic agent; trypanocidal drug
tolonium chloride	[no description available]	medium	22	1
sitagliptin phosphate	[no description available]	medium	1	0
cobalt	[no description available]	medium	24	0	cobalt group element atom; metal allergen	micronutrient
sucrose	[no description available]	medium	36	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
trehalose	[no description available]	medium	1	0	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ceefourin 1	[no description available]	medium	1	0
perovskite	[no description available]	medium	1	0
leukotriene e4	[no description available]	medium	70	7	amino dicarboxylic acid; L-cysteine thioether; leukotriene; non-proteinogenic L-alpha-amino acid; secondary alcohol
formaldehyde	[no description available]	medium	114	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
vonoprazan	[no description available]	medium	3	0	pyrroles
pyrrolidonecarboxylic acid	[no description available]	medium	8	0	5-oxoproline; L-proline derivative; non-proteinogenic L-alpha-amino acid	algal metabolite
manganese	[no description available]	medium	53	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
2,3-naphthalenedicarboxaldehyde	[no description available]	medium	2	0
o-phthalaldehyde	[no description available]	medium	43	0	benzaldehydes; dialdehyde	epitope
naphthalene	[no description available]	medium	4	0	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component
vitamin b 12	[no description available]	medium	63	2
indocyanine green	[no description available]	medium	3	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
D-fructopyranose	[no description available]	medium	18	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
baricitinib	[no description available]	medium	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
erlotinib hydrochloride	[no description available]	medium	1	1	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
luminol	[no description available]	medium	13	1
hydroxyl radical	[no description available]	medium	6	1	oxygen hydride; oxygen radical; reactive oxygen species
iridium	[no description available]	medium	3	1	cobalt group element atom; platinum group metal atom
chlorquinaldol	[no description available]	medium	1	1	monohydroxyquinoline; organochlorine compound	antibacterial drug; antiprotozoal drug; antiseptic drug
europium	[no description available]	medium	1	1	f-block element atom; lanthanoid atom
indigo carmine	[no description available]	medium	2	1
n-methyladenosine	[no description available]	medium	1	1	methyladenosine
nitrogen dioxide	[no description available]	medium	24	6	nitrogen oxide
sodium metabisulfite	[no description available]	medium	5	3	inorganic sodium salt	food antioxidant
zinc oxide	[no description available]	medium	6	3	zinc molecular entity
pyrroles	[no description available]	medium	62	2	pyrrole; secondary amine
melatonin	[no description available]	medium	25	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
dithiothreitol	[no description available]	medium	24	1	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
lead	[no description available]	medium	19	2	carbon group element atom; elemental lead; metal atom	neurotoxin
nickel	[no description available]	medium	36	2	metal allergen; nickel group element atom	epitope; micronutrient
hydrogen sulfide	[no description available]	medium	2	1	gas molecular entity; hydracid; mononuclear parent hydride; sulfur hydride	Escherichia coli metabolite; genotoxin; metabolite; signalling molecule; toxin; vasodilator agent
dimethyl sulfoxide	[no description available]	medium	31	3	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
carmine	[no description available]	medium	1	1
triclosan	[no description available]	medium	5	3	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
protocatechuic acid	[no description available]	medium	1	1	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite
galactose	[no description available]	medium	15	1	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
ethylene glycol	[no description available]	medium	1	1	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
uracil	[no description available]	medium	6	1	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
acebutolol	[no description available]	medium	1	1	alpha-D-glucosyl-(1->4)-D-mannopyranose
hydrogen	[no description available]	medium	48	2	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
shikimic acid	[no description available]	medium	2	1	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid; hydroxy monocarboxylic acid	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
shikimic acid	[no description available]	medium	2	0	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid; hydroxy monocarboxylic acid	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
mitomycin	[no description available]	medium	3	1	mitomycin	alkylating agent; antineoplastic agent
cefepime	[no description available]	medium	1	1	cephalosporin; oxime O-ether	antibacterial drug
mevalonic acid	[no description available]	medium	2	1	3,5-dihydroxy-3-methylpentanoic acid
zeolites	[no description available]	medium	3	1
triazoles	[no description available]	medium	79	2	1,2,3-triazole
ma-1	[no description available]	medium	1	1	carboxamidine; organochlorine compound; pyrimidone; pyrrolidines	antineoplastic agent; EC 2.4.2.4 (thymidine phosphorylase) inhibitor
regorafenib	[no description available]	medium	1	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
sulfites	[no description available]	medium	16	4	divalent inorganic anion; sulfur oxide; sulfur oxoanion
erythrosine	[no description available]	medium	54	2
arginine vasopressin	[no description available]	medium	67	1	vasopressin	cardiovascular drug; hematologic agent; mitogen
glucose, (beta-d)-isomer	[no description available]	medium	65	0	D-glucopyranose	epitope; mouse metabolite
alpha-synuclein	[no description available]	medium	4	0
pheophytin a	[no description available]	medium	1	0
(4-24)-ply(a)	[no description available]	medium	1	0
hydrogen carbonate	[no description available]	medium	120	0	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
6-cyano-7-nitroquinoxaline-2,3-dione	[no description available]	medium	5	0	quinoxaline derivative
an2728	[no description available]	medium	1	0	aromatic ether; benzoxaborole; nitrile	antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
oxytocin	[no description available]	medium	136	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
zirconium	[no description available]	medium	1	0	titanium group element atom
terbium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
milnacipran	[no description available]	medium	2	0	acetamides
sb 258585	[no description available]	medium	1	0	piperazines
amygdalin	[no description available]	medium	1	0
bw 723c86	[no description available]	medium	1	0
transforming growth factor beta	[no description available]	medium	25	0
2-aminoethoxydiphenyl borate	[no description available]	medium	9	0	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
1-methyl-3-isobutylxanthine	[no description available]	medium	161	0	3-isobutyl-1-methylxanthine
thromboxanes	[no description available]	medium	55	2
salophen	[no description available]	medium	1	0
aluminum oxide	[no description available]	medium	2	0
maleic anhydride	[no description available]	medium	2	0	cyclic dicarboxylic anhydride; furans	allergen
fluorides	[no description available]	medium	50	0	halide anion; monoatomic fluorine
mercury	[no description available]	medium	10	0	elemental mercury; zinc group element atom	neurotoxin
magnolin	[no description available]	medium	1	0
lignans	[no description available]	medium	11	0
methanol	[no description available]	medium	35	2	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
dimethyl sulfide	[no description available]	medium	2	0	aliphatic sulfide	algal metabolite; bacterial xenobiotic metabolite; EC 3.5.1.4 (amidase) inhibitor; Escherichia coli metabolite; marine metabolite
hesperidin	[no description available]	medium	6	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
stachyose	[no description available]	medium	1	0	raffinose family oligosaccharide; tetrasaccharide	mouse metabolite; plant metabolite
nitroarginine	[no description available]	medium	39	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
phenylephrine	[no description available]	medium	198	5	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
phosphoserine	[no description available]	medium	5	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
phosphotyrosine	[no description available]	medium	8	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
paxilline	[no description available]	medium	5	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
dinitrochlorobenzene	[no description available]	medium	31	0	C-nitro compound; monochlorobenzenes	allergen; epitope; sensitiser
bulleyaconitine a	[no description available]	medium	1	0
aconitine	[no description available]	medium	2	0
hyaluronoglucosaminidase	[no description available]	medium	75	0
involucrin	[no description available]	medium	3	0
lissamine rhodamine b	[no description available]	medium	1	0
tussilagone	[no description available]	medium	1	0
1,3-dipropyl-8-phenylxanthine	[no description available]	medium	1	0	oxopurine
tetraethoxysilane	[no description available]	medium	1	0
tellurium	[no description available]	medium	2	0	chalcogen; metalloid atom
titanium	[no description available]	medium	7	1	titanium group element atom
cadmium telluride	[no description available]	medium	1	0
titanium dioxide	[no description available]	medium	6	0	titanium oxides	food colouring
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene	[no description available]	medium	4	0	BODIPY compound
gastrin-releasing peptide	[no description available]	medium	17	0
vitamin b 6	[no description available]	medium	6	0
betadex	[no description available]	medium	6	0	cyclodextrin
potassium chloride	[no description available]	medium	352	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
acrolein	[no description available]	medium	8	1	enal	herbicide; human xenobiotic metabolite; toxin
cinnamaldehyde	[no description available]	medium	4	1	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
ammonium hydroxide	[no description available]	medium	58	1	azane; gas molecular entity; mononuclear parent hydride	EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant
melanotan-ii	[no description available]	medium	1	0	organic molecular entity
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine	[no description available]	medium	1	1	benzoxazole
gefitinib	[no description available]	medium	1	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
carboplatin	[no description available]	medium	4	1
1,2-epoxyhexane	[no description available]	medium	1	1
peroxynitrous acid	[no description available]	medium	4	1	nitrogen oxoacid
dapoxetine	[no description available]	medium	1	1	naphthalenes
calcium borate	[no description available]	medium	1	1
acetylcellulose	[no description available]	medium	1	1
thulium	[no description available]	medium	1	1	f-block element atom; lanthanoid atom
1,n(6)-ethenoadenine	[no description available]	medium	1	1	imidazo[2,1-i]purine	mutagen
permanganate	[no description available]	medium	1	1	manganese oxoacid
uranium	[no description available]	medium	2	1	actinoid atom; f-block element atom; monoatomic uranium
lopinavir	[no description available]	medium	3	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
caprolactam	[no description available]	medium	1	1	caprolactams	human blood serum metabolite
ozone	[no description available]	medium	56	5	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
isopropyl myristate	[no description available]	medium	1	1	fatty acid ester
muscone	[no description available]	medium	1	1
sorbitan monooleate	[no description available]	medium	1	1	fatty acid ester
arsenic	[no description available]	medium	13	1	metalloid atom; pnictogen	micronutrient
docetaxel anhydrous	[no description available]	medium	3	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
baicalein	[no description available]	medium	4	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
heme	[no description available]	medium	11	1
baicalin	[no description available]	medium	2	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
citric acid, anhydrous	[no description available]	medium	36	2	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
deoxycytidine	[no description available]	medium	2	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cellulose	[no description available]	medium	16	1	glycoside
phosphorus	[no description available]	medium	39	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
isoflurane	[no description available]	medium	10	1	organofluorine compound	inhalation anaesthetic
ketamine	[no description available]	medium	34	4	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
methadone	[no description available]	medium	9	2	benzenes; diarylmethane; ketone; tertiary amino compound
chitosan	[no description available]	medium	10	1
ethylene	[no description available]	medium	2	1	alkene; gas molecular entity	plant hormone; refrigerant
cholecalciferol	[no description available]	medium	6	1	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
voriconazole	[no description available]	medium	1	1	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
sulfur dioxide	[no description available]	medium	30	2	sulfur oxide	Escherichia coli metabolite; food bleaching agent; refrigerant
catalpol	[no description available]	medium	1	1
glucagon	[no description available]	medium	156	1	peptide hormone
propylene glycol	[no description available]	medium	4	3	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
ritonavir	[no description available]	medium	1	1	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
gemcitabine	[no description available]	medium	2	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
imatinib mesylate	[no description available]	medium	4	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
thiamethoxam	[no description available]	medium	1	1	1,3-thiazoles; 2-nitroguanidine derivative; organochlorine compound; oxadiazane	antifeedant; carcinogenic agent; environmental contaminant; neonicotinoid insectide; xenobiotic
axitinib	[no description available]	medium	1	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
menaquinone 6	[no description available]	medium	1	1
menaquinone 7	[no description available]	medium	1	1	menaquinone	bone density conservation agent; cofactor; Escherichia coli metabolite; human blood serum metabolite; Mycoplasma genitalium metabolite
quinoxalines	[no description available]	medium	17	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
thiophenes	[no description available]	medium	38	5	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
benzoxazoles	[no description available]	medium	4	1	1,3-benzoxazoles; mancude organic heterobicyclic parent
glycolipids	[no description available]	medium	6	1
nitrates	[no description available]	medium	24	2	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
galactose	[no description available]	medium	41	1
2,3-bis(bromomethyl)quinoxaline-1,4-dioxide	[no description available]	medium	1	1
apigenin	[no description available]	medium	3	0	trihydroxyflavone	antineoplastic agent; metabolite
phloretin	[no description available]	medium	11	0	dihydrochalcones	antineoplastic agent; plant metabolite
nootkatone	[no description available]	medium	1	0	carbobicyclic compound; enone; sesquiterpenoid	fragrance; insect repellent; plant metabolite
ng-nitroarginine methyl ester	[no description available]	medium	145	3	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
chlorogenic acid	[no description available]	medium	6	0	cinnamate ester; tannin	food component; plant metabolite
icatibant	[no description available]	medium	13	1
mannose	[no description available]	medium	9	0	D-aldohexose; D-mannose; mannopyranose	metabolite
trimethyloxamine	[no description available]	medium	1	0	tertiary amine oxide	Escherichia coli metabolite; metabolite; osmolyte
8-hydroxy-2'-deoxyguanosine	[no description available]	medium	1	0	guanosines	biomarker
thioctic acid	[no description available]	medium	9	0	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
2-methylpentane	[no description available]	medium	3	0	alkane
osteoprotegerin	[no description available]	medium	4	0	long-chain fatty acid
elafin	[no description available]	medium	1	0
peroxymonosulfate	[no description available]	medium	1	0	sulfur oxide; sulfur oxoanion
glycerophosphoinositol 4,5-bisphosphate	[no description available]	medium	6	0
fmrfamide	[no description available]	medium	12	0
cannabidiol	[no description available]	medium	2	0	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
pyridoxal phosphate	[no description available]	medium	50	0	methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate	coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hydroxyethyl methacrylate	[no description available]	medium	1	0	enoate ester	allergen; polymerisation monomer
almorexant	[no description available]	medium	3	0	isoquinolines
resolvin d5	[no description available]	medium	1	0
5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid	[no description available]	medium	1	0	hydroxy polyunsaturated fatty acid; long-chain fatty acid; nonclassic icosanoid; resolvin; triol	anti-inflammatory agent; human xenobiotic metabolite
perampanel	[no description available]	medium	2	0	bipyridines; nitrile; pyridone	AMPA receptor antagonist; anticonvulsant
diphenylcyclopropenone	[no description available]	medium	1	0	cyclopropenone	drug allergen; hapten; photosensitizing agent
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline	[no description available]	medium	2	0	naphthalenes; sulfonic acid derivative
mannans	[no description available]	medium	3	0
chiniofon	[no description available]	medium	11	0
viridicatol	[no description available]	medium	1	0
pregabalin	[no description available]	medium	1	1	gamma-amino acid	anticonvulsant; calcium channel blocker
imiquimod	[no description available]	medium	5	0	imidazoquinoline	antineoplastic agent; interferon inducer
endothelin-1	[no description available]	medium	45	1
luteolin	[no description available]	medium	5	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
gastrins	[no description available]	medium	962	17
picryl chloride	[no description available]	medium	13	0	C-nitro compound; monochlorobenzenes	allergen; epitope; explosive; hapten
nevadensin	[no description available]	medium	1	0	dihydroxyflavone; trimethoxyflavone	plant metabolite
fluorescein-5-isothiocyanate	[no description available]	medium	54	0	fluorescein isothiocyanate
gw9508	[no description available]	medium	1	0	aromatic amine
tak-875	[no description available]	medium	1	0	biphenyls
phencyclidine	[no description available]	medium	133	12	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
histamine phosphate	[no description available]	medium	90	13	phosphate salt	histamine agonist
imperatorin	[no description available]	medium	2	0	psoralens	EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite
alpha-fluoromethylhistidine	[no description available]	medium	195	1
alendronate	[no description available]	medium	3	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
hypoxanthine	[no description available]	medium	3	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
cloperastine	[no description available]	medium	1	0	diarylmethane
lysophosphatidylserine	[no description available]	medium	6	0	1-acyl-sn-glycero-3-phosphoserine
cilostamide	[no description available]	medium	1	0	quinolines
9-(2-hydroxy-3-nonyl)adenine	[no description available]	medium	2	0
trifluoromethanesulfonic acid	[no description available]	medium	1	0	one-carbon compound; perfluoroalkanesulfonic acid
lysophosphatidylcholines	[no description available]	medium	23	0	1-O-acyl-sn-glycero-3-phosphocholine
glyoxal	[no description available]	medium	1	0	dialdehyde	agrochemical; allergen; pesticide; plant growth regulator
phenylacetaldehyde	[no description available]	medium	1	0	alpha-CH2-containing aldehyde; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyruvaldehyde	[no description available]	medium	1	0	2-oxo aldehyde; propanals	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
acetaldehyde	[no description available]	medium	27	1	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	[no description available]	medium	1	0	imidazopyridine; primary amino compound	carcinogenic agent; mutagen
stannic oxide	[no description available]	medium	1	0	tin oxide
urea	[no description available]	medium	46	4	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
landiolol	[no description available]	medium	1	0	morpholines
lysophosphatidic acid	[no description available]	medium	1	0	1-acyl-sn-glycerol 3-phosphate
ferric ferrocyanide	[no description available]	medium	1	0
surfactin peptide	[no description available]	medium	1	0
salicylaldehyde	[no description available]	medium	3	0	hydroxybenzaldehyde	nematicide; plant metabolite
ethanolamine	[no description available]	medium	5	0	ethanolamines; primary alcohol; primary amine	Escherichia coli metabolite; human metabolite; mouse metabolite
metoprine	[no description available]	medium	39	0
gentamicin	[no description available]	medium	8	0
sisomicin	[no description available]	medium	1	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
capsazepine	[no description available]	medium	9	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
hc 030031	[no description available]	medium	2	0
arachidonic acid	[no description available]	medium	183	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
methylamine	[no description available]	medium	9	0	methylamines; one-carbon compound; primary aliphatic amine	mouse metabolite
4-methylimidazole	[no description available]	medium	2	0	imidazoles	carcinogenic agent; reaction intermediate
1-methyl-3-ethylimidazolium	[no description available]	medium	1	0	1-alkyl-3-methylimidazolium
beta-endorphin	[no description available]	medium	40	2
blz-100	[no description available]	medium	1	0
caseins	[no description available]	medium	36	1
mivacurium	[no description available]	medium	9	5	isoquinolines
naphthoquinones	[no description available]	medium	8	0
dora-22	[no description available]	medium	1	0
linarin	[no description available]	medium	1	0
glycosides	[no description available]	medium	17	0
nocodazole	[no description available]	medium	6	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
leukotriene b4	[no description available]	medium	139	8	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
thapsigargin	[no description available]	medium	93	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
kynurenine	[no description available]	medium	5	0	aromatic ketone; non-proteinogenic alpha-amino acid; substituted aniline	human metabolite
ferulic acid	[no description available]	medium	2	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
alpha-methylhistamine	[no description available]	medium	87	0	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
alpha-methylhistamine	[no description available]	medium	87	1	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
acetonitrile	[no description available]	medium	4	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
toluene	[no description available]	medium	14	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
trichloroacetic acid	[no description available]	medium	8	1	monocarboxylic acid; organochlorine compound	carcinogenic agent; metabolite; mouse metabolite
taurine	[no description available]	medium	21	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
erdosteine	[no description available]	medium	1	0	N-acyl-amino acid
ginsenoside f2	[no description available]	medium	1	0	12beta-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; plant metabolite
ginsenosides	[no description available]	medium	11	0
ginsenoside m1	[no description available]	medium	2	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; hepatoprotective agent; plant metabolite
carbidopa	[no description available]	medium	6	0
carbidopa, levodopa drug combination	[no description available]	medium	1	0
sinomenine	[no description available]	medium	9	0	morphinane alkaloid
morphinans	[no description available]	medium	15	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
methacrylic acid	[no description available]	medium	2	0	alpha,beta-unsaturated monocarboxylic acid
ethylene dimethacrylate	[no description available]	medium	2	0	enoate ester	allergen; cross-linking reagent; polymerisation monomer
skullcapflavone ii	[no description available]	medium	1	0	dihydroxyflavone; tetramethoxyflavone	anti-asthmatic drug; plant metabolite
nile red	[no description available]	medium	1	0	aromatic amine; cyclic ketone; organic heterotetracyclic compound; tertiary amino compound	fluorochrome; histological dye
tubastatin a	[no description available]	medium	1	0	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
xanthenes	[no description available]	medium	19	1	xanthene
chrysin	[no description available]	medium	1	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
silicon nitride	[no description available]	medium	1	0
n-methylaspartate	[no description available]	medium	26	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
tantalum	[no description available]	medium	4	0	vanadium group element atom
tantalum oxide	[no description available]	medium	1	0
palladium	[no description available]	medium	4	0	metal allergen; nickel group element atom; platinum group metal atom
2-methyl-5-ht	[no description available]	medium	4	0	tryptamines	serotonergic agonist
roflumilast	[no description available]	medium	3	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
tadalafil	[no description available]	medium	1	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
alpha-aminopyridine	[no description available]	medium	48	2
3,4-dihydroxyphenylacetic acid	[no description available]	medium	19	0	catechols; dihydroxyphenylacetic acid	human metabolite
phytic acid	[no description available]	medium	1	0	inositol phosphate
inositol 1,4,5-trisphosphate	[no description available]	medium	97	0	myo-inositol trisphosphate	mouse metabolite
casein kinase ii	[no description available]	medium	1	0
enkephalin, methionine	[no description available]	medium	23	0
oxazolone	[no description available]	medium	7	0
octopamine	[no description available]	medium	37	0	phenylethanolamines; tyramines	neurotransmitter
corilagin	[no description available]	medium	1	0	ellagitannin; gallate ester	antihypertensive agent; antioxidant; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; non-steroidal anti-inflammatory drug
lurasidone hydrochloride	[no description available]	medium	1	0	hydrochloride	adrenergic antagonist; dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
12-o-retinoylphorbol-13-acetate	[no description available]	medium	2	0
yil 781	[no description available]	medium	1	0
strontium	[no description available]	medium	17	1	alkaline earth metal atom
ro13-9904	[no description available]	medium	3	1
phenol	[no description available]	medium	6	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
croton oil	[no description available]	medium	12	0	N-acyl-hexosamine
serine	[no description available]	medium	28	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
butyrolactone i	[no description available]	medium	1	0	butenolide
4-butyrolactone	[no description available]	medium	2	0	butan-4-olide	metabolite; neurotoxin
suplatast tosilate	[no description available]	medium	3	0
g(m1) ganglioside	[no description available]	medium	3	0	alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide
clinoptilolite	[no description available]	medium	1	0
mordenite	[no description available]	medium	1	0
8-hydroxy-2-(di-n-propylamino)tetralin	[no description available]	medium	5	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
cytochalasin e	[no description available]	medium	2	0	cytochalasan alkaloid	metabolite
tetradecanoylphorbol acetate	[no description available]	medium	198	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
blister	[no description available]	medium	1	0	cyclic ketone; pyrroloquinoline; tertiary alcohol; tertiary alpha-hydroxy ketone	inhibitor
2,3,5,6-tetrafluorobenzenethiol	[no description available]	medium	1	0
cyclohexanone	[no description available]	medium	1	0	cyclohexanones	human xenobiotic metabolite
tiletamine hydrochloride	[no description available]	medium	4	0
chrysophanic acid	[no description available]	medium	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
fluorescamine	[no description available]	medium	14	0
5,6-dihydroxy-7,9,11,14-eicosatetraenoic acid	[no description available]	medium	1	0
s 1743	[no description available]	medium	3	0	magnesium salt	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
biocytin	[no description available]	medium	3	0	azabicycloalkane; L-alpha-amino acid zwitterion; L-lysine derivative; monocarboxylic acid amide; non-proteinogenic L-alpha-amino acid; thiabicycloalkane; ureas	mouse metabolite
cordycepin	[no description available]	medium	1	0	3'-deoxyribonucleoside; adenosines	antimetabolite; nucleoside antibiotic
hexamethonium	[no description available]	medium	45	1	quaternary ammonium salt
proline	[no description available]	medium	17	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
prolyl-glycyl-proline	[no description available]	medium	2	0	peptide
n-oleoyldopamine	[no description available]	medium	1	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide	TRPV1 agonist
phorbolol myristate acetate	[no description available]	medium	4	0
geraniol	[no description available]	medium	1	0	3,7-dimethylocta-2,6-dien-1-ol; monoterpenoid; primary alcohol	allergen; fragrance; plant metabolite; volatile oil component
calcimycin	[no description available]	medium	242	0	benzoxazole
fluorine	[no description available]	medium	10	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
betulinic acid	[no description available]	medium	3	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
concanavalin a	[no description available]	medium	104	0
spiradoline	[no description available]	medium	2	0
adrenomedullin	[no description available]	medium	7	0
rotenone	[no description available]	medium	5	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
muramidase	[no description available]	medium	49	3
hydroxychloroquine	[no description available]	medium	1	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
sapropterin	[no description available]	medium	3	0	5,6,7,8-tetrahydrobiopterin	coenzyme; cofactor; diagnostic agent; human metabolite
montelukast	[no description available]	medium	16	6	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
coptisine	[no description available]	medium	1	0	alkaloid	metabolite
berberine	[no description available]	medium	7	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
epinastine	[no description available]	medium	18	6	benzazepine; guanidines	anti-allergic agent; H1-receptor antagonist; histamine antagonist; ophthalmology drug
zoledronic acid	[no description available]	medium	3	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
uric acid	[no description available]	medium	25	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
cytosine	[no description available]	medium	3	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
trimellitic anhydride	[no description available]	medium	2	0	2-benzofurans; cyclic dicarboxylic anhydride; dioxo monocarboxylic acid	allergen; epitope; hapten
2-aminoadipic acid	[no description available]	medium	2	1	amino dicarboxylic acid; dicarboxylic fatty acid; non-proteinogenic alpha-amino acid	Caenorhabditis elegans metabolite; mammalian metabolite
fibrinopeptide a	[no description available]	medium	2	2
allysine	[no description available]	medium	1	0	allysine; amino acid zwitterion; aminoadipate semialdehyde; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
allysine	[no description available]	medium	1	1	allysine; amino acid zwitterion; aminoadipate semialdehyde; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thymoquinone	[no description available]	medium	4	0	1,4-benzoquinones	adjuvant; anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; cardioprotective agent; plant metabolite
hydroxyurea	[no description available]	medium	16	3	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
physcione	[no description available]	medium	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite
emodin	[no description available]	medium	3	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
colistin	[no description available]	medium	6	0
agar	[no description available]	medium	14	0
rn 1747	[no description available]	medium	1	0
rn 1734	[no description available]	medium	1	0
hc-067047	[no description available]	medium	1	0
homocysteine	[no description available]	medium	17	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
laccase	[no description available]	medium	1	0
propyl gallate	[no description available]	medium	1	0	trihydroxybenzoic acid
isoamylamine	[no description available]	medium	1	0	primary aliphatic amine	bacterial metabolite; plant metabolite
pci 32765	[no description available]	medium	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1,3,4-oxadiazole	[no description available]	medium	1	0
lupane	[no description available]	medium	1	0
oxadiazoles	[no description available]	medium	15	0
ecallantide	[no description available]	medium	2	0
sodium hypochlorite	[no description available]	medium	6	0	inorganic sodium salt	bleaching agent; disinfectant
enkephalin, ala(2)-mephe(4)-gly(5)-	[no description available]	medium	6	0
fluticasone furoate	[no description available]	medium	2	2	11beta-hydroxy steroid; 2-furoate ester; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; steroid ester; thioester	anti-allergic agent; anti-asthmatic drug; prodrug
itaconic acid	[no description available]	medium	1	0	dicarboxylic acid; dicarboxylic fatty acid; olefinic compound	fungal metabolite; human metabolite
n(1)-methylnicotinamide	[no description available]	medium	1	0	pyridinium ion	algal metabolite; anti-inflammatory agent; human urinary metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
3,3',4,5'-tetrahydroxystilbene	[no description available]	medium	1	0	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
stilbenes	[no description available]	medium	18	0	stilbene
neurokinin a	[no description available]	medium	50	3
anandamide	[no description available]	medium	3	0	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
phenylmethylsulfonyl fluoride	[no description available]	medium	1	0	acyl fluoride	serine proteinase inhibitor
virodhamine	[no description available]	medium	1	0	fatty acid ester
muscimol	[no description available]	medium	18	0	alkaloid; isoxazoles; primary amino compound	fungal metabolite; GABA agonist; oneirogen; psychotropic drug
bicuculline	[no description available]	medium	17	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
lauric acid	[no description available]	medium	3	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite
chlorin p6	[no description available]	medium	2	0
thromboxane a2	[no description available]	medium	95	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
ginkgolide b	[no description available]	medium	16	1
n-arachidonylglycine	[no description available]	medium	1	0	fatty amide; N-acylglycine
ag 3-5	[no description available]	medium	1	0	C-nitro compound
pyrimidinones	[no description available]	medium	28	1
glutathione disulfide	[no description available]	medium	1	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
methylimidazoleacetic acid	[no description available]	medium	58	0	imidazoles; monocarboxylic acid	GABA agonist; metabolite
methylimidazoleacetic acid	[no description available]	medium	58	1	imidazoles; monocarboxylic acid	GABA agonist; metabolite
iodine	[no description available]	medium	38	0	diatomic iodine	nutrient
iodine	[no description available]	medium	38	1	diatomic iodine	nutrient
u 73122	[no description available]	medium	21	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
4-amylcinnamoylanthranilic acid	[no description available]	medium	1	0	amidobenzoic acid; cinnamamides; secondary carboxamide	EC 3.1.1.4 (phospholipase A2) inhibitor; TRP channel blocker
staurosporine	[no description available]	medium	40	0	ammonium ion derivative
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc	[no description available]	medium	3	0	amino tetrasaccharide; glucosamine oligosaccharide	epitope
colforsin	[no description available]	medium	214	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
potassium bromide	[no description available]	medium	1	0	potassium salt
fpl 64176	[no description available]	medium	1	0	carboxylic ester; pyrroles	calcium channel agonist
bromide	[no description available]	medium	12	0	halide anion; monoatomic bromine
sodium hydroxide	[no description available]	medium	10	0	alkali metal hydroxide
neopterin	[no description available]	medium	2	0
y 27632	[no description available]	medium	16	0	aromatic amide
sphingosine	[no description available]	medium	18	0	sphing-4-enine	human metabolite; mouse metabolite
sphingosine 1-phosphate	[no description available]	medium	9	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
caulerpin	[no description available]	medium	1	0
nitroglycerin	[no description available]	medium	90	2	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
sophoricoside	[no description available]	medium	1	0	acrovestone; isoflavonoid
myelin oligodendrocyte glycoprotein (35-55)	[no description available]	medium	4	0
dehydroepiandrosterone	[no description available]	medium	5	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
bisphenol a	[no description available]	medium	3	0	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
fulvestrant	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
u 0126	[no description available]	medium	9	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
fura-2	[no description available]	medium	102	0
atrial natriuretic factor	[no description available]	medium	36	5	polypeptide
alloxan	[no description available]	medium	13	0	pyrimidone	hyperglycemic agent; metabolite
ginsenoside rk1	[no description available]	medium	1	0
2-octanol	[no description available]	medium	1	1	octanol; secondary alcohol	plant metabolite; volatile oil component
brefeldin a	[no description available]	medium	4	1	macrolide antibiotic	Penicillium metabolite
mefloquine	[no description available]	medium	2	1
glycidyl nitrate	[no description available]	medium	4	0
tangeretin	[no description available]	medium	1	0	pentamethoxyflavone	antineoplastic agent; plant metabolite
nobiletin	[no description available]	medium	1	0	methoxyflavone	antineoplastic agent; plant metabolite
saccharin	[no description available]	medium	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
2-amino-5-phosphonovalerate	[no description available]	medium	8	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
dizocilpine maleate	[no description available]	medium	14	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
sodium glutamate	[no description available]	medium	4	0	monosodium glutamate	flavouring agent
quassin	[no description available]	medium	1	0	triterpenoid
barium chloride	[no description available]	medium	28	0	barium salt; inorganic chloride	potassium channel blocker
1,1-diphenyl-2-picrylhydrazyl	[no description available]	medium	2	0
phenanthrene	[no description available]	medium	4	0	ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon; phenanthrenes	environmental contaminant; mouse metabolite
phenanthrenes	[no description available]	medium	9	0
kaempferol	[no description available]	medium	7	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
deuterium	[no description available]	medium	17	0	dihydrogen
trinitrobenzenesulfonic acid	[no description available]	medium	10	0	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
5-aminoindole	[no description available]	medium	1	0	indolamine
denbufylline	[no description available]	medium	1	0	oxopurine
org 30029	[no description available]	medium	1	0
rocuronium	[no description available]	medium	6	3	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide	[no description available]	medium	12	0
3,6-anhydrogalactose	[no description available]	medium	1	0	aldehyde; anhydrohexose
spinochrome a	[no description available]	medium	1	0
1,4-naphthoquinone	[no description available]	medium	1	0	1,4-naphthoquinones
alpha,beta-methyleneadenosine 5'-triphosphate	[no description available]	medium	10	0	nucleoside triphosphate analogue
tiotropium bromide	[no description available]	medium	3	0
olodaterol	[no description available]	medium	2	0	aromatic ether; benzoxazine; phenols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
dieckol	[no description available]	medium	1	0	aromatic ether; oxacycle; phlorotannin	anticoagulant; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; metabolite; radical scavenger
oleanolic acid	[no description available]	medium	6	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
oleanonic acid	[no description available]	medium	1	0
allyl sulfide	[no description available]	medium	1	0	organic sulfide
lactoferrin	[no description available]	medium	13	2
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one	[no description available]	medium	4	0
sodium arsenite	[no description available]	medium	2	0	arsenic molecular entity; inorganic sodium salt	antibacterial agent; antifungal agent; antineoplastic agent; carcinogenic agent; herbicide; insecticide; rodenticide
okadaic acid	[no description available]	medium	10	0	ketal
ns 1619	[no description available]	medium	2	0	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener
cardiovascular agents	[no description available]	medium	28	1
picrotoxin	[no description available]	medium	10	0
thymol	[no description available]	medium	1	0	monoterpenoid; phenols	volatile oil component
guanosine 5'-o-(3-thiotriphosphate)	[no description available]	medium	43	0	nucleoside triphosphate analogue
gamma-sitosterol	[no description available]	medium	2	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols	marine metabolite; plant metabolite
cytellin	[no description available]	medium	2	0
dihydrostreptomycin sulfate	[no description available]	medium	2	0
stearates	[no description available]	medium	1	0
vitamin k 1	[no description available]	medium	2	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
sodium dodecyl sulfate	[no description available]	medium	11	2	organic sodium salt	detergent; protein denaturant
sarcosine	[no description available]	medium	2	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
sarkosyl	[no description available]	medium	1	0
galangin	[no description available]	medium	1	0	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
acridine orange	[no description available]	medium	7	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
h 89	[no description available]	medium	13	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
fibrin	[no description available]	medium	29	0	peptide
alpha-methylhistidine	[no description available]	medium	6	0	alpha-methylhistidine
[2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium	[no description available]	medium	1	0	amino acid amide
noscapine	[no description available]	medium	2	0	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
dextromethorphan	[no description available]	medium	4	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
n-formylmethionine leucyl-phenylalanine	[no description available]	medium	80	1	tripeptide
ilaprazole	[no description available]	medium	2	0	benzimidazoles; sulfoxide
thymine	[no description available]	medium	3	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
ruthenium	[no description available]	medium	5	0	iron group element atom; platinum group metal atom
s-adenosylmethionine	[no description available]	medium	51	1	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
trk 820	[no description available]	medium	2	0	phenanthrenes
caffeic acid phenethyl ester	[no description available]	medium	4	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
phenylethyl alcohol	[no description available]	medium	6	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
ammonium sulfate	[no description available]	medium	14	0	ammonium salt; inorganic sulfate salt	fertilizer
neuropeptide y	[no description available]	medium	40	2
sb 705498	[no description available]	medium	2	1
dehydroeffusol	[no description available]	medium	1	0
pituitrin	[no description available]	medium	248	1
2,3,4-tri-o-acetylarabinopyranosyl isothiocyanate	[no description available]	medium	2	0
tramadol	[no description available]	medium	2	0	2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol	adrenergic uptake inhibitor; antitussive; capsaicin receptor antagonist; delta-opioid receptor agonist; kappa-opioid receptor agonist; metabolite; mu-opioid receptor agonist; muscarinic antagonist; nicotinic antagonist; NMDA receptor antagonist; opioid analgesic; serotonergic antagonist; serotonin uptake inhibitor
4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime	[no description available]	medium	1	0
cv 6209	[no description available]	medium	10	0
sk&f 91488	[no description available]	medium	27	0
polidocanol	[no description available]	medium	1	1	hydroxypolyether	hepatotoxic agent; nonionic surfactant; sclerotherapy agent
pyrethrins	[no description available]	medium	2	1
quercetagetin	[no description available]	medium	1	0	flavonols; hexahydroxyflavone	antioxidant; antiviral agent; plant metabolite
decamethrin	[no description available]	medium	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
radolmidine	[no description available]	medium	1	0
piperine	[no description available]	medium	5	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one	[no description available]	medium	41	20	21-hydroxy steroid
3,4-dihydroxyphenylethanol	[no description available]	medium	2	0	catechols; primary alcohol	antineoplastic agent; antioxidant; metabolite
potassium hydroxide	[no description available]	medium	1	0	alkali metal hydroxide
triiodothyronine	[no description available]	medium	36	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
2-octenal	[no description available]	medium	1	0	oct-2-enal	antifungal agent; volatile oil component
2-hexenal, z-isomer	[no description available]	medium	1	0	2-hexenal	antibacterial agent; flavouring agent; plant metabolite
omega-n-methylarginine	[no description available]	medium	42	2	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
phenolsulfonphthalein	[no description available]	medium	4	0	2,1-benzoxathiole; arenesulfonate ester; phenols; sultone	acid-base indicator; diagnostic agent; two-colour indicator
carbon tetrachloride	[no description available]	medium	13	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
iopromide	[no description available]	medium	4	1	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iohexol	[no description available]	medium	10	2	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine	[no description available]	medium	1	0
cystamine	[no description available]	medium	26	0	organic disulfide; primary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
4-aminobutanol	[no description available]	medium	1	0
bencycloquidium bromide	[no description available]	medium	1	0
sodium acetate	[no description available]	medium	1	0
s-777469	[no description available]	medium	1	0
beta-hederin	[no description available]	medium	2	0	triterpenoid
chloropyramine	[no description available]	medium	7	0	aminopyridine
singlet oxygen	[no description available]	medium	2	0	chalcogen; monoatomic oxygen; nonmetal atom	macronutrient
sphingosine kinase	[no description available]	medium	6	0
cyanates	[no description available]	medium	17	0
methysergide	[no description available]	medium	191	1	ergoline alkaloid
8-bromo cyclic adenosine monophosphate	[no description available]	medium	34	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
phosphoric acid, trisodium salt	[no description available]	medium	1	0	sodium phosphate
ly 392098	[no description available]	medium	1	0
al 8810	[no description available]	medium	1	0	long-chain fatty acid
hydrazine	[no description available]	medium	55	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid	[no description available]	medium	60	0
sq 29548	[no description available]	medium	4	0
17-phenyltrinorprostaglandin e2	[no description available]	medium	2	0	alicyclic ketone; beta-hydroxy ketone; hydroxy monocarboxylic acid; olefinic compound; oxo monocarboxylic acid; prostanoid; secondary alcohol	human metabolite; prostaglandin receptor agonist
pf-04418948	[no description available]	medium	1	0
butamirate	[no description available]	medium	1	1	alkylbenzene
squaric acid dibutyl ester	[no description available]	medium	1	0	cyclic ketone; diether	allergen; immunological adjuvant
f-chemotactic peptide-fluorescein	[no description available]	medium	1	0
galactosyl-(1-3)galactose	[no description available]	medium	1	0	O-acyl carbohydrate
boron	[no description available]	medium	5	0	boron group element atom; metalloid atom; nonmetal atom	micronutrient
leptin	[no description available]	medium	35	0
ergosterol	[no description available]	medium	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
mk 0663	[no description available]	medium	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
aristolochic acid i	[no description available]	medium	1	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
gamma-terpinene	[no description available]	medium	1	0	cyclohexadiene; monoterpene	antioxidant; human xenobiotic metabolite; plant metabolite; volatile oil component
clobetasol	[no description available]	medium	9	6	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone	anti-inflammatory drug; SMO receptor agonist
transforming growth factor alpha	[no description available]	medium	10	0
epsilon-viniferin	[no description available]	medium	1	0	1-benzofurans; polyphenol; stilbenoid	metabolite
dantrolene	[no description available]	medium	7	0	hydrazone; imidazolidine-2,4-dione	muscle relaxant; neuroprotective agent; ryanodine receptor antagonist
isobutyraldehyde	[no description available]	medium	1	0	2-methyl-branched fatty aldehyde; propanals	Saccharomyces cerevisiae metabolite
cesium	[no description available]	medium	12	0	alkali metal atom
cesium chloride	[no description available]	medium	3	0	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent
zd 7288	[no description available]	medium	1	0
thiazolidines	[no description available]	medium	5	0	thiazolidine
nicorandil	[no description available]	medium	4	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
4',5,7-trihydroxy-3,6-dimethoxyflavone	[no description available]	medium	1	0
3-methoxytyramine	[no description available]	medium	2	0	monomethoxybenzene; phenols; phenylethylamine; primary amino compound	biomarker; human blood serum metabolite; human urinary metabolite
imidazoleacetic acid	[no description available]	high	32	0	imidazoles; monocarboxylic acid	metabolite; mouse metabolite
homovanillic acid	[no description available]	medium	14	0	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
peoniflorin	[no description available]	medium	1	0
8-cyclopentyl-1,3-dimethylxanthine	[no description available]	medium	3	0	oxopurine
rifamycins	[no description available]	medium	1	0
bay 11-7082	[no description available]	medium	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
amarogentin	[no description available]	medium	1	0	monosaccharide derivative; secoiridoid glycoside	EC 5.99.1.2 (DNA topoisomerase) inhibitor; metabolite
iridoids	[no description available]	medium	5	0
toluene 2,4-diisocyanate	[no description available]	medium	32	0	toluene meta-diisocyanate	allergen; hapten
gadolinium	[no description available]	medium	9	0	f-block element atom; lanthanoid atom
glycopyrrolate	[no description available]	medium	9	0	organic bromide salt; quaternary ammonium salt
trimethylenediamine	[no description available]	medium	2	0	alkane-alpha,omega-diamine	human metabolite; mouse metabolite; reagent
tryptophol	[no description available]	medium	1	0	indolyl alcohol	auxin; plant metabolite; Saccharomyces cerevisiae metabolite
4-hydroxyphenylethanol	[no description available]	medium	1	0	phenols	anti-arrhythmia drug; antioxidant; cardiovascular drug; fungal metabolite; geroprotector; plant metabolite; protective agent
biliatresone	[no description available]	medium	1	0	aromatic ether; aromatic ketone; benzodioxoles; enone; phenols	plant metabolite; toxin
xe 991, anthracenone	[no description available]	medium	2	0	anthracenes
xanthine	[no description available]	medium	6	0	xanthine	Saccharomyces cerevisiae metabolite
androstane-3,17-diol glucuronide	[no description available]	medium	1	0	steroid ester
androstane-3,17-diol	[no description available]	medium	2	1	17-hydroxy steroid; 3-hydroxy steroid; androstanoid
allatotropin	[no description available]	medium	1	0
inosinic acid	[no description available]	medium	2	0	inosine phosphate; purine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
vortioxetine	[no description available]	medium	1	0	aryl sulfide; N-arylpiperazine	antidepressant; anxiolytic drug; serotonergic agonist; serotonergic antagonist
bambuterol	[no description available]	medium	2	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
2-chloromandelic acid	[no description available]	medium	1	0
glutaral	[no description available]	medium	16	0	dialdehyde	cross-linking reagent; disinfectant; fixative
lactulose	[no description available]	medium	2	1
4-hydroxybenzoic acid	[no description available]	medium	1	1	monohydroxybenzoic acid	algal metabolite; plant metabolite
aldosterone	[no description available]	medium	37	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
fingolimod hydrochloride	[no description available]	medium	2	0	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
procaterol	[no description available]	medium	13	2	quinolines
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	[no description available]	medium	1	0
platinum	[no description available]	medium	7	0	elemental platinum; nickel group element atom; platinum group metal atom
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	[no description available]	medium	1	0	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
1,3-propanediol	[no description available]	medium	1	0	propane-1,3-diols	metabolite; protic solvent
phosphatidylinositol 4-phosphate	[no description available]	medium	2	0
oleylamide	[no description available]	medium	1	0	primary fatty amide	human metabolite; plant metabolite
3-hydroxyflavone	[no description available]	medium	2	0	flavonols; monohydroxyflavone
oxalates	[no description available]	medium	4	0
morin	[no description available]	medium	3	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
tacrolimus	[no description available]	medium	10	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-	[no description available]	medium	3	0
trilostane	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
dihydrotestosterone	[no description available]	medium	3	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
pd 98059	[no description available]	medium	11	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	medium	4	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
magnesium sulfate	[no description available]	medium	13	3	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
isoquercitrin	[no description available]	medium	1	0
formononetin	[no description available]	medium	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
silicon	[no description available]	medium	3	0	carbon group element atom; metalloid atom; nonmetal atom
web 2086	[no description available]	medium	25	1	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
neuropeptide f	[no description available]	medium	1	0
11-cis-retinal	[no description available]	medium	2	0	retinal	chromophore; human metabolite; mouse metabolite
oseltamivir	[no description available]	medium	3	2	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
bilastine	[no description available]	medium	5	3	benzimidazoles
corazonin protein, insect	[no description available]	medium	1	0
valinomycin	[no description available]	medium	6	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
2,4-dinitrophenol	[no description available]	medium	6	0	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
monensin	[no description available]	medium	5	0	cyclic hemiketal; monocarboxylic acid; polyether antibiotic; spiroketal	antifungal agent; coccidiostat; ionophore
piperazine	[no description available]	medium	6	0	azacycloalkane; piperazines; saturated organic heteromonocyclic parent	anthelminthic drug
transferrin	[no description available]	medium	7	0
beta-eudesmol	[no description available]	medium	1	0	carbobicyclic compound; eudesmane sesquiterpenoid; tertiary alcohol	volatile oil component
way 100135	[no description available]	medium	2	0	piperazines
l 703606	[no description available]	medium	1	0
quinuclidines	[no description available]	medium	14	0	quinuclidines; saturated organic heterobicyclic parent
n(6)-cyclohexyladenosine	[no description available]	medium	3	0
nitrilotriacetic acid	[no description available]	medium	1	0	NTA; tricarboxylic acid	carcinogenic agent; nephrotoxic agent
fostriecin	[no description available]	medium	1	0	2-pyranones; olefinic compound; phosphate monoester; polyketide; primary allylic alcohol; secondary allylic alcohol; triol	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; topoisomerase II inhibitor
nitrous oxide	[no description available]	medium	17	5	gas molecular entity; nitrogen oxide	analgesic; bacterial metabolite; food packaging gas; food propellant; general anaesthetic; greenhouse gas; inhalation anaesthetic; NMDA receptor antagonist; raising agent; refrigerant; vasodilator agent
nitrogenase	[no description available]	medium	1	0
cytochrome c-t	[no description available]	medium	3	0
gabexate	[no description available]	medium	4	0	benzoate ester
dimethylsulfonioacetate	[no description available]	medium	1	0	sulfonium betaine
potassium iodide	[no description available]	medium	2	0	potassium salt	expectorant; radical scavenger
intrinsic factor	[no description available]	medium	86	2
l 733060	[no description available]	medium	2	0	piperidines
oxidopamine	[no description available]	medium	18	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
thromboxane b2	[no description available]	medium	92	5	thromboxanes B	human metabolite; mouse metabolite
1-palmitoyl-2-oleoylphosphatidylcholine	[no description available]	medium	1	0
phosphatidylcholines	[no description available]	medium	28	0	1,2-diacyl-sn-glycero-3-phosphocholine
7-epiclusianone	[no description available]	medium	1	0
pancreastatin	[no description available]	medium	22	0
tafluprost	[no description available]	medium	1	0	isopropyl ester; organofluorine compound; prostaglandins Falpha	prostaglandin receptor agonist
sevoflurane	[no description available]	medium	6	0	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
halothane	[no description available]	medium	34	1	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
fluo-3	[no description available]	medium	11	0	xanthene dye	fluorochrome
fura-2-am	[no description available]	medium	11	0
pentagastrin	[no description available]	medium	689	6	organic molecular entity
ribose	[no description available]	medium	11	0	D-ribose; ribopyranose
oxazoles	[no description available]	medium	23	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
organophosphonates	[no description available]	medium	4	0	divalent inorganic anion; phosphite ion
emedastine	[no description available]	medium	11	0	benzimidazoles	anti-allergic agent; antipruritic drug; H1-receptor antagonist
charybdotoxin	[no description available]	medium	11	0
fenamic acid	[no description available]	medium	12	0	aminobenzoic acid; secondary amino compound	membrane transport modulator
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid	[no description available]	medium	19	0	polyamino carboxylic acid; tetracarboxylic acid	chelator
egtazic acid	[no description available]	medium	82	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
vorinostat	[no description available]	medium	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
higenamine	[no description available]	medium	1	0	norcoclaurine
ascorbigen	[no description available]	medium	1	0	indolyl carbohydrate	metabolite
thonzylamine	[no description available]	medium	3	0	methoxybenzenes
rutin	[no description available]	medium	21	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
tubocurarine	[no description available]	medium	95	2	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
diethylamine	[no description available]	medium	3	0	secondary aliphatic amine
pyridine	[no description available]	medium	9	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
ethylenediamine	[no description available]	medium	13	0	alkane-alpha,omega-diamine	GABA agonist
ether	[no description available]	medium	33	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
dimethylethylenediamine	[no description available]	medium	7	0
caprylic aldehyde	[no description available]	medium	1	0	medium-chain fatty aldehyde; n-alkanal; saturated fatty aldehyde	plant metabolite
nonanal	[no description available]	medium	1	0	medium-chain fatty aldehyde; n-alkanal; saturated fatty aldehyde	human metabolite; plant metabolite
iridium oxide	[no description available]	medium	2	0
cyclosporine	[no description available]	medium	23	0
swertiamarin	[no description available]	medium	1	0	glycoside
chymostatin	[no description available]	medium	2	0
coformycin	[no description available]	medium	2	0	coformycins	EC 3.5.4.4 (adenosine deaminase) inhibitor
taurocholic acid	[no description available]	medium	11	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
iloprost	[no description available]	medium	9	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
6-ketoprostaglandin f1 alpha	[no description available]	medium	49	1	prostaglandins Falpha	human metabolite; mouse metabolite
cyn 154806	[no description available]	medium	2	0
dehydroxymethylepoxyquinomicin	[no description available]	medium	2	0
copper sulfate	[no description available]	medium	2	0	metal sulfate	emetic; fertilizer; sensitiser
pyrazole	[no description available]	medium	5	0	pyrazole
lubiprostone	[no description available]	medium	1	0
mastoparan	[no description available]	medium	9	0	mastoparans; peptidyl amide	antimicrobial agent
acetohexamide	[no description available]	medium	1	0
lanthanum	[no description available]	medium	44	0	f-block element atom; lanthanoid atom; scandium group element atom
sr 95531	[no description available]	medium	5	0	methoxybenzenes
aminophylline	[no description available]	medium	108	2	mixture	bronchodilator agent; cardiotonic drug
carbonyl cyanide m-chlorophenyl hydrazone	[no description available]	medium	3	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
salmeterol xinafoate	[no description available]	medium	19	11	naphthoic acid
sb 334867-a	[no description available]	medium	1	0	naphthyridine derivative
1,1'-diethyl-2,2'-cyanine	[no description available]	medium	3	0	1,1'-diethyl-2,2'-cyanine; quinolines
diphenyl sulfide	[no description available]	medium	1	0	aryl sulfide
methylphenylsulfide	[no description available]	medium	1	0	aryl sulfide; benzenes
vanadium	[no description available]	medium	5	0	elemental vanadium; vanadium group element atom	micronutrient
benzoin	[no description available]	medium	1	0	benzoins; secondary alpha-hydroxy ketone	EC 3.1.1.1 (carboxylesterase) inhibitor
sq-23377	[no description available]	medium	52	0	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
hydroxylamine	[no description available]	medium	2	0	hydroxylamines	algal metabolite; bacterial xenobiotic metabolite; EC 1.1.3.13 (alcohol oxidase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; nitric oxide donor; nucleophilic reagent
naltrexazone	[no description available]	medium	1	0
ym 022	[no description available]	medium	14	0
epiglucan	[no description available]	medium	2	0
20-hydroxy-5,8,11,14-eicosatetraenoic acid	[no description available]	medium	1	0	HETE; hydroxy monocarboxylic acid	human metabolite; mouse metabolite
1-aminobenzotriazole	[no description available]	medium	1	0
n-hydroxy-n'-(4-butyl-2-methylphenyl)formamidine	[no description available]	medium	1	0	toluenes
quinazolines	[no description available]	medium	20	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
ciglitazone	[no description available]	medium	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
methylphenidate	[no description available]	medium	5	0	beta-amino acid ester; methyl ester; piperidines
pseudomonas aeruginosa autoinducer	[no description available]	medium	1	0	N-acyl homoserine lactone
homoserine	[no description available]	medium	1	0	amino acid zwitterion; homoserine	algal metabolite; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
tau 284	[no description available]	medium	5	1	organosulfonate salt	anti-allergic agent; H1-receptor antagonist
5-(n-4-chlorobenzyl)-n-(2',4'-dimethyl)benzamil	[no description available]	medium	1	0
ellagic acid	[no description available]	medium	1	0	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
acetylacetone	[no description available]	medium	1	0	beta-diketone
benzo(a)pyrene	[no description available]	medium	4	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
doxantrazole	[no description available]	medium	8	0
phloroglucinol	[no description available]	medium	2	0	benzenetriol; phenolic donor	algal metabolite
cyanides	[no description available]	medium	43	0	pseudohalide anion	EC 1.9.3.1 (cytochrome c oxidase) inhibitor
scoparone	[no description available]	medium	1	0	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite
naringin	[no description available]	medium	1	0	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite
4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2h)-pyridazinone hydrochloride	[no description available]	medium	1	0
mecamylamine	[no description available]	medium	27	0	primary aliphatic amine
1,2-naphthoquinone-4-sulfonate	[no description available]	medium	1	0	arenesulfonic acid; naphthalenone	colorimetric reagent
phosphorylcholine	[no description available]	medium	5	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
sphingosine phosphorylcholine	[no description available]	medium	4	0
fk 156	[no description available]	medium	1	0
diaminopimelic acid	[no description available]	medium	1	0	2,6-diaminopimelic acid; amino acid zwitterion	Escherichia coli metabolite
fr 41565	[no description available]	medium	1	0
lipid a	[no description available]	medium	3	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
ag-490	[no description available]	medium	1	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
sodium selenite	[no description available]	medium	1	0	inorganic sodium salt; selenite salt	nutraceutical
sepharose	[no description available]	medium	7	0
am 251	[no description available]	medium	3	0	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
2-chloro-n(6)cyclopentyladenosine	[no description available]	medium	2	0
8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine	[no description available]	medium	1	0
propane	[no description available]	medium	1	0	alkane; gas molecular entity	food propellant
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine	[no description available]	medium	6	0	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine	[no description available]	medium	1	0
mrs 1191	[no description available]	medium	2	0	cinnamate ester
rs 39604	[no description available]	medium	1	0	hydrochloride	serotonergic antagonist
dihydropyridines	[no description available]	medium	12	0
alpha-fluoromethylhistamine	[no description available]	medium	12	0
sb 203580	[no description available]	medium	9	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
itraconazole	[no description available]	medium	1	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
carebastine	[no description available]	medium	5	1	diarylmethane
neurotensin	[no description available]	medium	43	1	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
alcian blue	[no description available]	medium	9	0
ly 379268	[no description available]	medium	1	0	amino dicarboxylic acid; bridged compound; organic heterobicyclic compound	antipsychotic agent; anxiolytic drug; metabotropic glutamate receptor agonist; neuroprotective agent
1-butanol	[no description available]	medium	10	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
ketanserin	[no description available]	medium	30	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
2-anthramine	[no description available]	medium	1	0	anthracenamine
ifenprodil	[no description available]	medium	2	0	piperidines
cgp 39653	[no description available]	medium	1	0
c-peptide	[no description available]	medium	2	0
benzylamine	[no description available]	medium	12	0	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
carbamylhydrazine	[no description available]	medium	9	0	carbohydrazide; monocarboxylic acid amide; one-carbon compound; ureas
sodium fluoride	[no description available]	medium	41	1	fluoride salt	mutagen
lipoteichoic acid	[no description available]	medium	3	0
s-nitroso-n-acetylpenicillamine	[no description available]	medium	11	0	nitroso compound; nitrosothio compound	nitric oxide donor; vasodilator agent
hederagenin	[no description available]	medium	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin	plant metabolite
kaurenoic acid	[no description available]	medium	1	0
17-hydroxy-ent-kaur-15-en-19-oic acid	[no description available]	medium	1	0	kaurane diterpenoid
diisononyl phthalate	[no description available]	medium	1	0	diester; phthalate ester	plasticiser
diethylhexyl phthalate	[no description available]	medium	1	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
1,1-diethyl-2-hydroxy-2-nitrosohydrazine	[no description available]	medium	1	0	organic anion
dieldrin	[no description available]	medium	2	0	epoxide; organochlorine compound; organochlorine insecticide	carcinogenic agent; xenobiotic
ddt	[no description available]	medium	2	0	benzenoid aromatic compound; chlorophenylethane; monochlorobenzenes; organochlorine insecticide	bridged diphenyl acaricide; carcinogenic agent; endocrine disruptor; persistent organic pollutant
dichlorodiphenyl dichloroethylene	[no description available]	medium	2	0	chlorophenylethylene; monochlorobenzenes	human xenobiotic metabolite; persistent organic pollutant
aica ribonucleotide	[no description available]	medium	1	0	1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole	cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein	[no description available]	medium	6	0
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide	[no description available]	medium	5	0
sulfur	[no description available]	medium	22	1	chalcogen; nonmetal atom	macronutrient
barium	[no description available]	medium	175	0	alkaline earth metal atom; elemental barium
cytochalasin d	[no description available]	medium	11	0
hydrocortisone aceponate	[no description available]	medium	1	1	corticosteroid hormone
panaxynol	[no description available]	medium	1	0	long-chain fatty alcohol
mercuric chloride	[no description available]	medium	6	0	mercury coordination entity	sensitiser
cytidine diphosphate choline	[no description available]	medium	4	1	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
zinc chloride	[no description available]	medium	5	0	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
filipin	[no description available]	medium	3	0
ergonovine	[no description available]	medium	23	1	ergot alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound; primary alcohol; secondary amino compound; tertiary amino compound	diagnostic agent; fungal metabolite; oxytocic; toxin
epidermal growth factor	[no description available]	medium	54	1
aniline	[no description available]	medium	4	0	anilines; primary arylamine
phosgene	[no description available]	medium	2	0	acyl chloride
peptones	[no description available]	medium	52	0
benzylaniline	[no description available]	medium	1	0
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine	[no description available]	medium	3	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
salicylates	[no description available]	medium	70	1	monohydroxybenzoate	plant metabolite
benzophenone	[no description available]	medium	1	0	benzophenones	photosensitizing agent; plant metabolite
acteoside	[no description available]	medium	2	0	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite
echinacoside	[no description available]	medium	1	0	oligosaccharide
bemesetron	[no description available]	medium	1	0
aminopyrine	[no description available]	medium	240	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
digoxigenin	[no description available]	medium	1	0	12beta-hydroxy steroid; 14beta-hydroxy steroid; 3beta-hydroxy steroid; 3beta-sterol	hapten; plant metabolite
iotrolan	[no description available]	medium	2	0	organic molecular entity
kb r7943	[no description available]	medium	5	0
carbamates	[no description available]	medium	22	0	amino-acid anion
sch 23390	[no description available]	medium	2	0	benzazepine
fluorexon	[no description available]	medium	1	0	xanthene dye	fluorochrome
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	[no description available]	medium	1	0	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor
fisetin	[no description available]	medium	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
stearoylethanolamide	[no description available]	medium	1	0	N-acylethanolamine 18:0
sertaconazole	[no description available]	medium	1	0	1-benzothiophenes; dichlorobenzene; ether; imidazoles
mk-0524	[no description available]	medium	1	0	indolyl carboxylic acid
fluorodeoxyglucose f18	[no description available]	medium	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
phytosphingosine	[no description available]	medium	1	0	amino alcohol; sphingoid; triol	mouse metabolite; Saccharomyces cerevisiae metabolite
su 1498	[no description available]	medium	1	0	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
levocabastine	[no description available]	medium	16	6	piperidines
sch 28080	[no description available]	medium	13	0	imidazopyridine
oxymetazoline	[no description available]	medium	19	3	carboxamidine; imidazolines; phenols	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
valine	[no description available]	medium	7	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
1-phenylpropanol	[no description available]	medium	1	0	organic molecular entity
safranal	[no description available]	medium	2	0	monoterpenoid
hydroxyindoleacetic acid	[no description available]	medium	102	1	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
5,7-dihydroxytryptamine	[no description available]	medium	2	0
sk&f-38393	[no description available]	medium	3	0	benzazepine; catechols; secondary amino compound
abarelix	[no description available]	medium	1	0	polypeptide	antineoplastic agent; hormone antagonist
cetrorelix	[no description available]	medium	1	0	oligopeptide	antineoplastic agent; GnRH antagonist
ganirelix	[no description available]	medium	1	0	polypeptide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide	[no description available]	medium	1	0	polypeptide
phosphoramidon	[no description available]	medium	14	1	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
ornithine	[no description available]	medium	12	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
betamethasone	[no description available]	medium	25	4	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
plumbagin	[no description available]	medium	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
camphor, (+-)-isomer	[no description available]	medium	2	1	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
trichloroethylene	[no description available]	medium	7	0	chloroethenes	inhalation anaesthetic; mouse metabolite
motilin	[no description available]	medium	7	1
hydrochloric acid	[no description available]	medium	125	4	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
carbodiimides	[no description available]	medium	8	0	carbodiimide
sulfapyridine	[no description available]	medium	1	0	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic
angiotensinogen	[no description available]	medium	1	0
cgp 52432	[no description available]	medium	1	0	dichlorobenzene
rottlerin	[no description available]	medium	2	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
lysophosphatidylinositol	[no description available]	medium	2	0
ethyl chloride	[no description available]	medium	2	2	chloroethanes	antipruritic drug; inhalation anaesthetic; local anaesthetic
oxatomide	[no description available]	medium	9	1	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
norlapachol	[no description available]	medium	1	0
lapachol	[no description available]	medium	1	0
ono 1078	[no description available]	medium	13	3	chromones
sto 609	[no description available]	medium	1	0	naphthoic acid
naphthalimides	[no description available]	medium	1	0
2-naphthylamine	[no description available]	medium	2	0	naphthylamine	carcinogenic agent
atractylenolide iii	[no description available]	medium	1	0	naphthofuran	metabolite
isocorydine	[no description available]	medium	1	0	aporphine alkaloid
n-methylcorydaldine	[no description available]	medium	1	0	quinolone	metabolite
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate	[no description available]	medium	2	0
theanine	[no description available]	medium	1	0	amino acid zwitterion; N(5)-alkyl-L-glutamine	geroprotector; neuroprotective agent; plant metabolite
naadp	[no description available]	medium	2	0	nicotinic acid dinucleotide	calcium channel agonist; metabolite; signalling molecule
2,2,6,6-tetramethylpiperidin-4-yl heptanoate	[no description available]	medium	1	0	fatty acid ester
ml 7	[no description available]	medium	2	0	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
acetone	[no description available]	medium	7	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
pimagedine	[no description available]	medium	57	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
n(omega)-hydroxyarginine	[no description available]	medium	1	0	amino acid zwitterion; N(5)-[(E)-amino(hydroxyimino)methyl]ornithine; N(5)-[(hydroxyamino)(imino)methyl]ornithine; N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine; N(5)-[amino(hydroxyimino)methyl]-L-ornithine; N(5)-[amino(hydroxyimino)methyl]ornithine; N(omega)-hydroxy-L-arginine
copper adenosine triphosphate	[no description available]	medium	1	0
deoxyglucose	[no description available]	medium	60	0
mdl 100907	[no description available]	medium	2	0
clonazepam	[no description available]	medium	10	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
cgp 37157	[no description available]	medium	9	0	benzothiazepine
triamcinolone	[no description available]	medium	9	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
boranes	[no description available]	medium	1	0	boranes; mononuclear parent hydride
ryanodine	[no description available]	medium	34	0
resiniferatoxin	[no description available]	medium	5	0	carboxylic ester; diterpenoid; enone; monomethoxybenzene; organic heteropentacyclic compound; ortho ester; phenols; tertiary alpha-hydroxy ketone	analgesic; neurotoxin; plant metabolite; TRPV1 agonist
(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	[no description available]	medium	1	0
sb 366791	[no description available]	medium	1	0
sulfuric acid	[no description available]	medium	5	0	sulfur oxoacid	catalyst
kanamycin a	[no description available]	medium	6	0	kanamycins	bacterial metabolite
muromonab-cd3	[no description available]	medium	1	0	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
ethane	[no description available]	medium	2	0	alkane; gas molecular entity	plant metabolite; refrigerant
iberiotoxin	[no description available]	medium	12	0
tram 34	[no description available]	medium	3	0	organochlorine compound
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole	[no description available]	medium	14	0	ether; imidazoles; monomethoxybenzene	TRP channel blocker
prucalopride	[no description available]	medium	2	0	benzamides
insulin detemir	[no description available]	medium	1	1
go 6976	[no description available]	medium	6	0	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
phalloidine	[no description available]	medium	6	0	homodetic cyclic peptide
carvacrol	[no description available]	medium	1	0	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
heparitin sulfate	[no description available]	medium	6	0
purine	[no description available]	medium	3	0	purine
selenium	[no description available]	medium	11	1	chalcogen; nonmetal atom	micronutrient
sodium oxybate	[no description available]	medium	1	0
phorbol-12-myristate	[no description available]	medium	2	0
methionyl-leucyl-phenylalanine	[no description available]	medium	1	0	oligopeptide
marmin	[no description available]	medium	1	0
ezogabine	[no description available]	medium	1	0	carbamate ester; organofluorine compound; secondary amino compound; substituted aniline	anticonvulsant; potassium channel modulator
flupirtine	[no description available]	medium	1	0	aminopyridine
budesonide, formoterol fumarate drug combination	[no description available]	medium	1	1
anidulafungin	[no description available]	medium	1	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
gsk 1004723	[no description available]	medium	1	0
orsellinic acid	[no description available]	medium	1	0	dihydroxybenzoic acid; resorcinols	fungal metabolite; marine metabolite; metabolite
pyocyanine	[no description available]	medium	1	0	iminium betaine; phenazines	antibacterial agent; bacterial metabolite; biological pigment; virulence factor
acetoacetic acid	[no description available]	medium	1	0	3-oxo fatty acid; ketone body	metabolite
carboxymethyl-beta-cyclodextrin	[no description available]	medium	1	0
estradiol 3-benzoate	[no description available]	medium	1	0	17beta-hydroxy steroid; benzoate ester	estrogen receptor agonist; xenoestrogen
tolvaptan	[no description available]	medium	1	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
ovalicin	[no description available]	medium	1	0
concanamycin a	[no description available]	medium	1	0	carbamate ester; concanamycin	antifungal agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; metabolite
gadolinium chloride	[no description available]	medium	2	0	gadolinium coordination entity	TRP channel blocker
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester	[no description available]	medium	7	0
carbenoxolone sodium	[no description available]	medium	6	0	triterpenoid
1-pyrenebutyrate	[no description available]	medium	1	0
n-hydroxysuccinimide	[no description available]	medium	2	0
peracetic acid	[no description available]	medium	1	0	a peroxy acid	disinfectant; oxidising agent
clenbuterol	[no description available]	medium	5	1	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
apelin-12 peptide	[no description available]	medium	1	0	oligopeptide	biomarker; human blood serum metabolite; human metabolite; neuroprotective agent
agnuside	[no description available]	medium	1	0	benzoate ester; beta-D-glucoside; cyclopentapyran; iridoid monoterpenoid; monosaccharide derivative; phenols; terpene glycoside	anti-inflammatory agent; cyclooxygenase 2 inhibitor; plant metabolite; pro-angiogenic agent
ono-ae1-329	[no description available]	medium	3	0
3-methyladenine	[no description available]	medium	1	0
bafilomycin a	[no description available]	medium	3	0
lafutidine	[no description available]	medium	3	0	organic molecular entity
sb 408124	[no description available]	medium	1	0	organohalogen compound; quinolines
td-5108	[no description available]	medium	1	0
tranexamic acid	[no description available]	medium	3	0	amino acid
tetrachloroethylene	[no description available]	medium	1	0	chlorocarbon; chloroethenes	nephrotoxic agent
cyclo(7-aminoheptanoylphenylalanyl-tryptophyl-lysyl-benzylthreonyl)	[no description available]	medium	1	0
ono 4057	[no description available]	medium	1	0
acid phosphatase	[no description available]	medium	38	0
2-methylthio-atp	[no description available]	medium	3	0
hydantoins	[no description available]	medium	3	0	imidazolidine-2,4-dione
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate	[no description available]	medium	11	0	trihydroxybenzoic acid
tetrafluoroaluminate	[no description available]	medium	2	0
sibutramine	[no description available]	medium	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
acetylglucosamine	[no description available]	medium	8	0	N-acetyl-D-glucosamine	epitope
4'-o-methylepigallocatechin	[no description available]	medium	1	0	catechin	metabolite
ethyl cellulose	[no description available]	medium	1	0	glycoside
cyclohexane	[no description available]	medium	1	0	cycloalkane; volatile organic compound	non-polar solvent
methyl nicotinate	[no description available]	medium	2	1	aromatic carboxylic acid; pyridines
rhod-2	[no description available]	medium	1	0
apyrase	[no description available]	medium	1	0
diethyl (ethoxymethylene)malonate	[no description available]	medium	1	0
cetyltrimethylammonium ion	[no description available]	medium	2	0	quaternary ammonium ion
phlorhizin	[no description available]	medium	3	0	aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative	antioxidant; plant metabolite
kn 62	[no description available]	medium	6	0	piperazines
kt 5720	[no description available]	medium	7	0	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
muscarine	[no description available]	medium	17	0	monosaccharide
diamide	[no description available]	medium	1	0	1,1'-azobis(N,N-dimethylformamide)
ginsenoside re	[no description available]	medium	1	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; nephroprotective agent; neuroprotective agent; plant metabolite
ginsenoside rh1	[no description available]	medium	1	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	plant metabolite
panduratin a	[no description available]	medium	1	0	diarylheptanoid	metabolite
aprepitant	[no description available]	medium	2	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
myelin basic protein	[no description available]	medium	10	0
calcium lactate	[no description available]	medium	1	0
mannobiose	[no description available]	medium	2	0	mannobiose
sodium sulfite	[no description available]	medium	3	0	inorganic sodium salt; sulfite salt	food preservative; reducing agent
anethole	[no description available]	medium	1	0	anethole	flavouring agent
estragole	[no description available]	medium	1	0	alkenylbenzene; monomethoxybenzene; phenylpropanoid	carcinogenic agent; flavouring agent; genotoxin; insect attractant; plant metabolite
bafilomycin a1	[no description available]	medium	2	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
carvone	[no description available]	medium	1	0	botanical anti-fungal agent; carvones	allergen
nad	[no description available]	medium	25	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
293b cpd	[no description available]	medium	2	0	1-benzopyran
c.i. 42510	[no description available]	medium	2	0
sulfan blue	[no description available]	medium	2	0	organic molecular entity
beta-escin	[no description available]	medium	9	0	triterpenoid saponin
cinnamamide	[no description available]	medium	1	0	cinnamamide
pholcodine	[no description available]	medium	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; mu-opioid receptor agonist; opioid analgesic
carbon monoxide	[no description available]	medium	16	0	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
dermatan sulfate	[no description available]	medium	3	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine	[no description available]	medium	7	0	adenosines; dicarboxylic acid monoamide; monocarboxylic acid	adenosine A2A receptor agonist; anti-inflammatory agent
tesmilifene	[no description available]	medium	9	0	diarylmethane
mercaptoethanol	[no description available]	medium	17	0	alkanethiol; primary alcohol	geroprotector
aucubin	[no description available]	medium	1	0	organic molecular entity	metabolite
dipyrone	[no description available]	medium	5	0	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
sym-trinitrobenzene	[no description available]	medium	6	0	trinitrobenzene	explosive
oxotremorine m	[no description available]	medium	8	0	quaternary ammonium ion	muscarinic agonist
masoprocol	[no description available]	medium	11	0	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
pramoxine	[no description available]	medium	2	0	aromatic ether; morpholines	local anaesthetic
lfm a13	[no description available]	medium	1	0
s-nitro-n-acetylpenicillamine	[no description available]	medium	3	0
pyrithiamine	[no description available]	medium	3	0
sb 202190	[no description available]	medium	2	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
anabasine	[no description available]	medium	1	0	anabasine
k 76 carboxylic acid	[no description available]	medium	1	0
isorhapontigenin	[no description available]	medium	1	0	stilbenoid
n-(1-methyl-2-phenylethyl)adenosine	[no description available]	medium	1	0
9-methylanthracene	[no description available]	medium	1	0
mibefradil	[no description available]	medium	2	0	tetralins	T-type calcium channel blocker
raclopride	[no description available]	medium	1	0	salicylamides
adenosine-3',5'-cyclic phosphorothioate	[no description available]	medium	9	0	nucleoside 3',5'-cyclic phosphorothioate
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide	[no description available]	medium	1	0	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
nystatin a1	[no description available]	medium	8	0	nystatins
isoluminol	[no description available]	medium	1	0
dithiadene	[no description available]	medium	6	0	dithiadene
casticin	[no description available]	medium	1	0	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite
mci 9038	[no description available]	medium	1	0	peptide
cp 99994	[no description available]	medium	5	0
substance p (6-11)	[no description available]	medium	3	0
guanosine triphosphate	[no description available]	medium	45	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine diphosphate	[no description available]	medium	10	0	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
way 123398	[no description available]	medium	1	0
wogonin	[no description available]	medium	1	0	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
wogonoside	[no description available]	medium	1	0	beta-D-glucosiduronic acid; glycosyloxyflavone; monohydroxyflavone; monomethoxyflavone; monosaccharide derivative
phosphoramidite	[no description available]	medium	1	0
mrs 1220	[no description available]	medium	2	0	quinazolines
dehydroepiandrosterone sulfate	[no description available]	medium	4	0	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
carbonyl cyanide p-trifluoromethoxyphenylhydrazone	[no description available]	medium	7	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
inositol 3-phosphate	[no description available]	medium	8	0
bradykinin, leu(8)-des-arg(9)-	[no description available]	medium	2	0
iodoacetamide	[no description available]	medium	4	0
kynurenic acid	[no description available]	medium	6	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
7-chlorokynurenic acid	[no description available]	medium	1	0	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist
fucose	[no description available]	medium	14	2	fucopyranose; L-fucose	Escherichia coli metabolite; mouse metabolite
tropisetron	[no description available]	medium	6	2	indolyl carboxylic acid
8-epi-prostaglandin f2alpha	[no description available]	medium	2	0	F2-isoprostane	biomarker; bronchoconstrictor agent; vasoconstrictor agent
acetyl chloride	[no description available]	medium	1	0	acyl chloride
ici 118551	[no description available]	medium	8	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
l 365260	[no description available]	medium	11	0	benzodiazepine
cycloheximide	[no description available]	medium	60	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
cathepsin g	[no description available]	medium	3	0
n-acetylsphingosine	[no description available]	medium	2	0	N-acylsphingosine
2,2-bis(bromomethyl)-1,3-propanediol	[no description available]	medium	1	0	primary alcohol
sincalide	[no description available]	medium	31	0	oligopeptide
indolactam v	[no description available]	medium	1	0	indoles
evodiamine	[no description available]	medium	1	0	beta-carbolines
milrinone	[no description available]	medium	6	1	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
pimobendan	[no description available]	medium	3	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
aurintricarboxylic acid	[no description available]	medium	1	0	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist
flunitrazepam	[no description available]	medium	2	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
osteum	[no description available]	medium	2	0	organic molecular entity
oleic acid	[no description available]	medium	6	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
technetium tc 99m pentetate	[no description available]	medium	6	0
cephalosporin c	[no description available]	medium	1	0	cephalosporin	fungal metabolite
dextrothyroxine	[no description available]	medium	2	0
avermectin	[no description available]	medium	1	0
thiazolyl blue	[no description available]	medium	3	1	organic bromide salt	colorimetric reagent; dye
metallothionein	[no description available]	medium	1	0
dehydroleucodine	[no description available]	medium	2	0
dactinomycin	[no description available]	medium	46	0	actinomycin	mutagen
thimerosal	[no description available]	medium	8	0	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
verlukast	[no description available]	medium	8	0
kainic acid	[no description available]	medium	12	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid	[no description available]	medium	2	0	non-proteinogenic alpha-amino acid
domoic acid	[no description available]	medium	1	0	L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid; tricarboxylic acid	algal metabolite; hapten; marine metabolite; neuromuscular agent; neurotoxin
zaprinast	[no description available]	medium	10	0	triazolopyrimidines
siguazodan	[no description available]	medium	5	0	pyridazinone
dronabinol	[no description available]	medium	13	1	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol	[no description available]	medium	1	1
ro 31-8220	[no description available]	medium	14	0	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
ha 1004	[no description available]	medium	2	0	isoquinolines
kt 5823	[no description available]	medium	2	0	gamma-lactam; hemiaminal; indolocarbazole; methyl ester; organic heterooctacyclic compound	EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor
8-((4-chlorophenyl)thio)cyclic-3',5'-gmp	[no description available]	medium	1	0	3',5'-cyclic purine nucleotide; aryl sulfide; organochlorine compound; ribonucleotide	protein kinase agonist
deoxyuridine	[no description available]	medium	2	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
herbimycin	[no description available]	medium	4	0	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
ag-213	[no description available]	medium	1	0
sk&f-96356	[no description available]	medium	1	0
fura-pe3	[no description available]	medium	1	0
s 3226	[no description available]	medium	2	0
deoxycholic acid	[no description available]	medium	6	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
amphotericin b	[no description available]	medium	4	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
l 743,872	[no description available]	medium	1	0
amphotericin b, deoxycholate drug combination	[no description available]	medium	1	0
cisatracurium	[no description available]	medium	7	4	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
trp-lys-tyr-met-val-met	[no description available]	medium	1	0
chloroform	[no description available]	medium	15	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
decamethonium	[no description available]	medium	1	0	quaternary ammonium ion	muscle relaxant; nicotinic acetylcholine receptor agonist
arsenic acid	[no description available]	medium	1	0	arsenic oxoacid	Escherichia coli metabolite
arsphenamine	[no description available]	medium	2	0
tetraphenylborate	[no description available]	medium	2	0
n-vinyl-2-pyrrolidinone	[no description available]	medium	24	0	pyrrolidin-2-ones
propylene	[no description available]	medium	1	0	alkene; gas molecular entity	refrigerant; xenobiotic
alkenes	[no description available]	medium	2	0
nikethamide	[no description available]	medium	4	0	pyridinecarboxamide
indole	[no description available]	medium	5	0	indole; polycyclic heteroarene	Escherichia coli metabolite
curarine	[no description available]	medium	1	0
veratrine	[no description available]	medium	35	0	alkaloid
sodium thiocyanate	[no description available]	medium	5	0	organic sodium salt
allyl formate	[no description available]	medium	1	0
adrenochrome	[no description available]	medium	11	0	indoles
sodium acetate, anhydrous	[no description available]	medium	2	0	organic sodium salt	NMR chemical shift reference compound
barbituric acid	[no description available]	medium	3	0	barbiturates	allergen; xenobiotic
methantheline	[no description available]	medium	5	0	xanthenes
1,10-diaminodecane	[no description available]	medium	1	0
octylamine	[no description available]	medium	3	0	primary aliphatic amine	metabolite
lobeline	[no description available]	medium	9	0
mechlorethamine	[no description available]	medium	8	0	nitrogen mustard; organochlorine compound	alkylating agent
betazole	[no description available]	medium	32	1	primary amino compound; pyrazoles	diagnostic agent; gastrointestinal drug; histamine agonist
ethionine	[no description available]	medium	3	0	S-ethylhomocysteine	antimetabolite; carcinogenic agent
protoverin	[no description available]	medium	2	0
sulfathiazole	[no description available]	medium	1	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
carbon disulfide	[no description available]	medium	2	0	one-carbon compound; organosulfur compound
acridines	[no description available]	medium	10	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
cyclopentane	[no description available]	medium	15	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
2-isopropylaminoethanol	[no description available]	medium	2	0
methyl salicylate	[no description available]	medium	11	0	benzoate ester; methyl ester; salicylates	flavouring agent; insect attractant; metabolite
methyl salicylate	[no description available]	medium	11	3	benzoate ester; methyl ester; salicylates	flavouring agent; insect attractant; metabolite
butyramide	[no description available]	medium	1	0	butanamides; primary fatty amide
diphenyl	[no description available]	medium	2	0	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
sodium salicylate	[no description available]	medium	19	0	organic molecular entity
iodine	[no description available]	medium	15	0	halide anion; monoatomic iodine	human metabolite
am 49	[no description available]	medium	1	0
3-methylcholanthrene	[no description available]	medium	9	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
ergothioneine	[no description available]	medium	4	0	1,3-dihydroimidazole-2-thiones; amino-acid betaine; L-histidine derivative; sulfur-containing amino acid	antioxidant; chelator; fungal metabolite; plant metabolite; xenobiotic metabolite
ammonium chloride	[no description available]	medium	12	1	ammonium salt; inorganic chloride	ferroptosis inhibitor
vitamin u	[no description available]	medium	2	0	methyl-L-methionine; sulfonium betaine
5-hydroxyindole	[no description available]	medium	2	0	hydroxyindoles	human metabolite
indoleacetic acid	[no description available]	medium	13	0	indole-3-acetic acids; monocarboxylic acid	auxin; human metabolite; mouse metabolite; plant hormone; plant metabolite
kallidin	[no description available]	medium	42	1	peptide
azure a	[no description available]	medium	2	0
tartaric acid	[no description available]	medium	3	0	tartaric acid	Escherichia coli metabolite
2-bromolysergic acid diethylamide	[no description available]	medium	2	0
mescaline	[no description available]	medium	11	0	methoxybenzenes; phenethylamine alkaloid; primary amino compound	hallucinogen
guanosine	[no description available]	medium	6	0	guanosines; purines D-ribonucleoside	fundamental metabolite
xanthosine	[no description available]	medium	1	0	purines D-ribonucleoside; xanthosines	Escherichia coli metabolite; human metabolite; mouse metabolite
thallium	[no description available]	medium	2	0	boron group element atom
murexine	[no description available]	medium	1	0
catechol	[no description available]	medium	2	0	catechols	allelochemical; genotoxin; plant metabolite
selenic acid	[no description available]	medium	1	0	selenium oxoacid
methylatropine	[no description available]	medium	7	0
chloralose	[no description available]	medium	14	0
benzo(c)phenanthrene	[no description available]	medium	2	0	benzenoid aromatic compound; ortho-fused polycyclic arene
tetrahydrodeoxycorticosterone	[no description available]	medium	1	0	21-hydroxy steroid
congo red	[no description available]	medium	4	0	bis(azo) compound
1h-tetrazole	[no description available]	medium	1	0	one-carbon compound; tetrazole
malonic acid	[no description available]	medium	2	0	alpha,omega-dicarboxylic acid	human metabolite
fluorescein	[no description available]	medium	13	1	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
allicin	[no description available]	medium	1	0	botanical anti-fungal agent; sulfoxide	antibacterial agent
hydroxydione	[no description available]	medium	1	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-5beta-steroid; primary alpha-hydroxy ketone	human xenobiotic metabolite
radium	[no description available]	medium	2	0	alkaline earth metal atom
azides	[no description available]	medium	12	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
nitrophenols	[no description available]	medium	10	0
carbonic acid	[no description available]	medium	1	0	carbon oxoacid; chalcocarbonic acid	mouse metabolite
pyrathiazine	[no description available]	medium	2	0	phenothiazines
beryllium	[no description available]	medium	2	0	alkaline earth metal atom; elemental beryllium; metal allergen	adjuvant; carcinogenic agent; epitope
thiocyanate	[no description available]	medium	3	0	pseudohalide anion; sulfur molecular entity	human metabolite
poldine	[no description available]	medium	2	0	diarylmethane
propantheline	[no description available]	medium	12	0	xanthenes
5-hydroxytryptophan	[no description available]	medium	60	0	hydroxytryptophan	human metabolite; neurotransmitter
4-hydroxyisophthalic acid	[no description available]	medium	1	0
chromium	[no description available]	medium	6	0	chromium group element atom; metal allergen	micronutrient
phthalic acid	[no description available]	medium	1	0	benzenedicarboxylic acid	human xenobiotic metabolite
theobromine	[no description available]	medium	7	0	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent
1,1'-(4,4,7,7-tetramethyl-4,7-diazaundecamethylene)bis-4-(3-methyl-2,3-dihydro(benzo-1,3-thiazole)-2-methylidene)quinolinium	[no description available]	medium	2	0	cyanine dye; organic iodide salt	fluorochrome
muscarone	[no description available]	medium	1	0
triphosphoric acid	[no description available]	medium	1	0	acyclic phosphorus acid anhydride; phosphorus oxoacid
dimercaprol	[no description available]	medium	4	0	dithiol; primary alcohol	chelator
trimethaphan camsylate	[no description available]	medium	3	0
trimethaphan	[no description available]	medium	8	0	sulfonium compound	anaesthesia adjuvant; antihypertensive agent; nicotinic antagonist; vasodilator agent
hexadimethrine bromide	[no description available]	medium	2	0
lysergic acid	[no description available]	medium	2	0
finalgon ointment	[no description available]	medium	1	0
pempidine	[no description available]	medium	6	0	piperidines
dichloroisoproterenol	[no description available]	medium	11	0
fludrocortisone	[no description available]	medium	5	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
17-ketosteroids	[no description available]	medium	9	0
alpha-chymotrypsin	[no description available]	medium	31	0
azulene	[no description available]	medium	2	0	azulenes; mancude carbobicyclic parent; ortho-fused bicyclic arene	plant metabolite; volatile oil component
neutral red	[no description available]	medium	3	0	hydrochloride	acid-base indicator; dye; two-colour indicator
bulbocapnine	[no description available]	medium	2	0	aporphine alkaloid; aromatic ether; oxacycle; phenols	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; EC 1.4.3.22 (diamine oxidase) inhibitor; plant metabolite
chloropicrin	[no description available]	medium	1	0	C-nitro compound; one-carbon compound; organochlorine compound	antifungal agrochemical; fumigant insecticide; nematicide
1-methylhistidine	[no description available]	medium	2	0	L-histidine derivative; non-proteinogenic L-alpha-amino acid; zwitterion	human metabolite
n-pentyl nitrite	[no description available]	medium	10	0	nitrite esters	vasodilator agent
citrulline	[no description available]	medium	1	0	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
prethcamide	[no description available]	medium	2	0
chlordiazepoxide	[no description available]	medium	13	0	benzodiazepine
hexobarbital	[no description available]	medium	14	0	barbiturates
1-methylimidazole	[no description available]	medium	3	0	imidazoles
arsenic trioxide	[no description available]	medium	1	0
barium sulfate	[no description available]	medium	11	1	barium salt; inorganic barium salt; metal sulfate	radioopaque medium
isoflurophate	[no description available]	medium	11	0	dialkyl phosphate
benactyzine	[no description available]	medium	11	0	diarylmethane
cystine	[no description available]	medium	4	0
lumisantonin	[no description available]	medium	1	0
santonin	[no description available]	medium	1	0	botanical anti-fungal agent; santonin	plant metabolite
bismuth	[no description available]	medium	3	0	metal atom; pnictogen
allantoin	[no description available]	medium	2	0	imidazolidine-2,4-dione; ureas	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite; vulnerary
anthranilic acid	[no description available]	medium	4	0	aminobenzoic acid	human metabolite; mouse metabolite
tetramethylammonium	[no description available]	medium	3	0	quaternary ammonium ion
mandelic acid	[no description available]	medium	6	0	2-hydroxy monocarboxylic acid; benzenes	antibacterial agent; human xenobiotic metabolite
dihydroergotoxine	[no description available]	medium	11	0
copper gluconate	[no description available]	medium	11	0	organic molecular entity
calcium gluconate	[no description available]	medium	4	0	calcium salt	nutraceutical
ethybenztropine	[no description available]	medium	1	0
pheniprazine	[no description available]	medium	2	0	amphetamines
chlorisondamine	[no description available]	medium	14	0	isoindoles
furaldehyde	[no description available]	medium	1	0	aldehyde; furans	Maillard reaction product; metabolite
carbonates	[no description available]	medium	5	1	carbon oxoanion
aminocaproic acid	[no description available]	medium	8	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
eledoisin	[no description available]	medium	51	0	peptide
candicine	[no description available]	medium	1	0	primary amine
pentolinium tartrate	[no description available]	medium	17	0	tartrate salt	antihypertensive agent
mipafox	[no description available]	medium	1	0	phosphoramide
aluminum	[no description available]	medium	12	0	boron group element atom; elemental aluminium; metal atom
angiotensin amide	[no description available]	medium	7	0	oligopeptide
trypan blue	[no description available]	medium	21	0
oxyphenbutazone	[no description available]	medium	9	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
vanillin	[no description available]	medium	2	0	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
1-propanol	[no description available]	medium	6	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
cantharidin	[no description available]	medium	5	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
pronethalol	[no description available]	medium	4	0	naphthalenes
diethylstilbestrol	[no description available]	medium	10	1	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
methiodal	[no description available]	medium	1	0	organosulfonic acid
diatrizoic acid	[no description available]	medium	19	2	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
guanine	[no description available]	medium	6	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
neoarsphenamine	[no description available]	medium	1	0
chondroitin	[no description available]	medium	11	0
iodopyracet	[no description available]	medium	4	0
tin	[no description available]	medium	2	0	carbon group element atom; elemental tin; metal atom	micronutrient
syrosingopine	[no description available]	medium	1	0	yohimban alkaloid
tomatine	[no description available]	medium	3	0
lysergamide	[no description available]	medium	1	0	ergoline alkaloid
dibenzheptropine	[no description available]	medium	1	0	organic tricyclic compound
tetrabenazine	[no description available]	medium	12	0	benzoquinolizine; cyclic ketone; tertiary amino compound
quinoline	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines
flavin-adenine dinucleotide	[no description available]	medium	6	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
cyromazine	[no description available]	medium	1	0	triamino-1,3,5-triazine	mouse metabolite; triazine insecticide
pronarcon	[no description available]	medium	1	0	barbiturates
potassium cyanide	[no description available]	medium	1	0	cyanide salt; one-carbon compound; potassium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; neurotoxin
dibenzylchlorethamine	[no description available]	medium	35	0
parathion	[no description available]	medium	6	0	C-nitro compound; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; mouse metabolite
ubiquinone	[no description available]	medium	4	0
cyclopentamine	[no description available]	medium	1	0	secondary amino compound
formiminoglutamic acid	[no description available]	medium	1	0	dicarboxylic acid; L-glutamic acid derivative
ribosylimidazole acetic acid	[no description available]	medium	3	0	1-ribosylimidazole
meprobamate	[no description available]	medium	11	0	organic molecular entity
amylopectin	[no description available]	medium	1	0
thymidine	[no description available]	medium	47	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
pentaerythritol tetranitrate	[no description available]	medium	1	0	pentaerythritol nitrate	explosive; vasodilator agent
rubidium	[no description available]	medium	21	0	alkali metal atom
veratramine	[no description available]	medium	3	0	piperidine alkaloid
sulfinpyrazone	[no description available]	medium	3	0	pyrazolidines; sulfoxide	uricosuric drug
glucuronic acid	[no description available]	medium	1	0	D-glucuronic acid	algal metabolite
metanephrine	[no description available]	medium	2	0	catecholamine
cinanserin	[no description available]	medium	4	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
thorium dioxide	[no description available]	medium	2	0	thorium molecular entity
phenylacetic acid	[no description available]	medium	2	0	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin
chlorobutanol	[no description available]	medium	1	0	tertiary alcohol
gastrin i	[no description available]	medium	5	0
kaolinite	[no description available]	medium	18	0	aluminosilicate mineral; mixture	antidiarrhoeal drug; excipient
mephenoxalone	[no description available]	medium	1	0	methoxybenzenes
vanilmandelic acid	[no description available]	medium	1	0
mofebutazone	[no description available]	medium	1	0	pyrazolidines	non-narcotic analgesic; non-steroidal anti-inflammatory drug
methylcellulose	[no description available]	medium	8	0
benzyloxyamine	[no description available]	medium	1	0
tropolone	[no description available]	medium	2	0	alpha-hydroxy ketone; cyclic ketone; enol	bacterial metabolite; fungicide; toxin
pyrophosphate	[no description available]	medium	2	0	diphosphate ion
decylamine	[no description available]	medium	2	0	alkylamine
1,2,4-triazole	[no description available]	medium	1	0	1,2,4-triazole
homarine	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid
oxophenarsine	[no description available]	medium	1	0	substituted aniline
diethylcarbamazine	[no description available]	medium	25	0	N-carbamoylpiperazine; N-methylpiperazine
testosterone propionate	[no description available]	medium	2	0	steroid ester
calcium thiosulfate	[no description available]	medium	1	0
thiosulfates	[no description available]	medium	8	0	divalent inorganic anion; sulfur oxide; sulfur oxoanion	human metabolite
silver nitrate	[no description available]	medium	7	0	inorganic nitrate salt; silver salt	astringent
antimycin a	[no description available]	medium	7	0	amidobenzoic acid
diplacin	[no description available]	medium	1	0
8-phenyltheophylline	[no description available]	medium	10	0
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	[no description available]	medium	7	0	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor
bisindolylmaleimide i	[no description available]	medium	17	0
isothiuronium	[no description available]	medium	2	0
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan	[no description available]	medium	2	0
cromakalim	[no description available]	medium	30	1
peptide yy	[no description available]	medium	8	1
bibp 3226	[no description available]	medium	1	0
neuropeptide y (18-36)	[no description available]	medium	1	0
1-naphthol	[no description available]	medium	1	0	naphthol	genotoxin; human xenobiotic metabolite
2-naphthol	[no description available]	medium	5	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
sb 242084	[no description available]	medium	1	0
hypochlorous acid	[no description available]	medium	6	0	chlorine oxoacid; reactive oxygen species	EC 2.5.1.18 (glutathione transferase) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; human metabolite
chloramine	[no description available]	medium	5	0	halide
thymalfasin	[no description available]	medium	1	0	polypeptide
thymosin	[no description available]	medium	4	0
dalteparin	[no description available]	medium	1	0
lisinopril	[no description available]	medium	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid	[no description available]	medium	1	0	(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
chelerythrine	[no description available]	medium	3	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
ethylmaleimide	[no description available]	medium	17	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
phorbol 12,13-dibutyrate	[no description available]	medium	46	0	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
phenylalanyl-leucyl-arginyl phenylalaninamide	[no description available]	medium	4	0
myricetin	[no description available]	medium	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
flavone	[no description available]	medium	1	0	flavones	metabolite; nematicide
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[no description available]	medium	7	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
bromfenac	[no description available]	medium	1	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
8-bromocyclic gmp	[no description available]	medium	12	0	3',5'-cyclic purine nucleotide; organobromine compound	muscle relaxant; protein kinase G agonist
shikonin	[no description available]	medium	2	0	hydroxy-1,4-naphthoquinone
alkannin	[no description available]	medium	2	0	hydroxy-1,4-naphthoquinone
bamipine	[no description available]	medium	1	0	aromatic amine
nitrobenzene	[no description available]	medium	2	0	nitroarene; nitrobenzenes
tuaminoheptane	[no description available]	medium	1	0	alkylamine
terconazole	[no description available]	medium	2	0	1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
sulfanilamide	[no description available]	medium	2	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
hematoxylin	[no description available]	medium	2	0	organic heterotetracyclic compound; oxacycle; polyphenol; tertiary alcohol	histological dye; plant metabolite
phosphorus radioisotopes	[no description available]	medium	16	0
uf 021	[no description available]	medium	1	0	isopropyl ester; ketone; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; prodrug
9-(tetrahydro-2-furyl)-adenine	[no description available]	medium	3	0
nisoxetine	[no description available]	medium	2	0	aromatic ether; secondary amino compound	adrenergic uptake inhibitor; antidepressant
1,7-diaminoheptane	[no description available]	medium	1	0
1,6-diaminohexane	[no description available]	medium	2	0	alkane-alpha,omega-diamine	human xenobiotic metabolite
15-deoxyprostaglandin j2	[no description available]	medium	1	0
cyclopentenone	[no description available]	medium	1	0	alicyclic ketone; enone	Hsp70 inducer
9-deoxy-delta-9-prostaglandin d2	[no description available]	medium	3	0	prostaglandins J	human metabolite
geranylgeranylacetone	[no description available]	medium	2	0
pd 123319	[no description available]	medium	1	0	imidazopyridine	angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent
zd 7155	[no description available]	medium	1	0
tramazoline	[no description available]	medium	1	0	tetralins
gantacurium	[no description available]	medium	2	0
hispidin	[no description available]	medium	1	0	2-pyranones; catechols	antioxidant; EC 2.7.11.13 (protein kinase C) inhibitor; fungal metabolite
linsidomine	[no description available]	medium	9	0	morpholines
molsidomine	[no description available]	medium	9	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
cupric chloride	[no description available]	medium	2	0	copper molecular entity; inorganic chloride	EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
sb 220025	[no description available]	medium	1	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pd 169316	[no description available]	medium	1	0	imidazoles
1-ethyl-2-benzimidazolinone	[no description available]	medium	3	0	imidazoles
n,n-carbonyldiimidazole	[no description available]	medium	1	0
8-isoprostaglandin e2	[no description available]	medium	1	0	cyclic ketone; diol; prostanoid; secondary alcohol	bronchoconstrictor agent; human metabolite; rat metabolite; vasoconstrictor agent
dinitrobenzenes	[no description available]	medium	5	0
ioxaglate	[no description available]	medium	4	2	benzenedicarboxamide; benzoic acids; organoiodine compound	radioopaque medium
fasudil	[no description available]	medium	3	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
ucn 1028 c	[no description available]	medium	9	0
alpha-terpineol	[no description available]	medium	1	1	terpineol	plant metabolite
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol	[no description available]	medium	1	1	terpineol; tertiary alcohol	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiparasitic agent; apoptosis inducer; plant metabolite; volatile oil component
eucalyptol	[no description available]	medium	1	1
cyclohexanol	[no description available]	medium	7	1	cyclohexanols; secondary alcohol	solvent
formal glycol	[no description available]	medium	2	0	cyclic acetal; dioxolane
maleic acid	[no description available]	medium	6	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
methaphenilene	[no description available]	medium	1	0	benzenes
dihydroergocornine	[no description available]	medium	1	0	ergot alkaloid
carbazole	[no description available]	medium	2	0	carbazole
diphenylamine	[no description available]	medium	2	0	aromatic amine; bridged diphenyl fungicide; secondary amino compound	antifungal agrochemical; antioxidant; carotogenesis inhibitor; EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor; ferroptosis inhibitor; radical scavenger
acetamidine	[no description available]	medium	1	0	carboxamidine
furan	[no description available]	medium	2	0	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
fumarates	[no description available]	medium	4	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
caramiphen	[no description available]	medium	1	0	benzenes
quetiapine fumarate	[no description available]	medium	1	0	fumarate salt
gastrin 17	[no description available]	medium	18	0	gastrin	antineoplastic agent
chlorine	[no description available]	medium	17	0	diatomic chlorine; gas molecular entity	bleaching agent
nefopam	[no description available]	medium	1	0	benzoxazocine; tertiary amino compound
gamma-linolenic acid	[no description available]	medium	2	0	linolenic acid; omega-6 fatty acid	human metabolite; mouse metabolite; plant metabolite
adamantane	[no description available]	medium	6	0	adamantanes; polycyclic alkane
u 37883a	[no description available]	medium	4	0
5-carboxamidotryptamine	[no description available]	medium	5	0	tryptamines
formycins	[no description available]	medium	1	0
formycin diphosphate	[no description available]	medium	1	0
obidoxime chloride	[no description available]	medium	1	0
pralidoxime	[no description available]	medium	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
sarin	[no description available]	medium	1	0	fluorine molecular entity; phosphinic ester
proanthocyanidin	[no description available]	medium	1	0
acrylic acid	[no description available]	medium	1	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
fullerene c60	[no description available]	medium	3	0	fullerene	geroprotector
cyclin d1	[no description available]	medium	3	0
hydroxyguanidine	[no description available]	medium	1	0	guanidines; one-carbon compound	antineoplastic agent; antiviral agent
vecuronium bromide	[no description available]	medium	16	10	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
enflurane	[no description available]	medium	5	1	ether; organochlorine compound; organofluorine compound	anaesthetic
inosine triphosphate	[no description available]	medium	6	0	inosine phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
carmoterol	[no description available]	medium	3	0
4-nitrophenylalanine	[no description available]	medium	1	0	C-nitro compound
ly 293558	[no description available]	medium	1	0
tryptophan tryptophylquinone	[no description available]	medium	1	0
genistein	[no description available]	medium	13	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
rtki cpd	[no description available]	medium	3	0
plaunotol	[no description available]	medium	1	0	diterpenoid; primary alcohol	anti-ulcer drug; antibacterial agent; antineoplastic agent; apoptosis inducer; nephroprotective agent; plant metabolite; vulnerary
4-chloro-7-nitrobenzofurazan	[no description available]	medium	1	0	benzoxadiazole; C-nitro compound; organochlorine compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.6.1.3 (adenosinetriphosphatase) inhibitor; fluorescent probe; fluorochrome
7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole	[no description available]	medium	1	0
glucagon-like peptide 1	[no description available]	medium	10	0
galantide	[no description available]	medium	2	0
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone	[no description available]	medium	10	0	methoxybenzenes
n-chlorotaurine	[no description available]	medium	2	0
calpain	[no description available]	medium	1	0
sulprostone	[no description available]	medium	3	0	prostanoid
2,5-di-tert-butylhydroquinone	[no description available]	medium	3	0	hydroquinones
methylene blue	[no description available]	medium	40	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
ici 204,219	[no description available]	medium	7	3	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
l 663536	[no description available]	medium	6	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
galactosamine	[no description available]	medium	6	0	D-galactosamine; primary amino compound	toxin
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane	[no description available]	medium	1	0
gefarnate	[no description available]	medium	1	0	organic molecular entity
dibutyryl cyclic gmp	[no description available]	medium	17	0
ns 2028	[no description available]	medium	1	0
lithium	[no description available]	medium	45	0	alkali metal atom
metastat	[no description available]	medium	1	0
ginsenoside rb1	[no description available]	medium	2	0	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
wortmannin	[no description available]	medium	6	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
hypocrellin a	[no description available]	medium	1	0
perylene	[no description available]	medium	1	0	ortho- and peri-fused polycyclic arene; perylenes
5-methylfurtrethonium	[no description available]	medium	3	0	aralkylamine
oxymethacil	[no description available]	medium	1	0
sodium cyanide	[no description available]	medium	2	0	cyanide salt; one-carbon compound; sodium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor
roxatidine acetate	[no description available]	medium	5	0	piperidines
4-phenylenediamine	[no description available]	medium	3	0	phenylenediamine	allergen; dye; hapten; reagent
perftoran	[no description available]	medium	1	0
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid	[no description available]	medium	1	0	monoterpenoid
cadmium chloride	[no description available]	medium	2	1	cadmium coordination entity
methanesulfonic acid	[no description available]	medium	2	0	alkanesulfonic acid; one-carbon compound	Escherichia coli metabolite
gt 2331	[no description available]	medium	1	0
natriuretic peptide, c-type	[no description available]	medium	3	0
atrial natriuretic factor (4-23)nh2, de-gln(18)-de-ser(19)-de-gly(20,22)-de-leu(21)-	[no description available]	medium	2	0
ginkgolide a	[no description available]	medium	1	1	diterpene lactone
ginkgolide c	[no description available]	medium	1	1
leupeptin	[no description available]	medium	2	0	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor
leupeptins	[no description available]	medium	3	0
1,4-dihydropyridine	[no description available]	medium	2	0
n-(3-(aminomethyl)benzyl)acetamidine	[no description available]	medium	1	0	aralkylamine; carboxamidine; primary amino compound	angiogenesis inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; geroprotector
nitric acid	[no description available]	medium	2	0	nitrogen oxoacid	protic solvent; reagent
3-methylkaempferol	[no description available]	medium	1	0	monomethoxyflavone; trihydroxyflavone	plant metabolite
xenon	[no description available]	medium	24	0	monoatomic xenon; noble gas atom; p-block element atom
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine	[no description available]	medium	1	0	pyridines
pyrrophenone	[no description available]	medium	1	0
n-methylpyrrolidone	[no description available]	medium	1	0	lactam; N-alkylpyrrolidine; pyrrolidin-2-ones	polar aprotic solvent
fk 409	[no description available]	medium	3	0
nor 4	[no description available]	medium	1	0
1-ethyl-3-(3-dimethylaminoethyl)carbodiimide	[no description available]	medium	1	0
ag 99	[no description available]	medium	1	0
su 5402	[no description available]	medium	1	0
ethyldimethylaminopropyl carbodiimide	[no description available]	medium	3	0
1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide methiodide	[no description available]	medium	1	0
losartan potassium	[no description available]	medium	9	2
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid	[no description available]	medium	5	0	arenesulfonic acid; azobenzenes; methylpyridines; monohydroxypyridine; organic phosphate; pyridinecarbaldehyde	purinergic receptor P2X antagonist
progesterone 11-hemisuccinate, (11alpha)-isomer	[no description available]	medium	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; dicarboxylic acid monoester; hemisuccinate; steroid ester
oxophenylarsine	[no description available]	medium	2	0	arsine oxides	antineoplastic agent; apoptosis inducer; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
furegrelate	[no description available]	medium	1	0	benzofurans
petasin	[no description available]	medium	1	1	alicyclic ketone; enoate ester; enone; sesquiterpenoid	anti-allergic agent; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activator; plant metabolite; vasodilator agent
acrivastine	[no description available]	medium	11	9	alpha,beta-unsaturated monocarboxylic acid; N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
pipecuronium	[no description available]	medium	3	2	steroid ester
n-acetyltyrosine, (dl)-isomer	[no description available]	medium	1	0	N-acetyl-amino acid; phenols; tyrosine derivative	human urinary metabolite
acetovanillone	[no description available]	medium	1	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
diphenyleneiodonium	[no description available]	medium	3	0	organic cation
marrubiin	[no description available]	medium	1	0	gamma-lactone
formazans	[no description available]	medium	1	0
6-aminoquinolyl-n-hydroxysuccinimidyl carbamate	[no description available]	medium	1	0
3-nitrotyrosine	[no description available]	medium	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
clorgyline	[no description available]	medium	7	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
5-hydroxydecanoate	[no description available]	medium	1	0	medium-chain fatty acid
hmr 1098	[no description available]	medium	1	0
2',3'-o-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate	[no description available]	medium	1	0	C-nitro compound; spiroketal	antagonist
pyrazolanthrone	[no description available]	medium	2	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
lipoxin a4	[no description available]	medium	1	0	hydroxy polyunsaturated fatty acid; lipoxin; long-chain fatty acid	human metabolite; metabolite
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine	[no description available]	medium	1	0
thiorphan	[no description available]	medium	11	1	N-acyl-amino acid
bifemelane	[no description available]	medium	1	0	diarylmethane
zm 241385	[no description available]	medium	3	0	diamino-1,3,5-triazine
mrs 1523	[no description available]	medium	1	0
am 404	[no description available]	medium	1	0	anilide
arachidonyl-2-chloroethylamide	[no description available]	medium	1	0	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
2'-deoxytubercidin	[no description available]	medium	1	0	deoxyribonucleoside; N-glycosylpyrrolopyrimidine
tubercidin	[no description available]	medium	2	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
veratridine	[no description available]	medium	10	0
sulbactam	[no description available]	medium	1	0	penicillanic acids
sultamicillin	[no description available]	medium	1	0	penicillanic acid ester
substance p	[no description available]	medium	1	0
bw a868c	[no description available]	medium	1	0	imidazolidine-2,4-dione
scopoletin	[no description available]	medium	3	0	hydroxycoumarin	plant growth regulator; plant metabolite
cariporide	[no description available]	medium	2	0
2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate	[no description available]	medium	4	0
n-benzyl-3-pyrrolidylacetate methobromide	[no description available]	medium	2	0
nnc 38-1049	[no description available]	medium	1	0
dihydroalprenolol	[no description available]	medium	13	0
epicatechin gallate	[no description available]	medium	1	0	catechin; gallate ester; polyphenol	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite
cgp 20712a	[no description available]	medium	2	0
butoxamine	[no description available]	medium	4	0
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride	[no description available]	medium	7	0
adenosine diphosphate ribose	[no description available]	medium	6	0	ADP-sugar	Escherichia coli metabolite; mouse metabolite
lithium chloride	[no description available]	medium	10	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
thymosin beta(4)	[no description available]	medium	1	0
dideoxyadenosine	[no description available]	medium	3	0	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
2',5'-dideoxyadenosine	[no description available]	medium	3	0	deoxyribonucleoside
4-(3,4-dibutoxybenzyl)-2-imidazolidinone	[no description available]	medium	2	0
rhodamine 123	[no description available]	medium	3	0	organic cation; xanthene dye	fluorochrome
2,3-diphosphoglycerate	[no description available]	medium	1	0	bisphosphoglyceric acid; tetronic acid derivative	human metabolite
8-bromoguanosino-3',5'-cyclic monophosphorothioate	[no description available]	medium	1	0
ethoxyresorufin	[no description available]	medium	1	0	phenoxazine
adenosine 5'-o-(3-thiotriphosphate)	[no description available]	medium	1	0	nucleoside triphosphate analogue
coelenterazine	[no description available]	medium	1	0
pyrazines	[no description available]	medium	14	0	diazine; pyrazines	Daphnia magna metabolite
latrunculin a	[no description available]	medium	1	0	cyclic hemiketal; macrolide; oxabicycloalkane; thiazolidinone	actin polymerisation inhibitor; metabolite; toxin
krn 7000	[no description available]	medium	1	0	glycophytoceramide; N-acyl-beta-D-galactosylphytosphingosine	allergen; antigen; antineoplastic agent; epitope; immunological adjuvant
8-aminohexylamino camp	[no description available]	medium	1	0
lupitidine	[no description available]	medium	2	0
1-deoxynojirimycin	[no description available]	medium	1	0	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
miglustat	[no description available]	medium	1	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone	[no description available]	medium	1	0
phorbol-12,13-diacetate	[no description available]	medium	4	0
edelfosine	[no description available]	medium	1	0	glycerophosphocholine
1,6-bis(cyclohexyloximinocarbonyl)hexane	[no description available]	medium	1	0	carbamate ester; organonitrogen compound
d 609	[no description available]	medium	1	0
ferric chloride	[no description available]	medium	1	0	iron coordination entity	astringent; Lewis acid
1-palmitoyl-2-(10-(4-((trifluoromethyl)diazirinyl)phenyl)-8-oxadecanoyl)-sn-glycero-3-phosphocholine	[no description available]	medium	1	0
dodecyl sulfate	[no description available]	medium	1	0	alkyl sulfate
sc 236	[no description available]	medium	1	0
2-aminopurine	[no description available]	medium	1	0	2-aminopurines; nucleobase analogue	antimetabolite
omega-agatoxin iva	[no description available]	medium	3	0
fluticasone propionate, salmeterol xinafoate drug combination	[no description available]	medium	1	1
peptide phi	[no description available]	medium	3	0
heliodermin	[no description available]	medium	2	0
pustulan	[no description available]	medium	1	0
scleroglucan	[no description available]	medium	1	0	oligosaccharide
curdlan	[no description available]	medium	1	0	hexose
laminaran	[no description available]	medium	1	0
chromotrope 2r	[no description available]	medium	1	0	organic sodium salt	histological dye
sodium tungstate(vi)	[no description available]	medium	1	0	inorganic sodium salt	reagent
nantenine	[no description available]	medium	2	0	oxoaporphine alkaloid	metabolite
hydromorphone	[no description available]	medium	4	1	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
chloramine-t	[no description available]	medium	2	0	organic sodium salt	allergen; antifouling biocide; disinfectant
dapi	[no description available]	medium	1	0	indoles	fluorochrome
2-chloroethylamine	[no description available]	medium	1	0
bromochloroacetic acid	[no description available]	medium	9	0	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
t0156	[no description available]	medium	1	0	naphthyridine derivative
flavin semiquinone	[no description available]	medium	1	0
atomoxetine hydrochloride	[no description available]	medium	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
bromodeoxyuridine	[no description available]	medium	2	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
ergoline	[no description available]	medium	10	0	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
helium	[no description available]	medium	8	0	monoatomic helium; noble gas atom; s-block element atom	food packaging gas
puromycin	[no description available]	medium	13	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
felypressin	[no description available]	medium	3	0	heterodetic cyclic peptide	vasoconstrictor agent; vasopressin receptor agonist
krypton	[no description available]	medium	5	0	monoatomic krypton; noble gas atom; p-block element atom
methoxyflurane	[no description available]	medium	10	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
indican	[no description available]	medium	2	0	beta-D-glucoside; exopolysaccharide; indolyl carbohydrate
nalbuphine	[no description available]	medium	4	1	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
saralasin	[no description available]	medium	5	0	oligopeptide
deuterium oxide	[no description available]	medium	5	0	deuterated compound; water	NMR solvent
quin2	[no description available]	medium	6	0
3-amino-2-methyl-8-phenylmethoxyimidazo(1,2-a)pyrazine	[no description available]	medium	2	0
thenalidine	[no description available]	medium	2	0	dialkylarylamine; tertiary amino compound
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid	[no description available]	medium	2	0	HPETE	human xenobiotic metabolite
15-hydroxy-5,8,11,13-eicosatetraenoic acid	[no description available]	medium	7	0
quifenadine	[no description available]	medium	4	0	diarylmethane
diazoline	[no description available]	medium	2	0	polymer
medroxalol	[no description available]	medium	1	0	salicylamides
kwd 2131	[no description available]	medium	4	3
enkephalin, leucine	[no description available]	medium	42	0	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
isospaglumic acid	[no description available]	medium	4	0	dipeptide	human metabolite
homocarnosine	[no description available]	medium	1	0	dipeptide zwitterion; dipeptide; homocarnosine; L-histidine derivative; N-acyl-L-alpha-amino acid anion; N-acyl-L-alpha-amino acid	human metabolite
salmefamol	[no description available]	medium	1	0
beta-aminoethyl isothiourea	[no description available]	medium	16	0
methamilane methiodide	[no description available]	medium	3	0
guanylyl imidodiphosphate	[no description available]	medium	30	0	nucleoside triphosphate analogue
aminopropionitrile	[no description available]	medium	2	0	aminopropionitrile	antineoplastic agent; antirheumatic drug; collagen cross-linking inhibitor; plant metabolite
dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide	[no description available]	medium	5	0
ciramadol	[no description available]	medium	1	0	cyclohexanols
pentazocine	[no description available]	medium	3	1	benzazocine
dezocine	[no description available]	medium	1	0	phenols; primary amino compound	opioid analgesic
angiotensin i	[no description available]	medium	6	0	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent
sodium thiosulfate	[no description available]	medium	2	0	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
n-formylmethionine	[no description available]	medium	3	0	L-methionine derivative; N-formyl amino acid; proteinogenic amino acid	metabolite
trichloroacetaldehyde	[no description available]	medium	1	0	aldehyde; organochlorine compound	mouse metabolite
chloral hydrate	[no description available]	medium	10	0	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic
benextramine	[no description available]	medium	3	0
oxyntomodulin	[no description available]	medium	17	0
tetragastrin	[no description available]	medium	36	1	peptidyl amide; tetrapeptide	anxiogenic; human metabolite
adenylyl imidodiphosphate	[no description available]	medium	2	0	adenosine 5'-phosphate
st 91	[no description available]	medium	1	0	substituted aniline
l 643441	[no description available]	medium	5	0
3,3'-dipentyl-2,2'-oxacarbocyanine	[no description available]	medium	1	0	benzoxazolium ion; cyanine dye	fluorochrome
carbocyanines	[no description available]	medium	6	0	cyanine dye; organic iodide salt	fluorochrome
sulmazole	[no description available]	medium	6	0	imidazopyridine; sulfoxide	adenosine A1 receptor antagonist; cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
butyrylcholine	[no description available]	medium	2	0	acylcholine
sk&f 93479	[no description available]	medium	8	0
azepexole	[no description available]	medium	2	0
lm 24056	[no description available]	medium	4	0
gallopamil	[no description available]	medium	26	2	benzenes; organic amino compound
pentetic acid	[no description available]	medium	7	0	pentacarboxylic acid	copper chelator
technetium	[no description available]	medium	15	0	manganese group element atom
erythritol	[no description available]	medium	3	0	butane-1,2,3,4-tetrol	antioxidant; human metabolite; plant metabolite
racemetirosine	[no description available]	medium	2	0
tartrazine	[no description available]	medium	7	1
l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide	[no description available]	medium	3	0
oxmetidine	[no description available]	medium	5	0	benzodioxoles; imidazoles; pyrimidone	anti-ulcer drug; H2-receptor antagonist
dimethylamine	[no description available]	medium	1	0	methylamines; secondary aliphatic amine	metabolite
sgb 1534	[no description available]	medium	1	0
bw-755c	[no description available]	medium	15	0
n-methylscopolamine	[no description available]	medium	3	0
monodansylcadaverine	[no description available]	medium	2	0	aminonaphthalene; primary amino compound; sulfonamide; tertiary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor; fluorochrome; protective agent
aaptamine	[no description available]	medium	1	0
tropodifene	[no description available]	medium	2	0
palytoxin	[no description available]	medium	1	0	polyol	toxin
dihydroteleocidin b	[no description available]	medium	1	0
quazinone	[no description available]	medium	2	0
5-methoxytryptamine	[no description available]	medium	7	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
ru 31156	[no description available]	medium	1	0
methoxyhydroxyphenylglycol	[no description available]	medium	5	0	methoxybenzenes; phenols
betamethasone valerate	[no description available]	medium	3	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; primary alpha-hydroxy ketone; steroid ester	anti-inflammatory drug
mast cell degranulating peptide	[no description available]	medium	2	0
elliptinium	[no description available]	medium	3	0	carbazoles
trypsinogen	[no description available]	medium	2	0
penicillanic acid	[no description available]	medium	2	0	penicillanic acids
nafcillin	[no description available]	medium	2	1	penicillin allergen; penicillin	antibacterial drug
penicilloate	[no description available]	medium	1	0
carbenicillin	[no description available]	medium	2	0	penicillin allergen; penicillin	antibacterial drug
sodium nitrate	[no description available]	medium	5	0	inorganic nitrate salt; inorganic sodium salt	fertilizer; NMR chemical shift reference compound
cremophor el	[no description available]	medium	4	0
ceruletide	[no description available]	medium	30	1	oligopeptide	diagnostic agent; gastrointestinal drug
lodoxamide ethyl	[no description available]	medium	9	1
oxamic acid	[no description available]	medium	12	1	dicarboxylic acid monoamide	Escherichia coli metabolite
d-ala(2),mephe(4),met(0)-ol-enkephalin	[no description available]	medium	4	0
tioxamast	[no description available]	medium	2	0
physalaemin	[no description available]	medium	7	0
sarcosine methyl ester	[no description available]	medium	1	0
glycine methyl ester	[no description available]	medium	1	0	glycinyl ester	metabolite
neurotensin, trp(11)-	[no description available]	medium	2	0
substance p, prolyl(2)-tryptophan(7,9)-	[no description available]	medium	2	0
dexbrompheniramine	[no description available]	medium	5	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
bl 5255	[no description available]	medium	1	0
arachidonic acid 5-hydroperoxide	[no description available]	medium	1	0	HPETE	human xenobiotic metabolite
homocysteic acid	[no description available]	medium	3	0	homocysteic acid	NMDA receptor agonist
amberlite irc50	[no description available]	medium	2	0
ioxitalamic acid	[no description available]	medium	2	0	acetamides; benzoic acids; dicarboxylic acid monoamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
inosine pranobex	[no description available]	medium	1	0
lasalocid	[no description available]	medium	5	0	beta-hydroxy ketone; monocarboxylic acid; monohydroxybenzoic acid; oxanes; oxolanes; polyether antibiotic; secondary alcohol; tertiary alcohol	bacterial metabolite; coccidiostat; ionophore
xylitol	[no description available]	medium	4	0
cyclamic acid	[no description available]	medium	1	0	sulfamic acids	environmental contaminant; human xenobiotic metabolite
picoprazole	[no description available]	medium	4	0
15-keto-13,14-dihydroprostaglandin f2alpha	[no description available]	medium	7	0	ketone; prostaglandins Falpha	metabolite
4-bromophenacyl bromide	[no description available]	medium	4	0
hydroquinone	[no description available]	medium	2	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
5'-adenylyl (beta,gamma-methylene)diphosphonate	[no description available]	medium	3	0	nucleoside triphosphate analogue
alpha-methylserotonin	[no description available]	medium	2	0	tryptamines	serotonergic agonist
tuftsin	[no description available]	medium	9	0	peptide
bufotenin	[no description available]	medium	3	0	tertiary amine; tryptamine alkaloid	coral metabolite; hallucinogen
3'-o-(3-(n-(4-azido-2-nitrophenyl)amino)propionyl)adenosine-5'-triphosphate	[no description available]	medium	2	0
oligomycins	[no description available]	medium	9	0
anisodamine	[no description available]	medium	4	0
fanetizole	[no description available]	medium	1	0
ibudilast	[no description available]	medium	5	1	pyrazolopyridine
technetium tc 99m medronate	[no description available]	medium	1	0
wb 4101	[no description available]	medium	1	0	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
nordimaprit	[no description available]	medium	3	0
6-ethyl-3-(1h-tetrazol-5-yl)chromone	[no description available]	medium	3	0
4-chloromercuribenzenesulfonate	[no description available]	medium	4	0	arenesulfonic acid; arylmercury compound
pentostatin	[no description available]	medium	2	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
6-ketoprostaglandin e1	[no description available]	medium	1	0	prostaglandins E	metabolite; platelet aggregation inhibitor
lithium carbonate	[no description available]	medium	1	0	carbonate salt; lithium salt	antimanic drug
5,6-dihydroprostacyclin	[no description available]	medium	1	0
5-methyltetrahydrohomofolic acid	[no description available]	medium	1	0
n,n-dimethyltryptamine	[no description available]	medium	1	0	tryptamine alkaloid; tryptamines
rmi 12330a	[no description available]	medium	2	0
leukotriene a4	[no description available]	medium	2	0	epoxy fatty acid; leukotriene; long-chain fatty acid; oxylipin; polyunsaturated fatty acid	human metabolite; mouse metabolite; plant metabolite
nalorphine	[no description available]	medium	6	0	morphinane alkaloid
phorbols	[no description available]	medium	8	0	diterpene; terpenoid fundamental parent
hydroxybenzylpindolol	[no description available]	medium	1	0
trimethyloxonium	[no description available]	medium	1	0
iodohydroxybenzylpindolol	[no description available]	medium	1	0
8-((4-chlorophenyl)thio)cyclic-3',5'-amp	[no description available]	medium	3	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; aryl sulfide; organochlorine compound	protein kinase agonist
9-hydroxy-11,15-dioxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid	[no description available]	medium	6	0
su 10603	[no description available]	medium	1	0
leukotriene c-3	[no description available]	medium	1	0
4,4'-diphenylmethane diisocyanate	[no description available]	medium	2	0	diisocyanate	allergen; hapten
rosin	[no description available]	medium	4	0
guanosine monophosphate	[no description available]	medium	2	0	guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	biomarker; Escherichia coli metabolite; metabolite; mouse metabolite
5'-guanylylmethylenebisphosphonate	[no description available]	medium	1	0	nucleoside triphosphate analogue
iothalamate meglumine	[no description available]	medium	2	0	amidobenzoic acid
nolinium bromide	[no description available]	medium	2	0
timoprazole	[no description available]	medium	4	0
u 44069	[no description available]	medium	12	0	prostanoid
sodium pertechnetate tc 99m	[no description available]	medium	5	0
hirudin	[no description available]	medium	5	0
w 7	[no description available]	medium	9	0
methyltestosterone	[no description available]	medium	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
lamtidine	[no description available]	medium	3	0	aromatic amine
ici 63197	[no description available]	medium	2	0	triazolopyrimidines
cholecystokinin 39	[no description available]	medium	1	0
talipexole	[no description available]	medium	2	0	azepine
inositol 1-phosphate	[no description available]	medium	8	0
d 2343	[no description available]	medium	1	0
vesnarinone	[no description available]	medium	3	0	organic molecular entity
methylprednisolone hemisuccinate	[no description available]	medium	5	2	corticosteroid hormone; hemisuccinate
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine	[no description available]	medium	1	0
sodium nitrite	[no description available]	medium	14	0	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison
tiletamine	[no description available]	medium	1	0	aralkylamine
cv 3988	[no description available]	medium	15	0
16,16-dimethylprostaglandin e2	[no description available]	medium	9	0	cyclopentanones; monocarboxylic acid; prostanoid; secondary allylic alcohol	anti-ulcer drug; gastrointestinal drug; radiation protective agent
ethyl acetimidate	[no description available]	medium	1	0
pirmagrel	[no description available]	medium	1	0
sq 80338	[no description available]	medium	2	0
enkephalin, leucine-2-alanine	[no description available]	medium	6	0
meciadanol	[no description available]	medium	3	0
n,n-di-n-propyldopamine	[no description available]	medium	1	0	catecholamine
phenylpropanolamine	[no description available]	medium	7	4	amphetamines; phenethylamine alkaloid	plant metabolite
enkephalin, alanh2(5)-	[no description available]	medium	1	0
mannosamine	[no description available]	medium	1	0	D-mannosamine
l 640035	[no description available]	medium	1	0
lentinan	[no description available]	medium	2	1
9,10-dimethyl-1,2-benzanthracene	[no description available]	medium	3	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
ozagrel	[no description available]	medium	19	1	cinnamic acids
2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid	[no description available]	medium	2	0
prostaglandin h2	[no description available]	medium	6	0	olefinic compound; oxylipin; prostaglandins H; secondary alcohol	mouse metabolite
meglumine iodipamide	[no description available]	medium	1	0	organoammonium salt	radioopaque medium
erabutoxin b	[no description available]	medium	2	0
13,14-dihydroprostaglandin f2alpha	[no description available]	medium	1	0
diazobenzenesulfonic acid	[no description available]	medium	2	0
rociverine	[no description available]	medium	2	0
nisoldipine	[no description available]	medium	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
metabisulfite	[no description available]	medium	1	0	sulfur oxide; sulfur oxoanion
methionine sulfoximine	[no description available]	medium	5	0	methionine derivative; non-proteinogenic alpha-amino acid; sulfoximide
s-adenosylhomocysteine	[no description available]	medium	6	0	adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide	cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite
triiodothyronine	[no description available]	medium	3	0	tetrahydrothiophenes; thiolactone	human metabolite
pentoxyl	[no description available]	medium	1	0	pyrimidone
2,2'-dithiobis(n-2-hydroxypropylbenzamide)	[no description available]	medium	1	0
phenylbenzoquinone	[no description available]	medium	2	0
15-keto-13,14-dihydroprostaglandin e2	[no description available]	medium	1	0	prostaglandins E
tetrabromophenolphthalein ethyl ester	[no description available]	medium	1	0
diatrizoate meglumine	[no description available]	medium	9	2	monocarboxylic acid anion	radioopaque medium
urografin 76	[no description available]	medium	3	2
cetraxate	[no description available]	medium	1	0	benzenes; monocarboxylic acid
irsogladine	[no description available]	medium	2	0	dichlorobenzene
troxerutin	[no description available]	medium	2	0
mexiprostil	[no description available]	medium	1	0
methylnitronitrosoguanidine	[no description available]	medium	5	0	nitroso compound	alkylating agent
mequitazine	[no description available]	medium	7	0	phenothiazines
thromboxane a2, carbocyclic	[no description available]	medium	1	0
sodium azide	[no description available]	medium	3	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
glaucine	[no description available]	medium	2	0	aporphine alkaloid; organic heterotetracyclic compound; polyether; tertiary amino compound	antibacterial agent; antineoplastic agent; antitussive; muscle relaxant; NF-kappaB inhibitor; plant metabolite; platelet aggregation inhibitor; rat metabolite
technetium tc 99m sulfur colloid	[no description available]	medium	1	0
xenon radioisotopes	[no description available]	medium	16	0
calcium oxalate	[no description available]	medium	1	0	organic calcium salt
octylonium	[no description available]	medium	1	0	benzamides
furtrethonium	[no description available]	medium	1	0	aralkylamine
dilazep	[no description available]	medium	3	0	benzoate ester; diazepane; diester; methoxybenzenes	cardioprotective agent; platelet aggregation inhibitor; vasodilator agent
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine-	[no description available]	medium	1	0
diphemanil methylsulfate	[no description available]	medium	1	1	piperidines; quaternary ammonium salt	bronchodilator agent; muscarinic antagonist; parasympatholytic
5-hydroxy-6,8,11,14-eicosatetraenoic acid	[no description available]	medium	6	0	HETE	human metabolite; mouse metabolite
trifluoroacetic acid	[no description available]	medium	1	0	fluoroalkanoic acid	human xenobiotic metabolite; NMR chemical shift reference compound; reagent
2-(2-methyl-4-chlorophenylamino)-2-imidazoline	[no description available]	medium	1	0
praseodymium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
ytterbium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
cholinophyllin	[no description available]	medium	1	1
thymopoietin iii	[no description available]	medium	1	0
cimoxatone	[no description available]	medium	1	0
oxazolidin-2-one	[no description available]	medium	1	0	carbamate ester; oxazolidinone	metabolite
bufrolin	[no description available]	medium	1	1
9a-12a-octadecadiynoic acid	[no description available]	medium	1	0	octadecadiynoic acid
unithiol	[no description available]	medium	2	0
phenyl biguanide	[no description available]	medium	11	0	guanidines	central nervous system drug
biguanides	[no description available]	medium	20	0	guanidines
vanilmandelic acid	[no description available]	medium	17	0	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite
echothiophate iodide	[no description available]	medium	1	0	iodide salt; quaternary ammonium salt	antiglaucoma drug; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
sq 26536	[no description available]	medium	1	0
trimethoprim, sulfamethoxazole drug combination	[no description available]	medium	1	0
phenidone	[no description available]	medium	4	0
glycocholic acid	[no description available]	medium	7	0	bile acid glycine conjugate	human metabolite
kyotorphin	[no description available]	medium	2	0	dipeptide
neo-kyotorphin	[no description available]	medium	2	0
mesudipine	[no description available]	medium	1	0
tyloxapol	[no description available]	medium	1	0
brocresine	[no description available]	medium	8	0
12-hydroxy-5,8,10,14-eicosatetraenoic acid	[no description available]	medium	7	0
troleandomycin	[no description available]	medium	1	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
erythromycin estolate	[no description available]	medium	2	0	aminoglycoside sulfate salt; erythromycin derivative	enzyme inhibitor
citrate phosphate dextrose	[no description available]	medium	1	0
cholestyramine resin	[no description available]	medium	2	0
cysteamine-s-phosphate	[no description available]	medium	1	0	organic phosphorothioate anion
mazindol	[no description available]	medium	1	0	organic molecular entity
melitten	[no description available]	medium	11	0
dermorphin	[no description available]	medium	1	0	oligopeptide
2-aminothiazoline	[no description available]	medium	1	0	1,3-thiazoles; primary amino compound
iodoacetic acid	[no description available]	medium	3	0	haloacetic acid; organoiodine compound	alkylating agent
puromycin aminonucleoside	[no description available]	medium	1	0	3'-deoxyribonucleoside; adenosines
1,6-hexamethylene diisocyanate	[no description available]	medium	1	0	diisocyanate	allergen; hapten
caffeine, sodium benzoate drug combination	[no description available]	medium	1	0
triamterene	[no description available]	medium	4	0	pteridines	diuretic; sodium channel blocker
hydrochlorothiazide-triamterene	[no description available]	medium	1	0
bencyclane	[no description available]	medium	1	0	benzenes
dithionitrobenzoic acid	[no description available]	medium	3	0	nitrobenzoic acid; organic disulfide	indicator
vasotocin	[no description available]	medium	6	0
adeturon	[no description available]	medium	1	0
hemicholinium 3	[no description available]	medium	8	0
dexamisole	[no description available]	medium	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antidepressant
tetramisole	[no description available]	medium	1	0	imidazothiazole	environmental contaminant; xenobiotic
strontium radioisotopes	[no description available]	medium	5	0
n-acetylcarnosine	[no description available]	medium	2	0	dipeptide	metabolite
dehydroascorbic acid	[no description available]	medium	2	0	dehydroascorbic acid; vitamin C	coenzyme; mouse metabolite
nitroblue tetrazolium	[no description available]	medium	4	0	organic cation
ricinoleic acid	[no description available]	medium	2	0	(9Z)-12-hydroxyoctadec-9-enoic acid
genipin	[no description available]	medium	1	0	iridoid monoterpenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cross-linking reagent; hepatotoxic agent; uncoupling protein inhibitor
norgestrel	[no description available]	medium	2	0
bromthymol blue	[no description available]	medium	1	0	2,1-benzoxathiole; arenesulfonate ester; organobromine compound; polyphenol; sultone	acid-base indicator; dye; two-colour indicator
11-hydroxy-5,8,12,14-eicosatetraenoic acid	[no description available]	medium	1	0
4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
pyridoxal	[no description available]	medium	5	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ganglerone	[no description available]	medium	1	0
3-hydroxybutyric acid	[no description available]	medium	2	0	(omega-1)-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; hydroxybutyric acid	human metabolite
2-hydroxybutyric acid	[no description available]	medium	1	0	2-hydroxy monocarboxylic acid; hydroxybutyric acid	algal metabolite; human metabolite
clofibrate	[no description available]	medium	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
isovaleric acid	[no description available]	medium	1	0	branched-chain saturated fatty acid; methylbutyric acid; short-chain fatty acid	mammalian metabolite; plant metabolite
valerates	[no description available]	medium	3	0	short-chain fatty acid anion; straight-chain saturated fatty acid anion	plant metabolite
methylene chloride	[no description available]	medium	1	0	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
4-amino-5-hexynoic acid	[no description available]	medium	1	0
sodium taurodeoxycholate	[no description available]	medium	2	0	bile acid taurine conjugate	human metabolite
16,16-dimethylprostaglandin e	[no description available]	medium	4	0	prostanoid
angiotensin ii, sar(1)-ile(5)-	[no description available]	medium	1	0
reproterol	[no description available]	medium	3	0	oxopurine
hexobendine	[no description available]	medium	1	0	trihydroxybenzoic acid
cepharanthine	[no description available]	medium	3	0	bisbenzylisoquinoline alkaloid; isoquinolines
u 0521	[no description available]	medium	2	0	acetophenones
brij-58	[no description available]	medium	1	0
cl 115574	[no description available]	medium	1	0
pentacaine	[no description available]	medium	3	0
heptacaine	[no description available]	medium	1	0
dimethylhydrazines	[no description available]	medium	3	0
bergenin	[no description available]	medium	1	0	trihydroxybenzoic acid	metabolite
chlorphenamidine	[no description available]	medium	1	0
lewis x antigen	[no description available]	medium	1	0
aluminum fluoride	[no description available]	medium	5	0	aluminium coordination entity
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid	[no description available]	medium	19	0
leminoprazole	[no description available]	medium	2	0
isbufylline	[no description available]	medium	1	0
sdz mks 492	[no description available]	medium	2	0
cp 96345	[no description available]	medium	10	0
phosphatidylethanol	[no description available]	medium	1	0
ds 4574	[no description available]	medium	4	0
cellulose sulfate	[no description available]	medium	2	0	ether; flavonoids
temelastine	[no description available]	medium	8	1	pyrimidone
methiothepin	[no description available]	medium	2	0	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
hirudin	[no description available]	medium	1	0
gliotoxin	[no description available]	medium	1	0	dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole	antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor
erythrosine	[no description available]	medium	2	0
acetylshikonin	[no description available]	medium	1	0
5,6-epoxy-8,11,14-eicosatrienoic acid	[no description available]	medium	3	0	EET	mouse metabolite
8,11,14-eicosatrienoic acid	[no description available]	medium	8	0	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
beta-naphthoflavone	[no description available]	medium	2	0	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist
sr 48968	[no description available]	medium	10	0
sr 48692	[no description available]	medium	2	0	N-acyl-amino acid
zinc carbonate	[no description available]	medium	1	0	organooxygen compound
zatebradine	[no description available]	medium	2	1	benzazepine
sr 140333	[no description available]	medium	7	0
inositol-1,3,4,5-tetrakisphosphate	[no description available]	medium	7	0	inositol phosphate
tert-butylhydroperoxide	[no description available]	medium	1	0	alkyl hydroperoxide	antibacterial agent; oxidising agent
2,3,4,6-tetrachlorophenol	[no description available]	medium	1	1	tetrachlorophenol	xenobiotic metabolite
2,4,5-trichlorophenol	[no description available]	medium	1	1	trichlorophenol
tetrahydrocortisol	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3alpha-hydroxy steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
propanidid	[no description available]	medium	17	2	methoxybenzenes
afdx 116	[no description available]	medium	9	0	benzodiazepine
hexahydrosiladifenidol	[no description available]	medium	2	0
ml 9	[no description available]	medium	3	0
n-(2-chloroethyl)-4-piperidinyl diphenylacetate	[no description available]	medium	5	0
methoctramine	[no description available]	medium	5	0	hydrochloride	muscarinic antagonist
acetylsalicylic acid lysinate	[no description available]	medium	5	4
foropafant	[no description available]	medium	1	0
setipafant	[no description available]	medium	1	0
technetium tc 99m gluceptate	[no description available]	medium	1	0
imidazoleacetic acid ribotide	[no description available]	medium	1	0	imidazoles; monocarboxylic acid; N-glycosyl compound; ribose monophosphate
isradipine	[no description available]	medium	2	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
midaglizole	[no description available]	medium	2	1
al 3264	[no description available]	medium	2	0
pyridinolcarbamate	[no description available]	medium	6	0	pyridines
loxtidine	[no description available]	medium	11	0	aromatic ether; piperidines; primary alcohol; triazoles	H2-receptor antagonist
s 145	[no description available]	medium	6	0	monoterpenoid
mezerein	[no description available]	medium	2	0	diterpenoid
methylprednisolone suleptanate	[no description available]	medium	2	1	organic sodium salt	anti-asthmatic drug; anti-inflammatory agent; glucocorticoid receptor agonist; prodrug
dexamethasone 21-phosphate	[no description available]	medium	1	0	11beta-hydroxy steroid; 17-hydroxy steroid; 3-oxo-Delta(4) steroid; fluorinated steroid; steroid phosphate; tertiary alpha-hydroxy ketone	glucocorticoid receptor agonist
cyclopropane	[no description available]	medium	1	0	cycloalkane; cyclopropanes	inhalation anaesthetic
brimonidine tartrate	[no description available]	medium	4	0
gr 89696	[no description available]	medium	1	0	acetamides
buthionine sulfoximine	[no description available]	medium	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
kn 93	[no description available]	medium	3	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
hesperidin methylchalcone	[no description available]	medium	1	0
fk 888	[no description available]	medium	7	0	peptide
substance p, sar(9)-met(o2)(11)-	[no description available]	medium	3	0
neurokinin a(4-10)	[no description available]	medium	3	0
inositol 2,4,5-trisphosphate	[no description available]	medium	1	0
13-hydroxy-9,11-octadecadienoic acid	[no description available]	medium	4	0	octadecadienoic acid
ibotenic acid	[no description available]	medium	6	0	non-proteinogenic alpha-amino acid	neurotoxin
big gastrin	[no description available]	medium	2	0
anguibactin	[no description available]	medium	1	0
mk 0591	[no description available]	medium	3	1
chenodeoxycholic acid	[no description available]	medium	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
aq-ra 741	[no description available]	medium	1	0	benzodiazepine
glucagon-like peptide 1 (7-36)amide	[no description available]	medium	3	0
ru-28362	[no description available]	medium	1	0
silver chloride	[no description available]	medium	1	0	inorganic chloride; silver salt
s-nitrosoglutathione	[no description available]	medium	1	0	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
flunisolide	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
1-oleoyl-2-acetylglycerol	[no description available]	medium	5	0	1,2-diglyceride
vapiprost	[no description available]	medium	4	0
exp3174	[no description available]	medium	1	0	biphenylyltetrazole; imidazoles; organochlorine compound	metabolite
exenatide	[no description available]	medium	1	0
exendin (9-39)	[no description available]	medium	2	0
enprostil	[no description available]	medium	9	2
4-diphenylacetoxy-1,1-dimethylpiperidinium	[no description available]	medium	7	0	quaternary ammonium ion	cholinergic antagonist; muscarinic antagonist
rp 73401	[no description available]	medium	4	0	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
n-(2-(dimethylamino)ethyl)-n-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)benzenesulfonamide	[no description available]	medium	1	0
anhydroecgonine methyl ester	[no description available]	medium	1	0	N-alkylpyrrolidine
3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile	[no description available]	medium	3	0
u-50488	[no description available]	medium	2	0	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
1-deoxyglucosamine	[no description available]	medium	1	0
ci 988	[no description available]	medium	2	0
6-anilino-5,8-quinolinedione	[no description available]	medium	2	0	aminoquinoline; aromatic amine; p-quinones; quinolone	antineoplastic agent; EC 4.6.1.2 (guanylate cyclase) inhibitor
ici 215001	[no description available]	medium	1	0	monocarboxylic acid
t 593	[no description available]	medium	4	0
candoxatril	[no description available]	medium	1	1
ono 8809	[no description available]	medium	8	0
ono-nt 126	[no description available]	medium	7	0
bay x 1005	[no description available]	medium	1	0
u 74389f	[no description available]	medium	1	0
1,2-dipalmitoyl-3-phosphatidylethanolamine	[no description available]	medium	8	0
phosphocreatine	[no description available]	medium	7	0	phosphagen; phosphoamino acid	human metabolite; mouse metabolite
linoleic acid	[no description available]	medium	5	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
s-(2-(n,n-diisopropylamino)ethyl)isothiourea	[no description available]	medium	1	0
6-hydroxy-4-(1-hydroxy-1-methylethyl)-1-cyclohexene-1-ethanol	[no description available]	medium	1	0
mar 99	[no description available]	medium	2	0
butyric acid	[no description available]	medium	7	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
4-fluorohexahydrosiladifenidol	[no description available]	medium	2	0
oxitropium	[no description available]	medium	5	2
gadolinium dtpa	[no description available]	medium	2	0	gadolinium coordination entity	MRI contrast agent
antibiotic g 418	[no description available]	medium	1	0
2'-hydroxy-5,9-dimethyl-2-allyl-6,7-benzomorphan	[no description available]	medium	3	0
1,3-ditolylguanidine	[no description available]	medium	1	0	toluenes
phenazocine	[no description available]	medium	4	0
lg 30435	[no description available]	medium	2	0
quisqualic acid	[no description available]	medium	2	0	non-proteinogenic alpha-amino acid
cisapride	[no description available]	medium	1	0	benzamides
vanadates	[no description available]	medium	6	0	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
noberastine	[no description available]	medium	2	1
buccalin	[no description available]	medium	2	0
guanosine 5'-o-(2-thiodiphosphate)	[no description available]	medium	4	0	nucleoside diphosphate analogue
broxaterol	[no description available]	medium	1	1
isoxazoles	[no description available]	medium	5	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
zd 7114	[no description available]	medium	1	0
preclamol	[no description available]	medium	1	0
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	[no description available]	medium	1	0	N-arylpiperazine
ici 198615	[no description available]	medium	2	0
indazoles	[no description available]	medium	5	0	indazole
pobilukast	[no description available]	medium	7	1
wy 48252	[no description available]	medium	2	0
mitoxantrone	[no description available]	medium	2	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
tosylarginine methyl ester	[no description available]	medium	4	1	guanidines; L-arginine ester; methyl ester; sulfonamide
bepafant	[no description available]	medium	3	0
ro 31-7549	[no description available]	medium	2	0
magnolol	[no description available]	medium	1	0	biphenyls
cefazolin	[no description available]	medium	1	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
ici 192605	[no description available]	medium	2	1
monoiodotyrosine	[no description available]	medium	1	0	amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite
kc 399	[no description available]	medium	1	0
mustard gas	[no description available]	medium	1	0	ethyl sulfide; organochlorine compound	alkylating agent; carcinogenic agent; vesicant
spiroglumide	[no description available]	medium	1	0
glucagon-like peptide 1 (7-36)	[no description available]	medium	2	0
dicarbine	[no description available]	medium	2	0
tocopheroxy radical	[no description available]	medium	1	0	tocopherol
nafazatrom	[no description available]	medium	2	0
bromocriptine	[no description available]	medium	6	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
salsolinol	[no description available]	medium	1	0	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol	human urinary metabolite
bismuth tripotassium dicitrate	[no description available]	medium	1	0
granisetron	[no description available]	medium	1	0	aromatic amide; indazoles
br-x 537a	[no description available]	medium	3	0
1-butyrylglycerol	[no description available]	medium	1	0	1-monoglyceride; butyrate ester; diol; fatty acid ester
1-amino-1,3-dicarboxycyclopentane	[no description available]	medium	3	0
cycloleucine	[no description available]	medium	3	0	non-proteinogenic alpha-amino acid	EC 2.5.1.6 (methionine adenosyltransferase) inhibitor
l 651392	[no description available]	medium	1	0
3-amino-1,2,4-triazine	[no description available]	medium	1	0
bw a1433u	[no description available]	medium	1	0
ono 3708	[no description available]	medium	3	0
3,5-dibromo-2-(2,4-dibromophenoxy)phenol	[no description available]	medium	1	0
furazolidone	[no description available]	medium	2	0	nitrofuran antibiotic; oxazolidines	antibacterial drug; antiinfective agent; antitrichomonal drug; EC 1.4.3.4 (monoamine oxidase) inhibitor
2-((2-dimethylaminobenzyl)sulfinyl)benzimidazole	[no description available]	medium	4	0
deferoxamine	[no description available]	medium	2	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
leukotoxin	[no description available]	medium	3	0
rs 5186	[no description available]	medium	1	0
omega-conotoxin (conus magus)	[no description available]	medium	1	0
gr 117289	[no description available]	medium	1	0	1-benzofurans; biaryl; imidazolyl carboxylic acid; monocarboxylic acid; organobromine compound; organochlorine compound; tetrazoles	angiotensin receptor antagonist; antihypertensive agent
diacetyl	[no description available]	medium	1	0	alpha-diketone	Escherichia coli metabolite; Saccharomyces cerevisiae metabolite
diacetylmonoxime	[no description available]	medium	1	0
lucifer yellow	[no description available]	medium	3	0	organic lithium salt	fluorochrome
sodium bicarbonate	[no description available]	medium	4	1	one-carbon compound; organic sodium salt	antacid; food anticaking agent
pca 4248	[no description available]	medium	1	0	dihydropyridine
brl 55834	[no description available]	medium	1	0
2-piperidone	[no description available]	medium	1	0	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
mepivacaine	[no description available]	medium	4	0	piperidinecarboxamide	drug allergen; local anaesthetic
5,5'-dimethyl-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetate	[no description available]	medium	1	0	polyamino carboxylic acid	chelator
vasoactive intestinal peptide, 4-chloro-phe(6)-leu(17)-	[no description available]	medium	1	0
inositol-1,3,4,6-tetrakisphosphate	[no description available]	medium	2	0
inositol-3,4,5,6-tetrakisphosphate	[no description available]	medium	1	0	myo-inositol tetrakisphosphate	mouse metabolite
ah 21-132	[no description available]	medium	2	0
trefentanil	[no description available]	medium	1	1
beta-glucono-1,5-lactone	[no description available]	medium	1	0	aldono-1,5-lactone; gluconolactone	animal metabolite; mouse metabolite
tetrandrine	[no description available]	medium	3	0	bisbenzylisoquinoline alkaloid; isoquinolines
promega	[no description available]	medium	2	2
fk 1052	[no description available]	medium	1	0	imidazoles; organic heterotricyclic compound	antiemetic; serotonergic antagonist
deamino arginine vasopressin	[no description available]	medium	5	1	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
bradykinin, des-arg(9)-	[no description available]	medium	3	1	oligopeptide	bradykinin receptor B2 agonist
n(g)-aminoarginine	[no description available]	medium	1	0	arginine derivative
met-enkephalinamide	[no description available]	medium	1	0
asialo gm1 ganglioside	[no description available]	medium	1	0
kt2 962	[no description available]	medium	1	0
rabeprazole	[no description available]	medium	4	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
sesamin	[no description available]	medium	1	0	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite
daidzein	[no description available]	medium	2	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
st 271	[no description available]	medium	1	0
peroxynitric acid	[no description available]	medium	1	0	nitrogen oxoacid
bivalirudin	[no description available]	medium	1	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
thrombin receptor peptide (42-55)	[no description available]	medium	2	0
4-bromo-a-23187	[no description available]	medium	2	0
ginsenoside rg1	[no description available]	medium	1	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	neuroprotective agent; pro-angiogenic agent
ro 46-2005	[no description available]	medium	1	0
calyculin a	[no description available]	medium	1	0
edrophonium	[no description available]	medium	4	2	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
hepes	[no description available]	medium	6	0	HEPES; organosulfonic acid
4-nitrophenylphosphate	[no description available]	medium	1	0	aryl phosphate	mouse metabolite
methylnitrosourea	[no description available]	medium	2	0	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
n-(ethoxycarbonylmethyl)-6-methoxyquinolinium	[no description available]	medium	1	0
rilmakalim	[no description available]	medium	2	0
fk 224	[no description available]	medium	4	0
nipradilol	[no description available]	medium	1	0	organic molecular entity
ranolazine	[no description available]	medium	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
s 9977	[no description available]	medium	1	0
n(1)-acetylspermidine	[no description available]	medium	1	0	acetylspermidine	Escherichia coli metabolite; metabolite
2-(nitrooxy)ethyl apovincaminate	[no description available]	medium	1	0
diosmin	[no description available]	medium	2	0	dihydroxyflavanone; disaccharide derivative; glycosyloxyflavone; monomethoxyflavone; rutinoside	anti-inflammatory agent; antioxidant
s 5682	[no description available]	medium	1	0
rmp 7	[no description available]	medium	1	0
tetramethylrhodamine isothiocyanate	[no description available]	medium	1	0
tcv 309	[no description available]	medium	2	0
fr 139317	[no description available]	medium	2	0
pd 145065	[no description available]	medium	2	0
irl 1620	[no description available]	medium	1	0
pros-methylimidazoleacetic acid	[no description available]	medium	4	0	imidazolyl carboxylic acid	metabolite
cellulase	[no description available]	medium	1	0	cellotriose
nip 121	[no description available]	medium	1	0
pristane	[no description available]	medium	1	0	long-chain alkane; norterpene	biomarker; immunological adjuvant
malathion	[no description available]	medium	4	0	diester; ethyl ester; organic thiophosphate
lanthanum chloride	[no description available]	medium	1	0
cp 80633	[no description available]	medium	1	0
sq 28603	[no description available]	medium	1	0
pk 11195	[no description available]	medium	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
tetrazepam	[no description available]	medium	1	0	benzodiazepine
lazabemide	[no description available]	medium	1	0
ro 41-1049	[no description available]	medium	1	0
lofentanil	[no description available]	medium	1	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic
etorphine	[no description available]	medium	1	0
diprenorphine	[no description available]	medium	1	0	morphinane alkaloid
norbinaltorphimine	[no description available]	medium	2	0	isoquinolines
dynorphins	[no description available]	medium	1	0
amanitins	[no description available]	medium	1	0
bimakalim	[no description available]	medium	2	0
sdz pco 400	[no description available]	medium	1	0	1-benzopyran
y 26763	[no description available]	medium	1	0	1-benzopyran
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole	[no description available]	medium	1	0	benzoic acid; imidazolines; organic radical	apoptosis inhibitor; radical scavenger
n(6),n(6)-dimethyladenine	[no description available]	medium	1	0	tertiary amine
peptide elongation factor 2	[no description available]	medium	2	0
n-methylephedrine	[no description available]	medium	2	0	amphetamines
ro 31-8425	[no description available]	medium	2	0
gizzerosine	[no description available]	medium	2	0
velnacrine	[no description available]	medium	1	0	acridines
sta 2	[no description available]	medium	6	0
atrinositol	[no description available]	medium	2	0
copper phthalocyanine	[no description available]	medium	3	0
pepstatin	[no description available]	medium	1	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
small cardioactive peptide b	[no description available]	medium	2	0
6-bromo-8-methylaminoimidazo(1,2-a)pyrazine-2-carbonitrile	[no description available]	medium	1	0
mitragynine	[no description available]	medium	1	0	monoterpenoid indole alkaloid
sodium carbonate	[no description available]	medium	1	1	carbonate salt; organic sodium salt
beraprost	[no description available]	medium	1	0	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent
inositol 1,4-bis(phosphate)	[no description available]	medium	1	0
pervanadate	[no description available]	medium	2	0
apaflurane	[no description available]	medium	1	0
seglitide	[no description available]	medium	1	0
indo-1	[no description available]	medium	3	0	indoles	fluorochrome
benzaldehyde	[no description available]	medium	1	0	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
3,5-diethoxy-4-aminomethylpyridine	[no description available]	medium	2	0
bay x 7195	[no description available]	medium	1	0
rutecarpine	[no description available]	medium	1	0	beta-carbolines
cdp 840	[no description available]	medium	1	1
hsr 609	[no description available]	medium	1	0
teroxirone	[no description available]	medium	1	0
ebrotidine	[no description available]	medium	1	0	sulfonamide
cytidine monophosphate	[no description available]	medium	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
1-arabinofuranosylcytosine-5'-stearylphosphate	[no description available]	medium	1	0
arl-67156	[no description available]	medium	1	0
4-nitrophenyl acetate	[no description available]	medium	1	0	C-nitro compound; phenyl acetates
n-acetylaspartic acid	[no description available]	medium	1	0	N-acetyl-L-amino acid; N-acyl-L-aspartic acid	antioxidant; human metabolite; mouse metabolite; nutraceutical; rat metabolite
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	[no description available]	medium	1	0	alkylbenzene; ring assembly
isoprene	[no description available]	medium	2	0	alkadiene; hemiterpene; volatile organic compound	plant metabolite
diadenosine tetraphosphate	[no description available]	medium	2	0	diadenosyl tetraphosphate	Escherichia coli metabolite; mouse metabolite
p(1),p(5)-di(adenosine-5'-)pentaphosphate	[no description available]	medium	2	0	organophosphate oxoanion
raffinose	[no description available]	medium	1	0	raffinose family oligosaccharide; trisaccharide	mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine	[no description available]	medium	2	0
protopine	[no description available]	medium	1	0	dibenzazecine alkaloid	plant metabolite
bpc 157	[no description available]	medium	1	0
benazepril	[no description available]	medium	1	1	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
t 440	[no description available]	medium	2	0
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide	[no description available]	medium	1	0
pibutidine hydrochloride	[no description available]	medium	3	0	hydrochloride	anti-ulcer drug; H2-receptor antagonist
sufotidine	[no description available]	medium	2	0	piperidines
tmk 688	[no description available]	medium	2	0
cytidine	[no description available]	medium	1	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3-iodobenzylguanidine	[no description available]	medium	2	0	organoiodine compound
2',3-dihydroxychalcone	[no description available]	medium	1	0
2',5'-dihydroxychalcone	[no description available]	medium	1	0	chalcones
tetramethylenedisulfotetramine	[no description available]	medium	1	0
1,3-dimethylthiourea	[no description available]	medium	1	0
bupivacaine	[no description available]	medium	6	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
plicatic acid	[no description available]	medium	3	0	lignan
methyl 2,5-dihydroxycinnamate	[no description available]	medium	1	0	cinnamate ester; hydroquinones; methyl ester	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; geroprotector; human urinary metabolite; plant metabolite
azetirelin	[no description available]	medium	1	0
dihydrofolate	[no description available]	medium	1	0	dihydrofolic acids	Escherichia coli metabolite; mouse metabolite
calcium dobesilate	[no description available]	medium	1	0
cicaprost	[no description available]	medium	2	0	monoterpenoid
ularitide	[no description available]	medium	1	0
fructose-1,6-diphosphate	[no description available]	medium	1	0
1,2-dioctanoylglycerol	[no description available]	medium	2	0
geldanamycin	[no description available]	medium	1	0
magnesium-pyridoxal-5'-phosphate glutamate	[no description available]	medium	1	0
propidium	[no description available]	medium	1	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
yf 476	[no description available]	medium	5	0
glycyltryptophan	[no description available]	medium	1	0	dipeptide	metabolite
t 3762	[no description available]	medium	1	0
5-(n,n-hexamethylene)amiloride	[no description available]	medium	1	0	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
fenspiride	[no description available]	medium	1	0	azaspiro compound
c.i. direct blue 1	[no description available]	medium	2	0
4-nitro-2-(3-phenylpropylamino)benzoate	[no description available]	medium	1	0
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide	[no description available]	medium	2	0	isoquinolines; sulfonamide
7-ketocholesterol	[no description available]	medium	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; 7-oxo steroid; cholestanoid	neuroprotective agent
19-hydroxycholesterol	[no description available]	medium	1	0	cholestanoid
bq 123	[no description available]	medium	3	0	cyclic peptide
n-acetylputrescine	[no description available]	medium	1	0	N-monoacetylalkane-alpha,omega-diamine; N-substituted putrescine	metabolite; mouse metabolite
batimastat	[no description available]	medium	1	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
ro 31-9790	[no description available]	medium	1	0
diethylenetriamine	[no description available]	medium	1	0	polyazaalkane; triamine
5-(biotinamido)pentylamine	[no description available]	medium	1	0
ecdysterone	[no description available]	medium	1	0	14alpha-hydroxy steroid; 20-hydroxy steroid; 22-hydroxy steroid; 25-hydroxy steroid; 2beta-hydroxy steroid; 3beta-sterol; ecdysteroid; phytoecdysteroid	animal metabolite; plant metabolite
gramicidin a	[no description available]	medium	3	0
9-anthroic acid	[no description available]	medium	2	0	anthroic acid
thymic factor, circulating	[no description available]	medium	3	0
3-mercaptopropionic acid	[no description available]	medium	3	0	mercaptopropanoic acid	algal metabolite
11,12-epoxy-5,8,14-eicosatrienoic acid	[no description available]	medium	2	0	11,12-EET	human xenobiotic metabolite
sodium iodide	[no description available]	medium	1	0	inorganic sodium salt; iodide salt
dithizone	[no description available]	medium	1	0
5,8,11-eicosatriynoic acid	[no description available]	medium	1	0	acetylenic fatty acid; icosanoid; long-chain fatty acid; polyunsaturated fatty acid	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor
p-dimethylaminoazobenzene	[no description available]	medium	2	0	azobenzenes
4-(n,n-dimethylaminoazobenzene)-4'-isothiocyanate	[no description available]	medium	1	0
snx 230	[no description available]	medium	3	0
n-acetylleukotriene e4	[no description available]	medium	1	0	leukotriene	human urinary metabolite
dihydrosterculic acid	[no description available]	medium	1	0
11-dehydro-thromboxane b2	[no description available]	medium	2	0	thromboxane	human metabolite
11-dehydro-thromboxane b2	[no description available]	medium	2	1	thromboxane	human metabolite
opc 12759	[no description available]	medium	1	0	secondary carboxamide
bn 50739	[no description available]	medium	2	0
perilla ketone	[no description available]	medium	1	0	aromatic ketone
acid citrate dextrose	[no description available]	medium	1	1
cilomilast	[no description available]	medium	2	0	methoxybenzenes
ah 6809	[no description available]	medium	1	0	xanthones
1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline	[no description available]	medium	1	0
tyrphostin 25	[no description available]	medium	2	0	benzenetriol
mezlocillin	[no description available]	medium	1	0	indolamine
palmitic acid	[no description available]	medium	1	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	[no description available]	medium	1	0
u 78517f	[no description available]	medium	1	0
pirfenidone	[no description available]	medium	1	0	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
clonixin	[no description available]	medium	1	0	aminopyridine; organochlorine compound; pyridinemonocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; vasodilator agent
flunixin meglumine	[no description available]	medium	1	0	organoammonium salt	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
nafagrel	[no description available]	medium	1	0
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine	[no description available]	medium	1	0	cyanine dye; indolium ion	fluorochrome
gr 73632	[no description available]	medium	1	0
whi p154	[no description available]	medium	1	0
ecopipam	[no description available]	medium	1	0	benzazepine
uroguanylin	[no description available]	medium	1	0
dithioerythritol	[no description available]	medium	1	1	1,4-dimercaptobutane-2,3-diol	reducing agent
ag-041r	[no description available]	medium	1	0
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-	[no description available]	medium	1	0	benzazepine
tenatoprazole	[no description available]	medium	1	0	imidazopyridine
arachidonyltrifluoromethane	[no description available]	medium	2	0	fatty acid derivative; ketone; olefinic compound; organofluorine compound	EC 3.1.1.4 (phospholipase A2) inhibitor
zinc sulfate	[no description available]	medium	6	0	metal sulfate; zinc molecular entity	fertilizer
sodium sulfate	[no description available]	medium	2	0	inorganic sodium salt
gt 2016	[no description available]	medium	2	0
isatin	[no description available]	medium	3	0	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
2-(2-benzofuranyl)-2-imidazoline	[no description available]	medium	1	0	benzofurans
bu 224	[no description available]	medium	1	0	quinolines
rapacuronium	[no description available]	medium	1	1	steroid ester
venlafaxine hydrochloride	[no description available]	medium	1	0	hydrochloride
fluconazole	[no description available]	medium	1	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
m 35	[no description available]	medium	2	0
5-(4-acetamidophenyl)pyrazin-2(1h)-one	[no description available]	medium	3	0
calcium crimson	[no description available]	medium	1	0	ammonium betaine; sulfonamide	fluorochrome
cresyl violet	[no description available]	medium	1	0
methyl gallate	[no description available]	medium	1	0	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite
ethyl gallate	[no description available]	medium	1	0	gallate ester	plant metabolite
safranine t	[no description available]	medium	4	0	organic chloride salt	fluorochrome; histological dye
xestospongin a	[no description available]	medium	2	0
piperacillin	[no description available]	medium	1	0
s6c sarafotoxin	[no description available]	medium	4	0
bp 2-94	[no description available]	medium	1	0
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid	[no description available]	medium	9	0	stilbenoid
dotarizine	[no description available]	medium	1	0	cyclic ketal; dioxolane; N-alkylpiperazine	calcium channel blocker; serotonergic antagonist; vasodilator agent
1-(3-chlorophenyl)piperazine	[no description available]	medium	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
arginyl-glycyl-aspartyl-serine	[no description available]	medium	1	0
rges peptide	[no description available]	medium	1	0
tetrabromophthalic anhydride	[no description available]	medium	1	0	2-benzofurans; cyclic dicarboxylic anhydride
fg 9041	[no description available]	medium	1	0	quinoxaline derivative
lead nitrate	[no description available]	medium	1	0	inorganic nitrate salt; lead coordination entity
isothiocyanic acid	[no description available]	medium	1	0	hydracid; one-carbon compound
iduronate	[no description available]	medium	1	0	idopyranuronic acid; L-iduronic acid
lavendustin a	[no description available]	medium	1	0	aromatic amine
antimycin	[no description available]	medium	1	0
alitretinoin	[no description available]	medium	1	0	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist
serotonin adipinate	[no description available]	medium	2	0
enkephalin, d-penicillamine (2,5)-	[no description available]	medium	2	0	heterodetic cyclic peptide	delta-opioid receptor agonist
strontium nitrate	[no description available]	medium	1	1
myristic acid	[no description available]	medium	1	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
cyanogen bromide	[no description available]	medium	1	0
azacitidine	[no description available]	medium	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
methyleugenol	[no description available]	medium	1	0	phenylpropanoid
clofibric acid	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
rhapontin	[no description available]	medium	1	0	rhaponticin	angiogenesis inhibitor; anti-allergic agent; anti-inflammatory agent; antilipemic drug; antineoplastic agent; apoptosis inducer; EC 2.3.1.85 (fatty acid synthase) inhibitor; hypoglycemic agent; neuroprotective agent; plant metabolite
thioinosine	[no description available]	medium	1	0
4-nitrobenzylthioinosine	[no description available]	medium	1	0	purine nucleoside
sr 142948a	[no description available]	medium	1	0
2-hydroxy-5-nitrobenzylthioguanosine	[no description available]	medium	1	0
n-acetylmannosamine	[no description available]	medium	1	0
n-propanoylmannosamine	[no description available]	medium	1	0
jte 522	[no description available]	medium	1	0	1,3-oxazoles; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor
diiodotyrosine	[no description available]	medium	2	0	diiodotyrosine; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite
sepiapterin	[no description available]	medium	2	0	sepiapterin
pteridines	[no description available]	medium	3	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; pteridines
xenopsin	[no description available]	medium	2	0
n-epsilon-acetyllysine	[no description available]	medium	1	0	acetyl-L-lysine; amino acid zwitterion; N(6)-acyl-L-lysine	human metabolite
n-methylacetamide	[no description available]	medium	1	0	acetamides; monocarboxylic acid amide	metabolite
nitecapone	[no description available]	medium	1	0	hydroxycinnamic acid
pinaverium	[no description available]	medium	2	0	monoterpenoid
my 1250	[no description available]	medium	1	0
motapizone	[no description available]	medium	1	0
zardaverine	[no description available]	medium	1	0	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
diadenosine 5',5''''-p1,p6-hexaphosphate	[no description available]	medium	1	0	diadenosyl hexaphosphate	vasoconstrictor agent
diadenosine triphosphate	[no description available]	medium	1	0	diadenosyl triphosphate	mouse metabolite
calvatic acid	[no description available]	medium	1	0
cuprizone	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
aminostigmine	[no description available]	medium	1	0
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline	[no description available]	medium	1	0
methyl angolensate	[no description available]	medium	1	0
an 1	[no description available]	medium	1	0	amphetamines
diquat	[no description available]	medium	1	0	organic cation	defoliant; herbicide
men 11420	[no description available]	medium	1	0
cp 105696	[no description available]	medium	1	0
ammonium peroxydisulfate	[no description available]	medium	1	0
firefly luciferin	[no description available]	medium	1	0	1,3-thiazolemonocarboxylic acid; benzothiazoles; imidothioate	luciferin
alpha-linolenic acid	[no description available]	medium	2	0	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
deoxypyridinoline	[no description available]	medium	1	0
8-(4-sulfophenyl)theophylline	[no description available]	medium	2	0
contrast agent p792	[no description available]	medium	1	0
denbinobin	[no description available]	medium	1	0
ethyl acetate	[no description available]	medium	1	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
arginyl-glycyl-aspartic acid	[no description available]	medium	1	0	oligopeptide
tetraglyme	[no description available]	medium	1	0	polyether
am-356	[no description available]	medium	1	0	fatty amide
gamma-glutamylmethylamide	[no description available]	medium	1	0
azuletil sodium	[no description available]	medium	1	0	organic sodium salt; organosulfonate salt	anti-ulcer drug; thromboxane A2 antagonist
isosorbide dinitrate	[no description available]	medium	5	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
atosiban	[no description available]	medium	1	0	oligopeptide
ha 1100	[no description available]	medium	1	0
sarpogrelate	[no description available]	medium	1	0	hemisuccinate; stilbenoid
nitrosoguanidines	[no description available]	medium	3	0
egta acetoxymethyl ester	[no description available]	medium	1	0
pyruvic acid	[no description available]	medium	2	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
harmine	[no description available]	medium	2	0	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
harman	[no description available]	medium	1	0	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
8-chloro-cyclic adenosine monophosphate	[no description available]	medium	1	0
tributyrin	[no description available]	medium	1	0	butyrate ester; triglyceride	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug; protective agent
u 73343	[no description available]	medium	1	0
2-butanol	[no description available]	medium	1	0	secondary alcohol
manoalide	[no description available]	medium	1	0	butenolide; lactol; sesterterpenoid	EC 3.1.1.4 (phospholipase A2) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite
ganhuangenin	[no description available]	medium	1	0
linopirdine	[no description available]	medium	1	0	indoles
dimethyl sulfone	[no description available]	medium	1	1	sulfone
ioversol	[no description available]	medium	1	0	amidobenzoic acid
iopamidol	[no description available]	medium	10	4	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
secologanin	[no description available]	medium	1	0	aldehyde; beta-D-glucoside; enoate ester; methyl ester; pyrans; secoiridoid glycoside	plant metabolite
labdane	[no description available]	medium	1	0	diterpene; terpenoid fundamental parent
xanthomicrol	[no description available]	medium	1	0	dihydroxyflavone; trimethoxyflavone	antineoplastic agent; plant metabolite
2-fluorohistidine	[no description available]	medium	2	0
benzene	[no description available]	medium	7	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
teprotide	[no description available]	medium	3	0	peptide
hs 310	[no description available]	medium	1	0
droxidopa	[no description available]	medium	1	0	catechols; L-tyrosine derivative	antihypertensive agent; prodrug; vasoconstrictor agent
nordefrin	[no description available]	medium	2	0	catecholamine
piperoxan	[no description available]	medium	2	0
tretoquinol	[no description available]	medium	2	0	isoquinolines
limestone	[no description available]	medium	2	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
dimethyldithiocarbamate	[no description available]	medium	1	0	dithiocarbamate anions
phenoperidine	[no description available]	medium	1	0	piperidines
chlorphenesin	[no description available]	medium	1	0	glycol; monochlorobenzenes; propane-1,2-diols	antibacterial drug; antifungal drug; muscle relaxant
disodium 4,4'-9((1,3-dioxo-1,3-propanediyl)diimino)dibenzoate	[no description available]	medium	1	0
4-aminobenzoic acid	[no description available]	medium	2	0	aminobenzoate; aromatic amino-acid anion	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
toxiferine	[no description available]	medium	1	1	alkaloid
1-isoamyl-3-isobutylxanthine	[no description available]	medium	1	0
pizotyline	[no description available]	medium	7	1	benzocycloheptathiophene	histamine antagonist; muscarinic antagonist; serotonergic antagonist
thenyldiamine	[no description available]	medium	1	0	dialkylarylamine; tertiary amino compound
bitolterol	[no description available]	medium	3	1	carboxylic ester; diester; ethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; prodrug
fenclonine	[no description available]	medium	8	0	phenylalanine derivative
p-chloroamphetamine	[no description available]	medium	1	0
pivampicillin	[no description available]	medium	1	0	penicillanic acid ester; pivaloyloxymethyl ester	prodrug
minocycline	[no description available]	medium	1	0
molybdenum	[no description available]	medium	1	0	chromium group element atom	micronutrient
acetyl coenzyme a	[no description available]	medium	1	0	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
lypressin	[no description available]	medium	5	0	cyclic peptide
amobarbital	[no description available]	medium	4	0	barbiturates
dimethoxyphenylethylamine	[no description available]	medium	2	0	alkaloid; aromatic ether; phenylethylamine	allergen; plant metabolite
bromine	[no description available]	medium	2	0	diatomic bromine
glycylglycine	[no description available]	medium	1	0	dipeptide zwitterion; dipeptide	human metabolite
ninhydrin	[no description available]	medium	2	0	aromatic ketone; beta-diketone; indanones; ketone hydrate	colour indicator; human metabolite
tosyllysine chloromethyl ketone	[no description available]	medium	1	0	sulfonic acid derivative
chymosin	[no description available]	medium	1	0
o-chlorobenzylidenemalonitrile	[no description available]	medium	1	0	organochlorine compound
dithionite	[no description available]	medium	1	0	sulfur oxide; sulfur oxoanion
hexylcaine	[no description available]	medium	1	0	benzoate ester
enclomiphene	[no description available]	medium	3	0
menotropins	[no description available]	medium	2	0
amitrole	[no description available]	medium	2	0	aromatic amine; triazoles	carotenoid biosynthesis inhibitor; EC 1.11.1.6 (catalase) inhibitor; herbicide
trenbolone acetate	[no description available]	medium	1	0	steroid ester
daunorubicin	[no description available]	medium	3	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
2,6-dinitro-4-trifluoromethylbenzenesulfonic acid	[no description available]	medium	1	0
antimony potassium tartrate	[no description available]	medium	1	0
tremorine	[no description available]	medium	8	0	N-alkylpyrrolidine
adenosine 5'-phosphoramidate	[no description available]	medium	1	0	organic phosphoramidate	Mycoplasma genitalium metabolite
trithiozine	[no description available]	medium	1	0	methoxybenzenes
samarium	[no description available]	medium	3	0	f-block element atom; lanthanoid atom
4-methylesculetin	[no description available]	medium	1	0	hydroxycoumarin	anti-inflammatory agent; antioxidant; hyaluronan synthesis inhibitor
nicotinyl alcohol	[no description available]	medium	2	0	aromatic primary alcohol; pyridines	antilipemic drug; vasodilator agent
trimecaine	[no description available]	medium	1	0	amino acid amide
dexetimide	[no description available]	medium	1	0	piperidines
ethoxazene	[no description available]	medium	1	0	azobenzenes
tritoqualine	[no description available]	medium	7	2	isoquinolines
anserine	[no description available]	medium	2	0	beta-alanine derivative; dipeptide; zwitterion	animal metabolite; mouse metabolite
butaclamol	[no description available]	medium	1	0
i(3)so3-galactosylceramide	[no description available]	medium	1	0	galactosylceramide sulfate; N-acyl-beta-D-galactosylsphingosine
bromopride	[no description available]	medium	1	0	benzamides
n 0164	[no description available]	medium	1	0
2-hydroxy-5-nitrobenzyl bromide	[no description available]	medium	1	0
bromosuccinimide	[no description available]	medium	1	0	dicarboximide; organobromine compound; pyrrolidinone	reagent
hexestrol	[no description available]	medium	1	0	stilbenoid
dianisidine	[no description available]	medium	1	0	biphenyls
thioacetamide	[no description available]	medium	3	0	thiocarboxamide	hepatotoxic agent
cephaloridine	[no description available]	medium	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
fenclorac	[no description available]	medium	1	0
thorium	[no description available]	medium	2	0	actinoid atom; f-block element atom
diphenoxylate	[no description available]	medium	1	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
thiamine pyrophosphate	[no description available]	medium	3	0	organic chloride salt; vitamin B1
levorphanol	[no description available]	medium	5	0	morphinane alkaloid
lynestrenol	[no description available]	medium	3	0	steroid
norleucine	[no description available]	medium	1	0	2-aminohexanoic acid; L-alpha-amino acid zwitterion; non-proteinogenic L-alpha-amino acid
deet	[no description available]	medium	1	0	benzamides; monocarboxylic acid amide	environmental contaminant; insect repellent; xenobiotic
prodolic acid	[no description available]	medium	1	0
caloreen	[no description available]	medium	1	0
quinacrine mustard	[no description available]	medium	1	0	hydrochloride	intercalator
skatole	[no description available]	medium	1	0	methylindole	human metabolite; mammalian metabolite
thebaine	[no description available]	medium	1	0	morphinane alkaloid; organic heteropentacyclic compound
aminorex	[no description available]	medium	1	0	benzenes
Brilliant Blue	[no description available]	medium	1	0	organic molecular entity
triphenyltin chloride	[no description available]	medium	1	0	chlorine molecular entity; organotin compound	antifungal agrochemical; immunosuppressive agent
andolast	[no description available]	medium	1	0
hydantoic acid	[no description available]	medium	1	0	monocarboxylic acid; N-acylglycine; ureas	rat metabolite; xenobiotic metabolite
cyclosporin h	[no description available]	medium	1	0
1,9-dideoxyforskolin	[no description available]	medium	1	0	acetate ester; labdane diterpenoid; organic heterotricyclic compound	plant metabolite
fructose 2,6-diphosphate	[no description available]	medium	1	0	D-fructofuranose 2,6-bisphosphate	human metabolite; mouse metabolite
3-o-methylglucose	[no description available]	medium	1	0	D-aldohexose derivative
n-formylmethionylphenylalanine	[no description available]	medium	1	0	peptide
15(s)-15-methylprostaglandin e1	[no description available]	medium	2	0	prostanoid
neurokinin a(4-10), tyr(5)-trp(6,8,9)-lys(10)-	[no description available]	medium	1	0
perezone	[no description available]	medium	1	0
hydroxymaprotilin	[no description available]	medium	2	0
prilocaine	[no description available]	medium	5	4	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
psd 502	[no description available]	medium	3	3
cefuroxime	[no description available]	medium	1	0	carbamate ester; cephalosporin
xamoterol	[no description available]	medium	1	0	morpholines
t 0509	[no description available]	medium	1	0
esaprazole	[no description available]	medium	1	0
t-kinin	[no description available]	medium	1	0	peptide
monocrotaline	[no description available]	medium	2	0	pyrrolizidine alkaloid
flutropium bromide	[no description available]	medium	3	0
amlexanox	[no description available]	medium	6	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
bw 443c	[no description available]	medium	2	0
nz 107	[no description available]	medium	4	0
sulotroban	[no description available]	medium	1	0
2-mercaptomethyl-3-guanidinoethylthiopropionic acid	[no description available]	medium	2	0
ethidium	[no description available]	medium	1	0	phenanthridines	fluorochrome; intercalator
betamethasone-17,21-dipropionate	[no description available]	medium	3	1
b 823-08	[no description available]	medium	1	0	aromatic ether
pd 136450	[no description available]	medium	1	0
9-anthroylcholine	[no description available]	medium	1	0
sennoside a&b	[no description available]	medium	1	0
bu-e 75	[no description available]	medium	1	0
inositol 1,3,4-trisphosphate	[no description available]	medium	1	0	inositol phosphate oxoanion	human metabolite
phenylalaninol	[no description available]	medium	1	0	amino alcohol; amphetamines; primary alcohol; primary amino compound
ifosfamide	[no description available]	medium	2	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
phenyltrimethylammonium	[no description available]	medium	1	0	quaternary ammonium ion
cicletanine	[no description available]	medium	10	0	organochlorine compound
digitonin	[no description available]	medium	5	0
s(alpha)-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid	[no description available]	medium	1	0
xylamine	[no description available]	medium	1	0
3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one	[no description available]	medium	1	0
neon	[no description available]	medium	1	0	monoatomic neon; noble gas atom; p-block element atom
propoxycaine	[no description available]	medium	1	0	benzoate ester
proxymetacaine	[no description available]	medium	1	0	benzoate ester
8,15-leukotriene b4	[no description available]	medium	1	0
phorbol-12,13-didecanoate	[no description available]	medium	2	0
as 35	[no description available]	medium	1	0
cgp 35348	[no description available]	medium	1	0
copper bis(histidinate)	[no description available]	medium	1	0
idazoxan	[no description available]	medium	4	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
lhrh, n-ac-2-nal(1)-4-cl-phe(2)-trp(3)-hci(6)-alanh2(10)-	[no description available]	medium	1	0
arg-3-hyp-7-phe-bradykinin	[no description available]	medium	1	0	oligopeptide	bradykinin receptor antagonist
substance p (4-11), pro(4)-trp(7,9,10)-	[no description available]	medium	2	0
dextrorphan	[no description available]	medium	1	0	morphinane alkaloid
4,4'-dinitro-2,2'-stilbenedisulfonic acid	[no description available]	medium	1	0	4,4'-dinitrostilbene-2,2'-disulfonic acid
glucagon-like peptide 1 (1-37)	[no description available]	medium	1	0
inositol 2-monophosphate	[no description available]	medium	1	0
repirinast	[no description available]	medium	1	0	organic molecular entity
cilazapril, anhydrous	[no description available]	medium	1	0	dicarboxylic acid monoester; ethyl ester; pyridazinodiazepine	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
cilazaprilat	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid
meglumine ioglicinate	[no description available]	medium	1	0
docusate	[no description available]	medium	2	0	diester; organosulfonic acid
chlormethiazole	[no description available]	medium	1	0	thiazoles
senktide	[no description available]	medium	1	0
6-methoxy-n-(3-sulfopropyl)quinolinium	[no description available]	medium	1	0
1,2-diaminopropane	[no description available]	medium	1	0	diamine	ligand
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt	[no description available]	medium	2	0	organosulfur compound; sulfonic acid derivative
enkephalin-leu, ala(2)-arg(6)-	[no description available]	medium	2	0
miltefosine	[no description available]	medium	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
1-hexadecyl-2-methoxyglycero-3-phosphocholine	[no description available]	medium	1	0
1-o-hexadecyl-2-o-methylglycerol	[no description available]	medium	1	0
n'-cyano-n-(3-pyridyl)-n''-(t-butyl)guanidine	[no description available]	medium	1	0
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	[no description available]	medium	1	0	1,1-diunsubstituted alkanesulfonate
y 20811	[no description available]	medium	1	0
gr 63799x	[no description available]	medium	1	0
2-phenyl-3-(n,n-dimethylaminopropyl)-1,3-thiazolidin-4-one	[no description available]	medium	1	0
cotinine	[no description available]	medium	2	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
pirarubicin	[no description available]	medium	1	0	anthracycline
4-aminomethylbenzoic acid	[no description available]	medium	1	0	benzoic acids
methoxsalen	[no description available]	medium	2	1	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
hydroxide ion	[no description available]	medium	1	0	oxygen hydride	mouse metabolite
biperiden	[no description available]	medium	1	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid	[no description available]	medium	1	0
bicuculline methochloride	[no description available]	medium	1	0
ethoxyquin	[no description available]	medium	1	0	aromatic ether; quinolines	antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator
s-ethyl glutathione	[no description available]	medium	1	0	oligopeptide
aminacrine	[no description available]	medium	2	0	aminoacridines; primary amino compound	acid-base indicator; antiinfective agent; antiseptic drug; fluorescent dye; MALDI matrix material; mutagen
cularine	[no description available]	medium	1	0	alkaloid
nuvenzepine	[no description available]	medium	1	0
nco 650	[no description available]	medium	3	0
3-tyr-octreotide	[no description available]	medium	1	0
strophanthidin	[no description available]	medium	1	0	14beta-hydroxy steroid; 19-oxo steroid; 3beta-hydroxy steroid; 5beta-hydroxy steroid; cardenolides; steroid aldehyde
detomidine	[no description available]	medium	1	0
7,8-(methylenedioxy)-14-hydroxyberbane	[no description available]	medium	1	0
setastine	[no description available]	medium	1	0	diarylmethane
clentiazem	[no description available]	medium	1	0
u 66985	[no description available]	medium	2	0
himbacine	[no description available]	medium	1	0	gamma-lactone; organic heterotricyclic compound; piperidine alkaloid	muscarinic antagonist
btm 1042	[no description available]	medium	1	0
2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran	[no description available]	medium	2	0
enkephalinamide-leu, ala(2)-	[no description available]	medium	1	0
3,4-dihydroxyphenylglycol	[no description available]	medium	1	0	catechols; tetrol	metabolite; mouse metabolite
azuletil	[no description available]	medium	1	0	arenesulfonic acid; azulenes	anti-ulcer drug; thromboxane A2 antagonist
9-hydroxy-10,12-octadecadienoic acid	[no description available]	medium	1	0	HODE; octadecadienoic acid	human metabolite; metabolite; mouse metabolite; plant metabolite
ticarcillin	[no description available]	medium	1	1	penicillin allergen; penicillin	antibacterial drug
lacidipine	[no description available]	medium	1	0	cinnamate ester; tert-butyl ester
hoe k86-4321	[no description available]	medium	1	0
2-phenyl-1,2-benzisothiazol-3-(2h)-one	[no description available]	medium	1	0
sch 37224	[no description available]	medium	2	0
carboxypeptidase b	[no description available]	medium	1	0
sr 2640	[no description available]	medium	1	0	quinolines
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2	[no description available]	medium	1	0	prostaglandins J; secondary alcohol	antineoplastic agent; antiviral agent
12-deoxyphorbol 13-isobutyrate	[no description available]	medium	2	0
glicentin	[no description available]	medium	2	0
tetrachlorophthalic anhydride	[no description available]	medium	1	0	cyclic dicarboxylic anhydride; tetrachlorobenzene	allergen; cross-linking reagent
phenosafranine	[no description available]	medium	1	0	organic chloride salt	fluorochrome; histological dye; photosensitizing agent
quinaldic acid	[no description available]	medium	1	0	quinolinemonocarboxylic acid	human metabolite; Saccharomyces cerevisiae metabolite
aluminum hydroxide, magnesium hydroxide, drug combination	[no description available]	medium	1	0
saxitoxin	[no description available]	medium	1	0	alkaloid; carbamate ester; guanidines; ketone hydrate; paralytic shellfish toxin; pyrrolopurine	cyanotoxin; marine metabolite; neurotoxin; sodium channel blocker; toxin
sch 37370	[no description available]	medium	1	0
sdz 64-412	[no description available]	medium	1	0
coenzyme q10	[no description available]	medium	2	0	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite
dimephosphon	[no description available]	medium	1	0
n'-acetylspermine	[no description available]	medium	1	0	acetamides; acetylspermine	human metabolite
bradykinin, met-lys-	[no description available]	medium	2	0
8-cyclopropyltheophylline	[no description available]	medium	1	0
n-hydroxysuccinimide suberic acid ester	[no description available]	medium	1	0
3-amino-6-methyl-5-phenyl-2(1h)-pyridinone	[no description available]	medium	1	0
darodipine	[no description available]	medium	4	0
dihydroouabain	[no description available]	medium	2	0
homoarginine	[no description available]	medium	1	0	homoarginine; L-lysine derivative; non-proteinogenic L-alpha-amino acid	biomarker; EC 3.1.3.1 (alkaline phosphatase) inhibitor; human metabolite; rat metabolite; xenobiotic metabolite
ioglicic acid	[no description available]	medium	2	1	amidobenzoic acid
quinone	[no description available]	medium	1	0	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
acitretin	[no description available]	medium	1	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid	[no description available]	medium	1	0
mezlocillin	[no description available]	medium	2	0
substance p (4-11), pro(4)-trp(7,9)-	[no description available]	medium	2	0
defibrotide	[no description available]	medium	2	0
vasopressin, deamino-homo-arg-	[no description available]	medium	1	0
alpha-hydrazinohistidine	[no description available]	medium	6	0
yc 170	[no description available]	medium	1	0	anilide
enkephalinamide-met, ala(2)-	[no description available]	medium	1	0
trimoprostil	[no description available]	medium	2	1
pn 202-791	[no description available]	medium	1	0	benzoxadiazole; isopropyl ester
perfluorotributylamine	[no description available]	medium	1	0	organofluorine compound	blood substitute; greenhouse gas; solvent
poloxalene	[no description available]	medium	1	0	epoxide
methoxyamine	[no description available]	medium	1	0	organooxygen compound
sulfolane	[no description available]	medium	1	0	sulfone; tetrahydrothiophenes	polar aprotic solvent
rhodanine	[no description available]	medium	1	0	thiazolidinone
emorfazone	[no description available]	medium	1	0	organic molecular entity
methohexital	[no description available]	medium	4	1	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene	[no description available]	medium	1	0
azo rubin s	[no description available]	medium	1	0
6-methyl-n-(1h-tetrazol-5-yl)-2-pyridinecarboxamide	[no description available]	medium	1	0
carbogen	[no description available]	medium	1	0
calmidazolium	[no description available]	medium	3	0	imidazolium ion	apoptosis inducer; calmodulin antagonist
dicetylphosphate	[no description available]	medium	1	0	dialkyl phosphate
r 59022	[no description available]	medium	1	0	diarylmethane
trimethionine	[no description available]	medium	1	0	oligopeptide
kp 136	[no description available]	medium	1	0
dihydro-dids	[no description available]	medium	1	0
picumast	[no description available]	medium	1	0
6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)	[no description available]	medium	1	0
orotirelin	[no description available]	medium	1	0
keratan sulfate	[no description available]	medium	1	0
dazmegrel	[no description available]	medium	1	0
l 648051	[no description available]	medium	3	1
lipoxin a5	[no description available]	medium	1	0	HEPE
lipoxin b5	[no description available]	medium	1	0
b 4162	[no description available]	medium	1	0
cdta	[no description available]	medium	1	0	organooxygen compound
tazifylline	[no description available]	medium	1	1
isofloxythepin	[no description available]	medium	1	0
3,3'-di-o-methylquercetin	[no description available]	medium	1	0	3'-methoxyflavones; dimethoxyflavone; trihydroxyflavone	antibacterial agent; antineoplastic agent; apoptosis inducer; plant metabolite
rilmenidine	[no description available]	medium	3	1	isourea
somatostatin, tyr(11)-	[no description available]	medium	1	0
medetomidine	[no description available]	medium	1	0	imidazoles
atipamezole	[no description available]	medium	1	0
na 0345	[no description available]	medium	1	0
bradykinin, (thi-ala)(5,8)-phe(7)-	[no description available]	medium	1	0
amoxicillin-potassium clavulanate combination	[no description available]	medium	1	1
bradykinin, des-phe(8)-des-arg(9)-	[no description available]	medium	1	0	oligopeptide	human metabolite; rat metabolite
ah 23848	[no description available]	medium	1	0	(4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid
cobra cardiotoxin proteins	[no description available]	medium	1	0
12-deoxyphorbol-13-isobutyrate-20-acetate	[no description available]	medium	1	0
vincamine	[no description available]	medium	1	0	alkaloid ester; hemiaminal; methyl ester; organic heteropentacyclic compound; vinca alkaloid	antihypertensive agent; metabolite; vasodilator agent
restacorin	[no description available]	medium	1	0
azodicarbonamide	[no description available]	medium	1	0	organic molecular entity
6-chloro-2-(1-piperazinyl)pyrazine	[no description available]	medium	1	0	N-arylpiperazine
threitol	[no description available]	medium	1	0	threitol	human metabolite
gossypol	[no description available]	medium	1	0
etimizol	[no description available]	medium	2	0
sk&f 102922	[no description available]	medium	1	0
2-amino-4-phosphonobutyric acid	[no description available]	medium	1	0
sri 63-441	[no description available]	medium	1	0
benzothiazole	[no description available]	medium	1	0	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic
isoguvacine	[no description available]	medium	1	0	tetrahydropyridine
amifostine anhydrous	[no description available]	medium	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
deltakephalin	[no description available]	medium	1	0
n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine	[no description available]	medium	1	0
propionylcholine	[no description available]	medium	1	0	acylcholine
2-octopamine	[no description available]	medium	1	0
medazepam	[no description available]	medium	1	0	organic molecular entity
ro 03-7894	[no description available]	medium	1	0
tzu 0460	[no description available]	medium	2	0	piperidines
oxepins	[no description available]	medium	1	0
etintidine	[no description available]	medium	3	0
amitraz	[no description available]	medium	1	0	formamidines; tertiary amino compound	acaricide; environmental contaminant; insecticide; xenobiotic
1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol	[no description available]	medium	1	0
hydroxybenzylisoproterenol	[no description available]	medium	1	0
fepradinol	[no description available]	medium	1	0	aralkylamine
colterol	[no description available]	medium	1	0	catechols; ethanolamines; secondary alcohol; secondary amino compound; triol	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent
2,3-diaminopropionic acid	[no description available]	medium	1	0	alanine derivative; amino acid zwitterion; beta-amino acid; diamino acid; non-proteinogenic alpha-amino acid	Escherichia coli metabolite
cyclazocine	[no description available]	medium	1	0
ethylketocyclazocine	[no description available]	medium	1	0
hypolaetin-8-glucoside	[no description available]	medium	1	0
bombesin nonapeptide	[no description available]	medium	1	0
parthenin	[no description available]	medium	1	0	sesquiterpene lactone
ips 339	[no description available]	medium	1	0
cysteine sulfinic acid	[no description available]	medium	1	0
sauvagine	[no description available]	medium	1	0
ly 53857	[no description available]	medium	1	0
sodium chromate(vi)	[no description available]	medium	1	0	inorganic sodium salt	carcinogenic agent; diagnostic agent; oxidising agent; poison
chromates	[no description available]	medium	3	0	chromium oxoanion; divalent inorganic anion	oxidising agent
androsta-1,4,6-triene-3,17-dione	[no description available]	medium	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; androstanoid	EC 1.14.14.14 (aromatase) inhibitor; human xenobiotic metabolite
4,17-dimethyltrilostane	[no description available]	medium	1	0
diflorasone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-inflammatory drug
l 649923	[no description available]	medium	4	1
enisoprost	[no description available]	medium	1	1
leukotriene f-4	[no description available]	medium	1	0	dipeptide; leukotriene; organic sulfide	human metabolite
8-azidoadenosine-3',5'-monophosphate	[no description available]	medium	1	0
be 2254	[no description available]	medium	1	0	tetralins
rubidium chloride	[no description available]	medium	1	0	inorganic chloride; rubidium molecular entity	antidepressant; biomarker
kadsurenone	[no description available]	medium	4	0	benzofurans
butaprost	[no description available]	medium	1	0
cis methyldioxolane	[no description available]	medium	1	0
fpl 57231	[no description available]	medium	2	0
5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid	[no description available]	medium	1	0
alprazolam	[no description available]	medium	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
mesulergine	[no description available]	medium	1	0	ergot alkaloid; sulfamides	antiparkinson drug; dopamine agonist; serotonergic antagonist
3-deazaadenosine	[no description available]	medium	1	0
cobaltous chloride	[no description available]	medium	2	0	cobalt salt; inorganic chloride	allergen; calcium channel blocker; sensitiser; two-colour indicator
vidarabine	[no description available]	medium	1	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
enkephalin-met, arg(6)-phe(7)-	[no description available]	medium	2	0	organic molecular entity
ramipril	[no description available]	medium	1	1	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
octyl glucoside	[no description available]	medium	1	0	beta-D-glucoside	plant metabolite
phorbol	[no description available]	medium	1	0	cyclic ketone; enone; tertiary alcohol; tertiary alpha-hydroxy ketone; tetracyclic diterpenoid
cortisol 21-mesylate	[no description available]	medium	1	0
nizatidine	[no description available]	medium	1	0
fce 20700	[no description available]	medium	1	0
aplysiatoxin	[no description available]	medium	1	0	aplysiatoxins; bromophenol; cyclic hemiketal; ether; organic heterotricyclic compound; secondary alcohol; spiroketal	algal metabolite; carcinogenic agent; cyanotoxin; marine metabolite; protein kinase C agonist
teleocidin b-4	[no description available]	medium	1	0
buserelin	[no description available]	medium	1	1	oligopeptide
piriprost	[no description available]	medium	1	0
chlorodiphenyl (54% chlorine)	[no description available]	medium	1	0
heptanal	[no description available]	medium	1	0	medium-chain fatty aldehyde; n-alkanal; saturated fatty aldehyde	biomarker
glycyl-histidyl-lysine	[no description available]	medium	2	0	tripeptide	chelator; hepatoprotective agent; metabolite; vulnerary
amifampridine	[no description available]	medium	1	0	aminopyridine
diphenylmethane	[no description available]	medium	1	0	diarylmethane
5-dimethylamiloride	[no description available]	medium	1	0
arachidonic acid omega-9 hydroperoxide	[no description available]	medium	1	0	HPETE	mouse metabolite
quin2-acetoxymethyl ester	[no description available]	medium	3	0
soman	[no description available]	medium	3	0	phosphonic ester
nickel chloride	[no description available]	medium	1	0	nickel coordination entity	calcium channel blocker; hapten
trimeperidine	[no description available]	medium	1	0
2,3-diketogulonic acid	[no description available]	medium	1	0
oxodipine	[no description available]	medium	1	0
almitrine	[no description available]	medium	1	0	piperazines; triamino-1,3,5-triazine	central nervous system stimulant
ru 42173	[no description available]	medium	1	0	benzazepine
bamifylline	[no description available]	medium	1	0	oxopurine
4-aminobutyraldehyde	[no description available]	medium	1	0	aminobutanal; omega-aminoaldehyde	Escherichia coli metabolite; mouse metabolite
bn 52063	[no description available]	medium	1	1
pirlindole	[no description available]	medium	1	0	carbazoles
kebuzone	[no description available]	medium	1	0	methyl ketone; pyrazolidines	non-narcotic analgesic; non-steroidal anti-inflammatory drug
benzotript	[no description available]	medium	1	0
bacampicillin	[no description available]	medium	1	0	penicillanic acid ester	prodrug
talampicillin	[no description available]	medium	1	0	penicillanic acid ester	prodrug
sulfur hexafluoride	[no description available]	medium	1	0	sulfur coordination entity	greenhouse gas; NMR chemical shift reference compound; ultrasound contrast agent
guanfacine	[no description available]	medium	1	0	acetamides
granular blue	[no description available]	medium	1	0
racecadotril	[no description available]	medium	1	0	N-acyl-amino acid
cyanopindolol	[no description available]	medium	1	0	indoles
arginine	[no description available]	medium	1	0
thioguanine anhydrous	[no description available]	medium	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
alpha-methyltyrosine methyl ester	[no description available]	medium	1	0
t-2 toxin	[no description available]	medium	2	0
thiamylal	[no description available]	medium	1	0	barbiturates; organosulfur compound	sedative
triolein	[no description available]	medium	4	0	triglyceride	Caenorhabditis elegans metabolite; plant metabolite
10,10'-dimethyl-9,9'-biacridinium	[no description available]	medium	1	0
5'-methylthioadenosine	[no description available]	medium	2	0	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
gaboxadol	[no description available]	medium	1	0	oxazole
aminooxyacetic acid	[no description available]	medium	1	0	amino acid; hydroxylamines; monocarboxylic acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; nootropic agent
cgp 28392	[no description available]	medium	1	0	aromatic ether
morantel	[no description available]	medium	1	0
osmium tetroxide	[no description available]	medium	1	0	osmium coordination entity	fixative; histological dye; oxidising agent; poison
hematoporphyrin	[no description available]	medium	1	0
13,14-didehydro-20-methylcarboprostacyclin	[no description available]	medium	1	0
ro 22-6923	[no description available]	medium	2	0
tocainide	[no description available]	medium	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
3-methyl-2-benzothiazolone hydrazone	[no description available]	medium	1	0
glycodeoxycholic acid	[no description available]	medium	1	0	bile acid glycine conjugate	human metabolite
cyclosporin c	[no description available]	medium	1	0
n-succinimidyl-3-(4-hydroxyphenyl)propionate	[no description available]	medium	1	0
3-dimethylaminopropylamine	[no description available]	medium	1	0
heptafluorobutyric anhydride	[no description available]	medium	1	0	acyclic carboxylic anhydride; organofluorine compound	chromatographic reagent
dimethylnitrosamine	[no description available]	medium	1	0	nitrosamine	geroprotector; mutagen
pentaquine	[no description available]	medium	1	0
pamaquine	[no description available]	medium	1	0	aminoquinoline
5,6-dihydroxytryptamine	[no description available]	medium	1	0
5,6-dihydroxy-2-dimethylaminotetralin	[no description available]	medium	1	0	tetralins
isophosphamide mustard	[no description available]	medium	1	0	phosphorodiamide
methylmercuric chloride	[no description available]	medium	1	0	chlorine molecular entity; mercury coordination entity; one-carbon compound
spizofurone	[no description available]	medium	1	0	benzofurans
acriflavine	[no description available]	medium	1	0
vitamin d 2	[no description available]	medium	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
paramethasone	[no description available]	medium	1	0	fluorinated steroid
oxyphenonium	[no description available]	medium	1	0	acylcholine
metaperiodate	[no description available]	medium	3	0	iodine oxoacid
ethylene oxide	[no description available]	medium	1	0	gas molecular entity; oxacycle; saturated organic heteromonocyclic parent	allergen; mouse metabolite; mutagen
tetrahydroharmane	[no description available]	medium	1	0
nitrofurazone	[no description available]	medium	1	0
methaqualone	[no description available]	medium	1	0	quinazolines	GABA agonist; sedative
iodohippuric acid	[no description available]	medium	1	0	benzamides; N-acylglycine; organoiodine compound
chlorates	[no description available]	medium	1	0	chlorine oxoanion; monovalent inorganic anion
phenylthiourea	[no description available]	medium	1	0	thioureas	EC 1.14.18.1 (tyrosinase) inhibitor
arbaprostil	[no description available]	medium	1	0	prostanoid
indium	[no description available]	medium	2	0	boron group element atom
dichlorodiphenyldichloroethane	[no description available]	medium	2	0	chlorophenylethane; monochlorobenzenes; organochlorine insecticide	xenobiotic metabolite
scandium	[no description available]	medium	2	0	d-block element atom; rare earth metal atom; scandium group element atom
hydroxocobalamin	[no description available]	medium	1	0
tricalcium phosphate	[no description available]	medium	1	0	calcium phosphate
oxazepam	[no description available]	medium	3	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
neodymium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
benperidol	[no description available]	medium	6	0	aromatic ketone
doxapram	[no description available]	medium	1	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
rimiterol	[no description available]	medium	1	1	catechols
isocarboxazid	[no description available]	medium	2	0	benzenes
pregnanediol	[no description available]	medium	5	0
acetylene	[no description available]	medium	1	0	alkyne; gas molecular entity; terminal acetylenic compound
lincomycin	[no description available]	medium	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
levoleucovorin	[no description available]	medium	1	0	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
niobium	[no description available]	medium	2	0	vanadium group element atom
megestrol	[no description available]	medium	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
levallorphan	[no description available]	medium	1	0	morphinane alkaloid
phenmetrazine	[no description available]	medium	1	0	morpholines	metabolite; sympathomimetic agent
diethylpropion	[no description available]	medium	1	0	aromatic ketone; tertiary amine	appetite depressant
cephalothin	[no description available]	medium	1	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
n-pentanol	[no description available]	medium	1	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
caprylates	[no description available]	medium	1	0	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
butoxybenzyl hyoscyamine	[no description available]	medium	1	0
wr 99210	[no description available]	medium	1	0
bemegride	[no description available]	medium	1	0	piperidones
chlormerodrin	[no description available]	medium	1	0	organomercury compound; ureas	diagnostic agent; diuretic
psilocybin	[no description available]	medium	1	0	organic phosphate; tertiary amino compound; tryptamine alkaloid	fungal metabolite; hallucinogen; prodrug; serotonergic agonist
trinitrotoluene	[no description available]	medium	1	0	trinitrotoluene	explosive
azaguanine	[no description available]	medium	1	0	nucleobase analogue; triazolopyrimidines	antimetabolite; antineoplastic agent; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
fusidic acid	[no description available]	medium	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
methylergonovine	[no description available]	medium	1	0	ergoline alkaloid
osmium	[no description available]	medium	1	0	iron group element atom; platinum group metal atom
glutaminase	[no description available]	medium	1	0
sorbose	[no description available]	medium	1	0	L-sorbose; sorbopyranose
rhamnose	[no description available]	medium	1	0	L-rhamnose
arabinose	[no description available]	medium	1	0	L-arabinose	Escherichia coli metabolite; mouse metabolite
radon	[no description available]	medium	1	0	monoatomic radon; noble gas atom; p-block element atom
francium	[no description available]	medium	1	0	alkali metal atom
antimony	[no description available]	medium	2	0	metalloid atom; pnictogen
ethyl biscoumacetate	[no description available]	medium	1	0	hydroxycoumarin
triaziquone	[no description available]	medium	1	0	1,4-benzoquinones; aziridines	alkylating agent; antineoplastic agent
delphinidin	[no description available]	medium	1	0	anthocyanidin chloride
pectins	[no description available]	medium	1	0	D-galactopyranuronic acid
fomesafen	[no description available]	medium	235	14	aromatic ether; C-nitro compound; monochlorobenzenes; N-sulfonylcarboxamide; organofluorine compound; phenols	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
eye	[no description available]	medium	44	2
exudates	[no description available]	medium	2	0
isomethyleugenol	[no description available]	medium	111	1	isomethyleugenol
s,n,n'-tripropylthiocarbamate	[no description available]	medium	11	0	tertiary amine
humulene	[no description available]	medium	7	0	alpha-humulene
sabinene	[no description available]	medium	6	0	thujene	plant metabolite
ants	[no description available]	medium	11	0
trolamine salicylate	[no description available]	medium	65	0
egg white	[no description available]	medium	28	0
arctiin	[no description available]	medium	1	0	glycoside; lignan
nociceptin	[no description available]	medium	7	0	organic molecular entity; polypeptide	human metabolite; rat metabolite
rosmarinic acid	[no description available]	medium	2	1	rosmarinic acid	geroprotector; plant metabolite
apnea	[no description available]	medium	11	0	purine nucleoside
phenoxyacetic acid	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid	allergen; Aspergillus metabolite; human xenobiotic metabolite; plant growth retardant
iodinated glycerol	[no description available]	medium	6	0	dioxolane
4-methoxyamphetamine	[no description available]	medium	9	0
sodium ethylxanthate	[no description available]	medium	4	1
2-propanol	[no description available]	medium	16	0	secondary alcohol; secondary fatty alcohol	protic solvent
cetylpyridinium chloride anhydrous	[no description available]	medium	3	1	chloride salt; organic chloride salt	antiseptic drug; surfactant
3,4-methylenedioxyamphetamine	[no description available]	medium	1	0	benzodioxoles
fenoxycarb	[no description available]	medium	1	0	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
propiconazole	[no description available]	medium	1	0	conazole fungicide; cyclic ketal; dichlorobenzene; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
fenpyroximate	[no description available]	medium	1	0	pyrazole acaricide; tert-butyl ester	mitochondrial NADH:ubiquinone reductase inhibitor
rome	[no description available]	medium	1	0	2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol	EC 2.7.1.91 (sphingosine kinase) inhibitor
hypericum	[no description available]	medium	1	0	penicillanic acids
torpedo	[no description available]	medium	1	0
fusarium	[no description available]	medium	1	0
pica	[no description available]	medium	1	0
foxes	[no description available]	medium	2	0
3-tyramine	[no description available]	low	0	0	primary amino compound; tyramines	human urinary metabolite; neurotransmitter
pterostilbene	[no description available]	low	0	0	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger
acetylcarnitine	[no description available]	low	0	0	O-acylcarnitine	human metabolite
2-oxo-3-methylvalerate	[no description available]	low	0	0	2-oxo monocarboxylic acid; branched-chain keto acid	human metabolite
alpha-ketoisovalerate	[no description available]	low	0	0	2-oxo monocarboxylic acid; branched-chain keto acid	human metabolite; Saccharomyces cerevisiae metabolite
2-keto-4-methylvalerate	[no description available]	low	0	0	2-oxo monocarboxylic acid; branched-chain keto acid	algal metabolite; human metabolite
3-hydroxyanthranilic acid	[no description available]	low	0	0	aminobenzoic acid; monohydroxybenzoic acid	human metabolite; mouse metabolite
3-hydroxykynurenine	[no description available]	low	0	0	hydroxykynurenine	human metabolite
3-oxoadipic acid	[no description available]	low	0	0	dicarboxylic fatty acid; oxo dicarboxylic acid	bacterial xenobiotic metabolite; human metabolite
3-mercaptopyruvic acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; thiol	antidote to cyanide poisoning; Escherichia coli metabolite; human metabolite; mouse metabolite
3-phenylpropionic acid	[no description available]	low	0	0	benzenes; monocarboxylic acid	antifungal agent; human metabolite; plant metabolite
4-hydroxyphenylacetic acid	[no description available]	low	0	0	monocarboxylic acid; phenols	fungal metabolite; human metabolite; mouse metabolite; plant metabolite
isocaproaldehyde	[no description available]	low	0	0	alpha-CH2-containing aldehyde	human metabolite; mouse metabolite
aminolevulinic acid	[no description available]	low	0	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
5-aminovaleric acid	[no description available]	low	0	0	amino acid zwitterion; delta-amino acid; omega-amino fatty acid	human metabolite
acetyl phosphate	[no description available]	low	0	0	acyl monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
betaine aldehyde	[no description available]	low	0	0	quaternary ammonium ion	Aspergillus metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite
ureidosuccinic acid	[no description available]	low	0	0	aspartic acid derivative; C4-dicarboxylic acid; N-carbamoyl-amino acid	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
aminoethylphosphonic acid	[no description available]	low	0	0	phosphonic acids; primary amino compound; zwitterion	human metabolite; metabolite; mouse metabolite
octanoic acid	[no description available]	low	0	0	medium-chain fatty acid; straight-chain saturated fatty acid	antibacterial agent; Escherichia coli metabolite; human metabolite
dihydrolipoic acid	[no description available]	low	0	0	thio-fatty acid	antioxidant; human metabolite; neuroprotective agent
methylmalonic acid	[no description available]	low	0	0	C4-dicarboxylic acid	human metabolite
pyrrolidonecarboxylic acid	[no description available]	low	0	0	oxoproline; pyrrolidin-2-ones; pyrrolidinemonocarboxylic acid	human metabolite
alpha-keto-delta-guanidinovaleric acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; zwitterion	human metabolite; mouse metabolite
dihydrouracil	[no description available]	low	0	0	pyrimidone	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
dihydrolipoamide	[no description available]	low	0	0	dithiol; monocarboxylic acid amide	cofactor; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
dihydroxyacetone phosphate	[no description available]	low	0	0	glycerone phosphates; primary alpha-hydroxy ketone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
dihydroxyacetone	[no description available]	low	0	0	ketotriose; primary alpha-hydroxy ketone	antifungal agent; Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
dimethylglycine	[no description available]	low	0	0	amino acid zwitterion; N-methyl-amino acid; N-methylglycines	Daphnia magna metabolite; human metabolite; mouse metabolite
5,6-dimethylbenzimidazole	[no description available]	low	0	0	dimethylbenzimidazole	Escherichia coli metabolite; human metabolite
gamma-butyrobetaine	[no description available]	low	0	0	amino-acid betaine	Escherichia coli metabolite; human metabolite
glutaric acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	Daphnia magna metabolite; human metabolite
glycolaldehyde	[no description available]	low	0	0	glycolaldehydes	fundamental metabolite; human metabolite
glyoxylic acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; aldehydic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycocyamine	[no description available]	low	0	0	guanidinoacetic acids; zwitterion	bacterial metabolite; human metabolite; mouse metabolite; nutraceutical; rat metabolite
hydrogen cyanide	[no description available]	low	0	0	hydracid; one-carbon compound	Escherichia coli metabolite; human metabolite; poison
homogentisic acid	[no description available]	low	0	0	dihydroxyphenylacetic acid; hydroquinones	human metabolite; plant metabolite
indole-3-acetaldehyde	[no description available]	low	0	0	indoleacetaldehyde	bacterial metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
potassium	[no description available]	low	0	0	alkali metal cation; elemental potassium; monoatomic monocation; monovalent inorganic cation	cofactor; human metabolite
lipoamide	[no description available]	low	0	0	dithiolanes; monocarboxylic acid amide	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
methylmercaptan	[no description available]	low	0	0	alkanethiol	human metabolite; Saccharomyces cerevisiae metabolite
n-acetylserotonin	[no description available]	low	0	0	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist
n-methylphenylethanolamine	[no description available]	low	0	0	alkaloid; phenylethanolamines	human metabolite; plant metabolite
hydroxypyruvic acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; 3-hydroxy monocarboxylic acid; primary alpha-hydroxy ketone	Escherichia coli metabolite; human metabolite
oxalic acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid	algal metabolite; human metabolite; plant metabolite
4-hydroxyphenylpyruvic acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; phenols	human metabolite
hexadecanal	[no description available]	low	0	0	2,3-saturated fatty aldehyde; long-chain fatty aldehyde	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-hydroxyphenethylamine	[no description available]	low	0	0	phenylethanolamines	human metabolite
phosphoric acid	[no description available]	low	0	0	phosphoric acids	algal metabolite; fertilizer; human metabolite; NMR chemical shift reference compound; solvent
phosphorylethanolamine	[no description available]	low	0	0	phosphoethanolamine; primary amino compound	algal metabolite; human metabolite; mouse metabolite
pyridoxamine phosphate	[no description available]	low	0	0	aminoalkylpyridine; methylpyridines; monohydroxypyridine; vitamin B6 phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-(4-methyl-1,3-thiazol-5-yl)ethanol	[no description available]	low	0	0	1,3-thiazoles; primary alcohol	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
perillic acid	[no description available]	low	0	0	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid	antineoplastic agent; human metabolite; mouse metabolite
meglutol	[no description available]	low	0	0	3-hydroxy carboxylic acid; dicarboxylic acid; tertiary alcohol	anticholesteremic drug; antimetabolite; EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; human metabolite; plant metabolite
3-hydroxy-4-methoxyphenethylamine	[no description available]	low	0	0	monomethoxybenzene; phenols; phenylethylamine; primary amino compound	human metabolite; rat metabolite
cetyl alcohol	[no description available]	low	0	0	hexadecanol; long-chain primary fatty alcohol	algal metabolite; flavouring agent; human metabolite; plant metabolite
4-cresol	[no description available]	low	0	0	cresol	Escherichia coli metabolite; human metabolite; uremic toxin
decanoic acid	[no description available]	low	0	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; anti-inflammatory agent; antibacterial agent; human metabolite; plant metabolite; volatile oil component
nordazepam	[no description available]	low	0	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
2,5-dihydroxybenzoic acid	[no description available]	low	0	0	dihydroxybenzoic acid	EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite
indolepropionic acid	[no description available]	low	0	0	indol-3-yl carboxylic acid	auxin; human metabolite; plant metabolite
3-phenyllactic acid	[no description available]	low	0	0	2-hydroxy monocarboxylic acid	human metabolite
2-amino-3-phosphonopropionic acid	[no description available]	low	0	0	alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids	human metabolite; metabotropic glutamate receptor antagonist
2-phenylglycine	[no description available]	low	0	0	non-proteinogenic alpha-amino acid	human metabolite
sebacic acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite
stearic acid	[no description available]	low	0	0	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
succinylacetone	[no description available]	low	0	0	beta-diketone; dioxo monocarboxylic acid	human metabolite
retinoic acid	[no description available]	low	0	0	alpha,beta-unsaturated monocarboxylic acid; retinoid	human metabolite
cysteine	[no description available]	low	0	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
etiocholanolone	[no description available]	low	0	0	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid	human metabolite; mouse metabolite
uridine monophosphate	[no description available]	low	0	0	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
3-methylpentane	[no description available]	low	0	0	alkane; volatile organic compound	allelochemical; human metabolite; non-polar solvent
methylcyclopentane	[no description available]	low	0	0	cycloalkane; volatile organic compound	human metabolite; plant metabolite
phosphoribosyl pyrophosphate	[no description available]	low	0	0	5-O-phosphono-D-ribofuranosyl diphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite
1-phenethylamine	[no description available]	low	0	0	phenylethylamine	human metabolite
isethionic acid	[no description available]	low	0	0	alkanesulfonic acid	human metabolite
methylcyclohexane	[no description available]	low	0	0	cycloalkane; volatile organic compound	aprotic solvent; human metabolite; plant metabolite
undecanoic acid	[no description available]	low	0	0	medium-chain fatty acid; straight-chain saturated fatty acid	antifungal agent; human metabolite
1-tridecanol	[no description available]	low	0	0	long-chain primary fatty alcohol; tridecanol	bacterial metabolite; human metabolite; plant metabolite
stearyl alcohol	[no description available]	low	0	0	long-chain primary fatty alcohol; octadecanol	algal metabolite; human metabolite; plant metabolite
acetol	[no description available]	low	0	0	methyl ketone; primary alcohol; primary alpha-hydroxy ketone; propanones	Escherichia coli metabolite; human metabolite; mouse metabolite
2-methylbutanoic acid	[no description available]	low	0	0	methylbutyric acid	bacterial metabolite; human metabolite
hexanoic acid	[no description available]	low	0	0	medium-chain fatty acid; straight-chain saturated fatty acid	human metabolite; plant metabolite
isopropyl palmitate	[no description available]	low	0	0	fatty acid ester; isopropyl ester	human metabolite
pregnenolone	[no description available]	low	0	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
dibenzo(a,l)pyrene	[no description available]	low	0	0	ortho- and peri-fused polycyclic arene	human metabolite; mutagen
3-methoxytyrosine	[no description available]	low	0	0	aromatic L-alpha-amino acid zwitterion; L-tyrosine derivative; monomethoxybenzene; non-proteinogenic L-alpha-amino acid	human metabolite
4-hydroxyphenyllactic acid	[no description available]	low	0	0	2-hydroxy carboxylic acid; phenols	bacterial metabolite; human metabolite
lithocholic acid	[no description available]	low	0	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
4-methylcatechol	[no description available]	low	0	0	methylcatechol	antioxidant; carcinogenic agent; hapten; human metabolite; plant metabolite
homocystine	[no description available]	low	0	0	amino acid zwitterion; homocystines	human metabolite
epitestosterone	[no description available]	low	0	0	17alpha-hydroxy steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen antagonist; human metabolite
indican	[no description available]	low	0	0	aryl sulfate; indoles	human metabolite
suberic acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite
hexadecanedioic acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite
pyridoxamine dihydrochloride	[no description available]	low	0	0	hydrochloride; vitamin B6	Escherichia coli metabolite; human metabolite; iron chelator; mouse metabolite; nephroprotective agent; plant metabolite; Saccharomyces cerevisiae metabolite
aceturic acid	[no description available]	low	0	0	N-acetyl-amino acid; N-acylglycine	human metabolite
lignoceric acid	[no description available]	low	0	0	straight-chain saturated fatty acid; very long-chain fatty acid	Daphnia tenebrosa metabolite; human metabolite; plant metabolite; volatile oil component
18-hydroxycorticosterone	[no description available]	low	0	0	11beta-hydroxy steroid; 18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo steroid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
3-methylhexane	[no description available]	low	0	0	alkane; volatile organic compound	human metabolite
ethylmalonic acid	[no description available]	low	0	0	dicarboxylic acid; dicarboxylic fatty acid	human metabolite
galactitol	[no description available]	low	0	0	hexitol	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
2-hydroxyphenylacetic acid	[no description available]	low	0	0	hydroxy monocarboxylic acid; phenols	human metabolite; mouse metabolite
5-methyl-2-furfural	[no description available]	low	0	0	aldehyde; furans	EC 2.2.1.6 (acetolactate synthase) inhibitor; flavouring agent; human metabolite; Maillard reaction product
2-hexanol	[no description available]	low	0	0	hexanol; secondary alcohol	human metabolite; plant metabolite; semiochemical
1,1,3,3-tetramethylurea	[no description available]	low	0	0	ureas	human metabolite
glycochenodeoxycholic acid	[no description available]	low	0	0	bile acid glycine conjugate	human metabolite
isocaproic acid	[no description available]	low	0	0	branched-chain saturated fatty acid; medium-chain fatty acid; methyl-branched fatty acid	human metabolite
dodecanedioic acid	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; human metabolite
2'-deoxyadenosine	[no description available]	low	0	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1-pentene-3-one	[no description available]	low	0	0	enone	flavouring agent; genotoxin; human metabolite; plant metabolite
9,10-epoxystearic acid	[no description available]	low	0	0	epoxystearic acid	human metabolite
beta-hydroxymyristic acid	[no description available]	low	0	0	3-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; long-chain fatty acid	bacterial metabolite; human metabolite
perillaldehyde	[no description available]	low	0	0	aldehyde; olefinic compound	human metabolite; mouse metabolite; volatile oil component
tricosanoic acid	[no description available]	low	0	0	straight-chain saturated fatty acid; very long-chain fatty acid	Daphnia magna metabolite; human metabolite; plant metabolite
uridine diphosphate glucuronic acid	[no description available]	low	0	0	UDP-D-glucuronic acid	Escherichia coli metabolite; human metabolite; mouse metabolite
tetrahydropapaveroline	[no description available]	low	0	0	benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; isoquinolinol	human metabolite
cyclic cmp	[no description available]	low	0	0	3',5'-cyclic pyrimidine nucleotide	human metabolite
furoylglycine	[no description available]	low	0	0	furans; N-acylglycine	human metabolite
3,3',5'-triiodothyronine	[no description available]	low	0	0	iodothyronine	human metabolite
limonene	[no description available]	low	0	0	cycloalkene; p-menthadiene	human metabolite
urobilinogen	[no description available]	low	0	0	bilanes	human metabolite
estetrol	[no description available]	low	0	0	15alpha-hydroxy steroid; 16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid; steroid hormone	estrogen receptor agonist; estrogen; human metabolite; human xenobiotic metabolite; oral contraceptive
iron	[no description available]	low	0	0	divalent metal cation; iron cation; monoatomic dication	cofactor; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1-methyladenosine	[no description available]	low	0	0	methyladenosine	human metabolite
dimethylacetamide	[no description available]	low	0	0	acetamides; monocarboxylic acid amide	human metabolite
pregnanolone	[no description available]	low	0	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
s-adenosylmethionine	[no description available]	low	0	0	sulfonium betaine	human metabolite
acetylgalactosamine	[no description available]	low	0	0	N-acetyl-D-hexosamine; N-acetylgalactosamine	Escherichia coli metabolite; human metabolite; mouse metabolite
norsalsolinol	[no description available]	low	0	0	isoquinolinol	animal metabolite; apoptosis inducer; human metabolite; marine metabolite
2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline	[no description available]	low	0	0	isoquinolinol; tertiary amino compound	human metabolite; neurotoxin; rat metabolite
1,5-anhydroglucitol	[no description available]	low	0	0	anhydro sugar	human metabolite
3-methylhistidine	[no description available]	low	0	0	L-histidine derivative; non-proteinogenic L-alpha-amino acid; zwitterion	human metabolite; Saccharomyces cerevisiae metabolite
5-methylcytosine	[no description available]	low	0	0	methylcytosine; pyrimidines	human metabolite
deoxyuridine triphosphate	[no description available]	low	0	0	deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-triphosphate	Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite
homocitrulline	[no description available]	low	0	0	amino acid zwitterion; L-lysine derivative; non-proteinogenic L-alpha-amino acid; ureas	human metabolite; mouse metabolite
cholesteryl sulfate	[no description available]	low	0	0	steroid sulfate	human metabolite
2'-deoxycytidine 5'-triphosphate	[no description available]	low	0	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
25-hydroxycholesterol	[no description available]	low	0	0	25-hydroxy steroid; oxysterol	human metabolite
n-acetylserine	[no description available]	low	0	0	acetyl-L-serine; N-acetyl-L-amino acid	human metabolite
o-4-methylthymine	[no description available]	low	0	0	aromatic ether; methylthymine	human metabolite
tetraiodothyroacetic acid	[no description available]	low	0	0	2-halophenol; aromatic ether; iodophenol; monocarboxylic acid	apoptosis inducer; human metabolite; thyroid hormone
lathosterol	[no description available]	low	0	0	3beta-sterol; C27-steroid; cholestanoid; Delta(7)-sterol	human metabolite; mouse metabolite
omega-aminocaprylic acid	[no description available]	low	0	0	medium-chain fatty acid; omega-amino fatty acid	human metabolite
parabanic acid	[no description available]	low	0	0	hydracid; imidazolidinone	human metabolite
n-acetyl-l-arginine	[no description available]	low	0	0	N-acetyl-L-amino acid	human metabolite
cystine	[no description available]	low	0	0	cystine zwitterion; cystine; L-cysteine derivative; non-proteinogenic L-alpha-amino acid	EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitor; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
6-methyladenine	[no description available]	low	0	0	6-alkylaminopurine; methyladenine	human metabolite
phenylacetylglycine	[no description available]	low	0	0	monocarboxylic acid amide; monocarboxylic acid; N-acylglycine	human metabolite; mouse metabolite
hydracrylic acid	[no description available]	low	0	0	3-hydroxy monocarboxylic acid; omega-hydroxy-short-chain fatty acid	Escherichia coli metabolite; human metabolite
hordenine	[no description available]	low	0	0	phenethylamine alkaloid	human metabolite; mouse metabolite
4-methoxyestradiol	[no description available]	low	0	0	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; phenols	estrogen; human metabolite; rat metabolite
glutaurine	[no description available]	low	0	0	dipeptide zwitterion; dipeptide; L-glutamine derivative; sulfonic acid	anticonvulsant; anxiolytic drug; hormone; human metabolite; mammalian metabolite; mouse metabolite
plasmenylserine	[no description available]	low	0	0	O-phosphoserine	EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ubiquinone-o	[no description available]	low	0	0	ubiquinones	Escherichia coli metabolite; human metabolite
beta-hydroxyisovaleric acid	[no description available]	low	0	0	3-hydroxy monocarboxylic acid	human metabolite
indole-3-carboxylic acid	[no description available]	low	0	0	indol-3-yl carboxylic acid	bacterial metabolite; human metabolite
5-hydroxymethylcytosine	[no description available]	low	0	0	aminopyrimidine; aromatic primary alcohol; nucleobase analogue; pyrimidone	human metabolite; mouse metabolite
n-acetylglutamic acid	[no description available]	low	0	0	N-acetyl-L-amino acid; N-acyl-L-glutamic acid	human metabolite; Saccharomyces cerevisiae metabolite
2,5-dihydroxybenzaldehyde	[no description available]	low	0	0	dihydroxybenzaldehyde	human metabolite; mouse metabolite; Penicillium metabolite
D-serine	[no description available]	low	0	0	D-alpha-amino acid; serine zwitterion; serine	Escherichia coli metabolite; human metabolite; NMDA receptor agonist
D-alanine	[no description available]	low	0	0	alanine zwitterion; alanine; D-alpha-amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite
2-ketopentanoic acid	[no description available]	low	0	0	2-oxo monocarboxylic acid; oxopentanoic acid	human metabolite
hydroxyindoleacetaldehyde	[no description available]	low	0	0	hydroxyindoles; indoleacetaldehyde	human metabolite; mouse metabolite
leucylleucine	[no description available]	low	0	0	dipeptide; L-aminoacyl-L-amino acid zwitterion	human metabolite; Mycoplasma genitalium metabolite
5-hydroxymethyluracil	[no description available]	low	0	0	primary alcohol; pyrimidone	human metabolite
12-hydroxydodecanoic acid	[no description available]	low	0	0	omega-hydroxy-medium-chain fatty acid	human metabolite
decane-1,2-diol	[no description available]	low	0	0	glycol; volatile organic compound	anti-inflammatory agent; antioxidant; human metabolite
4-nitrophenyl sulfate	[no description available]	low	0	0	aryl sulfate; C-nitro compound	human metabolite
glucose-1,6-bisphosphate	[no description available]	low	0	0	D-glucose 1,6-bisphosphate	Escherichia coli metabolite; human metabolite
biotinamide	[no description available]	low	0	0	biotins; monocarboxylic acid amide	human metabolite
3,4-dihydroxymandelic acid	[no description available]	low	0	0	2-hydroxy monocarboxylic acid; catechols	antioxidant; drug metabolite; human metabolite; mouse metabolite
3-hydroxymandelic acid	[no description available]	low	0	0	2-hydroxy monocarboxylic acid; phenols	human metabolite
n-acetylalanine	[no description available]	low	0	0	L-alanine derivative; N-acetyl-L-amino acid	human metabolite; Saccharomyces cerevisiae metabolite
17-alpha-hydroxypregnenolone	[no description available]	low	0	0	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; hydroxypregnenolone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
cholest-4-en-3-one	[no description available]	low	0	0	3-oxo-Delta(4) steroid; cholestanoid	human metabolite; plant metabolite
mephentermine	[no description available]	low	0	0	2-aminooctadecane-1,3-diol	EC 2.7.11.13 (protein kinase C) inhibitor; human metabolite; mouse metabolite
2-pinene oxide	[no description available]	low	0	0	epoxide; pinane monoterpenoid	bacterial xenobiotic metabolite; fragrance; human metabolite
3-hydroxybutyric acid	[no description available]	low	0	0	3-hydroxybutyric acid; ketone body	fungal metabolite; human metabolite; pheromone
L-2-aminoadipic acid	[no description available]	low	0	0	2-aminoadipic acid	Escherichia coli metabolite; human metabolite
testosterone acetate	[no description available]	low	0	0	3-oxo-Delta(4) steroid; androstanoid; sterol ester	human metabolite
phenylacetylglutamine	[no description available]	low	0	0	N(2)-phenylacetylglutamine	human metabolite
5beta-pregnane-3,20-dione	[no description available]	low	0	0	20-oxo steroid; 3-oxo-5beta-steroid; C21-steroid	human metabolite; mouse metabolite
zymosterol	[no description available]	low	0	0	3beta-sterol; cholestanoid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
brexanolone	[no description available]	low	0	0	3-hydroxy-5alpha-pregnan-20-one	antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative
5-alpha-dihydroprogesterone	[no description available]	low	0	0	20-oxo steroid; 3-oxo-5alpha-steroid; C21-steroid hormone	human metabolite; progestogen
2-hydroxyhexadecanoic acid	[no description available]	low	0	0	2-hydroxy fatty acid; hydroxypalmitic acid	human metabolite
19-oxo-delta(4) androstene-3,17-dione	[no description available]	low	0	0	17-oxo steroid; 19-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid; steroid aldehyde	human metabolite
gamma-glutamylglutamate	[no description available]	low	0	0	dipeptide	human metabolite
indole-3-lactic acid	[no description available]	low	0	0	hydroxy monocarboxylic acid; indol-3-yl carboxylic acid	human metabolite
n(alpha)-acetyllysine	[no description available]	low	0	0	acetyl-L-lysine; amino acid zwitterion	human metabolite
glycyl-l-phenylalanine	[no description available]	low	0	0	dipeptide zwitterion; dipeptide	human metabolite; metabolite
5,6-dihydrothymine	[no description available]	low	0	0	pyrimidone	human metabolite; metabolite; mouse metabolite
gamma-glutamyltyrosine	[no description available]	low	0	0	dicarboxylic acid; dipeptide; phenols; primary amino compound; secondary carboxamide	human metabolite
cholest-5-ene-3 beta,26-diol	[no description available]	low	0	0	26-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol	EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
2-hydroxyisovaleric acid	[no description available]	low	0	0	2-hydroxy monocarboxylic acid	human metabolite
aminomalonic acid	[no description available]	low	0	0	amino dicarboxylic acid	Daphnia magna metabolite; human metabolite
zymostenol	[no description available]	low	0	0	3beta-sterol; cholestanoid	human metabolite; mouse metabolite
16-hydroxydehydroepiandrosterone	[no description available]	low	0	0	16alpha-hydroxy steroid; 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid; secondary alpha-hydroxy ketone	human metabolite; mouse metabolite
cortisol 21-sulfate	[no description available]	low	0	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; cortisol ester; steroid sulfate; tertiary alpha-hydroxy ketone	human metabolite
1,2-distearoylphosphatidylethanolamine	[no description available]	low	0	0	phosphatidylethanolamine zwitterion; phosphatidylethanolamine	human metabolite
hydrogen sulfite	[no description available]	low	0	0	sulfur oxoanion	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aflatoxin b1-2,3-oxide	[no description available]	low	0	0	aflatoxin	human metabolite
pregnenolone sulfate	[no description available]	low	0	0	steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite
3,3'-diiodothyronine	[no description available]	low	0	0	3,3'-diiodothyronine; amino acid zwitterion	human metabolite
propionylcarnitine	[no description available]	low	0	0	O-acylcarnitine	analgesic; antirheumatic drug; cardiotonic drug; human metabolite; peripheral nervous system drug
hypotaurine	[no description available]	low	0	0	aminosulfinic acid; zwitterion	human metabolite; metabolite; mouse metabolite
testosterone 17-glucosiduronate	[no description available]	low	0	0	3-oxo steroid; beta-D-glucosiduronic acid; enone; steroid glucosiduronic acid	human metabolite
3-chloro-L-tyrosine	[no description available]	low	0	0	chloroamino acid; L-alpha-amino acid zwitterion; L-tyrosine derivative; monochlorobenzenes; non-proteinogenic L-alpha-amino acid	biomarker; human metabolite
androsterone glucuronide	[no description available]	low	0	0	beta-D-glucosiduronic acid; steroid glucosiduronic acid	human metabolite; metabolite; mouse metabolite
selenomethylselenocysteine	[no description available]	low	0	0	non-proteinogenic alpha-amino acid; selenocysteines	antineoplastic agent; human metabolite
1,5(10)-estradiene-3,4,17-trione	[no description available]	low	0	0	17-oxo steroid; 3-oxo-Delta(1) steroid; orthoquinones	human metabolite
s-sulphocysteine	[no description available]	low	0	0	organic thiosulfate; S-substituted L-cysteine	human metabolite; plant metabolite
estrone-3-glucuronide	[no description available]	low	0	0	17-oxo steroid; beta-D-glucosiduronic acid; steroid glucosiduronic acid	human metabolite; mouse metabolite
3,4-dihydroxyphenylacetaldehyde	[no description available]	low	0	0	alpha-CH2-containing aldehyde; catechols; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite
1-hydroxyethyl radical	[no description available]	low	0	0	organic anion	human metabolite; Saccharomyces cerevisiae metabolite
(20s)-20-hydroxycholesterol	[no description available]	low	0	0	20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol	human metabolite; mouse metabolite
deoxyhypusine	[no description available]	low	0	0	L-lysine derivative; non-proteinogenic L-alpha-amino acid	human metabolite
3,7,12-trihydroxycoprostanic acid	[no description available]	low	0	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; cholestanoic acid; hydroxy monocarboxylic acid	human metabolite
triiodothyronine sulfate	[no description available]	low	0	0	aryl sulfate; O-sulfoamino acid	human metabolite
3,7,12-trihydroxycholestan-26-oic acid	[no description available]	low	0	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; hydroxy monocarboxylic acid; steroid acid	human metabolite
erythrose 4-phosphate	[no description available]	low	0	0	erythrose phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
n(8)-acetylspermidine	[no description available]	low	0	0	acetylspermidine	Escherichia coli metabolite; human metabolite
7 alpha-hydroxy-4-cholesten-3-one	[no description available]	low	0	0	3-oxo-Delta(4) steroid; 7alpha-hydroxy steroid; cholestanoid	human metabolite; mouse metabolite
pristanic acid	[no description available]	low	0	0	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid	human metabolite
gamma-glutamylcysteine	[no description available]	low	0	0	gamma-glutamylcysteine	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
27-hydroxycholesterol	[no description available]	low	0	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid	[no description available]	low	0	0	dicarboxylic acid; furoic acid	human metabolite; uremic toxin
dehydroalanine	[no description available]	low	0	0	2,3-dehydroamino acid; alpha,beta-unsaturated monocarboxylic acid; amino acid zwitterion; enamine; non-proteinogenic alpha-amino acid	alkylating agent; human metabolite; mouse metabolite
hypothiocyanite ion	[no description available]	low	0	0	one-carbon compound; sulfur oxoacid	antibacterial agent; antifungal agent; antiviral agent; human metabolite; oxidising agent; rat metabolite
3-c-methylerythritol	[no description available]	low	0	0	tetritol	human metabolite
succinylacetoacetate	[no description available]	low	0	0	alpha,omega-dicarboxylic acid; beta-diketone	human metabolite
isoursodeoxycholic acid	[no description available]	low	0	0	dihydroxy-5beta-cholanic acid	human metabolite
mannitol-1-phosphate	[no description available]	low	0	0	alditol 1-phosphate; hexitol phosphate	Escherichia coli metabolite; human metabolite
kinetensin	[no description available]	low	0	0	oligopeptide	histamine releasing agent; human metabolite
estra-1(10),4-diene-2,3,17-trione	[no description available]	low	0	0	17-oxo steroid; 3-oxo-Delta(4) steroid; orthoquinones	human metabolite
2'-deoxycytidine diphosphate	[no description available]	low	0	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-diphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
n-methylserotonin	[no description available]	low	0	0	phenols; tryptamines	human metabolite; plant metabolite
gamma-glutamylglutamine	[no description available]	low	0	0	dipeptide	human metabolite
3,4-dihydroxybutanoic acid	[no description available]	low	0	0	3-hydroxy fatty acid; omega-hydroxy-short-chain fatty acid	human metabolite
n-palmitoylglycine	[no description available]	low	0	0	fatty amide; N-acylglycine 16:0	human metabolite; marine metabolite
gamma-glutamyl-leucine	[no description available]	low	0	0	glutamyl-L-amino acid	human metabolite
ribulose	[no description available]	low	0	0	ribulose	Escherichia coli metabolite; human metabolite
3,4-dihydroxyphenylglycolaldehyde	[no description available]	low	0	0	catechols; hydroxyaldehyde	human metabolite; mouse metabolite; neurotoxin
androsterone sulfate	[no description available]	low	0	0	17-oxo steroid; androstanoid; steroid sulfate	human metabolite; mouse metabolite
3,7,12-trihydroxycoprostane	[no description available]	low	0	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid	human metabolite; mouse metabolite
saccharopine	[no description available]	low	0	0	amino acid opine; L-lysine derivative	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
orotidylic acid	[no description available]	low	0	0	pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
allocholic acid	[no description available]	low	0	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; allo-bile acid; C24-steroid	human metabolite; marine metabolite; rat metabolite
beta-ureidoisobutyric acid	[no description available]	low	0	0	ureidocarboxylic acid	human metabolite; mouse metabolite
kynurenine	[no description available]	low	0	0	amino acid zwitterion; kynurenine; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nicotinate ribonucleoside	[no description available]	low	0	0	ammonium betaine	human metabolite
n(6)-(n-threonylcarbonyl)adenosine	[no description available]	low	0	0	L-threonine derivative; N-(adenosin-N(6)-ylcarbonyl)threonine	Escherichia coli metabolite; human metabolite
sedoheptulose 7-phosphate	[no description available]	low	0	0	ketoheptose phosphate; sedoheptulose derivative	Escherichia coli metabolite; human metabolite; mouse metabolite
thiocysteine	[no description available]	low	0	0	amino acid zwitterion; S-substituted L-cysteine	human metabolite; mouse metabolite
nicotinic acid adenine dinucleotide	[no description available]	low	0	0	nicotinic acid dinucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
4,4-dimethyl-5-alpha-cholesta-(8,24)-dien-3-beta-ol	[no description available]	low	0	0	3beta-sterol	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
isobutyryl-1-carnitine	[no description available]	low	0	0	methyl-branched fatty acyl-L-carnitine; O-isobutyrylcarnitine; saturated fatty acyl-L-carnitine	human metabolite
aceglutamide	[no description available]	low	0	0	N-acetyl-L-amino acid; N(2)-acetylglutamine; N(2)-acyl-L-glutamine	human metabolite
aflatoxin b1	[no description available]	low	0	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
2'-deoxyadenosine triphosphate	[no description available]	low	0	0	2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-diphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
2-ethylhydracrylic acid	[no description available]	low	0	0	branched-chain saturated fatty acid; hydroxy fatty acid; short-chain fatty acid	human metabolite
2-methyl-3-oxovaleric acid	[no description available]	low	0	0	3-oxo monocarboxylic acid	human metabolite
monoacetylcadaverine	[no description available]	low	0	0	acetamides; N-substituted cadaverine; primary amino compound; secondary carboxamide	human metabolite
beta-citrylglutamic acid	[no description available]	low	0	0	N-acyl-L-glutamic acid; tetracarboxylic acid	human metabolite; iron chelator
maltotriose	[no description available]	low	0	0	maltotriose trisaccharide	human metabolite
cholestane-3,7,12,26-tetrol	[no description available]	low	0	0	12alpha-hydroxy steroid; 26-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid	human metabolite; mouse metabolite
beta-leucine	[no description available]	low	0	0	beta-amino acid	human metabolite
2-methylbutyrylglycine	[no description available]	low	0	0	N-acylglycine	human metabolite
neurotensin (1-8)	[no description available]	low	0	0	peptide zwitterion; peptide	human metabolite
cholic acid	[no description available]	low	0	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
5 alpha-androstane-3 beta,17 beta-diol	[no description available]	low	0	0	17beta-hydroxy steroid; 3beta-hydroxy steroid; androstane-3,17-diol	Daphnia magna metabolite; human metabolite
cholesteryl palmitate	[no description available]	low	0	0	cholesteryl ester	human metabolite; mouse metabolite
lanosterol	[no description available]	low	0	0	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
5-hydroxyisourate	[no description available]	low	0	0	oxopurine	human metabolite; mouse metabolite
5-formyluracil	[no description available]	low	0	0	aldehyde; nucleobase analogue; pyrimidone	human metabolite; mutagen
taurochenodeoxycholic acid	[no description available]	low	0	0	bile acid taurine conjugate	human metabolite; mouse metabolite
5'-deoxyadenosine	[no description available]	low	0	0	5'-deoxyribonucleoside; adenosines	Escherichia coli metabolite; human metabolite; mouse metabolite
isomaltose	[no description available]	low	0	0	glycosylglucose	human metabolite; metabolite; mouse metabolite
glucosamine 6-phosphate	[no description available]	low	0	0	2-amino-2-deoxy-D-glucopyranose 6-phosphate	human metabolite; Saccharomyces cerevisiae metabolite
5-hydroxytryptophan	[no description available]	low	0	0	5-hydroxytryptophan; amino acid zwitterion; hydroxy-L-tryptophan; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; plant metabolite
dopaquinone	[no description available]	low	0	0	1,2-benzoquinones; amino acid zwitterion; L-phenylalanine derivative	human metabolite; mouse metabolite
pantetheine	[no description available]	low	0	0	pantetheines; thiol	human metabolite; metabolite; mouse metabolite
tryptophanamide	[no description available]	low	0	0	amino acid amide; tryptophan derivative	human metabolite
5-diphosphomevalonic acid	[no description available]	low	0	0	carboxyalkyl phosphate	human metabolite; mouse metabolite
7-dehydrocholesterol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; Delta(5),Delta(7)-sterol	human metabolite; mouse metabolite
cysteinylglycine	[no description available]	low	0	0	dipeptide zwitterion; dipeptide	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
desmosterol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C27-steroid; cholestanoid	human metabolite; mouse metabolite
taurolithocholic acid	[no description available]	low	0	0	bile acid taurine conjugate; monocarboxylic acid amide	human metabolite
n'-formylkynurenine	[no description available]	low	0	0	amino acid zwitterion; N-formylkynurenine; non-proteinogenic amino acid derivative; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
fuculose 1-phosphate	[no description available]	low	0	0	deoxyaldohexose phosphate	human metabolite
nicotinamide-beta-riboside	[no description available]	low	0	0	N-glycosylnicotinamide; pyridine nucleoside	geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
4-hydroxyphenylacetaldehyde	[no description available]	low	0	0	alpha-CH2-containing aldehyde; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite
trimethyllysine	[no description available]	low	0	0	alpha-amino-acid cation	human metabolite; mouse metabolite
inositol 3,4-bisphosphate	[no description available]	low	0	0	myo-inositol bisphosphate	human metabolite; mouse metabolite
n-acetylglucosamine-1-phosphate	[no description available]	low	0	0	N-acetyl-D-glucosamine 1-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
24,25-dihydrolanosterol	[no description available]	low	0	0	3beta-sterol; tetracyclic triterpenoid	human metabolite; mouse metabolite
2-hydroxyestrone	[no description available]	low	0	0	2-hydroxy steroid; catechols	human metabolite
2-methoxyestrone	[no description available]	low	0	0	17-oxo steroid; 3-hydroxy steroid; alicyclic ketone; aromatic ether; phenolic steroid; phenols	human metabolite; mouse metabolite
estradiol-3-glucuronide	[no description available]	low	0	0	17beta-hydroxy steroid; beta-D-glucosiduronic acid; steroid glucosiduronic acid	human metabolite; mouse metabolite
acetyl adenylate	[no description available]	low	0	0	5'-acylphosphoadenosin	human metabolite; mouse metabolite
epiandrosterone	[no description available]	low	0	0	17-oxo steroid; 3beta-hydroxy steroid; androstanoid	androgen; human metabolite
4,4-dimethylcholesta-8,14,24-trienol	[no description available]	low	0	0	3beta-sterol; Delta(14) steroid	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
enkephalin, methionine	[no description available]	low	0	0	pentapeptide; peptide zwitterion	analgesic; antineoplastic agent; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist
7-ketolithocholic acid	[no description available]	low	0	0	3alpha-hydroxy steroid; bile acid; monohydroxy-5beta-cholanic acid; oxo-5beta-cholanic acid	human metabolite
dephosphocoenzyme a	[no description available]	low	0	0	adenosine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
3-hydroxy-3-methylglutaryl-coenzyme a	[no description available]	low	0	0	3-hydroxy-3-methylglutaryl-CoA; 3-hydroxy fatty acyl-CoA	human metabolite; mouse metabolite
ribothymidine	[no description available]	low	0	0	methyluridine	antigen; Escherichia coli metabolite; human metabolite
hexanoyl-coenzyme a	[no description available]	low	0	0	medium-chain fatty acyl-CoA	Escherichia coli metabolite; human metabolite; mouse metabolite
tyrosine o-sulfate	[no description available]	low	0	0	aryl sulfate; L-tyrosine derivative; O-sulfoamino acid	human metabolite
retinaldehyde	[no description available]	low	0	0	retinal; vitamin A	gap junctional intercellular communication inhibitor; human metabolite; mouse metabolite
squalene	[no description available]	low	0	0	triterpene	human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
thyrotropin-releasing hormone	[no description available]	low	0	0	peptide hormone; tripeptide	human metabolite
n-methylproline	[no description available]	low	0	0	L-alpha-amino acid zwitterion; L-proline derivative; tertiary amino compound	human metabolite; plant metabolite
citraconic acid	[no description available]	low	0	0	dicarboxylic acid; dicarboxylic fatty acid	human metabolite
mannose 1-phosphate	[no description available]	low	0	0	mannose phosphate	fundamental metabolite; human metabolite
cysteine sulfinic acid	[no description available]	low	0	0	organosulfinic acid; S-substituted L-cysteine	Escherichia coli metabolite; human metabolite; metabotropic glutamate receptor agonist; mouse metabolite
cholesterol acetate	[no description available]	low	0	0	acetate ester; cholesteryl ester	human metabolite
1,6-anhydro-beta-glucopyranose	[no description available]	low	0	0	anhydrohexose	Arabidopsis thaliana metabolite; biomarker; human metabolite
glycylvaline	[no description available]	low	0	0	dipeptide	human metabolite
estrone sulfate	[no description available]	low	0	0	17-oxo steroid; steroid sulfate	human metabolite; mouse metabolite
hydroxylysine	[no description available]	low	0	0	5-hydroxylysine; hydroxy-L-lysine	human metabolite
isobutyryl-coenzyme a	[no description available]	low	0	0	methyl-branched fatty acyl-CoA; short-chain fatty acyl-CoA	human metabolite; mouse metabolite
galactaric acid	[no description available]	low	0	0	hexaric acid	human metabolite
dihydroxycoprostane	[no description available]	low	0	0	3alpha-hydroxy steroid; 7alpha-hydroxy steroid	human metabolite; mouse metabolite
angiotensin i, ile(5)-	[no description available]	low	0	0	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent
fructosyl-glycine	[no description available]	low	0	0	fructosamine; glycine derivative; glyco-amino acid	human metabolite
arachidoyl-coenzyme a	[no description available]	low	0	0	11,12-saturated fatty acyl-CoA; long-chain fatty acyl-CoA	human metabolite
lignoceroyl-coenzyme a	[no description available]	low	0	0	very long-chain fatty acyl-CoA	human metabolite; Saccharomyces cerevisiae metabolite
5-hydroxybenzimidazole	[no description available]	low	0	0	benzimidazoles; phenols	bacterial metabolite; human metabolite; rat metabolite
n-carbamylglutamate	[no description available]	low	0	0	glutamic acid derivative; ureas	human metabolite
citramalate	[no description available]	low	0	0	dicarboxylic acid dianion	human metabolite; plant metabolite
4-cresol sulfate	[no description available]	low	0	0	aryl sulfate	gut flora metabolite; human metabolite; uremic toxin
psychosine	[no description available]	low	0	0	glycosylsphingoid	human metabolite
ubiquinone 9	[no description available]	low	0	0	ubiquinones	antioxidant; human metabolite
prostaglandin f2beta	[no description available]	low	0	0	prostaglandins Fbeta	human metabolite
15-keto-5,8,11,13-eicosatetraenoic acid	[no description available]	low	0	0	oxoicosatetraenoic acid	human metabolite
15-hydroxy-5,8,11,13-eicosatetraenoic acid	[no description available]	low	0	0	(5Z,8Z,11Z,13E)-15-HETE	human metabolite; mouse metabolite
prostaglandin a2	[no description available]	low	0	0	prostaglandins A	human metabolite
prostaglandin b2	[no description available]	low	0	0	prostaglandins B	human metabolite
prostaglandin g2	[no description available]	low	0	0	prostaglandins G	human metabolite; mouse metabolite
prostaglandin e3	[no description available]	low	0	0	prostaglandins E	human metabolite
previtamin d(3)	[no description available]	low	0	0	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol	human metabolite
brassicasterol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	algal metabolite; animal metabolite; biomarker; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; human metabolite; marine metabolite; plant metabolite; sterol biosynthesis inhibitor
retinoyl beta-glucuronide	[no description available]	low	0	0	glucuronic acids; retinoid	human metabolite
prostaglandin d3	[no description available]	low	0	0	prostaglandins D	human metabolite
glyceryl 2-arachidonate	[no description available]	low	0	0	2-acylglycerol 20:4; endocannabinoid	human metabolite
tocotrienol, alpha	[no description available]	low	0	0	tocotrienol; vitamin E	ferroptosis inhibitor; human metabolite; neuroprotective agent; plant metabolite
11-ketotestosterone	[no description available]	low	0	0	11-oxo steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; human metabolite; marine xenobiotic metabolite
phthioic acid	[no description available]	low	0	0	branched-chain saturated fatty acid; fatty acid 26:0; methyl-branched fatty acid; very long-chain fatty acid	Aspergillus metabolite; human metabolite
2-decenoic acid	[no description available]	low	0	0	2-decenoic acid	human metabolite
9,11-linoleic acid	[no description available]	low	0	0	octadeca-9,11-dienoic acid	anti-inflammatory agent; antiatherogenic agent; antineoplastic agent; apoptosis inducer; bacterial xenobiotic metabolite; human metabolite
thromboxane b3	[no description available]	low	0	0	thromboxanes B	human metabolite; mouse metabolite
12-hydroxy-5,8,10,14-eicosatetraenoic acid	[no description available]	low	0	0	(5Z,8Z,10E,14Z)-12-hydroxyicosatetraenoic acid; HETE	human metabolite; pro-angiogenic agent
5-oxo-6,8,11,14-eicosatetraenoic acid	[no description available]	low	0	0	oxoicosatetraenoic acid	human metabolite; immunomodulator; mouse metabolite
monolinolein	[no description available]	low	0	0	1-acylglycerol 18:2; rac-1-monoacylglycerol	antiviral agent; human metabolite; plant metabolite
1,25-dihydroxy-24-oxo-vitamin d3	[no description available]	low	0	0	hydroxycalciol; oxocalciol; tertiary alpha-hydroxy ketone	human metabolite
calcifediol	[no description available]	low	0	0	D3 vitamins; diol; hydroxycalciol	bone density conservation agent; human metabolite; metabolite; mouse metabolite; nutraceutical
hyodeoxycholic acid	[no description available]	low	0	0	5beta-cholanic acids; 6alpha,20xi-murideoxycholic acid; bile acid; C24-steroid	human metabolite; mouse metabolite
cerium	[no description available]	low	0	0	CE(18:2); cholesteryl octadeca-9,12-dienoate	human metabolite; mouse metabolite
xylulose	[no description available]	low	0	0	xylulose	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
11-dehydrocorticosterone	[no description available]	low	0	0	11-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
1-butyl oleate	[no description available]	low	0	0	fatty acid ester	human metabolite
8-hydroxyadenine	[no description available]	low	0	0	6-aminopurines; heteroaryl hydroxy compound; nucleobase analogue; oxopurine	bacterial metabolite; human metabolite
erucyl amide	[no description available]	low	0	0	13-docosenamide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; human metabolite; mammalian metabolite; plant metabolite; rat metabolite
vitamin mk 8	[no description available]	low	0	0	menaquinone	Escherichia coli metabolite; human metabolite
2,3-oxidosqualene	[no description available]	low	0	0	2,3-epoxysqualene	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-keto-4-hydroxyglutarate	[no description available]	low	0	0	oxo dicarboxylate	human metabolite; Saccharomyces cerevisiae metabolite
deoxyribose	[no description available]	low	0	0	deoxypentose	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
iditol	[no description available]	low	0	0	iditol	fungal metabolite; human metabolite
glutamate	[no description available]	low	0	0	glutamate(1-); polar amino acid zwitterion	EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor; human metabolite; Saccharomyces cerevisiae metabolite
cerotate	[no description available]	low	0	0	fatty acid anion 26:0; omega-methyl fatty acid anion; very long-chain fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
adenosine triphosphate	[no description available]	low	0	0	nucleoside 5'-triphoshate(4-)	cofactor; fundamental metabolite; human metabolite
3-methylbutyrylcarnitine	[no description available]	low	0	0	C5-acylcarnitine	human metabolite
hexanoylcarnitine	[no description available]	low	0	0	hexanoate ester; O-acylcarnitine	human metabolite
linoleamide	[no description available]	low	0	0	primary fatty amide	human metabolite
13-cis-retinal	[no description available]	low	0	0	retinal	human metabolite
4-hydroxyretinoic acid	[no description available]	low	0	0	retinoid; secondary allylic alcohol	human metabolite
4-oxo-2-nonenal	[no description available]	low	0	0	enal; enone	human metabolite
20,22-dihydroxycholesterol	[no description available]	low	0	0	20-hydroxy steroid; 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; oxysterol	human metabolite; mouse metabolite
biotinate	[no description available]	low	0	0	monocarboxylic acid anion; vitamin B7	cofactor; human metabolite; Saccharomyces cerevisiae metabolite
fuculose	[no description available]	low	0	0	deoxyketohexose	Escherichia coli metabolite; human metabolite
gamma-glutamylvaline	[no description available]	low	0	0	glutamyl-L-amino acid	human metabolite
ophthalmic acid	[no description available]	low	0	0	L-glutamine derivative	biomarker; human metabolite
adenosine diphosphate	[no description available]	low	0	0	nucleoside 5'-diphosphate(3-)	fundamental metabolite; human metabolite
cyclic amp	[no description available]	low	0	0	organophosphate oxoanion	human metabolite; Saccharomyces cerevisiae metabolite
1,23,25-trihydroxyvitamin d3	[no description available]	low	0	0	D3 vitamins; hydroxy seco-steroid; hydroxycalciol; tetrol	human metabolite
ursodoxicoltaurine	[no description available]	low	0	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
arachidonoylserotonin	[no description available]	low	0	0	N-acylserotonin; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; capsaicin receptor antagonist; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; human metabolite; signalling molecule
3-hydroxyproline	[no description available]	low	0	0	3-hydroxyproline; amino acid zwitterion; D-proline derivative	bacterial metabolite; human metabolite
cytidine diphosphate choline	[no description available]	low	0	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
octanoylcarnitine	[no description available]	low	0	0	O-octanoylcarnitine; saturated fatty acyl-L-carnitine	human metabolite
palmitoylcarnitine	[no description available]	low	0	0	O-palmitoylcarnitine; saturated fatty acyl-L-carnitine	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; human metabolite; mouse metabolite
cyclic 3',5'-thymidine monophosphate	[no description available]	low	0	0	3',5'-cyclic pyrimidine nucleotide	human metabolite
pristanal	[no description available]	low	0	0	2-methyl-branched fatty aldehyde; saturated fatty aldehyde	human metabolite
lanosten-3-ol-32-al	[no description available]	low	0	0	14alpha-formyl steroid; 3beta-sterol; tetracyclic triterpenoid	human metabolite
thiamine pyrophosphate	[no description available]	low	0	0	organophosphate oxoanion; vitamin B1	human metabolite; Saccharomyces cerevisiae metabolite
adenosine monophosphate	[no description available]	low	0	0	nucleoside 5'-monophosphate(2-)	cofactor; fundamental metabolite; human metabolite
cob(ii)alamin	[no description available]	low	0	0	cobalamin	cofactor; human metabolite
3-hydroxy-3-methyl-hexanoic acid	[no description available]	low	0	0	3-hydroxy monocarboxylic acid; volatile organic compound	human metabolite
uridine diphosphate	[no description available]	low	0	0	nucleoside 5'-diphosphate(3-)	human metabolite; Saccharomyces cerevisiae metabolite
n-acetylgalactosamine-1-phosphate	[no description available]	low	0	0	D-galactosamine 1-phosphate	human metabolite
1-phospho-5-s-methylthioribulose	[no description available]	low	0	0	organophosphate oxoanion	human metabolite; Saccharomyces cerevisiae metabolite
10-nitro-oleic acid	[no description available]	low	0	0	long-chain fatty acid; monounsaturated fatty acid; nitro fatty acid	human metabolite
ticrynafen	[no description available]	low	0	0	monocarboxylic acid anion; organophosphate oxoanion	human metabolite
s-(1,2-dicarboxyethyl)cysteine	[no description available]	low	0	0	L-cysteine thioether; tricarboxylic acid	human metabolite; Maillard reaction product
apelin-13 peptide	[no description available]	low	0	0	oligopeptide	antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent
p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	[no description available]	low	0	0	polypeptide	apoptosis inhibitor; human metabolite; neuroprotective agent
taurolithocholic acid 3-sulfate	[no description available]	low	0	0	steroid sulfate oxoanion	human metabolite
diadenosine tetraphosphate	[no description available]	low	0	0	organophosphate oxoanion	human metabolite; Saccharomyces cerevisiae metabolite
2-ketoarginine	[no description available]	low	0	0	2-oxo monocarboxylic acid; zwitterion	human metabolite; mouse metabolite
adenosine diphosphate glucose	[no description available]	low	0	0	NDP-alpha-D-glucose(2-); ribonucleoside 5'-diphosphate-alpha-D-glucose(2-)	human metabolite
nicotinate mononucleotide	[no description available]	low	0	0	organophosphate oxoanion	human metabolite; Saccharomyces cerevisiae metabolite
oleoylcarnitine	[no description available]	low	0	0	monounsaturated fatty acyl-L-carnitine	glycine transporter 2 inhibitor; human metabolite
uridine diphosphate n-acetylgalactosamine	[no description available]	low	0	0	nucleotide-sugar oxoanion	human metabolite
6-phosphogluconolactone	[no description available]	low	0	0	organophosphate oxoanion	human metabolite; Saccharomyces cerevisiae metabolite
3-hydroxyisovalerylcarnitine	[no description available]	low	0	0	O-acylcarnitine	human metabolite
angiotensin i	[no description available]	low	0	0	angiotensin; peptide zwitterion	antihypertensive agent; cardioprotective agent; human metabolite; rat metabolite
9-PAHSA	[no description available]	low	0	0	FAHFA; long-chain fatty acid	anti-inflammatory agent; human metabolite; hypoglycemic agent
lugdunin	[no description available]	low	0	0	homodetic cyclic peptide; indoles; macrocycle; peptide antibiotic; thiazolidines	human metabolite; rat metabolite
deoxyguanosine	[no description available]	low	0	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyinosine	[no description available]	low	0	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
deoxyguanosine triphosphate	[no description available]	low	0	0	deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-triphosphate	Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
7,8-dihydroneopterin	[no description available]	low	0	0	dihydropterin; neopterins	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyinosine monophosphate	[no description available]	low	0	0	deoxyinosine phosphate; purine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
guanosine diphosphate mannose	[no description available]	low	0	0	GDP-D-mannose	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite
dyspropterin	[no description available]	low	0	0	biopterins; tetrahydropterin	human metabolite; metabolite; mouse metabolite
8-nitroguanosine 3',5'-cyclic monophosphate	[no description available]	low	0	0	3',5'-cyclic purine nucleotide; C-nitro compound	biomarker; Brassica napus metabolite; human metabolite; signalling molecule
n(2),n(2)-dimethylguanosine	[no description available]	low	0	0	methylguanosine	human metabolite
creatinine	[no description available]	low	0	0	imidazolidinone; lactam	diagnostic agent; human metabolite
alpha-hydroxyglutarate	[no description available]	low	0	0	2-hydroxydicarboxylic acid; dicarboxylic fatty acid	metabolite; mouse metabolite
alpha-ketoadipic acid	[no description available]	low	0	0	oxo dicarboxylic acid	human urinary metabolite; mouse metabolite
n-carbamoyl-beta-alanine	[no description available]	low	0	0	beta-alanine derivative	metabolite; mouse metabolite
4-hydroxybenzaldehyde	[no description available]	low	0	0	hydroxybenzaldehyde	EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite
allantoic acid	[no description available]	low	0	0	ureas	mouse metabolite; plant metabolite
aminoacetone	[no description available]	low	0	0	methyl ketone; propanones	Escherichia coli metabolite; mouse metabolite
hydrobromic acid	[no description available]	low	0	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
butyraldehyde	[no description available]	low	0	0	butanals	biomarker; Escherichia coli metabolite; mouse metabolite
carbamyl phosphate	[no description available]	low	0	0	acyl monophosphate; one-carbon compound	Escherichia coli metabolite; mouse metabolite
coproporphyrinogen iii	[no description available]	low	0	0	coproporphyrinogen	Escherichia coli metabolite; mouse metabolite
1,2-dihydroxy-1,2-dihydronaphthalene	[no description available]	low	0	0	dihydronaphthalenes; naphthalenediols	bacterial xenobiotic metabolite; mouse metabolite
phosphonoacetaldehyde	[no description available]	low	0	0	phosphonic acids	mouse metabolite
gamma-guanidinobutyric acid	[no description available]	low	0	0	guanidines; monocarboxylic acid; zwitterion	fungal metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
phosphoglycolate	[no description available]	low	0	0	carboxyalkyl phosphate	Escherichia coli metabolite; mouse metabolite
hydrogen selenide	[no description available]	low	0	0	mononuclear parent hydride; selenium hydride	Escherichia coli metabolite; mouse metabolite
3,3-dimethylallyl pyrophosphate	[no description available]	low	0	0	prenol phosphate	epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
diethyl phosphate	[no description available]	low	0	0	dialkyl phosphate	human xenobiotic metabolite; mouse metabolite
o,o-diethyl phosphorothionate	[no description available]	low	0	0	organic thiophosphate	human xenobiotic metabolite; mouse metabolite
hydantoin-5-propionic acid	[no description available]	low	0	0	imidazolidine-2,4-dione; monocarboxylic acid	metabolite; mouse metabolite
hydroxymethylbilane	[no description available]	low	0	0	bilanes	Escherichia coli metabolite; mouse metabolite
lactaldehyde	[no description available]	low	0	0	hydroxyaldehyde; propanals	mouse metabolite
orotic acid	[no description available]	low	0	0	pyrimidinemonocarboxylic acid	Escherichia coli metabolite; metabolite; mouse metabolite
4-nitrophenol	[no description available]	low	0	0	4-nitrophenols	human xenobiotic metabolite; mouse metabolite
pyridoxine 5-phosphate	[no description available]	low	0	0	vitamin B6 phosphate	Escherichia coli metabolite; mouse metabolite
succinic semialdehyde	[no description available]	low	0	0	aldehydic acid	Escherichia coli metabolite; mouse metabolite
tartronate semialdehyde	[no description available]	low	0	0	2-hydroxy monocarboxylic acid; 3-oxo monocarboxylic acid; aldehyde	Escherichia coli metabolite; mouse metabolite
uroporphyrinogen iii	[no description available]	low	0	0	uroporphyrinogen	Escherichia coli metabolite; mouse metabolite
isopentenyl pyrophosphate	[no description available]	low	0	0	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
6-hydroxymelatonin	[no description available]	low	0	0	acetamides; tryptamines	metabolite; mouse metabolite
adrenic acid	[no description available]	low	0	0	docosatetraenoic acid	mouse metabolite
1,7-dimethylxanthine	[no description available]	low	0	0	dimethylxanthine	central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite
uridine diphosphate	[no description available]	low	0	0	pyrimidine ribonucleoside 5'-diphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
cytidine diphosphate	[no description available]	low	0	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite
cytidine triphosphate	[no description available]	low	0	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
1-naphthaldehyde	[no description available]	low	0	0	naphthaldehyde	mouse metabolite
2-naphthaldehyde	[no description available]	low	0	0	naphthaldehyde	mouse metabolite
vinylidene chloride	[no description available]	low	0	0	chloroethenes	carcinogenic agent; mouse metabolite; mutagen
gibberellic acid	[no description available]	low	0	0	C19-gibberellin; gibberellin monocarboxylic acid; lactone; organic heteropentacyclic compound	mouse metabolite; plant metabolite
pyridoxic acid	[no description available]	low	0	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	human urinary metabolite; mouse metabolite
1-nitronaphthalene	[no description available]	low	0	0	mononitronaphthalene	environmental contaminant; mouse metabolite
methylphenyl carbinol	[no description available]	low	0	0	aromatic alcohol	mouse metabolite
4-hydroxyacetophenone	[no description available]	low	0	0	monohydroxyacetophenone	fungal metabolite; mouse metabolite; plant metabolite
styrene	[no description available]	low	0	0	styrenes; vinylarene; volatile organic compound	mouse metabolite; mutagen; plant metabolite
2-phenylacetamide	[no description available]	low	0	0	monocarboxylic acid amide	mouse metabolite
4-bromophenol	[no description available]	low	0	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
ethylene dibromide	[no description available]	low	0	0	bromoalkane; bromohydrocarbon	algal metabolite; carcinogenic agent; fumigant; marine metabolite; mouse metabolite; mutagen
bromobenzene	[no description available]	low	0	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
2-heptanone	[no description available]	low	0	0	dialkyl ketone; methyl ketone	mouse metabolite; pheromone
2,2,2-trichloroethanol	[no description available]	low	0	0	chloroethanol	mouse metabolite
D-proline	[no description available]	low	0	0	D-alpha-amino acid zwitterion; D-alpha-amino acid; proline	mouse metabolite
paraoxon	[no description available]	low	0	0	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
methyl-4-tyramine	[no description available]	low	0	0	tyramines	mouse metabolite
phosphoadenosine phosphosulfate	[no description available]	low	0	0	acyl sulfate; adenosine bisphosphate; purine ribonucleoside bisphosphate	Escherichia coli metabolite; mouse metabolite
adenosine phosphosulfate	[no description available]	low	0	0	acyl monophosphate; acyl sulfate; adenosine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
fructose-1,6-diphosphate	[no description available]	low	0	0	D-fructofuranose 1,6-bisphosphate	mouse metabolite
hydroxyhydroquinone	[no description available]	low	0	0	benzenetriol	mouse metabolite
1,2-dihydroxynaphthalene	[no description available]	low	0	0	naphthalenediol	mouse metabolite
propiolaldehyde	[no description available]	low	0	0	terminal acetylenic compound; ynal	mouse metabolite
phenylphosphate	[no description available]	low	0	0	aryl phosphate	mouse metabolite
n-cyclohexylformamide	[no description available]	low	0	0	alicyclic compound; formamides	mouse metabolite
deoxycytidine monophosphate	[no description available]	low	0	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; mouse metabolite
nicotinamide mononucleotide	[no description available]	low	0	0	nicotinamide mononucleotide	Escherichia coli metabolite; mouse metabolite
dihydroferulic acid	[no description available]	low	0	0	guaiacols; monocarboxylic acid; phenylpropanoid	antioxidant; human xenobiotic metabolite; mouse metabolite; plant metabolite
2'-deoxyadenosine triphosphate	[no description available]	low	0	0	2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
uridine diphosphate galactose	[no description available]	low	0	0	UDP-D-galactose	mouse metabolite
1-naphthalenemethanol	[no description available]	low	0	0	naphthylmethanol	mouse metabolite
hydroiodic acid	[no description available]	low	0	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
trichloroepoxyethane	[no description available]	low	0	0	epoxide	mouse metabolite
phosphopantothenic acid	[no description available]	low	0	0	amidoalkyl phosphate	Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thymidine 5'-triphosphate	[no description available]	low	0	0	pyrimidine 2'-deoxyribonucleoside 5'-triphosphate; thymidine phosphate	Escherichia coli metabolite; mouse metabolite
2'-deoxyuridylic acid	[no description available]	low	0	0	deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; metabolite; mouse metabolite
obtusifoliol	[no description available]	low	0	0	14alpha-methyl steroid; 3beta-sterol	mouse metabolite; plant metabolite
3'-cmp	[no description available]	low	0	0	cytidine 3'-phosphate; pyrimidine ribonucleoside 3'-monophosphate	Escherichia coli metabolite; metabolite; mouse metabolite
7-methylxanthine	[no description available]	low	0	0	oxopurine; purine alkaloid	human xenobiotic metabolite; mouse metabolite; plant metabolite
cifostodine	[no description available]	low	0	0	2',3'-cyclic pyrimidine nucleotide	Escherichia coli metabolite; mouse metabolite; Mycoplasma genitalium metabolite
n'-methyl-2-pyridone-5-carboxamide	[no description available]	low	0	0	methylpyridines; pyridinecarboxamide; pyridone	metabolite; mouse metabolite
1-methyluric acid	[no description available]	low	0	0	oxopurine	human xenobiotic metabolite; mouse metabolite
cyclopropylamine	[no description available]	low	0	0	primary aliphatic amine	mouse metabolite
6-hydroxynicotinic acid	[no description available]	low	0	0	monohydroxypyridine	Arabidopsis thaliana metabolite; human urinary metabolite; mouse metabolite
xanthosine 5'-triphosphate	[no description available]	low	0	0	purine ribonucleoside 5'-monophosphate; xanthosine 5'-phosphate	Escherichia coli metabolite; metabolite; mouse metabolite
2-naphthalenemethanol	[no description available]	low	0	0	naphthylmethanol	mouse metabolite; xenobiotic metabolite
xanthurenic acid 8-methyl ether	[no description available]	low	0	0	aromatic ether; monohydroxyquinoline; quinolinemonocarboxylic acid	carcinogenic agent; metabolite; mouse metabolite
glucose	[no description available]	low	0	0	D-glucopyranose	mouse metabolite
1,3,7-trimethylurate	[no description available]	low	0	0	oxopurine	human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; mouse metabolite
1-methylxanthine	[no description available]	low	0	0	1-methylxanthine	mouse metabolite
3,7-dimethyluric acid	[no description available]	low	0	0	oxopurine	metabolite; mouse metabolite
d-aspartic acid	[no description available]	low	0	0	aspartic acid; D-alpha-amino acid	mouse metabolite
1,7-dimethyluric acid	[no description available]	low	0	0	oxopurine	human xenobiotic metabolite; mouse metabolite
24-methylenecholesterol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol	mouse metabolite
succinyl-coenzyme a	[no description available]	low	0	0	omega-carboxyacyl-CoA	Escherichia coli metabolite; inhibitor; mouse metabolite
acetoacetyl coa	[no description available]	low	0	0	3-oxo-fatty acyl-CoA	Escherichia coli metabolite; mouse metabolite
2,8-dihydroxyadenine	[no description available]	low	0	0	6-aminopurines; diol; heteroaryl hydroxy compound; oxopurine	human urinary metabolite; mammalian metabolite; mouse metabolite; nephrotoxic agent
propionyl-coenzyme a	[no description available]	low	0	0	acyl-CoA	Escherichia coli metabolite; metabolite; mouse metabolite
stearoyl-coenzyme a	[no description available]	low	0	0	11,12-saturated fatty acyl-CoA; long-chain fatty acyl-CoA	Escherichia coli metabolite; mouse metabolite
1-hydroxyphenanthrene	[no description available]	low	0	0	phenanthrol	mouse metabolite
2,5-dihydroxypyridine	[no description available]	low	0	0	dihydroxypyridine	mouse metabolite
cerium	[no description available]	low	0	0	cholesteryl ester	mouse metabolite
6,6-dimethyl-2-methylenebicyclo(3.1.1)heptan-3-ol	[no description available]	low	0	0	carbobicyclic compound; pinane monoterpenoid; secondary alcohol	GABA modulator; mouse metabolite; plant metabolite; volatile oil component
ecgonine methyl ester	[no description available]	low	0	0	methyl ester; tertiary amino compound; tropane alkaloid	analgesic; central nervous system depressant; metabolite; mouse metabolite; opioid analgesic; peripheral nervous system drug
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	[no description available]	low	0	0	hydroxylamine; imidazopyridine	carcinogenic agent; genotoxin; human xenobiotic metabolite; mouse metabolite; mutagen; neurotoxin; rat metabolite
cholest-5-en-3 beta,7 alpha-diol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 7alpha-hydroxy steroid; oxysterol	mouse metabolite
s-chloromethylglutathione	[no description available]	low	0	0	organochlorine compound; S-substituted glutathione	alkylating agent; bacterial xenobiotic metabolite; mouse metabolite
5-acetylamino-6-formylamino-3-methyluracil	[no description available]	low	0	0	formamidopyrimidine	mouse metabolite
5,6-dihydroxyindole	[no description available]	low	0	0	dihydroxyindole	mouse metabolite
5,6-dihydroxy-2-indolylcarboxylic acid	[no description available]	low	0	0	dihydroxyindole	mouse metabolite
protoporphyrinogen	[no description available]	low	0	0	porphyrinogens	Escherichia coli metabolite; mouse metabolite
24-hydroxycholesterol	[no description available]	low	0	0	24-hydroxycholesterol	biomarker; human blood serum metabolite; mouse metabolite
butyryl-coenzyme a	[no description available]	low	0	0	butanoyl-CoAs	Escherichia coli metabolite; mouse metabolite
cdp ethanolamine	[no description available]	low	0	0	nucleotide-(amino alcohol)s; phosphoethanolamine	mouse metabolite
galactose-1-phosphate	[no description available]	low	0	0	alpha-D-hexose 1-phosphate; D-galactopyranose 1-phosphate	Escherichia coli metabolite; mouse metabolite
1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine	[no description available]	low	0	0	1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 30:0; tetradecanoate ester	mouse metabolite
d-glutamine	[no description available]	low	0	0	amino acid zwitterion; D-alpha-amino acid; glutamine	mouse metabolite
diquafosol	[no description available]	low	0	0	pyrimidine ribonucleoside 5'-tetraphosphate; uridine 5'-phosphate	mouse metabolite; P2Y2 receptor agonist
19-hydroxytestosterone	[no description available]	low	0	0	17beta-hydroxy steroid; 19-hydroxy steroid; 3-oxo-Delta(4) steroid	mouse metabolite
2-hydroxy-1,4-benzoquinone	[no description available]	low	0	0	monohydroxy-1,4-benzoquinones	mouse metabolite
sorbitol 6-phosphate	[no description available]	low	0	0	alditol 6-phosphate; glucitol phosphate	Escherichia coli metabolite; mouse metabolite
adenosine 3'-phosphate-5'-phosphate	[no description available]	low	0	0	adenosine bisphosphate	Escherichia coli metabolite; mouse metabolite
alpha-ribazole	[no description available]	low	0	0	1-ribosylbenzimidazole; dimethylbenzimidazole	Escherichia coli metabolite; mouse metabolite
saicar	[no description available]	low	0	0	1-(phosphoribosyl)imidazolecarboxamide	Escherichia coli metabolite; mouse metabolite
thymidine 5'-diphosphate	[no description available]	low	0	0	pyrimidine 2'-deoxyribonucleoside 5'-diphosphate; thymidine phosphate	Escherichia coli metabolite; mouse metabolite
hydromethylthionine	[no description available]	low	0	0	aromatic amine; phenothiazines; tertiary amino compound	bacterial xenobiotic metabolite; fluorochrome; mouse metabolite; rat metabolite
5-hydroxykynuramine	[no description available]	low	0	0	hydroxykynurenamine; primary amino compound	mouse metabolite
sedoheptulose 1,7-bisphosphate	[no description available]	low	0	0	ketoheptose phosphate; sedoheptulose derivative	Escherichia coli metabolite; mouse metabolite
carboxyaminoimidazole ribotide	[no description available]	low	0	0	1-(phosphoribosyl)imidazole; aminoimidazole; imidazole-4-carboxylic acid	Escherichia coli metabolite; mouse metabolite
isovaleryl-coenzyme a	[no description available]	low	0	0	methylbutanoyl-CoA; short-chain fatty acyl-CoA	mouse metabolite
lauroyl-coenzyme a	[no description available]	low	0	0	medium-chain fatty acyl-CoA	Escherichia coli metabolite; mouse metabolite
phenylacetyl-coenzyme a	[no description available]	low	0	0	acyl-CoA	Escherichia coli metabolite; metabolite; mouse metabolite
5-formamidoimidazole-4-carboxamide ribotide	[no description available]	low	0	0	1-(phosphoribosyl)imidazolecarboxamide	Escherichia coli metabolite; mouse metabolite
campesterol	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C28-steroid; phytosterols	mouse metabolite
gamma-glutamyl phosphate	[no description available]	low	0	0	gamma-glutamyl phosphate	Escherichia coli metabolite; mouse metabolite
5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione	[no description available]	low	0	0	aminouracil; hydroxypyrimidine	Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
sitosterol, (3beta)-isomer	[no description available]	low	0	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
androstane-3,17-dione, (5alpha)-isomer	[no description available]	low	0	0	3-oxo-5alpha-steroid; androstane-3,17-dione	mouse metabolite
21-hydroxypregnenolone	[no description available]	low	0	0	21-hydroxy steroid; hydroxypregnenolone; primary alpha-hydroxy ketone	mouse metabolite
epietiocholanolone	[no description available]	low	0	0	17-oxo steroid; 3beta-hydroxy steroid; androstanoid	androgen; animal metabolite; human blood serum metabolite; mouse metabolite; rat metabolite
19-hydroxy-4-androstene-3,17-dione	[no description available]	low	0	0	17-oxo steroid; 19-hydroxy steroid; 3-oxo steroid; androstanoid	mouse metabolite
glyceraldehyde 3-phosphate	[no description available]	low	0	0	glyceraldehyde 3-phosphate	mouse metabolite
ribulose 5-phosphate	[no description available]	low	0	0	ribulose 5-phosphate	mouse metabolite
xylulose-5-phosphate, (d)-isomer	[no description available]	low	0	0	xylulose 5-phosphate	Escherichia coli metabolite; mouse metabolite
glycerate 1,3-biphosphate	[no description available]	low	0	0	2,3-bisphosphoglyceric acid; acyl monophosphate	Escherichia coli metabolite; mouse metabolite
xanthosine 5'-triphosphate	[no description available]	low	0	0	purine ribonucleoside 5'-triphosphate; xanthosine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
galactose	[no description available]	low	0	0	D-galactopyranose	epitope; mouse metabolite
galactose	[no description available]	low	0	0	D-galactopyranose	mouse metabolite
s-adenosyl-3-methylthiopropylamine	[no description available]	low	0	0	adenosines; sulfonium compound	Escherichia coli metabolite; human urinary metabolite; mouse metabolite; rat metabolite
6-phosphonoglucono-delta-lactone	[no description available]	low	0	0	aldonolactone phosphate	Escherichia coli metabolite; mouse metabolite
ketodihydrosphingosine	[no description available]	low	0	0	2-amino-1-hydroxyoctadecan-3-one	mouse metabolite
androstane-3,17-dione, (5beta)-isomer	[no description available]	low	0	0	3-oxo-5beta-steroid; androstane-3,17-dione	mouse metabolite
pantothenylcysteine 4'-phosphate	[no description available]	low	0	0	L-cysteine derivative	Escherichia coli metabolite; mouse metabolite
beta-sulfopyruvic acid	[no description available]	low	0	0	carboxyalkanesulfonic acid	mouse metabolite
2-hydroxypropylphosphonic acid	[no description available]	low	0	0	phosphonic acids; secondary alcohol	mouse metabolite
inositol-1,4,5,6-tetrakisphosphate	[no description available]	low	0	0	myo-inositol tetrakisphosphate	mouse metabolite
n(1)-(5-phosphoribosyl)-5,6-dimethylbenzimidazole	[no description available]	low	0	0	1-ribosylbenzimidazole; dimethylbenzimidazole; ribose monophosphate	Escherichia coli metabolite; mouse metabolite
farnesyl pyrophosphate	[no description available]	low	0	0	farnesyl diphosphate	Escherichia coli metabolite; mouse metabolite
geranyl pyrophosphate	[no description available]	low	0	0	polyprenyl diphosphate	Escherichia coli metabolite; mouse metabolite
1,5-dihydro-fad	[no description available]	low	0	0	flavin adenine dinucleotide	Escherichia coli metabolite; mouse metabolite
s-hydroxymethylglutathione	[no description available]	low	0	0	S-substituted glutathione	Escherichia coli metabolite; mouse metabolite
geranylgeranyl pyrophosphate	[no description available]	low	0	0	geranylgeranyl diphosphate	mouse metabolite
cytidine monophosphate n-acetylneuraminic acid	[no description available]	low	0	0	CMP-N-acyl-beta-neuraminic acid	mouse metabolite
4-phosphoerythronate	[no description available]	low	0	0	4-phosphoerythronic acid	Escherichia coli metabolite; mouse metabolite
colfosceril palmitate	[no description available]	low	0	0	1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 32:0	mouse metabolite; surfactant
lyso-pc	[no description available]	low	0	0	1-O-acyl-sn-glycero-3-phosphocholine; lysophosphatidylcholine 16:0	mouse metabolite
trans-4-coumaric acid	[no description available]	low	0	0	4-coumaric acid	food component; mouse metabolite; plant metabolite
3-hydroxybutyryl-coenzyme a	[no description available]	low	0	0	3-hydroxyacyl-CoA; hydroxybutanoyl-CoA	mouse metabolite
malonyl coenzyme a	[no description available]	low	0	0	malonyl-CoAs	EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor; Escherichia coli metabolite; metabolite; mouse metabolite
palmitoyl coenzyme a	[no description available]	low	0	0	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite
dihydrosphingosine 1-phosphate	[no description available]	low	0	0	sphingoid 1-phosphate	mouse metabolite
coniferyl alcohol	[no description available]	low	0	0	guaiacols; phenylpropanoid	animal metabolite; monolignol; mouse metabolite; pheromone; plant metabolite; volatile oil component
raphanusamic acid	[no description available]	low	0	0	thiazolidinemonocarboxylic acid	Arabidopsis thaliana metabolite; mouse metabolite; xenobiotic metabolite
glutaryl-coenzyme a	[no description available]	low	0	0	glutaryl-CoAs	mouse metabolite
arachidonic acid 5-hydroperoxide	[no description available]	low	0	0	5-HPETE	mouse metabolite
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (s)-(e,z,z,z)-isomer	[no description available]	low	0	0	15-HPETE	mouse metabolite
1-palmitoyl-2-oleoyl-sn-glycerol	[no description available]	low	0	0	1,2-diacyl-sn-glycerol; 1-palmitoyl-2-oleoylglycerol	mouse metabolite
11,12-dihydroxyeicosatrienoic acid	[no description available]	low	0	0	DHET	mouse metabolite
14,15-dihydroxyeicosatrienoic acid	[no description available]	low	0	0	DHET; diol; secondary allylic alcohol	mouse metabolite
8,9-epoxyeicosatrienoic acid	[no description available]	low	0	0	EET	mouse metabolite
1-palmitoyl-2-oleoylphosphatidylethanolamine, (z & r)-isomer	[no description available]	low	0	0	1,2-diacyl-sn-glycero-3-phosphoethanolamine; phosphatidylethanolamine 34:1 zwitterion; phosphatidylethanolamine	mouse metabolite
cholesteryl oleate	[no description available]	low	0	0	CE(18:1); cholesteryl octadec-9-enoate	mouse metabolite
stearidonic acid	[no description available]	low	0	0	long-chain fatty acid; octadecatetraenoic acid; omega-3 fatty acid	Daphnia galeata metabolite; mouse metabolite; plant metabolite
trilinolein	[no description available]	low	0	0	1,2-diacyl-3-linoleoylglycerol; 1,3-diacyl-2-linoleoylglycerol; linoleoyl containing 1,2,3-triacyl-sn-glycerol; TG(18:2/18:2/18:2); triglyceride	mouse metabolite
dimyristoylphosphatidylcholine	[no description available]	low	0	0	1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester	antigen; mouse metabolite
monodehydroascorbate	[no description available]	low	0	0	organic radical	mouse metabolite
oleoyl-coenzyme a	[no description available]	low	0	0	octadecenoyl-CoA	Escherichia coli metabolite; mouse metabolite
vitamin a2	[no description available]	low	0	0	retinoid; vitamin A	human xenobiotic metabolite; marine xenobiotic metabolite; mouse metabolite
1,2-dioleoylphosphatidylserine	[no description available]	low	0	0	phosphatidylserine(18:1/18:1)	mouse metabolite
5-hydroxy-6,8,11,14,17-eicosapentaenoic acid	[no description available]	low	0	0	HEPE	mouse metabolite
1-stearoyl-2-linoleoylphosphatidylcholine	[no description available]	low	0	0	phosphatidylcholine 36:2	mouse metabolite
1-stearoyl-2-linoleoyl-sn-glycerol	[no description available]	low	0	0	1,2-diacyl-sn-glycerol; diacylglycerol 36:2	mouse metabolite
1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine	[no description available]	low	0	0	phosphatidylcholine 38:6	mouse metabolite
13(S)-HODE	[no description available]	low	0	0	HODE	antineoplastic agent; human xenobiotic metabolite; mouse metabolite
1-stearoyl-2-oleoyl-sn-glycerol	[no description available]	low	0	0	1,2-diacyl-sn-glycerol; 1-stearoyl-2-oleoylglycerol; diacylglycerol 36:1	mouse metabolite
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine	[no description available]	low	0	0	1-acyl-2-palmitoleoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 32:1	mouse metabolite
13-oxo-9,11-octadecadienoic acid	[no description available]	low	0	0	13-oxo-9,11-octadecadienoic acid	metabolite; mouse metabolite
n-stearoylsphingomyelin	[no description available]	low	0	0	sphingomyelin 36:1; sphingomyelin d18:1	mouse metabolite
cholesteryl arachidonate	[no description available]	low	0	0	cholesteryl icosatetraenoate	antibacterial agent; mouse metabolite
acryloyl-coenzyme a	[no description available]	low	0	0	2-enoyl-CoA; monounsaturated fatty acyl-CoA	mouse metabolite
samarium	[no description available]	low	0	0	sphingomyelin d18:1/16:0	mouse metabolite
n-palmitoylgalactosylsphingosine	[no description available]	low	0	0	HexCer(d18:1/16:0); N-acyl-beta-D-galactosylsphingosine	mouse metabolite
s-tetradecanoyl-coenzyme a	[no description available]	low	0	0	11,12-saturated fatty acyl-CoA; long-chain fatty acyl-CoA	Escherichia coli metabolite; mouse metabolite
prosomatostatin	[no description available]	low	0	0	heterodetic cyclic peptide; peptide hormone	fungal metabolite; mouse metabolite; rat metabolite
phosphatidylcholines	[no description available]	low	0	0	phosphatidylcholine 40:6	mouse metabolite
cyclosporine	[no description available]	low	0	0	keto-disaccharide	mouse metabolite
g(m3) ganglioside	[no description available]	low	0	0	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide; sialodiosylceramide; sialotriaosylceramide	mouse metabolite
diguanosine tetraphosphate	[no description available]	low	0	0	guanosine 5'-phosphate; purine ribonucleoside 5'-tetraphosphate	Escherichia coli metabolite; mouse metabolite
2'-deoxyguanosine 5'-phosphate	[no description available]	low	0	0	deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; mouse metabolite
dihydroneopterin triphosphate	[no description available]	low	0	0	dihydropterin; neopterins; pterin phosphate	Escherichia coli metabolite; mouse metabolite
2'-deoxyinosine triphosphate	[no description available]	low	0	0	deoxyinosine phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
gdp-4-keto-6-deoxymannose	[no description available]	low	0	0	GDP-sugar	Escherichia coli metabolite; mouse metabolite
guanosine pentaphosphate	[no description available]	low	0	0	guanosine 5'-phosphate; guanosine bisphosphate	Escherichia coli metabolite; mouse metabolite
guanosine tetraphosphate	[no description available]	low	0	0	guanosine bisphosphate	Escherichia coli metabolite; mouse metabolite
5,10-methenyltetrahydrofolate	[no description available]	low	0	0	methylenetetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
10-formyltetrahydrofolate	[no description available]	low	0	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
1-(2-trifluoromethylphenyl)imidazole	[no description available]	low	0	0	imidazoles
4-imidazolemethanol	[no description available]	low	0	0	imidazoles; primary alcohol
alosetron	[no description available]	low	0	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
cgp 20712a	[no description available]	low	0	0	imidazoles
dacarbazine	[no description available]	low	0	0	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; carcinogenic agent; prodrug
dimetridazole	[no description available]	low	0	0	C-nitro compound; imidazoles	antiparasitic agent; antiprotozoal drug
etanidazole	[no description available]	low	0	0	C-nitro compound; imidazoles; monocarboxylic acid amide	alkylating agent; antineoplastic agent; prodrug; radiosensitizing agent
flutrimazole	[no description available]	low	0	0	imidazole antifungal drug; imidazoles; monofluorobenzenes	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
isoconazole	[no description available]	low	0	0	dichlorobenzene; ether; imidazoles
sb 239063	[no description available]	low	0	0	imidazoles
sk&f 86002	[no description available]	low	0	0	imidazoles
sulconazole	[no description available]	low	0	0	dichlorobenzene; imidazoles; monochlorobenzenes; organic sulfide
tioconazole	[no description available]	low	0	0	dichlorobenzene; ether; imidazoles; thiophenes
azomycin	[no description available]	low	0	0	C-nitro compound; imidazoles	antitubercular agent
5-methylbenzimidazole	[no description available]	low	0	0	imidazoles
2-methyl-5-nitroimidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
zolimidine	[no description available]	low	0	0	imidazoles
1,2-dimethylimidazole	[no description available]	low	0	0	imidazoles
4-nitroimidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
metomidate	[no description available]	low	0	0	imidazoles
nimorazole	[no description available]	low	0	0	C-nitro compound; imidazoles
ipronidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
lofexidine	[no description available]	low	0	0	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent
benzonidazole	[no description available]	low	0	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
enilconazole	[no description available]	low	0	0	dichlorobenzene; ether; imidazoles
climbazole	[no description available]	low	0	0	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
butoconazole nitrate	[no description available]	low	0	0	aryl sulfide; conazole antifungal drug; imidazole antifungal drug; imidazoles; organic nitrate salt
butoconazole	[no description available]	low	0	0	aryl sulfide; conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; monochlorobenzenes
fenticonazole	[no description available]	low	0	0	aryl sulfide; dichlorobenzene; ether; imidazoles
2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-c)pyridine	[no description available]	low	0	0	imidazoles
5-imidazolepropionic acid	[no description available]	low	0	0	imidazoles; monocarboxylic acid
nitrefazole	[no description available]	low	0	0	imidazoles
eberconazole	[no description available]	low	0	0	dibenzannulene; imidazoles; organochlorine compound
prochloraz	[no description available]	low	0	0	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
5-(3-methyl-1-triazeno)imidazole-4-carboxamide	[no description available]	low	0	0	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent
1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
histidinal	[no description available]	low	0	0	amino aldehyde; imidazoles
tipifarnib	[no description available]	low	0	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cimicoxib	[no description available]	low	0	0	aromatic ether; imidazoles; organochlorine compound; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
dabuzalgron	[no description available]	low	0	0	aromatic ether; imidazoles; monochlorobenzenes; sulfonamide	alpha-adrenergic agonist
l 778,123	[no description available]	low	0	0	imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor
1-methylpropyl-2-imidazolyl disulfide	[no description available]	low	0	0	imidazoles
2-pentan-3-yl-1H-imidazole	[no description available]	low	0	0	imidazoles
2-(1-adamantyl)imidazole	[no description available]	low	0	0	imidazoles
6-(4-chlorophenyl)-2,3-dihydroimidazo[2,1-b]thiazole	[no description available]	low	0	0	imidazoles
bromodeoxytopsentin	[no description available]	low	0	0	aromatic ketone; bromoindole; imidazoles; indole alkaloid	antibacterial agent; EC 2.7.1.40 (pyruvate kinase) inhibitor; marine metabolite
pifithrin-beta	[no description available]	low	0	0	imidazoles
bms 214662	[no description available]	low	0	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
s 1033	[no description available]	low	0	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
N-[1-methyl-5-(4-methylphenyl)-2-imidazolyl]-4-oxo-4-(1-piperidinyl)butanamide	[no description available]	low	0	0	imidazoles
2-[[5-(4-fluorophenyl)-1-methyl-2-imidazolyl]thio]-1-(1-piperidinyl)ethanone	[no description available]	low	0	0	imidazoles
2-[[5-(4-chlorophenyl)-1-(2-methoxyethyl)-2-imidazolyl]thio]-N-(thiophen-2-ylmethyl)acetamide	[no description available]	low	0	0	imidazoles
2-(4-chlorophenyl)-3-(2-furanylmethyl)imidazo[4,5-b]quinoxaline	[no description available]	low	0	0	imidazoles
2-(4-methoxyphenyl)-3-propylimidazo[4,5-b]quinoxaline	[no description available]	low	0	0	imidazoles
4-(3-amino-2-imidazo[1,2-a]pyridinyl)-2-methoxyphenol	[no description available]	low	0	0	imidazoles
aeg 3482	[no description available]	low	0	0	imidazoles
2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine	[no description available]	low	0	0	imidazoles
1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one	[no description available]	low	0	0	imidazoles
3-(4-methoxyphenyl)imidazo[1,5-a]pyridine	[no description available]	low	0	0	imidazoles
N-(2-phenyl-3-imidazo[1,2-a]pyridinyl)carbamic acid methyl ester	[no description available]	low	0	0	imidazoles
N-[3-(6-imidazo[2,1-b]thiazolyl)phenyl]butanamide	[no description available]	low	0	0	imidazoles
N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide	[no description available]	low	0	0	imidazoles
2-phenyl-3-imidazo[1,2-a]pyridinecarboxaldehyde	[no description available]	low	0	0	imidazoles
N-(2-phenyl-6-imidazo[1,2-a]pyridinyl)acetamide	[no description available]	low	0	0	imidazoles
N,N-dimethylcarbamic acid [4-[6-(trifluoromethyl)-2-imidazo[1,2-a]pyridinyl]phenyl] ester	[no description available]	low	0	0	imidazoles
2-(2-furanyl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline	[no description available]	low	0	0	imidazoles
2-[(1,5-diphenyl-2-imidazolyl)thio]-N-(2-furanylmethyl)acetamide	[no description available]	low	0	0	imidazoles
4-chloro-2-[[(1-methyl-5-phenyl-2-imidazolyl)amino]methyl]phenol	[no description available]	low	0	0	imidazoles
5-(4-bromophenyl)-1-methyl-N-(3-pyridinylmethyl)-2-imidazolamine	[no description available]	low	0	0	imidazoles
N'-methyl-N-[1-methyl-5-(4-methylphenyl)-2-imidazolyl]-N'-(phenylmethyl)butanediamide	[no description available]	low	0	0	imidazoles
5-(4-fluorophenyl)sulfonyl-1-(2-methylpropyl)-4-nitro-2-propan-2-ylimidazole	[no description available]	low	0	0	imidazoles
2-(3,5-dinitrophenyl)-3-(2-phenylethyl)imidazo[4,5-b]quinoxaline	[no description available]	low	0	0	imidazoles
2-(4-methylsulfonylphenyl)-6-imidazo[1,2-a]pyridinecarboxylic acid methyl ester	[no description available]	low	0	0	imidazoles
1-[[[1-(6-methyl-2-pyridinyl)-4-imidazolyl]-oxomethyl]amino]-3-phenylthiourea	[no description available]	low	0	0	imidazoles
4,5-dichloro-2-methyl-1-(2-phenoxyethyl)imidazole	[no description available]	low	0	0	imidazoles
2-Chloro-6-(1H-imidazol-1-yl)benzonitrile	[no description available]	low	0	0	imidazoles
[1-Benzyl-2-(methylsulfanyl)-1H-imidazol-5-yl]methanol	[no description available]	low	0	0	imidazoles
2-(1-benzyl-1H-imidazol-5-yl)phenol	[no description available]	low	0	0	imidazoles
1-[2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-nitrophenyl]-1H-imidazole	[no description available]	low	0	0	imidazoles
2-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyrimidine	[no description available]	low	0	0	imidazoles
6-methyl-2-[4-(1-piperidinylsulfonyl)phenyl]imidazo[1,2-a]pyridine	[no description available]	low	0	0	imidazoles
1-[(4-tert-butylphenyl)methyl]-4-(4-nitrophenyl)imidazole	[no description available]	low	0	0	imidazoles
carnidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
2-methoxy-4-[5-methyl-3-(2-oxolanylmethylamino)-2-imidazo[1,2-a]pyridinyl]phenol	[no description available]	low	0	0	imidazoles
4-[3-(1,3-benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol	[no description available]	low	0	0	imidazoles
2-[[5-(4-fluorophenyl)-1-methyl-2-imidazolyl]thio]-1-(2-methyl-2,3-dihydroindol-1-yl)ethanone	[no description available]	low	0	0	imidazoles
N-[3-(diethylamino)propyl]-6-(4-fluorophenyl)-3-methyl-2-imidazo[2,1-b]thiazolecarboxamide	[no description available]	low	0	0	imidazoles
N-(1,3-benzodioxol-5-yl)-3-methyl-6-phenyl-2-imidazo[2,1-b]thiazolecarboxamide	[no description available]	low	0	0	imidazoles
N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-2-[[1-(3-methylphenyl)-2-imidazolyl]thio]acetamide	[no description available]	low	0	0	imidazoles
4-[[2-(4-methoxyphenyl)-6-imidazo[2,1-b][1,3]benzothiazolyl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester	[no description available]	low	0	0	imidazoles
4-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-imidazo[1,2-a]pyrimidinyl]phenol	[no description available]	low	0	0	imidazoles
5-(1,3-benzodioxol-5-yl)-3-[3-(methylthio)phenyl]-1H-imidazol-2-one	[no description available]	low	0	0	imidazoles
2-(2-ethoxyphenyl)-8-oxo-9-phenyl-7H-purine-6-carboxamide	[no description available]	low	0	0	imidazoles
1-phenyl-2-[[4-(trifluoromethyl)phenyl]methylthio]imidazole	[no description available]	low	0	0	imidazoles
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine	[no description available]	low	0	0	imidazoles
1-[4-(2-chlorophenoxy)butyl]imidazole	[no description available]	low	0	0	aromatic ether; imidazoles; monochlorobenzenes
4-[(3-methyl-5-nitro-4-imidazolyl)amino]phenol	[no description available]	low	0	0	C-nitro compound; imidazoles
4-(4-ethoxyphenyl)-1-(4-methoxyphenyl)-2-(methylthio)imidazole	[no description available]	low	0	0	imidazoles
4-[(7-methyl-2-phenyl-3-imidazo[1,2-a]pyridinyl)methyl]morpholine	[no description available]	low	0	0	imidazoles
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	[no description available]	low	0	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[1-(4-ethoxyphenyl)-2-imidazolyl]thio]ethanone	[no description available]	low	0	0	imidazoles
2-[[1-(3-methoxyphenyl)-2-imidazolyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide	[no description available]	low	0	0	imidazoles
N-(4-tert-butylphenyl)-2-[4-(1-imidazolyl)phenoxy]acetamide	[no description available]	low	0	0	imidazoles
2-[[4-(3,4-dimethylphenyl)-1-phenyl-2-imidazolyl]thio]-N-(1,1-dioxo-3-thiolanyl)acetamide	[no description available]	low	0	0	imidazoles
6-(4-methoxyphenyl)-N,3-dimethyl-2-imidazo[2,1-b]thiazolecarboxamide	[no description available]	low	0	0	imidazoles
neticonazole	[no description available]	low	0	0	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
2-(2-chlorophenyl)-9-(3-methylphenyl)-8-oxo-7H-purine-6-carboxamide	[no description available]	low	0	0	imidazoles
N-[(3-methyl-6-imidazo[2,1-b]thiazolyl)methyl]-1-propanesulfonamide	[no description available]	low	0	0	imidazoles
oxiconazole	[no description available]	low	0	0	conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; oxime O-ether	antiinfective agent
3-[(1S)-1-phenylethyl]-4-imidazolecarboxylic acid ethyl ester	[no description available]	low	0	0	imidazoles
d 4476	[no description available]	low	0	0	imidazoles
azanidazole	[no description available]	low	0	0	C-nitro compound; imidazoles
4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine	[no description available]	low	0	0	imidazoles
N-[5-(2-imidazo[1,2-a]pyrimidinyl)-2-methoxyphenyl]-2-methylpropanamide	[no description available]	low	0	0	imidazoles
4-[3-(3-methylanilino)-2-imidazo[1,2-a]pyrimidinyl]phenol	[no description available]	low	0	0	imidazoles
2-[4-(dimethylamino)phenyl]-N-(4-methylphenyl)-3-imidazo[1,2-a]pyrimidinamine	[no description available]	low	0	0	imidazoles
N-(1,3-benzodioxol-5-yl)-2-(4-methylphenyl)-3-imidazo[1,2-a]pyrazinamine	[no description available]	low	0	0	imidazoles
sb-505124	[no description available]	low	0	0	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist
cyazofamid	[no description available]	low	0	0	imidazole fungicide; imidazoles; nitrile; organochlorine compound; sulfamides; sulfonamide fungicide	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor
npi 2358	[no description available]	low	0	0	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
l-779,450	[no description available]	low	0	0	imidazoles
chir 99021	[no description available]	low	0	0	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline	[no description available]	low	0	0	imidazoles
eluxadoline	[no description available]	low	0	0	amino acid amide; benzamides; imidazoles; L-phenylalanine derivative; methoxybenzoic acid	delta-opioid receptor antagonist; gastrointestinal drug; kappa-opioid receptor agonist; mu-opioid receptor agonist
cenicriviroc	[no description available]	low	0	0	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist
4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine	[no description available]	low	0	0	aminopyrimidine; imidazoles; monofluorobenzenes	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cefpodoxime	[no description available]	low	0	0	imidazoles
sgi 1776	[no description available]	low	0	0	imidazoles
bms-790052	[no description available]	low	0	0	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile	[no description available]	low	0	0	imidazoles
chir 98014	[no description available]	low	0	0	aminopyrimidine; C-nitro compound; diaminopyridine; dichlorobenzene; imidazoles; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; hypoglycemic agent; tau aggregation inhibitor; Wnt signalling activator
ledipasvir	[no description available]	low	0	0	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor
gs-5816	[no description available]	low	0	0	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor
mk-8742	[no description available]	low	0	0	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent
sb-590885	[no description available]	low	0	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
vanillylamine	[no description available]	low	0	0	aralkylamino compound
4-methoxybenzylamine	[no description available]	low	0	0	aralkylamino compound; aromatic ether; primary amino compound

Article	Year
Dynamical questions in volume transmission. Journal of biological dynamics, Volume: 17, Issue: 1	2023
Contribution of astrocytic histamine N-methyltransferase to histamine clearance and brain function in mice. Neuropharmacology, 07-01, Volume: 212	2022
Glycosylation site Asn168 is important for slow in vivo clearance of recombinant human diamine oxidase heparin-binding motif mutants. Glycobiology, 04-21, Volume: 32, Issue: 5	2022
Identifying bronchoconstriction from the ratio of diaphragm EMG to tidal volume. Respiratory physiology & neurobiology, Volume: 291	2021
Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology research & perspectives, Volume: 9, Issue: 3	2021
Organic Cation Transporters in Brain Histamine Clearance: Physiological and Psychiatric Implications. Handbook of experimental pharmacology, Volume: 266	2021
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Sep-01, Volume: 152	2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clinical drug investigation, Volume: 40, Issue: 7	2020
Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands. Pulmonary pharmacology & therapeutics, Volume: 59	2019
Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. Veterinary dermatology, Volume: 30, Issue: 2	2019
Profiling wines in China for the biogenic amines: A nationwide survey and pharmacokinetic fate modelling. Food chemistry, Jun-01, Volume: 250	2018
Histamine Clearance Through Polyspecific Transporters in the Brain. Handbook of experimental pharmacology, Volume: 241	2017
Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. Journal of pharmacokinetics and pharmacodynamics, Volume: 43, Issue: 4	2016
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Journal of psychopharmacology (Oxford, England), Volume: 30, Issue: 10	2016
Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study. Clinical therapeutics, Oct-01, Volume: 37, Issue: 10	2015
Comparison of capnovolumetry-derived dead space parameters with pulmonary function test in normal adults using histamine provocation. The clinical respiratory journal, Volume: 9, Issue: 2	2015
Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Volume: 27, Issue: 12	2013
Variability of histamine pharmacodynamic response in children with allergic rhinitis. Journal of clinical pharmacology, Volume: 53, Issue: 7	2013
Molecular mechanism of histamine clearance by primary human astrocytes. Glia, Volume: 61, Issue: 6	2013
[Influence of acupuncture or thermal acupuncture stimulation at "Zusanli" (ST 36) on thoracic duct lymph volume and the relevant chemical substances in normal rats]. Zhen ci yan jiu = Acupuncture research, Volume: 37, Issue: 6	2012
Microencapsulation of hydroxyzine HCl by thermal phase separation: in vitro release enhancement and in vivo pharmacodynamic evaluation. Pharmaceutical development and technology, Volume: 18, Issue: 1	2013
Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. The Journal of neuroscience : the official journal of the Society for Neuroscience, Nov-10, Volume: 30, Issue: 45	2010
Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology, Volume: 202, Issue: 4	2009
Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clinical therapeutics, Volume: 30, Issue: 1	2008
Patterns of intrathoracic gas volume and airway resistance in children with asthma. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, Volume: 58 Suppl 5, Issue: Pt 1	2007
Edemagenic gain and interstitial fluid volume regulation. American journal of physiology. Regulatory, integrative and comparative physiology, Volume: 294, Issue: 2	2008
Area under the maximum expiratory flow-volume curve--a sensitive parameter in the evaluation of airway patency. Respiration; international review of thoracic diseases, Volume: 75, Issue: 1	2008
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. Journal of clinical pharmacology, Volume: 46, Issue: 5	2006
Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism. Journal of clinical pharmacology, Volume: 46, Issue: 4	2006
Ndn, volume transmission, and self-organization in brain dynamics. Journal of integrative neuroscience, Volume: 4, Issue: 4	2005
A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies. The Journal of pharmacy and pharmacology, Volume: 57, Issue: 2	2005
Ca(2+)- and volume-sensitive chloride currents are differentially regulated by agonists and store-operated Ca2+ entry. The Journal of general physiology, Volume: 125, Issue: 2	2005
Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. Journal of cardiothoracic and vascular anesthesia, Volume: 18, Issue: 6	2004
Modulation of histamine-induced Ca2+ release by protein kinase C. Effects on cytosolic and mitochondrial [Ca2+] peaks. The Journal of biological chemistry, Dec-12, Volume: 278, Issue: 50	2003
Studies of basal and peak acid output with an augmented histamine test. Gut, Volume: 4	1963
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole. Journal of pharmacokinetics and pharmacodynamics, Volume: 29, Issue: 4	2002
Accelerated clearance of Escherichia coli in experimental peritonitis of histamine-deficient mice. Journal of immunology (Baltimore, Md. : 1950), Aug-15, Volume: 169, Issue: 4	2002
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. Journal of clinical pharmacology, Volume: 42, Issue: 7	2002
Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. Life sciences, Jan-11, Volume: 70, Issue: 8	2002
Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Investigative radiology, Volume: 36, Issue: 8	2001
Volume dependence of respiratory system resistance during artificial ventilation in rabbits. Intensive care medicine, Volume: 27, Issue: 5	2001
Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. Clinical pharmacology and therapeutics, Volume: 68, Issue: 6	2000
The effect of inflammation on mucociliary clearance in asthma: an overview. Chest, Volume: 118, Issue: 4	2000
Abnormalities in histamine pharmacodynamics in chronic urticaria. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, Volume: 23, Issue: 12	1993
BN52021 inhibits activation of peritoneal mast cells caused by hemorrhage and blood volume restoration. Polish journal of pathology : official journal of the Polish Society of Pathologists, Volume: 50, Issue: 4	1999
A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. International journal of clinical pharmacology and therapeutics, Volume: 37, Issue: 10	1999
Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. The European respiratory journal, Volume: 13, Issue: 3	1999
Clearance in small ciliated airways in allergic asthmatics after bronchial allergen provocation. Respiration; international review of thoracic diseases, Volume: 66, Issue: 2	1999
Changes in lung volumes and poor perception of bronchoconstriction-induced respiratory symptoms. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, Volume: 81, Issue: 4	1998
Time to peak tidal expiratory flow and the neuromuscular control of expiration. The European respiratory journal, Volume: 12, Issue: 3	1998
Excessive bronchoconstriction induced by histamine and effects of volume history in patients with bronchial asthma. Respirology (Carlton, Vic.), Volume: 2, Issue: 2	1997
Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability? The British journal of general practice : the journal of the Royal College of General Practitioners, Volume: 47, Issue: 421	1997
Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. British journal of clinical pharmacology, Volume: 43, Issue: 6	1997
Peak flow variation in childhood asthma: relationship to symptoms, atopy, airways obstruction and hyperresponsiveness. Dutch CNSLD Study Group. The European respiratory journal, Volume: 10, Issue: 6	1997
Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects. European journal of clinical pharmacology, Volume: 49, Issue: 4	1996
Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine. European journal of clinical pharmacology, Volume: 50, Issue: 4	1996
Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics, Volume: 59, Issue: 3	1996
The effects of three models of airway disease on tidal breathing flow-volume loops of thoroughbred horses. Veterinary research communications, Volume: 19, Issue: 6	1995
Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scandinavian journal of immunology, Volume: 43, Issue: 1	1996
Assessment of forced expiratory volume-time parameters in detecting histamine-induced bronchoconstriction in wheezy infants. Pediatric pulmonology, Volume: 15, Issue: 4	1993
Regional blood flow volume in the eustachian tube. Acta oto-laryngologica. Supplementum, Volume: 500	1993
Acute pulmonary response to intravenous histamine at fixed lung volume in dogs. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 75, Issue: 1	1993
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics, Volume: 54, Issue: 4	1993
Temporal dynamics of pulmonary response to intravenous histamine in dogs: effects of dose and lung volume. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 76, Issue: 2	1994
Pharmacodynamic bioequivalence: evaluation of different brands of terfenadine hydrochloride. Indian journal of physiology and pharmacology, Volume: 37, Issue: 4	1993
Effect of S-carboxymethylcysteine on the clearance of middle ear effusion. An experimental study. The Annals of otology, rhinology, and laryngology, Volume: 103, Issue: 7	1994
Serum eosinophil cationic protein (ECP) in chronic asthma. Relationship to spirometry, flow-volume curves, PC20, and exacerbations. Respiratory medicine, Volume: 88, Issue: 8	1994
The limitations of peak nasal flow measurement. Clinical otolaryngology and allied sciences, Volume: 19, Issue: 6	1994
Changes in regional lung impedance after intravenous histamine bolus in dogs: effects of lung volume. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 78, Issue: 3	1995
Bronchial responsiveness to inhaled histamine in both adults with intrinsic and extrinsic asthma: the importance of prechallenge forced expiratory volume in 1 second. The Journal of allergy and clinical immunology, Volume: 91, Issue: 1 Pt 1	1993
Nasal pressure-volume relationships determined with acoustic rhinometry. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 79, Issue: 2	1995
Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Trial Group Mainz/Marburg. Lancet (London, England), Apr-16, Volume: 343, Issue: 8903	1994
Volume adjustment of maximal midexpiratory flow. Importance of changes in total lung capacity. Chest, Volume: 78, Issue: 4	1980
Changes of regional gastric flow measured by hydrogen clearance techniques after histamine stimulation in conscious animals. Scandinavian journal of gastroenterology, Volume: 16, Issue: 6	1981
Relationship between intestinal volume secretion and oxygen uptake. Digestive diseases and sciences, Volume: 27, Issue: 1	1982
Measurement of gastric mucosal blood flow in dogs by the 99mTc-4-methylaminophenazone clearance technique. Gastroenterology, Volume: 83, Issue: 1 Pt 2	1982
Skin blood flow during histamine flare using the clearance of epicutaneous applied Xenon-133 in diabetic and non-diabetic subjects. Angiology, Volume: 34, Issue: 4	1983
Monitoring of maximum expiratory peak flow rates and histamine inhalation tests in the investigation of occupational asthma. Clinical allergy, Volume: 14, Issue: 2	1984
Measurement of regional gastric mucosal blood flow by hydrogen gas clearance. American journal of surgery, Volume: 147, Issue: 1	1984
Diameter, thickness, area, and volume of skin-prick histamine weals. Measurement of skin thickness by 15 MHz A-mode ultrasound. Allergy, Volume: 39, Issue: 5	1984
Effect of 5-HT on basal and stimulated secretions of acid and pepsin and on gastric volume outflow in the in vivo gastrically and intestinally perfused cod, Gadus morhua. Agents and actions, Volume: 15, Issue: 3-4	1984
Clearance of histamine from the peritoneal cavity of rats. Agents and actions, Volume: 15, Issue: 3-4	1984
Measurements of gastric mucosal blood flow by hydrogen gas clearance. The American journal of physiology, Volume: 247, Issue: 4 Pt 1	1984
Comparative study of hydrogen and aminopyrine clearance methods for determination of gastric mucosal blood flow in dogs. Digestive diseases and sciences, Volume: 29, Issue: 9	1984
Inotropic responses, cyclic AMP, and time to peak tension in isolated cardiac preparations. Advances in myocardiology, Volume: 3	1982
The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvascular research, Volume: 28, Issue: 2	1984
Volume flow, hydraulic conductivity and electrical properties across bovine tracheal epithelium in vitro: effect of histamine. Pflugers Archiv : European journal of physiology, Volume: 392, Issue: 1	1981
Variations in small and large vessel volumes caused by cations, adrenaline and histamine. The Journal of physiology, Volume: 188, Issue: 2	1967
Effects of histamine on hepatic volume (outflow block) in anaesthetized dogs. British journal of pharmacology, Volume: 47, Issue: 2	1973
The measurement of dog gastric mucosal blood flow by radioactive aniline clearance compared with amidopyrine clearance. The Journal of physiology, Volume: 229, Issue: 1	1973
The effect of edema, hydrocortisone acetate, concurrent viral infection and immunization on the clearance of Pasteurella hemolytica from the bovine lung. Canadian journal of comparative medicine : Revue canadienne de medecine comparee, Volume: 38, Issue: 3	1974
Effects of infusions of catecholamines, angiotensin, vasopressin and histamine on hepatic blood volume in the anaesthetized cat. British journal of pharmacology, Volume: 44, Issue: 2	1972
Observation of changes in volume of a congested limb as a means of studying the behaviour of capacity vessels. The Journal of physiology, Volume: 194, Issue: 3	1968
Gastric clearance of serum albumin in normal man and in certain gastroduodenal disorders. Gut, Volume: 15, Issue: 3	1974
An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects. The Journal of allergy and clinical immunology, Volume: 77, Issue: 2	1986
Effect of expiratory glottic constriction on lung volume and pattern of breathing in adult dogs. Respiration physiology, Volume: 67, Issue: 1	1987
Changes in flow-volume curve configuration with bronchoconstriction and bronchodilation. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 61, Issue: 6	1986
Effect of tidal volume and anesthetic agent on airway responsiveness to histamine. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 60, Issue: 5	1986
Enprofylline: pharmacokinetics and comparison with theophylline of acute effects on bronchial reactivity in normal subjects. European journal of clinical pharmacology, Volume: 30, Issue: 1	1986
Concentrations of histamine in the hypothalamus of the rat: effect of extraction volume and interpretation of the effects of acutely-administered morphine. Neuropharmacology, Volume: 26, Issue: 8	1987
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659. Journal of industrial microbiology & biotechnology, Feb-17, Volume: 50, Issue: 1	2023
Can histamine cause an enhancement of the cellular uptake and cytotoxicity of doxorubicin-loaded polylactide nanoparticles? European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jun-01, Volume: 185	2023
A Review on Bio- and Chemosensors for the Detection of Biogenic Amines in Food Safety Applications: The Status in 2022. Sensors (Basel, Switzerland), Jan-05, Volume: 23, Issue: 2	2023
Investigation of the Adverse Events Associated with Bee Venom Pharmacopuncture in Patients Hospitalized in a Korean Hospital: A Retrospective Chart Review Study. Toxins, 09-23, Volume: 14, Issue: 10	2022
Improving the safety and quality of Roucha using amine-degrading lactic acid bacteria starters. Food research international (Ottawa, Ont.), Volume: 161	2022
Safety and efficacy of intratympanic histamine injection as an adjuvant to dexamethasone in a noise-induced murine model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-01, Volume: 178	2022
Pharmacogenomics for the efficacy and side effects of antihistamines. Experimental dermatology, Volume: 31, Issue: 7	2022
Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 07-11, Volume: 62, Issue: 2	2022
Analysis of histamine and sisomicin in gentamicin: Search for the causative agents of adverse effects. Archiv der Pharmazie, Volume: 354, Issue: 12	2021
Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology research & perspectives, Volume: 9, Issue: 3	2021
Benefits and Adverse Effects of Histidine Supplementation. The Journal of nutrition, 10-01, Volume: 150, Issue: Suppl 1	2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clinical drug investigation, Volume: 40, Issue: 7	2020
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus. Molecules (Basel, Switzerland), Apr-27, Volume: 25, Issue: 9	2020
Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands. Pulmonary pharmacology & therapeutics, Volume: 59	2019
Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells. Human & experimental toxicology, Volume: 38, Issue: 5	2019
An altered gene expression profile in tyramine-exposed intestinal cell cultures supports the genotoxicity of this biogenic amine at dietary concentrations. Scientific reports, 11-19, Volume: 8, Issue: 1	2018
Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine. British journal of haematology, Volume: 180, Issue: 5	2018
Towards replacement of the acellular pertussis vaccine safety test: Comparison of in vitro cytotoxic activity and in vivo activity in mice. Vaccine, 12-18, Volume: 35, Issue: 51	2017
Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives. Human vaccines & immunotherapeutics, 11-02, Volume: 13, Issue: 11	2017
The efficacy and safety of mivacurium in pediatric patients. BMC anesthesiology, 04-17, Volume: 17, Issue: 1	2017
The dietary biogenic amines tyramine and histamine show synergistic toxicity towards intestinal cells in culture. Food chemistry, Mar-01, Volume: 218	2017
Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, Volume: 51	2016
Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. Journal of neuroinflammation, 06-04, Volume: 13, Issue: 1	2016
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Journal of psychopharmacology (Oxford, England), Volume: 30, Issue: 10	2016
Phytochemical screening, safety evaluation, anti-inflammatory and analgesic studies of the leaf extracts of Sterculia tragacantha. Journal of complementary & integrative medicine, Sep-01, Volume: 13, Issue: 3	2016
Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine. Food chemistry, Apr-15, Volume: 197, Issue: Pt A	2016
Hepato and Cardiotoxicity of Chemotherapeutic Treatment Evaluated by Means of Small Animal Imaging. Anti-cancer agents in medicinal chemistry, Volume: 17, Issue: 3	2017
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget, Dec-15, Volume: 6, Issue: 40	2015
Role of the KATP channel in the protective effect of nicorandil on cyclophosphamide-induced lung and testicular toxicity in rats. Scientific reports, Sep-25, Volume: 5	2015
Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study. Clinical therapeutics, Oct-01, Volume: 37, Issue: 10	2015
Fish protein hydrolysates: application in deep-fried food and food safety analysis. Journal of food science, Volume: 80, Issue: 1	2015
[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], Volume: 59, Issue: 5-6	2014
Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice. PloS one, Volume: 8, Issue: 4	2013
Melatonin is formed during winemaking at safe levels of biogenic amines. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 57	2013
The safety and efficacy of sublingual and oral immunotherapy for milk allergy. The Journal of allergy and clinical immunology, Volume: 129, Issue: 2	2012
Biological toxicity and inflammatory response of semi-single-walled carbon nanotubes. PloS one, Volume: 6, Issue: 10	2011
Could halophilic archaea improve the traditional salted anchovies (Engraulis encrasicholus L.) safety and quality? Letters in applied microbiology, Volume: 51, Issue: 6	2010
Conjugation of chlorin p(6) to histamine enhances its cellular uptake and phototoxicity in oral cancer cells. Cancer chemotherapy and pharmacology, Volume: 68, Issue: 2	2011
Histamine modulates γδ-T lymphocyte migration and cytotoxicity, via Gi and Gs protein-coupled signalling pathways. British journal of pharmacology, Volume: 161, Issue: 6	2010
Post-thaw removal of DMSO does not completely abrogate infusional toxicity or the need for pre-infusion histamine blockade. Cytotherapy, Volume: 1, Issue: 6	1999
Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines. Pharmeuropa bio & scientific notes, Volume: 2010, Issue: 1	2010
Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology, Jun-16, Volume: 260, Issue: 1-3	2009
Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax, Volume: 64, Issue: 9	2009
Age-related differences in pulmonary and cardiovascular responses to SiO2 nanoparticle inhalation: nanotoxicity has susceptible population. Environmental science & technology, Dec-01, Volume: 42, Issue: 23	2008
Pharmacological and biological screening of ascorbigen: protection against glucose-induced endothelial cell toxicity. Phytotherapy research : PTR, Volume: 22, Issue: 12	2008
Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clinical therapeutics, Volume: 30, Issue: 1	2008
Synthesis and cytotoxicity of platinum(II) complexes of a physiologically active carrier histamine. Archiv der Pharmazie, Volume: 341, Issue: 2	2008
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, Volume: 18, Issue: 10	2007
[Reversing effect of histamine on neurotoxicity induced by beta-amyloid1-42]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, Volume: 36, Issue: 2	2007
Validated safety predictions of airway responses to house dust mite in asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, Volume: 37, Issue: 1	2007
Carnosine protects against NMDA-induced neurotoxicity in differentiated rat PC12 cells through carnosine-histidine-histamine pathway and H(1)/H(3) receptors. Biochemical pharmacology, Mar-01, Volume: 73, Issue: 5	2007
Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, Volume: 33, Issue: 2	2006
A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone marrow transplantation, Volume: 37, Issue: 8	2006
Effect of carvedilol on Ca2+ movement and cytotoxicity in human MG63 osteosarcoma cells. Basic & clinical pharmacology & toxicology, Volume: 95, Issue: 2	2004
Toxicity and potency evaluation of pertussis vaccines. Expert review of vaccines, Volume: 3, Issue: 1	2004
RNA synthesis-dependent potentiation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor-mediated toxicity by antihistamine terfenadine in cultured rat cerebellar neurons. Neuroscience letters, Jul-17, Volume: 345, Issue: 2	2003
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma research, Volume: 13, Issue: 3	2003
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. Journal of viral hepatitis, Volume: 9, Issue: 5	2002
A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. Journal of alternative and complementary medicine (New York, N.Y.), Volume: 8, Issue: 2	2002
Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug safety, Volume: 24, Issue: 1	2001
Potentiation by histamine of synaptically mediated excitotoxicity in cultured hippocampal neurones: a possible role for mast cells. Journal of neurochemistry, Volume: 76, Issue: 1	2001
Dermal and systemic toxicity after application of semisynthetic metal-working fluids in B6C3F1 mice. Journal of toxicology and environmental health. Part A, Dec-15, Volume: 61, Issue: 7	2000
Solvent for etomidate may cause pain and adverse effects. British journal of anaesthesia, Volume: 83, Issue: 3	1999
A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. Forschende Komplementarmedizin, Volume: 6, Issue: 3	1999
[Evaluation of efficacy and safety of intrabronchial specific immunotherapy with allergy medication against allergies to house mites among patients with bronchial asthma]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, Volume: 6, Issue: 35	1999
Duration and mechanisms of the increased natural cytotoxicity seen after chronic voluntary exercise in rats. Acta physiologica Scandinavica, Volume: 160, Issue: 4	1997
Role of the central histaminergic neuronal system in the CNS toxicity of the first generation H1-antagonists. Progress in neurobiology, Volume: 52, Issue: 2	1997
Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. Biologicals : journal of the International Association of Biological Standardization, Volume: 25, Issue: 1	1997
Safety and potency of ANQ 9040 in male volunteers. Anesthesiology, Volume: 80, Issue: 1	1994
Intestinal mucosal lymphocytes have H1 receptors: H1 antagonists reduce their proliferation and cytotoxicity. Cellular immunology, Volume: 156, Issue: 1	1994
Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. Journal of leukocyte biology, Volume: 55, Issue: 3	1994
The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. The Journal of allergy and clinical immunology, Volume: 91, Issue: 5	1993
Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacology & toxicology, Volume: 75, Issue: 2	1994
A possible approach to the suppression of side effects induced by PGE1. Prostaglandins, leukotrienes, and essential fatty acids, Volume: 52, Issue: 1	1995
Use and safety of a shortened histamine challenge test in an occupational study. The European respiratory journal, Volume: 8, Issue: 5	1995
Intravenous histamine in otologic practice. Side effects in 2,347 administrations. Archives of otolaryngology (Chicago, Ill. : 1960), Volume: 106, Issue: 3	1980
Pulmonary toxicity of inhaled coal liquid aerosols (boiling range 230-450 degrees C). Toxicology and applied pharmacology, Mar-15, Volume: 67, Issue: 3	1983
Bronchoalveolar lavage. Its safety in subjects with mild asthma. Chest, Volume: 85, Issue: 6	1984
Histidine decarboxylase inhibition: a novel approach towards the development of an effective and safe gastric anti-ulcer drug. Agents and actions, Volume: 15, Issue: 5-6	1984
Pertussis antigens--screening models on toxicity. Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, Volume: 5	1982
Impaired monocyte cyclic AMP responses and monocyte cytotoxicity in atopic dermatitis. Allergy, Volume: 35, Issue: 8	1980
Effect of histamine and histamine antagonists on natural and antibody-dependent cellular cytotoxicity of human lymphocytes in vitro. Cellular immunology, Oct-01, Volume: 81, Issue: 1	1983
Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents and actions, Volume: 12, Issue: 1-2	1982
Effect of histamine receptor blocking on human antibody-dependent cell-mediated cytotoxicity. Scandinavian journal of immunology, Volume: 13, Issue: 4	1981
Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis. Archives of dermatological research, Volume: 276, Issue: 5	1984
Effect of histamine-receptor blocking on human natural and lectin-dependent cell-mediated cytotoxicity against adherent HEP-2 cells. Thymus, Volume: 7, Issue: 2	1985
In vivo mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. The Journal of investigative dermatology, Volume: 88, Issue: 3	1987
Counteraction of the genotoxicity of some cooked-food mutagens by biogenic amines. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 25, Issue: 8	1987
Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides. Cancer chemotherapy and pharmacology, Volume: 19, Issue: 3	1987
Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine. Vaccine, Volume: 6, Issue: 6	1988
Regulation of antibody-dependent cellular cytotoxicity in multiple sclerosis by central nervous system hormones. International archives of allergy and applied immunology, Volume: 82, Issue: 2	1987
Expert examination of the immunogenic activity and toxicity of the pertussis component of adsorbed and non-adsorbed diphtheria-tetanus-pertussis vaccines. Results of interlaboratory investigations under the WHO project "Reactogenicity and Toxicity of DPT Journal of hygiene, epidemiology, microbiology, and immunology, Volume: 33, Issue: 4	1989
Immunological safety assessments of anti-IgE antibody which is detached from therapeutic immunoadsorbents for removing IgE. Journal of biomedical materials research, Volume: 23, Issue: 11	1989
Lung mechanics and airway reactivity in sheep during development of oxygen toxicity. Journal of applied physiology (Bethesda, Md. : 1985), Volume: 69, Issue: 5	1990
Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. International archives of allergy and applied immunology, Volume: 92, Issue: 4	1990
Antihistaminic activity and side effect profile of epinastine and terfenadine in healthy volunteers. International journal of clinical pharmacology, therapy, and toxicology, Volume: 28, Issue: 12	1990
Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques. Developments in biological standardization, Volume: 73	1991
A 90-day subcutaneous toxicity and fertility study of a LHRH antagonist in rats. Fundamental and applied toxicology : official journal of the Society of Toxicology, Volume: 14, Issue: 4	1990
Toxicity and pharmacology of extracts from dorid nudibranches. The Biological bulletin, Volume: 156, Issue: 3	1979
The effectiveness and safety of electroconvulsive therapy (ECT). The Journal of nervous and mental disease, Volume: 164, Issue: 6	1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H Disease markers, Volume: 2022	2022
Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats. Life sciences, Nov-01, Volume: 284	2021
Striatal histamine mechanism in the pathogenesis of restless legs syndrome. Sleep, 02-13, Volume: 43, Issue: 2	2020
In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist. European journal of pharmacology, May-15, Volume: 803	2017
HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats. PloS one, Volume: 11, Issue: 10	2016
Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, Volume: 274, Issue: 2	2017
Bronchodilatory, antitussive and anti-inflammatory effect of morin in the setting of experimentally induced allergic asthma. The Journal of pharmacy and pharmacology, Volume: 68, Issue: 8	2016
Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in neuro-psychopharmacology & biological psychiatry, Jul-04, Volume: 68	2016
[Ultrastructural changes in brain histaminergic neurons under the influence of alcohol]. Morfologiia (Saint Petersburg, Russia), Volume: 146, Issue: 5	2014
Influence of roflumilast on airway reactivity and apoptosis in ovalbumin-sensitized Guinea pigs. Advances in experimental medicine and biology, Volume: 838	2015
Use of a novel one-nostril mask-spacer device to evaluate airway hyperresponsiveness (AHR) in horses after chronic administration of albuterol. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, Volume: 78, Issue: 3	2014
Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders. Behavioural brain research, Jan-15, Volume: 237	2013
Effects of 2-azafluorenones on phosphatidyl-inositol specific phospholipase C activation in c6 glioma cells. The Chinese journal of physiology, Apr-30, Volume: 55, Issue: 2	2012
The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. British journal of pharmacology, Volume: 166, Issue: 5	2012
L-Dopa activates histaminergic neurons. The Journal of physiology, Mar-15, Volume: 589, Issue: Pt 6	2011
Oral contraceptive administration attenuates endothelium-dependent relaxation in response to histamine but not to acetylcholine in aortic rings of female rats. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, Volume: 45, Issue: 6	2009
Histamine modulates the cellular stress response in yeast. Amino acids, Volume: 38, Issue: 4	2010
Evaluation of the effect of Myrica sapida on bronchoconstriction and bronchial hyperreactivity. Die Pharmazie, Volume: 63, Issue: 4	2008
LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts Correlation with pharmacological activity. Journal of pharmaceutical and biomedical analysis, Feb-24, Volume: 40, Issue: 3	2006
Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. British journal of pharmacology, Volume: 145, Issue: 6	2005
Toxicology and toxicokinetics of acute and subchronic administration of histamine dihydrochloride in rats. Drug and chemical toxicology, Volume: 26, Issue: 1	2003
Clinical advantages of dual activity in urticaria. Allergy, Volume: 55 Suppl 64	2000
The role of brain histamine in acute and chronic stresses. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Volume: 54, Issue: 5	2000
Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Japanese journal of pharmacology, Volume: 78, Issue: 1	1998
Salbutamol-induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect. European journal of pharmacology, Dec-04, Volume: 287, Issue: 1	1995
Effects of ethanol on contractile response of gall bladder isolated from guinea pig. European journal of pharmacology, Aug-02, Volume: 248, Issue: 2	1993
The effects of chronic administration of chloroquine and quinacrine on the response of normal and denervated smooth muscle to agonist drugs. Physiology & behavior, Volume: 54, Issue: 2	1993
Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. The American journal of physiology, Volume: 269, Issue: 5 Pt 1	1995
Effect of alpha-monofluoromethyl histidine, an irreversible inhibitor of histidine decarboxylase, on gestation in mice. Contraception, Volume: 26, Issue: 5	1982
Effects of chronic administration of bronchodilators on microshock in sensitized guinea-pigs. International journal of immunopharmacology, Volume: 4, Issue: 6	1982
THA increases action potential duration of central histamine neurons in vitro. European journal of pharmacology, Oct-18, Volume: 155, Issue: 3	1988
Correlations between histamine and opioid peptides on the modulation of inflammatory processes in rats exposed to stress. Agents and actions, Volume: 23, Issue: 3-4	1988
Effects of chronic administration of doxorubicin on myocardial alpha-adrenergic receptors, histamine, cyclic nucleotides, calcium, norepinephrine, calmodulin, and guanylate cyclase activity, and plasma catecholamines in rats. Virchows Archiv. B, Cell pathology including molecular pathology, Volume: 54, Issue: 3	1987
Antral gastrin and somatostatin cell populations in rats after chronic administration of histamine. Digestion, Volume: 36, Issue: 1	1987
Effect of long-term administration of platelet-activating factor on pulmonary responsiveness and morphology in the guinea pig. International archives of allergy and applied immunology, Volume: 88, Issue: 1-2	1989
Inhibition by cow's milk of histamine-induced gastric acid secretion in the rat. Journal of pediatric gastroenterology and nutrition, Volume: 9, Issue: 3	1989
Neurophysiological and endocrine consequences of immune activity. Psychoneuroendocrinology, Volume: 14, Issue: 1-2	1989
Chronic administration of H2-antagonists does not alter gastric secretory responses to histamine, or the antisecretory activity of sufotidine. Alimentary pharmacology & therapeutics, Volume: 4 Suppl 1	1990
Effect of long-term infusion of platelet-activating factor on pulmonary responsiveness and morphology in the guinea-pig. Pulmonary pharmacology, Volume: 4, Issue: 1	1991
The effect of disodium cromoglycate against bronchial hyperresponsiveness in asthmatic children. The Journal of asthma : official journal of the Association for the Care of Asthma, Volume: 29, Issue: 2	1992
Smooth muscle sensitization and neuromuscular depression induced by chronic administration of antimalarial drugs. Physiology & behavior, Volume: 51, Issue: 5	1992
[Effect of long-term administration of antisecretary drugs on rat gastric histamine synthesis and acid secretion--compare with omeprazole and cimetidine]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Volume: 89, Issue: 10	1992
Histamine leukocytosis. I. Effect of histamine on peripheral leukocyte counts. Methods and findings in experimental and clinical pharmacology, Volume: 14, Issue: 9	1992
Tolerance to sympathomimetic bronchodilators in guinea-pig isolated lungs following chronic administration in vivo. British journal of pharmacology, Volume: 55, Issue: 4	1975
Effect of L-DOPA on endogenous histamine metabolism. Medical biology, Volume: 53, Issue: 2	1975
Therapeutic effect of histidine decarboxylase inhibitor on chronic active hepatitis. Gastroenterologia Japonica, Volume: 13, Issue: 2	1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, Volume: 23, Issue: 4	2007
Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, Volume: 93, Issue: 6	2004
Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, Volume: 23, Issue: 9	1993
Topical azelastine has a 12-hour duration of action as assessed by histamine challenge-induced exudation of alpha 2-macroglobulin into human nasal airways. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, Volume: 27, Issue: 4	1997
Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy, Volume: 52, Issue: 2	1997
Time of onset of action of acrivastine in the skin of pollen-allergic subjects. A double-blind, randomized, placebo-controlled comparative study. Allergy, Volume: 49, Issue: 1	1994
Famotidine and ranitidine: any difference in the duration of action? Pharmacological research communications, Volume: 19, Issue: 1	1987
A comparative study of the bronchodilator effect and duration of action of liposome encapsulated beta-2 adrenergic agonists in the guinea-pig. Pulmonary pharmacology, Volume: 4, Issue: 3	1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology, Volume: 238, Issue: 6	2021
Pharmaceutical development and technology, Volume: 25, Issue: 8	2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46	2019
Characterization of thymoquinone/hydroxypropyl-β-cyclodextrin inclusion complex: Application to anti-allergy properties. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, May-15, Volume: 133	2019
Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients, May-10, Volume: 10, Issue: 5	2018
Towards replacement of the acellular pertussis vaccine safety test: Comparison of in vitro cytotoxic activity and in vivo activity in mice. Vaccine, 12-18, Volume: 35, Issue: 51	2017
Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. Journal of pharmacokinetics and pharmacodynamics, Volume: 43, Issue: 4	2016
Intranasal curcumin and its evaluation in murine model of asthma. International immunopharmacology, Volume: 17, Issue: 3	2013
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. International journal of nanomedicine, Volume: 7	2012
Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Journal of clinical pharmacology, Volume: 50, Issue: 2	2010
Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology, Jun-16, Volume: 260, Issue: 1-3	2009
In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties. British journal of pharmacology, Volume: 157, Issue: 1	2009
Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists. Journal of medicinal chemistry, Nov-27, Volume: 51, Issue: 22	2008
Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clinical therapeutics, Volume: 30, Issue: 1	2008
Formulation and evaluation of ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate. Biological & pharmaceutical bulletin, Volume: 29, Issue: 3	2006
Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. European journal of pharmacology, Nov-19, Volume: 504, Issue: 3	2004
Clinical pharmacology of clemastine in healthy dogs. Veterinary dermatology, Volume: 15, Issue: 3	2004
Antihistamines in rhinoconjunctivitis. Clinical allergy and immunology, Volume: 17	2002
[Transition metals and nitric oxide production in human endothelial cells]. Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie, Volume: 324, Issue: 1	2001
Exogenous nitric oxide regulates the degranulation of human basophils and rat peritoneal mast cells. International archives of allergy and immunology, Volume: 115, Issue: 2	1998
Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. British journal of clinical pharmacology, Volume: 43, Issue: 6	1997
Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. European journal of pharmacology, Apr-28, Volume: 235, Issue: 2-3	1993
An assessment of the physiological significance of cimetidine interactions with copper and zinc in biofluids as based on the computer-simulated distribution of the involved complexes at therapeutic levels of the drug. Agents and actions, Volume: 15, Issue: 5-6	1984
Pharmacological actions of various inotropic agents. European heart journal, Volume: 4 Suppl A	1983
Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs. Archives internationales de pharmacodynamie et de therapie, Volume: 256, Issue: 1	1982
Pharmacological profile of etintidine, a new histamine H2-receptor antagonist. Archives internationales de pharmacodynamie et de therapie, Volume: 281, Issue: 1	1986
Effects of airway luminal concentration of albumin on histamine-induced mucosal exudation of radio-iodine labelled albumin. Acta physiologica Scandinavica, Volume: 142, Issue: 3	1991
Evidence that nitric oxide participates in non-adrenergic inhibitory transmission to intestinal muscle in the guinea-pig. Neuroscience letters, Sep-02, Volume: 130, Issue: 1	1991
The histamine H3-receptor: pharmacology, roles and clinical implications studied with agonists. Agents and actions. Supplements, Volume: 33	1991
Inhaled histamine increases the rate of absorption of sodium cromoglycate from the lung. British journal of clinical pharmacology, Volume: 33, Issue: 3	1992
Bioavailability of trithiozine (TR) in man and its relation to gastric secretion and gastrin plasma level. International journal of clinical pharmacology and biopharmacy, Volume: 17, Issue: 1	1979
Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. Journal of pharmaceutical sciences, Volume: 68, Issue: 6	1979
Oral disodium cromoglycate in the treatment of systemic mastocytosis. The New England journal of medicine, Aug-30, Volume: 301, Issue: 9	1979
Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. British journal of clinical pharmacology, Volume: 2, Issue: 6	1975
The objective and timing of drug disposition studies, appendix V. A comparison of the bioavailability of three dosage forms of terfenadine. Drug metabolism reviews, Volume: 4, Issue: 2	1975
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Recombinant human diamine oxidase prevents hemodynamic effects of continuous histamine infusion in guinea pigs. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 72, Issue: 10-11	2023
The potential mechanism of histamine-inducing cardiopulmonary inflammation and apoptosis in a novel oral model of rat intoxication. Toxicology, 01-15, Volume: 484	2023
Decreased Arterial Vascular Tone in Small Arteries in Severe Hidradenitis Suppurativa - A Study Using Finger Photopulseplethysmography. Acta dermatovenerologica Croatica : ADC, Volume: 30, Issue: 2	2022
Anticonvulsant activity of the histamine H3 receptor inverse agonist pitolisant in an electrical kindling model of epilepsy. Neuroscience letters, 06-21, Volume: 782	2022
Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm. Molecular medicine (Cambridge, Mass.), 05-16, Volume: 28, Issue: 1	2022
Histamine Intolerance-The More We Know the Less We Know. A Review. Nutrients, Jun-29, Volume: 13, Issue: 7	2021
Chitosan-centered nanosystems as sustained therapeutics for allergic rhinitis intervention: Inhibition of histamine-induced cascades. Journal of controlled release : official journal of the Controlled Release Society, 07-10, Volume: 335	2021
Severe scombroid poisoning and life-threatening hypotension. BMJ case reports, Apr-26, Volume: 14, Issue: 4	2021
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clinical drug investigation, Volume: 40, Issue: 7	2020
Towards a catheter-based impedimetric sensor for the assessment of intestinal histamine levels in IBS patients. Biosensors & bioelectronics, Jun-15, Volume: 158	2020
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays. Journal of visualized experiments : JoVE, 02-21, Issue: 156	2020
Effect of diphenhydramine and cetirizine on immediate and late-phase cutaneous allergic reactions in healthy dogs: a randomized, double-blinded crossover study. Veterinary dermatology, Volume: 31, Issue: 4	2020
Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands. Pulmonary pharmacology & therapeutics, Volume: 59	2019
Maintenance of contractile function of isolated airway smooth muscle after cryopreservation. American journal of physiology. Lung cellular and molecular physiology, 11-01, Volume: 315, Issue: 5	2018
Relaxant effect of ghrelin on guinea pig isolated tracheal smooth muscle: role of epithelial NO and PGE Pflugers Archiv : European journal of physiology, Volume: 470, Issue: 6	2018
The efficacy and safety of mivacurium in pediatric patients. BMC anesthesiology, 04-17, Volume: 17, Issue: 1	2017
Effects of nebulised magnesium sulphate on inflammation and function of the guinea-pig airway. European journal of pharmacology, Apr-15, Volume: 801	2017
Phospholipid scramblase 1 amplifies anaphylactic reactions in vivo. PloS one, Volume: 12, Issue: 3	2017
Heterogeneity of mast cells and expression of Annexin A1 protein in a second degree burn model with silver sulfadiazine treatment. PloS one, Volume: 12, Issue: 3	2017
A Reliable Method for the Evaluation of the Anaphylactoid Reaction Caused by Injectable Drugs. Molecules (Basel, Switzerland), Oct-12, Volume: 21, Issue: 10	2016
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Journal of psychopharmacology (Oxford, England), Volume: 30, Issue: 10	2016
Histamine H3 receptor antagonists display antischizophrenic activities in rats treated with MK-801. Journal of basic and clinical physiology and pharmacology, Sep-01, Volume: 27, Issue: 5	2016
Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clinical and experimental immunology, Volume: 185, Issue: 1	2016
Effects of histamine H1 receptor signaling on glucocorticoid receptor activity. Role of canonical and non-canonical pathways. Scientific reports, Dec-04, Volume: 5	2015
Longitudinal assessment of airway responsiveness from 1 month to 18 years in the PIAF birth cohort. The European respiratory journal, Volume: 46, Issue: 6	2015
Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study. Clinical therapeutics, Oct-01, Volume: 37, Issue: 10	2015
Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat. Neuropharmacology, Volume: 99	2015
Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog. Toxicology and applied pharmacology, Sep-15, Volume: 287, Issue: 3	2015
Evaluation of methods for the estimation of threshold concentrations by the skin prick test. International archives of allergy and immunology, Volume: 166, Issue: 1	2015
Histamine receptor expression in human renal tubules: a comparative pharmacological evaluation. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 64, Issue: 3-4	2015
Addition of histamine to subcutaneously injected Plasmodium berghei sporozoites increases the parasite liver load and could facilitate whole-parasite vaccination. Malaria journal, Jan-28, Volume: 14	2015
In vivo evaluation of the antitussive, expectorant and bronchodilating effects of extract and fractions from aerial parts of Peganum harmala linn. Journal of ethnopharmacology, Mar-13, Volume: 162	2015
[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], Volume: 59, Issue: 5-6	2014
Intestinal permeability--a new target for disease prevention and therapy. BMC gastroenterology, Nov-18, Volume: 14	2014
Airways resistance in bronchial challenge testing. The Journal of asthma : official journal of the Association for the Care of Asthma, Volume: 52, Issue: 1	2015
[Experimental study on pseudoallergic reaction of Qingkailing injection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Volume: 39, Issue: 3	2014
Assessment of the effects of contingent histamine injections on the reinforcing effectiveness of cocaine using behavioral economic and progressive-ratio designs. Psychopharmacology, Volume: 231, Issue: 12	2014
Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24-h period: a double-blind, randomized, cross-over, placebo-controlled comparison in skin responses induced by histamine iontophoresis. The Journal of dermatology, Volume: 40, Issue: 12	2013
Phenanthrene binding by humic acid-protein complexes as studied by passive dosing technique. Environmental pollution (Barking, Essex : 1987), Volume: 184	2014
A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors. Pharmacology, Volume: 92, Issue: 1-2	2013
The anaphylactoid constituents in Xue-Sai-Tong injection. Planta medica, Volume: 79, Issue: 12	2013
[Normative research on bacteriostasis and relieving itching external therapeutic function of kochiae fructus]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, Volume: 35, Issue: 12	2012
New insights in endogenous modulation of ligand-gated ion channels: histamine is an inverse agonist at strychnine sensitive glycine receptors. European journal of pharmacology, Jun-15, Volume: 710, Issue: 1-3	2013
Histamine-induced vasodilatation in the human forearm vasculature. British journal of clinical pharmacology, Volume: 76, Issue: 5	2013
Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers. The Journal of dermatological treatment, Volume: 24, Issue: 6	2013
Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Molecular medicine reports, Volume: 7, Issue: 3	2013
Predicting asthma treatment outcome at diagnosis: the role of symptom perception during a histamine challenge test. The Journal of asthma : official journal of the Association for the Care of Asthma, Volume: 49, Issue: 3	2012
Bronchial hyperresponsiveness in an adult population in Helsinki: decreased FEV1 , the main determinant. The clinical respiratory journal, Volume: 7, Issue: 1	2013
Effect of prednisolone and cetirizine on D. farinae and histamine-induced wheal and flare response in healthy dogs. Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere, Volume: 39, Issue: 1	2011
Antihistamine therapy in allergic rhinitis. Immunology and allergy clinics of North America, Volume: 31, Issue: 3	2011
[Effect of traditional Chinese medicine injections on type I allergy]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Volume: 36, Issue: 6	2011
Anti-scratching behavioral effect of Lactobacillus plantarum PM008 isolated from kimchi in mice. Immunopharmacology and immunotoxicology, Volume: 33, Issue: 3	2011
L-Dopa activates histaminergic neurons. The Journal of physiology, Mar-15, Volume: 589, Issue: Pt 6	2011
Mesenteric lymph node transcriptome profiles in BALB/c mice sensitized to three common food allergens. BMC genomics, Jan-06, Volume: 12	2011
Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation. The Journal of pharmacology and experimental therapeutics, Volume: 335, Issue: 3	2010
Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. The British journal of dermatology, Volume: 163, Issue: 6	2010
Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils. International archives of allergy and immunology, Volume: 153, Issue: 4	2010
Antiinflammatory and antinociceptive activities of Zingiber zerumbet methanol extract in experimental model systems. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, Volume: 19, Issue: 4	2010
Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat. Pharmacology, Volume: 85, Issue: 5	2010
Scombroid poisoning: a review. Toxicon : official journal of the International Society on Toxinology, Aug-15, Volume: 56, Issue: 2	2010
Inhibitory effects of diterpene acids from root of Aralia cordata on IgE-mediated asthma in guinea pigs. Pulmonary pharmacology & therapeutics, Volume: 23, Issue: 3	2010
Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. The Journal of neuroscience : the official journal of the Society for Neuroscience, Nov-18, Volume: 29, Issue: 46	2009
Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Journal of clinical pharmacology, Volume: 50, Issue: 2	2010
Histamine interaction with Zn2+ and Cu2+ porphyrins. Die Pharmazie, Volume: 64, Issue: 8	2009
Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology, Jun-16, Volume: 260, Issue: 1-3	2009
Comparison of the effects of low-dose vs. high-dose aminophylline on lung function in experimental meconium aspiration syndrome. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, Volume: 59 Suppl 6	2008
Time-dependent inhibition of histamine-induced cutaneous responses by oral and intramuscular diphenhydramine and oral fexofenadine. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, Volume: 100, Issue: 5	2008
Effect of disease duration on dose-response of inhaled budesonide in asthma. Respiratory medicine, Volume: 102, Issue: 7	2008
The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. Pharmacology, Volume: 81, Issue: 3	2008
Advantages of human umbilical vein scaffolds derived from cesarean section vs. vaginal delivery for vascular tissue engineering. Biomaterials, Volume: 29, Issue: 8	2008
Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs. Journal of veterinary pharmacology and therapeutics, Volume: 30, Issue: 6	2007
Prostaglandin E2 sensitizes primary sensory neurons to histamine. Neuroscience, Nov-30, Volume: 150, Issue: 1	2007
Pretreatment of cromolyn sodium prior to reperfusion attenuates early reperfusion injury after the small intestine ischemia in rats. World journal of gastroenterology, Oct-14, Volume: 13, Issue: 38	2007
Secretion of ghrelin from rat stomach ghrelin cells in response to local microinfusion of candidate messenger compounds: a microdialysis study. Regulatory peptides, Oct-04, Volume: 143, Issue: 1-3	2007
Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring, Md.), Volume: 14, Issue: 12	2006
Effect of Astragalus membranaceus injection on the activity of the intestinal mucosal mast cells after hemorrhagic shock-reperfusion in rats. Chinese medical journal, Nov-20, Volume: 119, Issue: 22	2006
A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 55, Issue: 6	2006
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum. Autonomic & autacoid pharmacology, Volume: 26, Issue: 3	2006
Ascorbate enhancement of H1 histamine receptor sensitivity coincides with ascorbate oxidation inhibition by histamine receptors. American journal of physiology. Cell physiology, Volume: 291, Issue: 5	2006
Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain, Volume: 124, Issue: 1-2	2006
Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. European journal of pharmacology, Jan-13, Volume: 530, Issue: 1-2	2006
Acute bacterial rhinosinusitis causes hyperresponsiveness to histamine challenge in mice. Archives of otolaryngology--head & neck surgery, Volume: 131, Issue: 10	2005
Dose- and duration-dependent effects of betahistine dihydrochloride treatment on histamine turnover in the cat. European journal of pharmacology, Oct-31, Volume: 523, Issue: 1-3	2005
Histidine enhances carbamazepine action against seizures and improves spatial memory deficits induced by chronic transauricular kindling in rats. Acta pharmacologica Sinica, Volume: 26, Issue: 11	2005
[Assessment of the BALB/c mice as a suitable animal model for the investigation of food allergy]. Wei sheng yan jiu = Journal of hygiene research, Volume: 34, Issue: 2	2005
Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells. Shock (Augusta, Ga.), Volume: 23, Issue: 5	2005
Airway closure after antigen challenge in cynomolgus monkeys: effect of the histamine H1 receptor antagonist, chlorpheniramine maleate. International archives of allergy and immunology, Volume: 137, Issue: 1	2005
Determinants of airway responsiveness to histamine in children. The European respiratory journal, Volume: 25, Issue: 3	2005
A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies. The Journal of pharmacy and pharmacology, Volume: 57, Issue: 2	2005
Host-specific differences in the physiology of acid secretion related to prostaglandins may play a role in gastric inflammation and injury. American journal of physiology. Gastrointestinal and liver physiology, Volume: 288, Issue: 6	2005
Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs, Volume: 65, Issue: 3	2005
[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, Volume: 26, Issue: 6	2004
The effect of EGF application in gel form on histamine content of experimentally induced wound in mice. Amino acids, Volume: 27, Issue: 3-4	2004
Disruption of microtubular network attenuates histamine-induced dilation in rat mesenteric vessels. American journal of physiology. Cell physiology, Volume: 288, Issue: 2	2005
Classification of perioperative histamine-related reactions. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 53 Suppl 2	2004
Clinical pharmacology of clemastine in healthy dogs. Veterinary dermatology, Volume: 15, Issue: 3	2004
Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology, Volume: 100, Issue: 4	2004
Randomized controlled trial of unflued gas heater replacement on respiratory health of asthmatic schoolchildren. International journal of epidemiology, Volume: 33, Issue: 1	2004
Relationship between exhaled carbon monoxide and airway hyperresponsiveness in asthmatic patients. The Journal of asthma : official journal of the Association for the Care of Asthma, Volume: 41, Issue: 1	2004
Studies of the "antihistaminic" effect of pyribenzamine administered by various routes. California medicine, Volume: 74, Issue: 4	1951
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Pollution, Exposure and Risk of Biogenic Amines in Canned Sea Fish: Classification of Analytical Methods Based on Carbon Spheres QuEChERS Extraction Combined with HPLC. Molecules (Basel, Switzerland), Sep-22, Volume: 27, Issue: 19	2022
A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability. The Clinical journal of pain, Volume: 37, Issue: 1	2021
Reduction of the histamine content and immunoreactivity of parvalbumin in Decapterus maruadsi by a Maillard reaction combined with pressure treatment. Food & function, Sep-19, Volume: 9, Issue: 9	2018
Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. British journal of pharmacology, Volume: 167, Issue: 3	2012
Membrane depolarization combined with Gq-activated G-protein-coupled receptors induce transient receptor potential channel 1 (TRPC1)- dependent potentiation of catecholamine release. Neuroscience, Aug-25, Volume: 189	2011
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain research, May-31, Volume: 1045, Issue: 1-2	2005
Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown norway rats anaphylactic shock. Shock (Augusta, Ga.), Volume: 19, Issue: 1	2003
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, Volume: 13, Issue: 3	2002
Benazepril, an angiotensin converting enzyme inhibitor: drug interaction with salbutamol and bronchial response to histamine in normal subjects. British journal of clinical pharmacology, Volume: 44, Issue: 6	1997
The effect of tripelennamine alone and in combination with opiates to produce antinociception in mice. Life sciences, Apr-04, Volume: 32, Issue: 14	1983
Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man. British journal of pharmacology, Volume: 44, Issue: 1	1972
The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. British journal of clinical pharmacology, Volume: 20, Issue: 4	1985
Bronchoconstriction due to exercise combined with cold air inhalation does not generally influence bronchial responsiveness to inhaled histamine in asthmatic subjects. The European respiratory journal, Volume: 1, Issue: 2	1988
The connections between the septum-diagonal band complex and histaminergic neurons in the posterior hypothalamus of the rat. Anterograde tracing with Phaseolus vulgaris-leucoagglutinin combined with immunocytochemistry of histidine decarboxylase. Neuroscience, Volume: 26, Issue: 3	1988
The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma. The American review of respiratory disease, Volume: 139, Issue: 2	1989
Innervation of histaminergic neurons in the posterior hypothalamic region by medial preoptic neurons. Anterograde tracing with Phaseolus vulgaris leucoagglutinin combined with immunocytochemistry of histidine decarboxylase in the rat. Brain research, Jul-05, Volume: 455, Issue: 1	1988
Subicular efferents to histaminergic neurons in the posterior hypothalamic region of the rat studied with PHA-L tracing combined with histidine decarboxylase immunocytochemistry. Journal fur Hirnforschung, Volume: 33, Issue: 4-5	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Flavones derived from nature attenuate the immediate and late-phase asthmatic responses to aerosolized-ovalbumin exposure in conscious guinea pigs. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 63, Issue: 1	2014
Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications. Critical reviews in biochemistry and molecular biology, Volume: 38, Issue: 1	2003
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

histamine

Cross-References

Synonyms (196)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (3)

Drug Classes (2)

Pathways (110)

Protein Targets (79)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (160)

Molecular Functions (55)

Ceullar Components (49)

Bioassays (598)

Research

Studies (35,334)

Study Types

Clinical Trials (60)

Trial Overview

Trial Outcomes

Reaction to Test Article

Sensitivity

Skin Prick Techniques/Methodology Ratio

Wheal Response

Number of Participants With Healed Peptic Ulcer

Allergic Erythema Size in the Intent-to-Treat Population (ITT)

Allergic Erythema Size in the Per-Protocol Population (PPP)

Allergic Wheal Size in the Intent-to-Treat Population (ITT)

Allergic Wheal Size in the Per-Protocol Population (PPP)

Erythema Responder Rate in the Intent-to-Treat Population (ITT)

Erythema Responder Rate in the Per-Protocol Population (PPP)

Local Itchiness Rate in the Intent-to-Treat Population (ITT)

Local Itchiness Rate in the Per-Protocol Population (PPP)

Observed Erythema Size in the Intent-to-Treat Population (ITT)

Observed Erythema Size in the Per-Protocol Population (PPP)

Observed Wheal Size in the Intent-to-Treat Population (ITT)

Observed Wheal Size in the Per-Protocol Population (PPP)

Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)

Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)

Number of Participants With Ulcer Recurrence

Related Drugs (5,503)

Related Conditions (8,388)

Research Highlights

Safety/Toxicity (106)

Long-term Use (49)

Pharmacokinetics (141)

Onset of Action (8)

Bioavailability (37)

Dosage (831)

Interactions (20)

Natural Sources (2)